
<html lang="en"     class="pb-page"  data-request-id="ee3804aa-65f7-4779-a69e-44b25a9568fa"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.1c00270;issue:issue:10.1021/jmcmar.2021.64.issue-13;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK)" /></meta><meta name="dc.Creator" content="Shaowen  Xie" /></meta><meta name="dc.Creator" content="Yuan  Sun" /></meta><meta name="dc.Creator" content="Yulin  Liu" /></meta><meta name="dc.Creator" content="Xinnan  Li" /></meta><meta name="dc.Creator" content="Xinuo  Li" /></meta><meta name="dc.Creator" content="Wenyi  Zhong" /></meta><meta name="dc.Creator" content="Feiyan  Zhan" /></meta><meta name="dc.Creator" content="Jingjie  Zhu" /></meta><meta name="dc.Creator" content="Hong  Yao" /></meta><meta name="dc.Creator" content="Dong-Hua  Yang" /></meta><meta name="dc.Creator" content="Zhe-Sheng  Chen" /></meta><meta name="dc.Creator" content="Jinyi  Xu" /></meta><meta name="dc.Creator" content="Shengtao  Xu" /></meta><meta name="dc.Description" content="A series of novel anaplastic lymphoma kinase (ALK) degraders were designed and synthesized based on proteolysis-targeting chimera (PROTAC) technology by linking two alectinib analogs (36 and 37) wi..." /></meta><meta name="Description" content="A series of novel anaplastic lymphoma kinase (ALK) degraders were designed and synthesized based on proteolysis-targeting chimera (PROTAC) technology by linking two alectinib analogs (36 and 37) wi..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 28, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00270" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00270" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00270" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00270" /></link>
        
    
    

<title>Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK) | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00270" /></meta><meta property="og:title" content="Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0024.jpeg" /></meta><meta property="og:description" content="A series of novel anaplastic lymphoma kinase (ALK) degraders were designed and synthesized based on proteolysis-targeting chimera (PROTAC) technology by linking two alectinib analogs (36 and 37) with pomalidomide through linkers of different lengths and types. The most promising degrader 17 possessed a high ALK-binding affinity and potent antiproliferative activity in the ALK-dependent cell lines and did not exhibit obvious cytotoxicity in ALK fusion-negative cells. More importantly, the efficacy of compound 17 in a Karpas 299 xenograft mouse model was further evaluated based on its ALK-sustained degradation ability in vivo. The reduction in tumor weight in the compound 17-treated group (10 mg/kg/day, I.V.) reached 75.82%, while alectinib reduced tumor weight by 63.82% at a dose of 20 mg/kg/day (P.O.). Taken together, our findings suggest that alectinib-based PROTACs associated with the degradation of ALK may have promising beneficial effects for treating ALK-driven malignancies." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00270"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00270">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00270&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00270&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00270&amp;href=/doi/10.1021/acs.jmedchem.1c00270" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 13</span><span class="cit-fg-pageRange">, 9120-9140</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/13" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00204" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.1c00362" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK)</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Shaowen Xie</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shaowen Xie</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shaowen++Xie">Shaowen Xie</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yuan Sun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yuan Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yuan++Sun">Yuan Sun</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yulin Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yulin Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</div><div class="loa-info-affiliations-info">Department of Organic Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yulin++Liu">Yulin Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xinnan Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xinnan Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xinnan++Li">Xinnan Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xinuo Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xinuo Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Lab of Drug Metabolism & Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xinuo++Li">Xinuo Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wenyi Zhong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wenyi Zhong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Organic Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wenyi++Zhong">Wenyi Zhong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Feiyan Zhan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Feiyan Zhan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Feiyan++Zhan">Feiyan Zhan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jingjie Zhu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jingjie Zhu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jingjie++Zhu">Jingjie Zhu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hong Yao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hong Yao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hong++Yao">Hong Yao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dong-Hua Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dong-Hua Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">College of Pharmacy and Health Sciences, St. John’s University, 8000 Utopia Parkway, Queens, New York 11439, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dong-Hua++Yang">Dong-Hua Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhe-Sheng Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhe-Sheng Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">College of Pharmacy and Health Sciences, St. John’s University, 8000 Utopia Parkway, Queens, New York 11439, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhe-Sheng++Chen">Zhe-Sheng Chen</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-8289-097X" title="Orcid link">https://orcid.org/0000-0002-8289-097X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jinyi Xu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jinyi Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#89e3e0e7f0e0f1fcc9eae1e0e7e8a7eae6e4"><span class="__cf_email__" data-cfemail="264c4f485f4f5e5366454e4f48470845494b">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jinyi++Xu">Jinyi Xu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-1961-0402" title="Orcid link">https://orcid.org/0000-0002-1961-0402</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Shengtao Xu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shengtao Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#e48794919c9790a4d5d2d7ca878b89"><span class="__cf_email__" data-cfemail="375447424f4443770601041954585a">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shengtao++Xu">Shengtao Xu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-5705-6377" title="Orcid link">https://orcid.org/0000-0002-5705-6377</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00270&amp;href=/doi/10.1021%2Facs.jmedchem.1c00270" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 13</span><span class="cit-pageRange">, 9120–9140</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 28, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>11 February 2021</li><li><span class="item_label"><b>Published</b> online</span>28 June 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 July 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00270" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00270</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9120%26pageCount%3D21%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DShaowen%2BXie%252C%2BYuan%2BSun%252C%2BYulin%2BLiu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D13%26contentID%3Dacs.jmedchem.1c00270%26title%3DDevelopment%2Bof%2BAlectinib-Based%2BPROTACs%2Bas%2BNovel%2BPotent%2BDegraders%2Bof%2BAnaplastic%2BLymphoma%2BKinase%2B%2528ALK%2529%26numPages%3D21%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9140%26publicationDate%3DJuly%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00270"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1981</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00270" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK)&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Shaowen&quot;,&quot;last_name&quot;:&quot;Xie&quot;},{&quot;first_name&quot;:&quot;Yuan&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Yulin&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Xinnan&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Xinuo&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Wenyi&quot;,&quot;last_name&quot;:&quot;Zhong&quot;},{&quot;first_name&quot;:&quot;Feiyan&quot;,&quot;last_name&quot;:&quot;Zhan&quot;},{&quot;first_name&quot;:&quot;Jingjie&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;Yao&quot;},{&quot;first_name&quot;:&quot;Dong-Hua&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Zhe-Sheng&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Jinyi&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Shengtao&quot;,&quot;last_name&quot;:&quot;Xu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;28&quot;,&quot;issue&quot;:&quot;13&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;9120-9140&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00270&quot;},&quot;abstract&quot;:&quot;A series of novel anaplastic lymphoma kinase (ALK) degraders were designed and synthesized based on proteolysis-targeting chimera (PROTAC) technology by linking two alectinib analogs (36 and 37) with pomalidomide through linkers of different lengths and types. The most promising degrader 17 possessed a high ALK-binding affinity and potent antiproliferative activity in the ALK-dependent cell lines and did not exhibit obvious cytotoxicity in ALK fusion-negative cells. More importantly, the efficacy of compound 17 in a Karpas 299 xenograft mouse model was further evaluated based on its ALK-sustained degradation ability in vivo. The reduction in tumor weight in the compound 17-treated group (10 mg/kg/day, I.V.) reached 75.82%, while alectinib reduced tumor weight by 63.82% at a dose of 20 mg/kg/day (P.O.). Taken together, our findings suggest that alectinib-based PROTACs associated with the degradation of ALK may have promising beneficial effects for treating ALK-driven malignancies.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00270&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00270" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00270&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00270" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00270&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00270" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00270&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00270&amp;href=/doi/10.1021/acs.jmedchem.1c00270" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00270" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00270" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (10 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00270%26sid%3Dliteratum%253Aachs%26pmid%3D34176264%26genre%3Darticle%26aulast%3DXie%26date%3D2021%26atitle%3DDevelopment%2Bof%2BAlectinib-Based%2BPROTACs%2Bas%2BNovel%2BPotent%2BDegraders%2Bof%2BAnaplastic%2BLymphoma%2BKinase%2B%2528ALK%2529%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D13%26spage%3D9120%26epage%3D9140%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291781" title="Degradation">Degradation</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/13" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0024.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A series of novel anaplastic lymphoma kinase (ALK) degraders were designed and synthesized based on proteolysis-targeting chimera (PROTAC) technology by linking two alectinib analogs (<b>36</b> and <b>37</b>) with pomalidomide through linkers of different lengths and types. The most promising degrader <b>17</b> possessed a high ALK-binding affinity and potent antiproliferative activity in the ALK-dependent cell lines and did not exhibit obvious cytotoxicity in ALK fusion-negative cells. More importantly, the efficacy of compound <b>17</b> in a Karpas 299 xenograft mouse model was further evaluated based on its ALK-sustained degradation ability <i>in vivo</i>. The reduction in tumor weight in the compound <b>17</b>-treated group (10 mg/kg/day, I.V.) reached 75.82%, while alectinib reduced tumor weight by 63.82% at a dose of 20 mg/kg/day (P.O.). Taken together, our findings suggest that alectinib-based PROTACs associated with the degradation of ALK may have promising beneficial effects for treating ALK-driven malignancies.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17546" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17546" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Anaplastic lymphoma kinase (ALK) is a transmembrane protein tyrosine kinase that belongs to the insulin receptor kinase subfamily.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> It was first identified in anaplastic large cell lymphoma (ALCL) with a nucleophosmin (NPM)-ALK fusion form, a subtype of T-cell non-Hodgkin’s lymphoma, which is frequently associated with chromosomal translocation.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> Thereafter, many cancers were found to be associated with different forms of the ALK fusion. These include non-small-cell lung cancer (NSCLC, EML4-ALK),<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> inflammatory myofibroblastic tumor (IMT, TPM3-ALK),<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> and diffuse large B-cell lymphoma (DLBCL, CLTC-ALK).<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> In addition, amplification of the ALK gene and mutations of the wild-type ALK protein have been reported in various tumors.<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8−10)</a></div><div class="NLM_p">ALK has become an attractive therapeutic target, partly due to its low level in normal adult tissues, which is assumed to reduce the opportunities for off-target toxicities caused by ALK inhibitors.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> Therefore, the treatment strategy of inhibiting ALK kinase activity is presumed to produce fewer side effects. So far, the U.S. Food and Drug Administration (FDA) has approved five ALK small-molecule inhibitors, including <b>1</b> (crizotinib),<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a><b>2</b> (ceritinib),<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a><b>3</b> (alectinib),<a onclick="showRef(event, 'ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17">(15−17)</a><b>4</b> (brigatinib),<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and <b>5</b> (lorlatinib),<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> for the treatment of ALK-positive NSCLC patients (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Although these ALK inhibitors have shown promising curative effects in clinical applications, drug resistance remains a severe challenge over time.<a onclick="showRef(event, 'ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref22">(20−22)</a> Hence, new strategies to develop novel ALK drugs and alternative targeted ALK approaches to overcome drug resistance are urgently needed.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of FDA-approved ALK small-molecule inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Currently, the “proteolysis-targeting chimera” (PROTAC) technique has become one of the most promising cancer therapeutic strategies.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> PROTACs consist of three parts, a ligand for binding targets, an E3-ubiquitin ligase ligand for hijacking an endogenous E3 ligase, and a linker that connects these two moieties, thus causing the ubiquitination and degradation of the targeted protein via the ubiquitin-proteasome system.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The PROTAC technique has been reported in the field of ALK fusion protein degradation (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). In 2018, Gray and Jin’s groups reported two sets of ALK degraders <b>6a</b> (TL13-12) and <b>6b</b> (TL13-112)<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> and <b>7</b> (MS4077) and <b>8a</b> (MS4078).<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> All of these degraders can mediate the ubiquitination and degradation of NPM-ALK and EML4-ALK <i>in vitro</i>. Subsequently, Wei’s group introduced a light-inducible switch on <b>8a</b>, named opto-PROTAC <b>8b</b> (opto-dALK), which enables the degradation of ALK in a spatiotemporal manner.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Hwang and Li’s groups also developed ALK degraders <b>9</b> (TD-004) and <b>10</b> (B3) by linking ceritinib (<b>2</b>) to Von Hippel–Lindau (VHL) and CRBN E3 ligases, respectively.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a> Both of them showed acceptable efficacy in reducing tumor growth in the H3122 xenograft model. Very recently, Jiang’s group reported brigatinib (<b>4</b>)-based degrader <b>11</b> (SIAIS117), which can degrade the G1202R mutant ALK protein <i>in vitro</i>.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> However, these reported ALK degraders were mainly based on the 2,4-diaminopyrimidine scaffold (<b>2</b> and <b>4</b>) as an ALK-binding moiety. During the preparation of our revised paper, we found that Jiang’s group reported alectinib-based PROTAC <b>12</b> (SIAIS001), which showed potent antiproliferative activity against SR cells <i>in vitro</i>.<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31,32)</a> However, so far, the antiproliferative activities in other ALK-addicted cell lines <i>in vitro</i> and antitumor activities as well as mechanisms of alectinib-based PROTACs <i>in vivo</i> have not been reported yet.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structures of reported ALK degraders.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Alectinib is the only tetracyclic benzo[<i>b</i>]carbazolone scaffold that adopts a planar conformation among FDA-approved ALK tyrosine kinase inhibitors (TKIs) and shows a lighter molecular weight compared with the other two second-generation ALK inhibitors. The development of alectinib-based PROTACs is supposed to enrich the structure–activity relationship of ALK degraders and contribute to the druggability of PROTACs.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> The high kinase selectivity against ALK and good tolerance in advanced crizotinib-refractory ALK-positive NSCLC patients would guarantee safety while choosing alectinib (<b>3</b>) as the ALK-binding moiety of PROTAC molecules.<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34,35)</a> Moreover, alectinib (<b>3</b>) had excellent potency in a broad panel of crizotinib-resistant mutants and a longer median duration (25.7 months) in first- and second-generation ALK inhibitors.<a onclick="showRef(event, 'ref20 ref36 ref37 ref38 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref20 ref36 ref37 ref38 ref39 ref40">(20,36−40)</a></div><div class="NLM_p last">Based on the above reasons, accordingly, we designed and synthesized a series of novel alectinib-based CRBN-recruiting ALK PROTACs by linking two alectinib analogs (<b>36</b> and <b>37</b>) and pomalidomide through linkers of different lengths and types. The potency of degrading ALK fusion proteins and inhibiting cancer cell proliferation of all targeted compounds in H3122 (EML4-ALK) and Karpas 299 (NPM-ALK) cell lines was evaluated. The most potent compound, compound <b>17</b>, mediated the complement degradation of the ALK fusion protein at 0.1–1 μM in ALK-positive cancer cell lines and exhibited effective antiproliferation with an IC<sub>50</sub> value of 62 ± 2 nM in the H3122 cell line and 42 ± 5 nM in the Karpas 299 cell line. In addition, it achieved potent tumor growth inhibition in the Karpas 299 xenograft mouse model at well-tolerated dose schedules. More importantly, this work first explored the antitumor mechanism of ALK degraders in a Karpas 299 xenograft mouse model, and the results showed that their antitumor activities were mediated by the degradation of ALK.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75113" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75113" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Design and Initial Evaluation of ALK Bifunctional Small-Molecule Degraders</h3><div class="NLM_p">Although the design strategies and rules of PROTACs have not been fully elucidated, safety and efficacy are still the cornerstones of new drug research and development. We selected alectinib as the ALK-binding moiety for the design of novel ALK degraders mainly due to its unique tetracyclic system, high selectivity, and good tolerance among ALK inhibitors approved by the FDA or currently in clinical trials.<a onclick="showRef(event, 'ref17 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref17 ref34 ref35">(17,34,35)</a> The cocrystal structure of the ALK kinase domain in complex with alectinib (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3AOX">3AOX</a>) indicates that the morpholine group of alectinib projects to the surface of the binding pocket (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). Therefore, we designed and synthesized <b>37</b> as an ALK-binding moiety by replacing the solvent-exposed morpholine group with a piperazine group and used the outer nitrogen of the piperazine group as the tethering site. To further improve the druggability of the PROTACs, we decreased the molecular weight of the ALK-binding moiety by removing the piperazine group from <b>37</b> to obtain <b>36</b>.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Compounds <b>36</b> and <b>37</b> bind to ALK with high affinities (<b>36</b>: IC<sub>50</sub> = 0.32 ± 0.04 nM; <b>37</b>: IC<sub>50</sub> = 0.29 ± 0.13 nM) and are >3 times more potent than alectinib (<b>3</b>: IC<sub>50</sub> = 1.03 ± 0.29 nM) (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B and <a href="/doi/suppl/10.1021/acs.jmedchem.1c00270/suppl_file/jm1c00270_si_001.pdf" class="ext-link">Figure S1</a>). Moreover, <b>36</b> and <b>37</b> also exhibited potent activities in inhibiting cell proliferation in the ALK-driven NSCLC line H3122 (<b>36</b>: IC<sub>50</sub> = 38 ± 1 nM; <b>37</b>: IC<sub>50</sub> = 40 ± 1 nM) and ALCL line Karpas 299 (<b>36</b>: IC<sub>50</sub> = 46 ± 2 nM; <b>37</b>: IC<sub>50</sub> = 50 ± 1 nM), which were comparable to those of alectinib (<b>3</b>) (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C). Therefore, compounds <b>36</b> and <b>37</b> were employed as warheads in the further design of ALK degraders.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Chemical structures, molecular weights, and cocrystal structure of ALK with alectinib (left; PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3AOX">3AOX</a>) and modeled structures of ALK in a complex with alectinib precursors <b>37</b> (middle) or <b>36</b> (right). (B) ALK binding affinities of alectinib and compounds <b>36</b> and <b>37</b> were measured by TR-FRTE ALK kinase assay. Data are presented as the mean ± SD from three independent experiments. (C) Cell growth inhibition in H3122 and Karpas 299 cell lines. The cells were treated with the indicated doses of alectinib (<b>3</b>) and compounds <b>36</b> and <b>37</b> for 72 h, and the IC<sub>50</sub> values were determined by an MTT assay. Data are presented as the mean ± SD of duplicate independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Both the H3122 and Karpas 299 cell lines expressed high levels of CRBN (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00270/suppl_file/jm1c00270_si_001.pdf" class="ext-link">Figure S2</a>). Pomalidomide has been applied in most of the reported ALK degraders as the CRBN-recruiting moiety, which has shown potent degradation capability and antiproliferative ability <i>in vitro</i>.<a onclick="showRef(event, 'ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27">(25−27)</a> Therefore, we employed pomalidomide as a CRBN binding moiety in this study on account of its outstanding pharmacokinetic performance and more “oral drug-like” starting point compared with other E3 ligands.<a onclick="showRef(event, 'ref42 ref43 ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref42 ref43 ref44 ref45">(42−45)</a> It has been widely recognized that the linker plays an important role in the generation of the E3 enzyme-PROTAC-target protein ternary complex.<a onclick="showRef(event, 'ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref46 ref47">(46,47)</a> In addition, the right combination of linker type and warhead in the design of PROTACs can also affect protein degradation potency and antiproliferative activity.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Therefore, we initially developed six ALK degraders by connecting ALK-binding moieties (<b>36</b> and <b>37</b>) and the CRBN-recruiting moiety pomalidomide directly (<b>13</b> and <b>21</b>) or using two different types of linkers (<b>14</b>, <b>17</b>, <b>22</b>, and <b>25</b>) to explore the impacts of the linkers on cell growth inhibition and protein degradation ability (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Chemical structures of designed alectinib-based ALK degraders and negative control <b>20</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The degradative potency and antiproliferative activity of the initially designed ALK-targeting PROTACs were evaluated in the ALK-dependent cell lines H3122 and Karpas 299 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Unfortunately, compounds <b>13</b> and <b>21</b>, which were synthesized by connecting two different ALK ligands <b>36</b> and <b>37</b> to pomalidomide directly, showed sharply decreased potencies in the inhibition of cell growth compared with their parent inhibitors <b>36</b> and <b>37</b> in two ALK-positive cell lines. Meanwhile, western blotting analysis showed that compounds <b>13</b> and <b>21</b> had little or no effect on the expression level of the ALK fusion protein in H3122 and Karpas 299 cell lines (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), indicating that compounds <b>13</b> and <b>21</b> function by inhibition but not degradation. Interestingly, the efficacy of degradation and antiproliferation of compounds <b>14</b>, <b>17</b>, <b>22</b>, and <b>25</b>, in which the linker employed was 2-amino acetic acid or <i>N</i>-(2-aminoethyl) acetamide, were significantly improved. The degradative potency of compounds <b>17</b> and <b>25</b>, with the 2-amino acetic acid linker, was more potent than those of the <i>N</i>-(2-aminoethyl) acetamide series (compounds <b>14</b> and <b>22</b>). Moreover, degrader <b>25</b> achieved the complete degradation of ALK at a concentration of 1 μM in both cell lines (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Interestingly, compounds <b>14</b> and <b>22</b> can effectively reduce the EML4-ALK level by over 80% at a concentration of 1 μM in H3122 cells. However, their degradative potency was sharply reduced in Karpas 299 cells, whi<u class="uu">c</u>h implied that the <i>N</i>-(2-aminoethyl) acetamide linker was not tolerated by the NPM-ALK fusion protein and CRBN ligase. Compounds <b>14</b>, <b>22</b>, and <b>25</b> all showed slightly reduced antiproliferative activity in two ALK-positive cell lines, with IC<sub>50</sub> values of approximately 100 nM. Interestingly, degrader <b>17</b> exhibited comparably potent antiproliferative activity with alectinib and parent inhibitor <b>36</b> in both ALK-positive cell lines (H3122: IC<sub>50</sub> = 62 ± 2; Karpas 299: IC<sub>50</sub> = 42 ± 5). So, these results validated the important role of the linker in the design of PROTACs.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effects of compounds <b>13</b>–<b>19</b> and <b>21</b>–<b>25</b> on reducing the ALK protein level in (A) H3122 cells and (B) Karpas 299 cells. Both cell lines were treated with the indicated compounds and concentrations for 16 or 24 h, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Initial Evaluation of ALK Degraders</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0019.gif" alt="" id="gr18" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0020.gif" alt="" id="gr19" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values were obtained from three independent experiments (mean ± SD). With a treatment time of 72 h in H3122 and Karpas 299 cell lines.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Percent degradation at a concentration of 1 or 0.1 μM in H3122 and Karpas 299 cells obtained from three independent experiments.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">NDE: no degradation is observed at the indicated concentration.</p></div></div><div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Determination of the Optimal Linker Length and Type</h3><div class="NLM_p">The type and length of linker can also affect the development of effective PROTACs by modulating biological activities and physicochemical properties.<a onclick="showRef(event, 'ref42 ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref42 ref50 ref51">(42,50,51)</a> Therefore, we next sought to investigate the optimal linkers, and compounds <b>15</b>, <b>16</b>, <b>18</b>, <b>19</b>, <b>23</b>, and <b>24</b> that incorporated different lengths of alkyl acid or alkyl diamine were further synthesized (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). We first compared the potency in ALK degradation and antiproliferation of compounds <b>14</b>–<b>16</b> and <b>22</b>–<b>24</b>, which employed different lengths of alkyl diamine. In the western blotting assay, the two series of compounds effectively induced EML4-ALK degradation by >75% at 1 μM in H3122 cells. However, NPM-ALK degradation was not observed at the indicated concentration mediated by compounds <b>22</b>–<b>24</b> in Karpas 299 cells (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), which is a sharp contrast compared with compounds <b>14</b>–<b>16</b>. This result indicated that warhead <b>36</b> was more tolerant in the design of ALK PROTACs to degrade the EML4-ALK and NPM-ALK fusion protein than compound <b>37</b>. Compounds <b>22</b>–<b>24</b> still maintain good potency in the inhibition of cell growth in Karpas 299 cells, implying that their antiproliferative activity might be mediated by inhibiting ALK kinase activity. In regard to compounds <b>17</b>–<b>19</b>, a sharp decrease in the ability to degrade ALK fusion protein was observed in both cell lines with increasing linker length, especially in H3122 cells. Meanwhile, the antiproliferative potency of the two ALK-positive cell lines also decreased with increasing linker length, indicating that the degradation of compounds <b>17</b>–<b>19</b> plays an important role in the antiproliferative potency. In addition, we selected compounds <b>14</b>, <b>15</b>, <b>16</b>, <b>17</b>, <b>18</b>, <b>19</b>, and <b>25</b> as representative compounds to evaluate their detailed degradative potency in Karpas 299 cells (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00270/suppl_file/jm1c00270_si_001.pdf" class="ext-link">Figures S3 and S4</a>). Interestingly, although these compounds exhibited a different degradation behavior on unphosphorylated ALK, they all showed good inhibitory effects on the phosphorylated ALK and STAT-3. According to the western blotting and antiproliferative data, we selected the most potent compound, <b>17</b>, with a relatively smaller size (MW = 711.78), as the representative compound for further study. Notably, although degrader <b>17</b> exhibited comparably potent antiproliferative activity with alectinib in both ALK-positive cell lines in the present study, its degradation potencies still need to be improved in the further study.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Further Optimization of the Linker Length and Type</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0021.gif" alt="" id="gr20" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0022.gif" alt="" id="gr21" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values were obtained from three independent experiments (mean ± SD).</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Percent degradation at a concentration of 1 or 0.1 μM in H3122 and Karpas 299 cells obtained from three independent experiments.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">NDE: no degradation is observed at the indicated concentration.</p></div></div><div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Investigation of the CRBN Binding Ability on Antiproliferative Activity of ALK Degraders</h3><div class="NLM_p">To further investigate the cellular mechanism of action of alectinib-based PROTACs, we designed analog <b>20</b> bearing a methylated pomalidomide moiety as the negative control of degrader <b>17</b> to abolish CRBN engagement.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Compared to alectinib and two alectinib precursors (<b>36</b> and <b>37</b>), compounds <b>17</b> and <b>20</b> still maintained high binding affinities to ALK, with IC<sub>50</sub> values of 13.63 ± 4.34 and 30.63 ± 6.62 nM, respectively (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.1c00270/suppl_file/jm1c00270_si_001.pdf" class="ext-link">Figure S1</a>), proving our primitive strategy that modification at the solvent-exposed region could ensure the ALK PROTAC binding affinities to the ALK protein (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). However, compound <b>20</b> failed to induce the degradation of the ALK fusion protein in ALK-positive cell lines and exhibited weaker efficacy in inhibiting ALK phosphorylation than <b>17</b> (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.1c00270/suppl_file/jm1c00270_si_001.pdf" class="ext-link">Figure S5</a>). Thus, compound <b>20</b> caused 4.4–6.5 times less potent antiproliferative activity than compound <b>17</b> in both cell lines. These results suggest that our designed PROTACs inhibit cell growth by acting not only as ALK degraders but also as ALK inhibitors.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Investigation of the Effect of CRBN Binding on Cellular Potencies of ALK Degraders</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0023.gif" alt="" id="gr22" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">H3122 cell line</th><th class="rowsep1 colsep0" colspan="3" align="center">Karpas 299 cell line</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">EML4-ALK degradation %<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">NPM-ALK degradation %</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cpds</th><th class="colsep0 rowsep0" align="center"><i>R</i></th><th class="colsep0 rowsep0" align="center">ALK binding affinities (IC<sub>50</sub>, nM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">@ 1 μM</th><th class="colsep0 rowsep0" align="center">@ 0.1 μM</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">@ 1 μM</th><th class="colsep0 rowsep0" align="center">@ 0.1 μM</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">13.63 ± 4.34</td><td class="colsep0 rowsep0" align="left">62 ± 2</td><td class="colsep0 rowsep0" align="left">83.6 ± 1.0</td><td class="colsep0 rowsep0" align="left">50.3 ± 1.0</td><td class="colsep0 rowsep0" align="center">42 ± 5</td><td class="colsep0 rowsep0" align="center">85.0 ± 4.0</td><td class="colsep0 rowsep0" align="left">8.6 ± 6.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">30.63 ± 6.62</td><td class="colsep0 rowsep0" align="left">272 ± 7</td><td class="colsep0 rowsep0" align="left">NDE<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">NDE</td><td class="colsep0 rowsep0" align="center">275 ± 8</td><td class="colsep0 rowsep0" align="center">NDE</td><td class="colsep0 rowsep0" align="left">NDE</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">ALK binding affinities of compounds <b>17</b> and <b>20</b> were measured by TR-FRTE ALK kinase assay. Data are presented as the mean ± SD from three independent experiments.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">IC<sub>50</sub> values were obtained from three independent experiments (mean ± SD).</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">Percent degradation at a concentration of 1 or 0.1 μM in H3122 and Karpas 299 cells obtained from three independent experiments.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">NDE: no degradation is observed at the indicated concentration.</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Compound <b>17</b> Potently Degraded the ALK Fusion Protein and Inhibited ALK Downstream Signaling in a Concentration- and Time-Dependent Manner</h3><div class="NLM_p">We selected compound <b>17</b> to further study its degradation behavior in H3122 and Karpas 299 cells, given its excellent performance in ALK binding affinity and antiproliferative activity in ALK-positive cancer cells. As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, compound <b>17</b> could degrade the ALK fusion protein in a dose-dependent manner and thoroughly degrade the ALK fusion protein in H3122 and Karpas 299 cells with DC<sub>50</sub> (50% degradation) values of 27.4 and 116.5 nM, respectively. Meanwhile, compound <b>17</b> can also firmly inhibit the phosphorylation of ALK at a low concentration of 100 nM in Karpas 299 cells, which is more potent than alectinib. In addition, it has been reported that the STAT3 pathway plays an important role in NPM-ALK-mediated lymphomagenesis in ALCL.<a onclick="showRef(event, 'ref34 ref53'); return false;" href="javascript:void(0);" class="ref ref34 ref53">(34,53)</a> Over 85% inhibition of p-STAT3 was observed by treatment with compound <b>17</b> at a concentration of 100 nM for 24 h in the ALK-positive ALCL cell line Karpas 299 (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00270/suppl_file/jm1c00270_si_001.pdf" class="ext-link">Figure S4</a>), which was consistent with the antiproliferation activity in Karpas 299 cells. These results indicate that compound <b>17</b> is an extremely potent degrader of ALK proteins.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>17</b> concentration-dependently reduced ALK fusion protein levels and inhibited ALK phosphorylation. (A) H3122 and (B) Karpas 299 cells were treated with DMSO or serial dilutions of compounds for the indicated length of time. Data are presented as the mean ± SD from three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Next, time-course studies were conducted in both H3122 (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A) and Karpas 299 cells (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B). EML4-ALK could be thoroughly degraded by compound <b>17</b> (0.25 μM) at 16 h in H3122 cells. The maximum degradation of NPM-ALK mediated by <b>17</b> (2 μM) in Karpas 299 cells was observed after 24 h of treatment. These results indicated that H3122 and Karpas 299 cells had different sensitivities to compound <b>17</b>. Meanwhile, alectinib (<b>3</b>) and negative control compound <b>20</b> did not reduce the expression level of the ALK fusion protein but potently inhibited ALK phosphorylation at the indicated time and concentration in either ALK-positive cell line. The comparable inhibition of p-ALK by compounds <b>3</b> and <b>20</b> is most likely due to the inhibition of ALK kinase but not degradation, as they maintained high binding affinities to ALK (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.1c00270/suppl_file/jm1c00270_si_001.pdf" class="ext-link">Figure S1</a>). These results indicated that the degradation of ALK can enhance the inhibition of downstream signaling. This also suggested that the antiproliferative activity of compound <b>17</b> on ALK-positive cells may be derived from both the inhibition and degradation of the ALK protein.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Compound <b>17</b> reduced ALK fusion protein levels in a time-dependent manner and inhibited ALK phosphorylation. (A) H3122 and (B) Karpas 299 cells were treated with DMSO or compounds for the indicated times.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Compound <b>17</b>-Induced ALK Fusion Protein Degradation Is Mediated through the E3 Ubiquitin Ligase Component CRBN</h3><div class="NLM_p">To investigate the mechanism of action of compound <b>17</b> in H3122 and Karpas 299 cells, we performed a set of rescue assays. H3122 (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A) and Karpas 299 (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B) cells were pretreated with the NEDD8-activating enzyme (NAE) inhibitor MLN4924 or the proteasome inhibitor carfilzomib to block proteasome function. The results indicated that they drastically diminished the degradation effect of compound <b>17</b>, suggesting that compound <b>17</b>-induced ALK fusion protein degradation is mediated through the E3 ubiquitin ligase component CRBN by activating the CRBN E3 ligase complex and the proteasome system. Meanwhile, pretreatment with pomalidomide or alectinib (<b>3</b>) can also prevent the ALK fusion protein from degrading in both cell lines. This demonstrated that the engagement of ALK and CRBN is required for the observed degradation. Taken together, these results demonstrated that compound <b>17</b>-induced ALK fusion protein degradation is mediated through the E3 ubiquitin ligase component CRBN.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Compound <b>17</b>-induced ALK fusion protein degradation is mediated through the E3 ubiquitin ligase component CRBN. Immunoblots after 4 h of pretreatment with DMSO, carfilzomib (Car), pomalidomide (Pom), MLN4924 (MLN), or alectinib (<b>3</b>) followed by (A) 16 h (H3122 cells) or (B) 24 h (Karpas 299 cells) of treatment with <b>17</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Different Sustained Cellular Degradative Activities Induced by Compound <b>17</b> after Drug Removal in H3122 and Karpas 299 Cells</h3><div class="NLM_p">Next, we performed drug removal experiments in H3122 and Karpas 299 cell lines to test sustained cellular degradative activity induced by compound <b>17</b>. The results in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A show that the EML4-ALK protein levels were reduced to 22.6% after 16 h of treatment with compound <b>17</b> at 100 nM, and EML4-ALK protein degradation started to diminish at 2 h after removal of degrader <b>17</b>. In addition, the expression levels of EML4-ALK and p-ALK were fully recovered in 24 h. In contrast to the fast recovery in H3122 cells, the phosphorylation of ALK was thoroughly inhibited by maintaining the expression of NPM-ALK at a low level after removal of compound <b>17</b> for 72 h in Karpas 299 cells (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B). Karpas 299 cells were selected as a pharmacological evaluation cell line for further study.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Sustained cellular degradative activity induced by compound <b>17</b> upon washout in (A) H3122 and (B) Karpas 299 cells. Cells were treated with compound <b>17</b> at the indicated times and concentrations, washed three times with PBS, and harvested at the indicated time points for western blot analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Pharmacokinetic (PK) Study of Compound <b>17</b></h3><div class="NLM_p">To evaluate the efficacy of compound <b>17</b><i>in vivo</i>, pharmacokinetic studies of <b>17</b> were first conducted by single-dose intravenous (I.V.) and intraperitoneal (I.P.) injections (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Pharmacokinetic data following I.V. administration indicated that the maximum plasma concentration (1.4 μM) was achieved at 0.03 h post dosing. In contrast, the maximum plasma concentration (0.154 μM) was achieved at 0.25 h via I.P. administration. After that, the plasma concentration was maintained at 0.040 μM for 24 h. However, compound <b>17</b> has a high clearance rate in both I.V. and I.P. dosing, which needs to be improved in the future. Interestingly, <i>t</i><sub>1/2</sub> determined by I.P. administration achieved 30.50 ± 12.71 h, which is 73-fold longer than that of I.V. administration. This may be caused by a sustained release process with I.P. administration. Furthermore, we did not observe any side effects in the two kinds of administrations, which indicated that the administration methods and dosage were well tolerated by the treated rats. Taken together, these results suggested that compound <b>17</b> is worthy of further investigation for the pharmacological degradation of ALK <i>in vivo</i>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. PK Profiles of <b>17</b> Following a Single I.V. or I.P. Administration in Rats (<i>n</i> = 3 per Group)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="center" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="2" align="center">administration</th><th class="rowsep1 colsep0" align="center" char="."><i>t</i><sub>1/2</sub> (h)</th><th class="rowsep1 colsep0" align="center" char="."><i>t</i><sub>max</sub> (h)</th><th class="rowsep1 colsep0" align="center" char="."><i>C</i><sub>max</sub> (ng/mL)</th><th class="rowsep1 colsep0" align="center" char=".">AUC<sub>0–<i>t</i></sub> (h·ng/mL)</th><th class="rowsep1 colsep0" align="center" char="."><i>V</i><sub>d</sub> (L/kg)</th><th class="rowsep1 colsep0" align="center" char=".">CL<sub>_F_obs</sub> (mL/h/kg)</th><th class="rowsep1 colsep0" align="center" char=".">MRT<sub>last</sub> (h)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="center">I.V. 1 mg/kg</td><td class="colsep0 rowsep0" align="left">mean</td><td class="colsep0 rowsep0" align="char" char=".">0.42</td><td class="colsep0 rowsep0" align="char" char=".">0.03</td><td class="colsep0 rowsep0" align="char" char=".">994.34</td><td class="colsep0 rowsep0" align="char" char=".">146.43</td><td class="colsep0 rowsep0" align="char" char=".">3.89</td><td class="colsep0 rowsep0" align="char" char=".">8253</td><td class="colsep0 rowsep0" align="char" char=".">0.07</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SD</td><td class="colsep0 rowsep0" align="char" char=".">0.30</td><td class="colsep0 rowsep0" align="char" char=".">0.00</td><td class="colsep0 rowsep0" align="char" char=".">376.32</td><td class="colsep0 rowsep0" align="char" char=".">87.54</td><td class="colsep0 rowsep0" align="char" char=".">0.46</td><td class="colsep0 rowsep0" align="char" char=".">3797</td><td class="colsep0 rowsep0" align="char" char=".">0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="center">I.P. 50 mg/kg</td><td class="colsep0 rowsep0" align="left">mean</td><td class="colsep0 rowsep0" align="char" char=".">30.50</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td><td class="colsep0 rowsep0" align="char" char=".">109.45</td><td class="colsep0 rowsep0" align="char" char=".">546.37</td><td class="colsep0 rowsep0" align="char" char=".">1685.67</td><td class="colsep0 rowsep0" align="char" char=".">44,569</td><td class="colsep0 rowsep0" align="char" char=".">9.93</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SD</td><td class="colsep0 rowsep0" align="char" char=".">12.71</td><td class="colsep0 rowsep0" align="char" char=".">0.00</td><td class="colsep0 rowsep0" align="char" char=".">54.52</td><td class="colsep0 rowsep0" align="char" char=".">172.32</td><td class="colsep0 rowsep0" align="char" char=".">504.73</td><td class="colsep0 rowsep0" align="char" char=".">30,048</td><td class="colsep0 rowsep0" align="char" char=".">1.41</td></tr></tbody></table></div></div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Pharmacodynamic Studies of Compound <b>17</b></h3><div class="NLM_p">Before the performance of <i>in vivo</i> antitumor evaluation of ALK degraders, it is necessary to conduct pharmacodynamic studies to clarify the antitumor mechanism of compound <b>17</b><i>in vivo</i>. Mice bearing Karpas 299 xenograft tumors were intravenously administered a single dose of compound <b>17</b> at 10 mg/kg. Mice were sacrificed at 0, 12, and 24 h after administration of compound <b>17</b>, and tumor samples were collected and probed for ALK expression levels. The western blotting data showed that a single dose of compound <b>17</b> at 10 mg/kg was very effective in reducing the expression levels of ALK by >85% compared to the control at the 12 h time point and was maintained at a low level (18.7%) until 24 h (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). These results indicated that a single dose of compound <b>17</b> is highly effective in inducing nearly complete elimination of the ALK protein in tumor tissue of mice, with the effect persisting for >24 h.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Pharmacodynamic study of compound <b>17</b> in Karpas 299 xenograft tumors in NCG (NOD/ShiltJGpt-Prkdcem26Cd52Il2rgem26Cd22/Gpt) mice. NCG mice bearing Karpas 299 xenograft tumors were treated with 10 mg/kg compound <b>17</b> (I.V.). Tumor lysates were analyzed by immunoblotting.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> <i>In Vivo</i> Antitumor Activity of Compound <b>17</b> in the Karpas 299 Xenograft Mouse Model</h3><div class="NLM_p">Compound <b>17</b> significantly inhibited the proliferation of Karpas 299 cells and exhibited favorable pharmacodynamic properties with sustained cellular degradative activity <i>in vivo</i> (see <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). We further evaluated compound <b>17</b> for its efficacy in the Karpas 299 xenograft mouse model. Once the tumors reached approximately 90 mm<sup>3</sup>, the mice were randomly assigned into six treatment groups: the vehicle control group (I.V., DMSO), positive control group (P.O., alectinib, 20 mg/kg), and <b>17</b>-treated groups (I.V., 5 and 10 mg/kg; I.P., 25 and 50 mg/kg). The mice were treated once every 24 h for 3 weeks at the indicated doses and routes of administration before euthanasia 12 h following the final dose. The tumor volume and weight were significantly reduced in the positive control group and all <b>17</b>-treated groups compared with the vehicle group (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>A,C). In addition, the tumor volumes of the <b>17</b>-treated group (I.V., 10 mg/kg) were significantly reduced with a tumor growth inhibition rate of 75.82%, which was smaller (<i>P</i> = 0.0017) than those in the positive control group (63.82%, P.O., alectinib, 20 mg/kg), (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>C,D). Moreover, none of the treatment groups showed significant body weight loss or other signs of toxicity (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>B,E). After sacrifice, two tumor samples from six treatment groups were randomly collected and probed for ALK expression levels. As expected, all <b>17</b>-treated groups were capable of inducing the degradation of the ALK protein, but no significant changes in the vehicle control group and positive control group were observed (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>F). It should be noted that compound <b>17</b> has a high clearance in both I.V. and I.P. dosing (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>); if the degradation happens in the linker region, then the pharmacological effects might be due to the inhibition of the parent compound as well as degradation. Above all, compound <b>17</b> showed potent efficacy, with a tumor inhibition rate of 75.82%, which was superior to that of alectinib (63.82%) by oral dosing of 20 mg/kg. This <i>in vivo</i> result clearly established the value of ALK degraders.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. <i>In vivo</i> antitumor activity of compound <b>17</b> in a Karpas 299 xenograft mouse model. Tumor volume and changes in body weight were measured for each group. (A) Tumor growth; (B) body weight changes of the mice during treatment; (C) weight of the excised tumors of each group (**<i>P</i> < 0.01; ***<i>P</i> < 0.001; ****<i>P</i> < 0.0001); (D) images of Karpas 299 tumors from the mice at 21 days after initiation of treatment. (E) H&E staining of the heart, liver, spleen, lung, and kidney of the mice. No abnormality of these organs was observed. (F) Immunoblotting of Karpas 299 xenograft tissue after 21 days of treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Compound <b>17</b> Inhibited the Growth of Ba/F3 Cells Expressing EML4-ALK and TEL-ALK with Secondary Mutations</h3><div class="NLM_p">Some ALK-positive tumors treated with crizotinib (<b>1</b>) developed resistance-associated ALK mutants, including L1196M, G1202R, L1152R, C1156Y, F1174L, and S1206Y, which have been identified in the clinic.<a onclick="showRef(event, 'ref20 ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref20 ref54 ref55">(20,54,55)</a> There are high expectations that the PROTAC technique can combat drug resistance. In this work, we used Ba/F3 cells expressing EML4-ALK or TEL-ALK with secondary mutations (L1152R, G1202R, and L1196M) to evaluate the ability of ALK inhibitors (<b>3</b>, <b>36</b>, and <b>37</b>) and ALK degraders (<b>15</b>, <b>17</b>, and <b>23</b>) to overcome drug resistance. The data showed that ALK degraders <b>15</b>, <b>17</b>, and <b>23</b> extended moderate inhibitory activity against Ba/F3 cells expressing EML4-ALK<sup>L1152R</sup> and TEL-ALK<sup>L1196M</sup>, which was comparable to that of their parental ALK inhibitors <b>3</b>, <b>36</b>, and <b>37</b> at 1 μM (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.1c00270/suppl_file/jm1c00270_si_001.pdf" class="ext-link">Figure S6</a>). Interestingly, neither alectinib (<b>3</b>) nor ALK degraders (<b>15</b>, <b>17</b>, and <b>23</b>) exhibited potent antiproliferative activity against Ba/F3 cells expressing the TEL-ALK<sup>G1202R</sup> mutant at a concentration of 1 μM, while their precursors (<b>36</b> and <b>37</b>) effectively inhibited the growth of TEL-ALK<sup>G1202R</sup> Ba/F3 cells with percent viability values of 0.5 and 0.3%, respectively. These results implied that the potency of ALK degraders against resistant mutations might be improved via structural modification of the warhead of PROTACs and by hunting for suitable linking positions.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Single-Point Inhibition Assay (1 μM) of ALK Inhibitors (<b>3</b>, <b>36</b>, and <b>37</b>) and ALK Degraders (<b>15</b>, <b>17</b>, and <b>23</b>) against EML4-ALK<sup>WT</sup>, EML4-ALK<sup>L1152R</sup>, TEL-ALK<sup>G1202R</sup>, TEL-ALK<sup>L1196M</sup>, and Untransduced Ba/F3 Cells<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" colspan="5" align="center">% viability at 1 μM</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">comp.</th><th class="colsep0 rowsep0" align="center">untransduced Ba/F3</th><th class="colsep0 rowsep0" align="center" char=".">EML4-ALK wt</th><th class="colsep0 rowsep0" align="center" char=".">EML4-ALK L1152R</th><th class="colsep0 rowsep0" align="center" char=".">TEL-ALK G1202R</th><th class="colsep0 rowsep0" align="center" char=".">TEL-ALK L1196M</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">alectinib</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">73.3</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="left">74.0</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="left">nt<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">0.3</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">116</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">77.6</td><td class="colsep0 rowsep0" align="char" char=".">6.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">nt</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">76.1</td><td class="colsep0 rowsep0" align="char" char=".">4.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">nt</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">70.9</td><td class="colsep0 rowsep0" align="char" char=".">3.6</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">EML4-ALK<sup>WT</sup>, EML4-ALK<sup>L1152R</sup>, TEL-ALK<sup>G1202R</sup>, TEL-ALK<sup>L1196M</sup>, and untransduced Ba/F3 cells were treated with a single dose (1 μM) of ALK inhibitors (<b>3</b>, <b>36</b>, and <b>37</b>) and ALK degraders (<b>15</b>, <b>17</b>, and <b>23</b>). The percent viability of the untreated control for each compound was determined by CellTiter-Glo (CTG) assay after 72 h.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Not tested.</p></div></div></div></div><div id="sec2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Selective Inhibition and Degradation of ALK by Degrader <b>17</b></h3><div class="NLM_p">ALK has been identified to be scantly expressed in normal adult tissue, which makes it possible to become an attractive target with high efficiency and low toxicity.<a onclick="showRef(event, 'ref11 ref56'); return false;" href="javascript:void(0);" class="ref ref11 ref56">(11,56)</a> Thus, we performed an antiproliferative assay of alectinib, <b>36</b>, and <b>17</b> in HFL-1 and A549 cells, both of which are ALK fusion-negative cells, to evaluate the safety of the ALK degrader (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>A,B and <a href="/doi/suppl/10.1021/acs.jmedchem.1c00270/suppl_file/jm1c00270_si_001.pdf" class="ext-link">Figure S2</a>).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The data showed that in ALK fusion-negative cells, the degraders had low antiproliferative activity as alectinib and the parental inhibitor <b>36</b>. Although alectinib is known as a high kinase selectivity ALK inhibitor, it can potently inhibit leukocyte tyrosine kinase (LTK), which shows the greatest sequence similarity to ALK, with >50% inhibition at 10 nM as profiled among 402 kinases.<a onclick="showRef(event, 'ref12 ref34'); return false;" href="javascript:void(0);" class="ref ref12 ref34">(12,34)</a> Thus, we mediated the degradation of ALK and LTK by treating Karpas 299 cells with compound <b>17</b> and alectinib to assess the kinase selectivity of ALK degrader <b>17</b>. The results showed that degrader <b>17</b> can thoroughly degrade NPM-ALK after 24 h of treatment at 1 μM, while it did not significantly reduce the expression levels of LTK in Karpas 299 cells (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>C and <a href="/doi/suppl/10.1021/acs.jmedchem.1c00270/suppl_file/jm1c00270_si_001.pdf" class="ext-link">Figure S2</a>). This result suggests that degrader <b>17</b> has a higher selectivity than alectinib. In addition, we checked the expression levels of a few common CRBN neo-substrates (GSPT1 and IKZF1/3) by treating Karpas 299 cells with serial dilutions of compound <b>17</b>, alectinib (compound <b>3</b>, 1 μM), and pomalidomide (Pom, 1 μM) to assess the degradation selectivity of ALK degrader <b>17</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00270/suppl_file/jm1c00270_si_001.pdf" class="ext-link">Figure S7A</a>).<a onclick="showRef(event, 'ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref57 ref58">(57,58)</a> The results showed that IKZF1/3 could be thoroughly degraded by pomalidomide (1 μM) at 24 h in Karpas 299 cells, while IKZF1/3 was only degraded by 34 and 48% when treated with compound <b>17</b> at the same dose and time. All the tested compounds showed no significant influence on the protein level of GSPT1. We then evaluated the antiproliferative activity of pomalidomide in Karpas 299 cells to exclude the influence of down-regulation of CRBN neo-substrates on the antiproliferation activity of compound <b>17</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00270/suppl_file/jm1c00270_si_001.pdf" class="ext-link">Figure S7B</a>). The results showed that pomalidomide exhibited weak activities in inhibiting cell proliferation of Karpas 299 cells with an IC<sub>50</sub> value of above 10 μM, although it was a powerful IKZF1/3 degrader. This result indicated that the antiproliferative activity of compound <b>17</b> is not due to the down-regulation of CRBN neo-substrates. Furthermore, the proteomic iTRAQ (isobaric tags for relative and absolute quantitation) was performed to evaluate the proteome selectivity of degrader <b>17</b>. Karpas 299 cells were treated with DMSO or 1 μM degrader <b>17</b> for 24 h. As shown in <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>D, out of 6766 proteins quantified in Karpas 299 cells, ALK and other three unrelated proteins, Transcription factor jun-B (JUNB), Sestrin-2 (SESN2), and Suppressor of cytokine signaling 3 (SOCS3), were the only proteins whose levels were significantly decreased by degrader <b>17</b> compared with DMSO (<i>P</i> < 0.001 and log<sub>2</sub>FC > 1).</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Selective inhibition and degradation of ALK by degrader <b>17</b>. Antiproliferative activity of alectinib, <b>36</b>, and <b>17</b> in (A) HFL-1 and (B) A549 cells. (C) Karpas 299 cells were treated with serial dilutions of compound <b>17</b> or alectinib for the indicated length of time. (D) Volcano plot showing changes in protein abundance. Karpas 299 cells were treated with DMSO or 1 μM degrader <b>17</b> for 24 h. The proteins were analyzed by the proteomic iTRAQ. The <i>x</i> axis displays the relative abundance of all identified proteins (6766) in DMSO-treated versus compound <b>17</b>-treated cells (log<sub>2</sub>FC). The <i>y</i> axis displays the <i>P</i> value (−log<sub>10</sub>) from triplicate experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66116" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66116" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, intermediate <b>35</b> was synthesized by following patent US 20120083488 A1.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Briefly, 2-bromo-2-methylpropanoic acid (<b>26</b>) was acylated with thionyl dichloride to produce compound <b>27</b> followed by treatment with ethylbenzene and Lewis acid to produce compound <b>28</b>. The ester bond in <b>29</b> was built from α-bromoketones in <b>28</b> via quasi-Favorskii rearrangement. Then, compound <b>30</b> was obtained by iodination of compound <b>29</b> with NIS in the presence of H<sub>2</sub>SO<sub>4</sub>/CH<sub>3</sub>COOH, followed by ester hydrolysis to produce compound <b>31</b> (the crystal structure of <b>31</b> is shown in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00270/suppl_file/jm1c00270_si_001.pdf" class="ext-link">Figure S8</a> to establish the position of iodine). Then, ketoester <b>32</b> was built from the carboxylic acid of compound <b>31</b> with malonate half-ester to obtain a 2-carbon chain extension, followed by treatment with 4-chloro-3-nitrobenzonitrile to produce compound <b>33</b>. Next, indole <b>34</b> was synthesized by nitro reduction and ring closure. Last, ester hydrolysis and the intramolecular Friedel–Crafts reaction of compound <b>34</b> mediated by the Eaton reagent closes the final ring of the tetracycle to produce intermediate <b>35</b>. Compounds with an alkyl heterocyclic ring substituent were prepared by subjecting <b>35</b> to Buchwald–Hartwig coupling conditions using the desired Boc-protected amines, which were followed by BOC deprotection to produce <b>36</b> and <b>37</b>, respectively. Alkylation of the piperidinyl nitrogen of <b>36</b> and <b>37</b> with bromoacetate, followed by <i>t</i>-butyl ester deprotection, provided another two intermediates <b>40</b> and <b>41</b>.</div><figure id="sch1" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0014.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>36</b>, <b>37</b>, <b>40</b>, and <b>41</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reaction conditions: (a) thionyl chloride (SOCl<sub>2</sub>), room temperature (rt) to 80 °C, 92.1%; (b) ethylbenzene, AlCl<sub>3</sub>, carbon tetrachloride (CCl<sub>4</sub>), −20 °C, 65.7%; (c) trimethyl orthoformate, ZnBr<sub>2</sub>, 100 °C, 96.3%; (d) <i>N</i>-iodosuccinimide (NIS), H<sub>2</sub>SO<sub>4</sub>, CH<sub>3</sub>COOH, 0 °C to rt, 84.2%; (e) NaOH, H<sub>2</sub>O:methanol (MeOH) = 1:5, 100 °C, 62.9%; (f) <i>N</i>,<i>N</i>′-carbonyldiimidazole (CDI), triethylamine (Et<sub>3</sub>N), MgCl<sub>2</sub>, MeCN, 80 °C, 84.7%; (g) 4-chloro-3-nitrobenzonitrile, Cs<sub>2</sub>CO<sub>3</sub>, dimethyl sulfoxide (DMSO), rt, 56.9%; (h) Na<sub>2</sub>S<sub>2</sub>O<sub>4</sub>, tetrahydrofuran (THF):MeOH:H<sub>2</sub>O = 2:2:1, 100 °C, 50.2%; (i) Eaton reagent, rt, 47.4%; (j) heterocyclic compounds, 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl (S-phos), tris(dibenzylideneacetone)dipalladium (Pd<sub>2</sub>(dba)<sub>3</sub>), sodium bis(trimethylsilyl)amide (NaHMDS), 1,4-dioxane, 80 °C, 47.8%; (k) trifluoroacetic acid (TFA), dichloromethane (DCM), rt, 66.7–73.3%; (l) <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA), DMSO, 90 °C, 76.7–91.1%.</p></p></figure><div class="NLM_p">Linker-attached pomalidomide analogs (<b>47–49</b> and <b>52–55</b>) were synthesized by following literature procedures (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).<a onclick="showRef(event, 'ref46 ref60'); return false;" href="javascript:void(0);" class="ref ref46 ref60">(46,60)</a> The amide coupling reaction between intermediates (<b>40</b> and <b>41</b>) and compounds (<b>47</b>–<b>49</b>) provides the desired targeted compounds (<b>14</b>–<b>16</b> and <b>22–24</b>) (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). ALK degraders <b>17–20</b> and <b>25</b> could be synthesized using a similar method (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). The synthesis of compounds <b>13</b> and <b>21</b> is outlined in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>. Halogenating the reaction of <b>36</b> and <b>37</b> with <b>42</b> in the presence of DIPEA generated the desired compounds <b>13</b> and <b>21</b>.</div><figure id="sch2" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0015.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>47</b>–<b>49</b> and <b>52</b>–<b>55</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reaction conditions: (a) DIPEA, DMSO, 90 °C, 73.2–80.4%; (b) TFA, DCM, rt., 54.7–69.8%.</p></p></figure><figure id="sch3" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0016.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>14</b>–<b>16</b> and <b>22</b>–<b>24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reaction conditions: (a) 2-(7-azabenzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium hexafluorophosphate (HATU), DIPEA, DMF, rt, 69.8–91.1%.</p></p></figure><figure id="sch4" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0017.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>17–20</b> and <b>25</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reaction conditions: (a) HATU, DIPEA, DMF, rt, 71.3–86.5%.</p></p></figure><figure id="sch5" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0018.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compound <b>13</b> and <b>21</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reaction conditions: (a) DIPEA, DMSO, 90 °C, 69.2–73.3%.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84230" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84230" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In this study, a series of alectinib-based PROTACs were designed and synthesized by linking two alectinib precursors (<b>36</b> and <b>37</b>) with pomalidomide through linkers of different lengths and types as a novel class of ALK degraders. The biological activity screen showed that the most promising compound <b>17</b> possessed potent <i>in vitro</i> ALK binding affinities, effectively induced ALK fusion protein degradation, and antiproliferative activity in two major ALK-positive cell lines while exhibiting comparatively weak cytotoxic activity in the low ALK-expressing cell lines A549 and HFL-1. The degradation mechanism study revealed that compound <b>17</b> mediated the degradation of the ALK fusion protein via the E3 ubiquitin ligase component CRBN. Compound <b>17</b> also had favorable pharmacodynamic properties and sustained cellular degradative activity <i>in vivo</i>. Moreover, compound <b>17</b> showed the potent and efficacious inhibition of tumor growth with an inhibition rate of 75.82% via intravenous injection (10 mg/kg/day) without any body weight loss, which was superior to that of alectinib (63.82%, P.O., 20 mg/kg/day) in a Karpas 299 xenograft mouse model. In addition, compound <b>17</b> had the ability to overcome some ALK inhibitor-resistant mutants in Ba/F3 cells (L1152R, G1202R, and L1196M) equivalent to the effect of alectinib and the alectinib precursor (<b>36</b>). Above all, these results demonstrated that alectinib-based PROTACs have opened a new avenue for ALK-targeted therapies, and further optimization is underway in our laboratory to make alectinib a more promising ALK degrader for advanced preclinical development.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48333" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48333" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> General Methods</h3><div class="NLM_p last">All commercially available reagents were used without further purification. Solvents were dried through routine protocols. Flash column chromatography was carried out on 200–300 mesh silica gel (Qingdao Haiyang Chemical, China). Reactions were monitored by thin-layer chromatography (TLC) on 0.25 mm silica gel plates (GF254) and visualized under UV light. The <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded with a Bruker Advance 400 or 300 MHz spectrometer (Bruker Company, Germany) in the indicated solvents (CDCl<sub>3</sub>, DMSO-<i>d</i><sub>6</sub>, or C<sub>5</sub>D<sub>5</sub>N; TMS as an internal standard): the values of the chemical shifts are expressed in δ values (ppm) and the coupling constants (<i>J</i>) in Hz. The low- and high-resolution mass spectra (LRMS and HRMS) were measured on a Finnigan MAT 95 spectrometer (Finnigan, Germany). The purity of all tested compounds was ≥95%, as estimated by HPLC (SHIMADZU Labsolutions, UV detection at λ = 254 nm) analysis on the Agilent C18 column (4.6 × 150 mm, 5 μm) eluting at 1 mL/min of menthol and water (80:20).</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Chemistry Methods</h3><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 8-(4-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperazin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>13</b>)</h4><div class="NLM_p last">To a solution of <b>36</b> (40 mg, 0.10 mmol) in DMSO were added compound <b>42</b> (33 mg, 0.12 mmol) and DIPEA (66 μL, 0.40 mmol), and then the mixture was heated at 90 °C for 2 h until the completion of the reaction. The mixture was diluted with EtOAc (15 mL) and extracted with ethyl acetate (3 × 15 mL), dried, filtered, and concentrated. The residue was purified by a chromatograph (DCM/MeOH, 20:1, v/v) to afford compound <b>13</b> (45 mg, 69.2% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.73 (s, 1H), 11.14 (s, 1H), 8.33 (d, <i>J</i> = 8.1 Hz, 1H), 8.09 (s, 1H), 8.00 (s, 1H), 7.74 (t, <i>J</i> = 7.8 Hz, 1H), 7.61 (dd, <i>J</i> = 1.4, 8.0 Hz, 1H), 7.46 (s, 1H), 7.41 (dd, <i>J</i> = 4.8, 7.9 Hz, 2H), 5.14 (dd, <i>J</i> = 5.5, 12.8 Hz, 1H), 3.52–3.45 (m, 4H), 3.18 (t, <i>J</i> = 4.8 Hz, 4H), 2.96–2.86 (m, 1H), 2.78 (q, <i>J</i> = 7.5 Hz, 2H), 2.66–2.60 (m, 1H), 2.51 (q, <i>J</i> = 1.9 Hz, 1H), 2.12–2.02 (m, 1H), 1.78 (s, 6H), 1.30 (t, <i>J</i> = 7.4 Hz, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.6, 173.3, 170.5, 166.9, 160.6, 155.3, 150.2, 136.9, 136.5, 136.1, 128.2, 126.9, 126.4, 125.2, 124.4, 122.1, 117.3, 116.8, 109.8, 105.0, 52.1, 51.5, 49.3, 37.0, 30.5, 30.5, 23.1, 14.8; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>38</sub>H<sub>35</sub>N<sub>6</sub>O<sub>5</sub> [M + H]<sup>+</sup>, 655.2663; found, 655.2667.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 2-(4-(3-Cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazol-8-yl)piperazin-1-yl)-<i>N</i>-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)acetamide (<b>14</b>)</h4><div class="NLM_p last">To a solution of compound <b>40</b> (40 mg, 0.088 mmol) in dry DMF were added compound <b>47</b> (42 mg, 0.13 mmol), DIPEA (43 μL, 0.26 mmol), and HATU (50 mg, 0.13 mmol). Also, the mixture was then stirred at room temperature for 2 h until the completion of the reaction. The mixture was diluted with EtOAc (15 mL) and extracted with ethyl acetate (3 × 15 mL), dried, filtered, and concentrated. The residue was purified by a chromatograph (DCM/MeOH, 25:1, v/v) to afford the intermediate <b>14</b> (225 mg, 91.1% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.73 (s, 1H), 11.11 (s, 1H), 8.33 (d, <i>J</i> = 8.2 Hz, 1H), 8.06 (s, 1H), 8.04–7.97 (m, 1H), 7.85 (t, <i>J</i> = 6.0 Hz, 1H), 7.61 (dd, <i>J</i> = 1.4, 8.1 Hz, 1H), 7.59–7.55 (m, 1H), 7.34 (s, 1H), 7.11 (d, <i>J</i> = 8.6 Hz, 1H), 7.01 (d, <i>J</i> = 7.0 Hz, 1H), 6.58 (t, <i>J</i> = 6.0 Hz, 1H), 5.05 (dd, <i>J</i> = 5.4, 12.9 Hz, 1H), 3.32 (t, <i>J</i> = 6.4 Hz, 2H), 3.18 (q, <i>J</i> = 6.4 Hz, 2H), 3.01 (d, <i>J</i> = 4.7 Hz, 4H), 2.92–2.83 (m, 1H), 2.75–2.58 (m, 6H), 2.57–2.53 (m, 1H), 2.06–1.96 (m, 1H), 1.76 (s, 6H), 1.56 (td, <i>J</i> = 4.0, 8.9 Hz, 4H), 1.27 (t, <i>J</i> = 7.5 Hz, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.6, 173.3, 170.6, 169.5, 169.4, 167.8, 160.5, 155.5, 147.2, 146.9, 136.7, 136.7, 136.1, 132.7, 128.2, 126.7, 126.4, 125.3, 122.1, 120.6, 117.7, 116.9, 116.8, 110.9, 109.9, 109.5, 105.0, 61.7, 55.4, 53.7, 52.0, 49.0, 42.0, 38.4, 36.9, 31.4, 30.5, 27.2, 26.7, 23.1, 22.6, 14.8; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>42</sub>H<sub>43</sub>N<sub>8</sub>O<sub>6</sub> [M + H]<sup>+</sup>, 755.3300; found, 755.3309.</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 2-(4-(3-Cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazol-8-yl)piperazin-1-yl)-<i>N</i>-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butyl)acetamide (<b>15</b>)</h4><div class="NLM_p last">Compound <b>15</b> was synthesized from compound <b>40</b> and compound <b>48</b> by following the general procedure for preparing compound <b>14</b>. Yellow solid (72.4% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.73 (s, 1H), 11.11 (s, 1H), 8.33 (d, <i>J</i> = 8.2 Hz, 1H), 8.05 (s, 1H), 8.03–7.98 (m, 1H), 7.85 (t, <i>J</i> = 6.0 Hz, 1H), 7.61 (dd, <i>J</i> = 1.4, 8.2 Hz, 1H), 7.57 (dd, <i>J</i> = 7.0, 8.5 Hz, 1H), 7.34 (s, 1H), 7.11 (d, <i>J</i> = 8.6 Hz, 1H), 7.01 (d, <i>J</i> = 7.0 Hz, 1H), 6.58 (t, <i>J</i> = 6.0 Hz, 1H), 5.05 (dd, <i>J</i> = 5.5, 13.0 Hz, 1H), 3.33 (q, <i>J</i> = 6.5 Hz, 2H), 3.17 (q, <i>J</i> = 6.4 Hz, 2H), 3.02 (d, <i>J</i> = 5.2 Hz, 6H), 2.92–2.82 (m, 1H), 2.73–2.58 (m, 6H), 2.54 (d, <i>J</i> = 7.8 Hz, 1H), 2.52–2.50 (m, 1H), 2.05–1.99 (m, 1H), 1.76 (s, 6H), 1.64–1.45 (m, 4H), 1.26 (t, <i>J</i> = 7.5 Hz, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.6, 173.3, 170.6, 169.6, 169.4, 167.8, 160.5, 155.5, 147.2, 146.9, 136.7, 136.7, 136.1, 132.7, 128.2, 126.7, 126.4, 125.2, 122.1, 120.6, 117.7, 116.8, 110.9, 109.9, 109.5, 105.0, 61.7, 60.2, 53.7, 52.0, 49.0, 42.0, 38.4, 36.9, 31.4, 30.5, 27.2, 26.7, 23.1, 22.6, 14.8, 14.6; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>44</sub>H<sub>47</sub>N<sub>8</sub>O<sub>6</sub> [M + H]<sup>+</sup>, 783.3613; found, 783.3616.</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 2-(4-(3-Cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazol-8-yl)piperazin-1-yl)-<i>N</i>-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexyl)acetamide (<b>16</b>)</h4><div class="NLM_p last">Compound <b>16</b> was synthesized from compound <b>40</b> and compound <b>49</b> by following the general procedure for preparing compound <b>14</b>. Yellow solid (69.8% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.72 (s, 1H), 11.12 (s, 1H), 8.33 (d, <i>J</i> = 8.1 Hz, 1H), 8.05 (s, 1H), 8.01 (d, <i>J</i> = 1.3 Hz, 1H), 7.78 (t, <i>J</i> = 5.9 Hz, 1H), 7.60 (dd, <i>J</i> = 1.6, 8.1 Hz, 1H), 7.55 (ddd, <i>J</i> = 2.0, 7.1, 8.6 Hz, 1H), 7.35 (s, 1H), 7.11–7.04 (m, 1H), 7.00 (d, <i>J</i> = 7.1 Hz, 1H), 6.57–6.49 (m, 1H), 5.06 (ddd, <i>J</i> = 1.6, 5.5, 12.9 Hz, 1H), 3.28 (q, <i>J</i> = 6.9 Hz, 2H), 3.12 (q, <i>J</i> = 6.7 Hz, 2H), 3.02 (d, <i>J</i> = 6.6 Hz, 6H), 2.88 (ddd, <i>J</i> = 4.6, 10.0, 18.6 Hz, 1H), 2.66 (ddt, <i>J</i> = 5.2, 11.4, 20.1 Hz, 6H), 2.56 (d, <i>J</i> = 8.0 Hz, 1H), 2.52–2.50 (m, 1H), 2.03 (ddt, <i>J</i> = 4.1, 8.1, 13.2 Hz, 1H), 1.75 (s, 6H), 1.58 (t, <i>J</i> = 7.1 Hz, 2H), 1.46 (p, <i>J</i> = 7.1 Hz, 2H), 1.39–1.30 (m, 4H), 1.26 (t, <i>J</i> = 7.5 Hz, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.6, 173.3, 170.6, 169.4, 167.8, 160.5, 155.5, 147.2, 146.9, 136.7, 136.7, 136.1, 132.7, 128.2, 126.7, 126.4, 125.2, 122.1, 120.6, 117.6, 116.8, 110.8, 109.9, 109.5, 105.0, 61.7, 55.4, 53.7, 52.1, 49.0, 42.3, 38.7, 36.9, 31.5, 30.5, 29.7, 29.1, 26.6, 26.5, 23.1, 22.6, 14.8; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>46</sub>H<sub>51</sub>N<sub>8</sub>O<sub>6</sub> [M + H]<sup>+</sup>, 811.3926; found, 811.3927.</div></div><div id="sec5_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 8-(4-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)glycyl)piperazin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>17</b>)</h4><div class="NLM_p last">Compound <b>17</b> was synthesized by compound <b>36</b> and compound <b>52</b> from following the general procedure for preparing compound <b>14</b>. Yellow solid (73.4% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.75 (s, 1H), 11.13 (s, 1H), 8.33 (d, <i>J</i> = 8.1 Hz, 1H), 8.09 (s, 1H), 8.01 (s, 1H), 7.69–7.57 (m, 2H), 7.43 (s, 1H), 7.21–7.04 (m, 3H), 5.10 (dd, <i>J</i> = 5.4, 12.9 Hz, 1H), 4.29 (d, <i>J</i> = 4.5 Hz, 2H), 3.73 (d, <i>J</i> = 13.0 Hz, 4H), 3.62 (s, 1H), 3.04 (d, <i>J</i> = 18.1 Hz, 4H), 2.91 (ddd, <i>J</i> = 5.3, 13.9, 18.4 Hz, 1H), 2.79 (q, <i>J</i> = 7.5 Hz, 2H), 2.64–2.58 (m, 1H), 2.06 (d, <i>J</i> = 12.3 Hz, 1H), 1.76 (s, 6H), 1.30 (t, <i>J</i> = 7.4 Hz, 3H); <sup>13</sup>C NMR (101 MHz, C<sub>5</sub>D<sub>5</sub>N-<i>d</i><sub>5</sub>) δ 180.0, 173.0, 170.7, 168.2, 166.5, 160.2, 154.9, 147.1, 145.7, 137.5, 136.8, 133.1, 128.7, 128.2, 127.4, 122.7, 120.5, 117.6, 117.0, 116.4, 111.3, 111.1, 110.9, 105.8, 52.3, 51.8, 49.7, 44.6, 44.3, 42.5, 40.8, 36.9, 31.9, 30.5, 23.3, 23.1, 14.5; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>40</sub>H<sub>38</sub>N<sub>7</sub>O<sub>6</sub> [M + H]<sup>+</sup>, 712.2878; found, 712.2888.</div></div><div id="sec5_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 8-(4-(4-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butanoyl)piperazin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>18</b>)</h4><div class="NLM_p last">Compound <b>18</b> was synthesized from compound <b>36</b> and compound <b>53</b> by following the general procedure for preparing compound <b>14</b>. Yellow solid (71.3% yield): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.73 (s, 1H), 11.12 (s, 1H), 8.33 (d, <i>J</i> = 8.2 Hz, 1H), 8.07 (s, 1H), 8.01 (s, 1H), 7.67–7.56 (m, 2H), 7.38 (s, 1H), 7.21 (d, <i>J</i> = 8.6 Hz, 1H), 7.04 (d, <i>J</i> = 7.0 Hz, 1H), 6.71 (t, <i>J</i> = 6.1 Hz, 1H), 5.07 (dd, <i>J</i> = 5.4, 12.9 Hz, 1H), 3.65 (d, <i>J</i> = 16.9 Hz, 4H), 2.95 (m, 4H), 2.87 (t, <i>J</i> = 7.9 Hz, 1H), 2.75 (q, <i>J</i> = 7.5 Hz, 2H), 2.62 (t, <i>J</i> = 3.3 Hz, 1H), 2.59–2.55 (m, 1H), 2.52 (q, <i>J</i> = 1.8 Hz, 2H), 2.48 (t, <i>J</i> = 7.5 Hz, 2H), 2.05 (dt, <i>J</i> = 4.8, 12.8 Hz, 1H), 1.86 (t, <i>J</i> = 7.1 Hz, 2H), 1.76 (s, 6H), 1.29 (t, <i>J</i> = 7.5 Hz, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.6, 173.3, 170.8, 170.6, 169.3, 167.8, 160.6, 155.2, 147.3, 146.9, 137.0, 136.7, 136.1, 132.7, 128.2, 127.1, 126.4, 125.3, 122.1, 120.6, 117.8, 117.6, 116.9, 110.9, 109.8, 109.6, 105.1, 52.6, 52.2, 49.0, 45.8, 42.1, 42.0, 36.9, 31.5, 30.5, 30.0, 24.8, 23.1, 22.7, 14.8; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>40</sub>H<sub>38</sub>N<sub>7</sub>O<sub>6</sub> [M + H]<sup>+</sup>, 740.3191; found, 740.3203.</div></div><div id="sec5_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 8-(4-(6-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexanoyl)piperazin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>19</b>)</h4><div class="NLM_p last">Compound <b>19</b> was synthesized from compound <b>36</b> and compound <b>54</b> by following the general procedure for preparing compound <b>14</b>. Yellow solid (86.5% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.86 (s, 1H), 11.20 (s, 1H), 8.41 (d, <i>J</i> = 8.6 Hz, 1H), 8.15 (s, 1H), 8.09 (s, 1H), 7.73–7.64 (m, 2H), 7.48 (s, 1H), 7.19 (d, <i>J</i> = 8.6 Hz, 1H), 7.11 (d, <i>J</i> = 6.9 Hz, 1H), 6.64 (t, <i>J</i> = 5.9 Hz, 1H), 5.14 (dd, <i>J</i> = 5.4, 12.9 Hz, 1H), 3.72 (s, 4H), 3.43–3.37 (m, 2H), 3.09–2.99 (m, 4H), 2.99–2.91 (m, 1H), 2.83 (q, <i>J</i> = 7.5 Hz, 2H), 2.60–2.58 (m, 2H), 2.47 (t, <i>J</i> = 7.4 Hz, 2H), 2.12 (ddd, <i>J</i> = 4.3, 8.3, 9.8 Hz, 1H), 1.84 (s, 6H), 1.69 (dp, <i>J</i> = 7.3, 14.7 Hz, 4H), 1.53–1.45 (m, 2H), 1.37 (t, <i>J</i> = 7.5 Hz, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.6, 173.3, 171.1, 170.6, 169.4, 167.8, 160.6, 155.2, 147.3, 146.9, 137.0, 136.8, 136.1, 132.7, 128.2, 127.1, 126.4, 125.3, 122.1, 120.6, 117.7, 117.6, 116.9, 110.9, 109.8, 109.5, 105.0, 55.4, 52.7, 52.2, 49.0, 45.9, 42.3, 41.9, 40.9, 37.0, 32.7, 31.5, 30.5, 29.1, 26.6, 25.1, 23.1, 22.6, 14.8; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>44</sub>H<sub>46</sub>N<sub>7</sub>O<sub>6</sub> [M + H]<sup>+</sup>, 768.3504; found, 768.3515.</div></div><div id="sec5_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 9-Ethyl-6,6-dimethyl-8-(4-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)glycyl)piperazin-1-yl)-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>20</b>)</h4><div class="NLM_p last">Compound <b>20</b> was synthesized from compound <b>36</b> and compound <b>55</b> by following the general procedure for preparing compound <b>14</b>. Yellow solid (83.2% yield). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.73 (s, 1H), 8.33 (d, <i>J</i> = 8.1 Hz, 1H), 8.09 (s, 1H), 8.01 (s, 1H), 7.69–7.56 (m, 2H), 7.43 (s, 1H), 7.15 (d, <i>J</i> = 7.9 Hz, 2H), 7.09 (d, <i>J</i> = 7.0 Hz, 1H), 5.17 (dd, <i>J</i> = 5.4, 12.9 Hz, 1H), 4.28 (s, 2H), 3.72 (s, 4H), 3.06–3.02 (m, 8H), 2.78 (q, <i>J</i> = 6.6 Hz, 3H), 2.59 (dt, <i>J</i> = 6.8, 13.7 Hz, 1H), 2.08 (d, <i>J</i> = 12.6 Hz, 1H), 1.76 (s, 6H), 1.30 (t, <i>J</i> = 7.4 Hz, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.6, 172.3, 170.3, 169.3, 167.81, 167.0, 160.5, 155.1, 147.3, 145.9, 137.1, 136.7, 136.1, 132.5, 128.1, 127.2, 126.4, 125.3, 122.1, 120.6, 118.7, 117.7, 116.9, 111.4, 110.0, 109.8, 105.1, 52.4, 52.0, 49.6, 44.8, 44.2, 42.6, 36.9, 31.6, 30.5, 27.1, 23.1, 21.9, 14.8; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>41</sub>H<sub>40</sub>N<sub>7</sub>O<sub>6</sub> [M + H]<sup>+</sup>, 726.3035; found, 726.3042.</div></div><div id="sec5_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 8-(4-(4-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperazin-1-yl)piperidin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>21</b>)</h4><div class="NLM_p last">Compound <b>21</b> was synthesized from compound <b>37</b> and compound <b>42</b> by following the general procedure for preparing compound <b>13</b>. Yellow solid (73.3% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.73 (s, 1H), 11.12 (s, 1H), 8.33 (d, <i>J</i> = 8.2 Hz, 1H), 8.05 (s, 1H), 8.00 (s, 1H), 7.71 (t, <i>J</i> = 7.8 Hz, 1H), 7.61 (dd, <i>J</i> = 1.4, 8.1 Hz, 1H), 7.41–7.29 (m, 3H), 5.11 (dd, <i>J</i> = 5.5, 12.8 Hz, 1H), 3.34–3.28 (m, 4H), 3.23 (d, <i>J</i> = 11.3 Hz, 2H), 2.94–2.85 (m, 1H), 2.83–2.67 (m, 8H), 2.64–2.55 (m, 2H), 2.44 (s, 1H), 2.09–2.01 (m, 1H), 1.97–1.89 (m, 2H), 1.76 (s, 6H), 1.70–1.59 (m, 2H), 1.29 (t, <i>J</i> = 7.5 Hz, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.7, 173.3, 170.5, 167.6, 166.8, 160.5, 156.0, 150.2, 147.2, 136.7, 136.4, 136.1, 134.1, 128.2, 126.5, 126.3, 125.2, 124.2, 122.1, 120.6, 116.9, 116.9, 115.3, 109.9, 105.0, 61.4, 52.2, 51.4, 49.2, 31.4, 30.5, 29.5, 29.0, 23.1, 22.6, 14.8; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>43</sub>H<sub>44</sub>N<sub>7</sub>O<sub>5</sub> [M + H]<sup>+</sup>, 738.3398; found, 738.3417.</div></div><div id="sec5_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 2-(4-(1-(3-Cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazol-8-yl)piperidin-4-yl)piperazin-1-yl)-<i>N</i>-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)acetamide (<b>22</b>)</h4><div class="NLM_p last">Compound <b>22</b> was synthesized from compound <b>41</b> and compound <b>47</b> by following the general procedure for preparing compound <b>14</b>. Yellow solid (76.3% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.76 (s, 1H), 11.09 (s, 1H), 8.33 (d, <i>J</i> = 8.2 Hz, 1H), 8.07–8.00 (m, 2H), 7.62 (d, <i>J</i> = 7.7 Hz, 2H), 7.38–7.20 (m, 2H), 7.05 (d, <i>J</i> = 7.1 Hz, 1H), 6.75 (t, <i>J</i> = 6.4 Hz, 1H), 5.04 (dd, <i>J</i> = 5.5, 12.6 Hz, 1H), 4.01 (d, <i>J</i> = 25.7 Hz, 1H), 3.01 (s, 7H), 2.83 (d, <i>J</i> = 13.3 Hz, 2H), 2.78–2.57 (m, 7H), 1.97 (d, <i>J</i> = 21.6 Hz, 2H), 1.76 (s, 6H), 1.36 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.6, 173.3, 170.6, 169.5, 169.4, 167.8, 160.5, 155.5, 147.2, 146.9, 136.7, 136.7, 136.1, 132.7, 128.2, 126.7, 126.4, 125.3, 122.1, 120.6, 117.7, 116.9, 116.8, 110.9, 109.9, 109.5, 105.0, 61.7, 55.4, 53.7, 52.0, 49.0, 42.0, 38.4, 36.9, 31.4, 30.5, 27.2, 26.7, 23.1, 22.6, 14.8; ESI-MS <i>m</i>/<i>z</i> 838.4 [M + H]<sup>+</sup>.</div></div><div id="sec5_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 2-(4-(1-(3-Cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazol-8-yl)piperidin-4-yl)piperazin-1-yl)-<i>N</i>-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butyl)acetamide (<b>23</b>)</h4><div class="NLM_p last">Compound <b>23</b> was synthesized from compound <b>41</b> and compound <b>48</b> from following the general procedure for preparing compound <b>14</b>. Yellow solid (81.4% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.72 (s, 1H), 11.11 (s, 1H), 8.33 (d, <i>J</i> = 8.1 Hz, 1H), 8.06 (s, 1H), 8.04–7.99 (m, 1H), 7.85 (t, <i>J</i> = 6.0 Hz, 1H), 7.63–7.53 (m, 2H), 7.34 (s, 1H), 7.11 (d, <i>J</i> = 8.7 Hz, 1H), 7.01 (d, <i>J</i> = 7.0 Hz, 1H), 6.57 (t, <i>J</i> = 6.0 Hz, 1H), 5.05 (dd, <i>J</i> = 5.4, 12.9 Hz, 1H), 3.33 (q, <i>J</i> = 6.5 Hz, 2H), 3.18 (q, <i>J</i> = 6.3 Hz, 2H), 3.02 (d, <i>J</i> = 5.0 Hz, 6H), 2.88 (dt, <i>J</i> = 8.5, 11.6 Hz, 1H), 2.78–2.64 (m, 4H), 2.62 (d, <i>J</i> = 17.1 Hz, 4H), 2.57–2.51 (m, 2H), 2.01 (ddt, <i>J</i> = 3.0, 5.3, 10.3 Hz, 1H), 1.76 (s, 6H), 1.61–1.49 (m, 4H), 1.26 (t, <i>J</i> = 7.4 Hz, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.6, 173.3, 170.6, 169.5, 169.4, 167.8, 160.5, 155.5, 147.2, 146.9, 136.7, 136.1, 132.7, 128.2, 126.7, 126.4, 125.2, 122.1, 120.6, 117.7, 116.8, 110.9, 109.9, 109.5, 105.0, 55.4, 53.7, 52.0, 49.0, 42.0, 38.4, 36.9, 31.5, 30.5, 27.2, 26.7, 23.1, 22.6, 14.8; ESI-MS <i>m</i>/<i>z</i> 866.4 [M + H]<sup>+</sup>.</div></div><div id="sec5_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 2-(4-(1-(3-Cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazol-8-yl)piperidin-4-yl)piperazin-1-yl)-<i>N</i>-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexyl)acetamide (<b>24</b>)</h4><div class="NLM_p last">Compound <b>24</b> was synthesized from compound <b>41</b> and compound <b>49</b> by following the general procedure for preparing compound <b>14</b>. Yellow solid (77.3% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.76 (s, 1H), 11.12 (s, 1H), 8.33 (d, <i>J</i> = 8.1 Hz, 1H), 8.05 (s, 1H), 8.00 (d, <i>J</i> = 1.4 Hz, 1H), 7.79 (t, <i>J</i> = 6.0 Hz, 1H), 7.60 (dd, <i>J</i> = 1.4, 8.1 Hz, 1H), 7.54 (dd, <i>J</i> = 7.1, 8.6 Hz, 1H), 7.34 (s, 1H), 7.06 (d, <i>J</i> = 8.6 Hz, 1H), 7.00 (d, <i>J</i> = 7.0 Hz, 1H), 6.52 (t, <i>J</i> = 5.9 Hz, 1H), 5.06 (dd, <i>J</i> = 5.4, 12.9 Hz, 1H), 3.28 (q, <i>J</i> = 6.7 Hz, 2H), 3.12 (q, <i>J</i> = 6.7 Hz, 2H), 3.02 (d, <i>J</i> = 3.9 Hz, 6H), 2.89 (ddd, <i>J</i> = 5.5, 14.1, 17.4 Hz, 2H), 2.69 (q, <i>J</i> = 7.6 Hz, 4H), 2.63 (d, <i>J</i> = 14.4 Hz, 4H), 2.58–2.53 (m, 1H), 2.07–2.00 (m, 1H), 1.75 (s, 6H), 1.57 (t, <i>J</i> = 7.1 Hz, 2H), 1.46 (t, <i>J</i> = 7.0 Hz, 2H), 1.33 (p, <i>J</i> = 6.4 Hz, 4H), 1.26 (t, <i>J</i> = 7.5 Hz, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.6, 173.3, 170.6, 169.4, 167.8, 160.5, 155.4, 147.2, 146.9, 136.7, 136.7, 136.1, 132.6, 128.2, 126.7, 126.4, 125.2, 122.1, 120.6, 117.6, 116.8, 110.8, 109.9, 109.5, 105.0, 61.7, 60.2, 53.7, 52.0, 49.0, 42.3, 38.7, 36.9, 31.5, 30.5, 29.7, 29.1, 26.6, 26.5, 23.1, 22.6, 21.2, 14.8, 14.5; ESI-MS <i>m</i>/<i>z</i> 894.4 [M + H]<sup>+</sup>.</div></div><div id="sec5_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 8-(4-(4-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)glycyl)piperazin-1-yl)piperidin-1-yl)-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>25</b>)</h4><div class="NLM_p last">Compound <b>25</b> was synthesized from compound <b>37</b> and compound <b>52</b> by following the general procedure for preparing compound <b>14</b>. Yellow solid (78.4% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.73 (s, 1H), 11.13 (s, 1H), 8.33 (d, <i>J</i> = 8.2 Hz, 1H), 8.05 (s, 1H), 8.01 (s, 1H), 7.61 (d, <i>J</i> = 8.5 Hz, 2H), 7.34 (s, 1H), 7.18–7.02 (m, 3H), 5.09 (dd, <i>J</i> = 5.5, 12.9 Hz, 1H), 4.21 (d, <i>J</i> = 4.4 Hz, 2H), 3.53 (d, <i>J</i> = 14.6 Hz, 4H), 3.23 (d, <i>J</i> = 11.1 Hz, 2H), 2.94–2.86 (m, 1H), 2.83–2.66 (m, 5H), 2.65–2.55 (m, 5H), 2.12–1.96 (m, 2H), 1.90 (d, <i>J</i> = 11.8 Hz, 2H), 1.75 (s, 6H), 1.64 (d, <i>J</i> = 11.3 Hz, 2H), 1.28 (t, <i>J</i> = 7.5 Hz, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.7, 174.9, 173.3, 170.6, 169.3, 167.8, 166.7, 160.5, 155.9, 145.9, 136.7, 136.1, 132.5, 128.2, 126.3, 125.2, 122.1, 116.9, 111.3, 109.8, 105.0, 61.4, 52.2, 49.1, 36.9, 31.8, 31.5, 30.5, 29.5, 28.9, 23.1, 22.6, 14.8, 14.4; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>45</sub>H<sub>47</sub>N<sub>8</sub>O<sub>6</sub> [M + H]<sup>+</sup>, 795.3613; found, 795.3616.</div></div><div id="sec5_2_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 2-Bromo-1-(4-ethylphenyl)-2-methylpropan-1-one (<b>28</b>)</h4><div class="NLM_p last">A solution of compound <b>26</b> (20 g, 120 mmol) in SOCl<sub>2</sub> (15 mL) was stirred at room temperature for 2 h. Also, the solution was heated at 80 °C for 4 h until the completion of the reaction. Then, the solvent was removed under reduced pressure to afford the intermediate <b>27</b>, which was used directly for the next step without purification. To a solution of compound <b>27</b> (20 g, 108 mmol) and ethylbenzene (22.9 g, 216 mmol) in dry CHCl<sub>3</sub> (40 mL) at an ice bath was added AlCl<sub>3</sub> (14.4 g, 108 mmol) in batches. After stirring at 0 °C for 1 h, the mixture was stirred at room temperature until the completion of the reaction. The mixture was diluted by 1 N HCl solution and extracted with DCM (3 × 15 mL), dried, filtered, and concentrated. The residue was purified by a chromatograph (PE) to afford the intermediate <b>28</b> as a colorless transparent liquid (25.6 g, 65.7%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.10 (d, <i>J</i> = 8.5 Hz, 2H), 7.25 (d, <i>J</i> = 8.2 Hz, 2H), 2.70 (q, <i>J</i> = 7.6 Hz, 2H), 2.03 (s, 6H), 1.26 (t, <i>J</i> = 7.6 Hz, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 195.8, 148.86, 131.7, 130.0, 127.1, 60.0, 31.2, 31.1, 28.4, 14.6.</div></div><div id="sec5_2_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> Methyl 2-(4-Ethylphenyl)-2-methylpropanoate (<b>29</b>)</h4><div class="NLM_p last">Compound <b>28</b> (20.0 g, 78 mmol) and ZnBr<sub>2</sub> (20.8 g, 196 mmol) were dissolved in trimethoxymethane (40 mL). The mixture was degassed with argon for 10 min and then heated at 100 °C overnight until the completion of the reaction. The mixture was diluted with H<sub>2</sub>O (30 mL) and extracted with EtOAc (3 × 35 mL), dried, filtered, and concentrated. The residue was purified by a chromatograph (PE) to afford the intermediate <b>29</b> as a yellow liquid (15.6 g, 96.3%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.30 (d, <i>J</i> = 6.5 Hz, 2H), 7.21 (d, <i>J</i> = 8.3 Hz, 2H), 3.69 (s, 3H), 2.68 (q, <i>J</i> = 7.6 Hz, 2H), 1.62 (s, 6H), 1.28 (t, <i>J</i> = 7.9 Hz, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 195.8, 148.9, 131.7, 130.0, 127.1, 60.0, 31.2, 31.1, 28.4, 14.6; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>13</sub>H<sub>18</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 207.1380; found, 207.1413.</div></div><div id="sec5_2_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> Methyl 2-(4-Ethyl-3-iodophenyl)-2-methylpropanoate (<b>30</b>)</h4><div class="NLM_p last">To a solution of compound <b>29</b> (15.0 g, 73 mmol) and NIS (17.2 g, 73 mmol) in acetic acid (20 mL) at an ice bath was added H<sub>2</sub>SO<sub>4</sub> (20 mL) dropwise over 20 min. Thereafter, the mixture was stirred at room temperature overnight until the completion of the reaction. The mixture was diluted with 1 N NaOH solution (50 mL) and extracted with EtOAc (3 × 35 mL), dried, filtered, and concentrated. The residue was purified by a chromatograph (PE/EtOAc, 500:1, v/v) to afford the intermediate <b>30</b> as a brown liquid (15.6 g, 96.3%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.75 (d, <i>J</i> = 2.1 Hz, 1H), 7.27–7.22 (m, 1H), 7.16 (d, <i>J</i> = 8.0 Hz, 1H), 3.66 (s, 3H), 2.70 (q, <i>J</i> = 7.5 Hz, 2H), 1.54 (s, 6H), 1.19 (t, <i>J</i> = 7.5 Hz, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 176.8, 144.9, 144.1, 136.5, 128.3, 126.0, 100.7, 52.3, 45.8, 33.7, 26.5, 14.5; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>13</sub>H<sub>18</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 207.1380; found, 207.1413.</div></div><div id="sec5_2_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> Methyl 4-(4-Ethyl-3-iodophenyl)-4-methyl-3-oxopentanoate (<b>32</b>)</h4><div class="NLM_p last">Compound <b>30</b> (15 g, 45 mmol) was dissolved in 25 mL of 2 N NaOH (MeOH:H<sub>2</sub>O = 5:1) solution. Then, the mixture was stirred at 100 °C for 4 h until the completion of the reaction. The mixture was diluted by 1 N HCl and extracted with EtOAc (3 × 15 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and filtered. Then, the solvent was removed under reduced pressure to afford the intermediate <b>31</b>, which was used directly in the next step without purification (the crystal structure of <b>31</b> is shown in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00270/suppl_file/jm1c00270_si_001.pdf" class="ext-link">Figure S8</a> to establish the position of iodine). To a solution of compound <b>31</b> in dry MeCN (20 mL) were added CDI (5.0 g, 35 mmol), MgCl<sub>2</sub> (6.7 g, 71 mmol), monomethyl monopotassium malonate (9.3 g, 59 mmol), and Et<sub>3</sub>N (12.6 mL, 91 mmol). The mixture was degassed with argon for 10 min and then heated at 100 °C overnight until the completion of the reaction. The mixture was diluted by EtOAc and extracted with EtOAc (3 × 15 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by a chromatograph (PE/EtOAc, 200:1, v/v) to afford the intermediate <b>32</b> as a yellow liquid (24.0 g, 84.7%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.70 (d, <i>J</i> = 2.0 Hz, 1H), 7.20 (d, <i>J</i> = 8.0 Hz, 1H), 7.16 (dd, <i>J</i> = 8.0, 2.0 Hz, 1H), 3.67 (s, 3H), 3.28 (s, 2H), 2.71 (q, <i>J</i> = 7.5 Hz, 2H), 1.48 (s, 6H), 1.20 (t, <i>J</i> = 7.6 Hz, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 204.0, 167.2, 145.2, 141.7, 136.4, 128.3, 126.0, 100.7, 51.8, 51.7, 43.9, 33.2, 24.3, 13.9; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>15</sub>H<sub>19</sub>IO<sub>3</sub> [M + Na]<sup>+</sup>, 397.0271; found, 397.0366.</div></div><div id="sec5_2_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> Methyl 2-(4-Cyano-2-nitrophenyl)-4-(4-ethyl-3-iodophenyl)-4-methyl-3-oxopentanoate (<b>33</b>)</h4><div class="NLM_p last">To a solution of compound <b>32</b> (20.0 g, 53 mmol) and Cs<sub>2</sub>CO<sub>3</sub> (17.4 g, 53 mmol) in DMSO (10 mL) was added 4-chloro-3-nitrobenzonitrile (17.4 g, 53 mmol) in batches. Then, the mixture was stirred at room temperature overnight until the completion of the reaction. The mixture was diluted with H<sub>2</sub>O (60 mL) and extracted with EtOAc (3 × 70 mL), dried, filtered, and concentrated. The residue was purified by a chromatograph (PE/EtOAc) to afford the intermediate <b>33</b> as a yellow liquid (14.4 g, 56.9% yield). <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 7.99 (d, <i>J</i> = 1.7 Hz, 1H), 7.92 (d, <i>J</i> = 8.2 Hz, 1H), 7.84 (dd, <i>J</i> = 8.3, 1.7 Hz, 1H), 7.13 (d, <i>J</i> = 2.1 Hz, 1H), 7.08 (dd, <i>J</i> = 8.0, 2.0 Hz, 1H), 7.01 (d, <i>J</i> = 8.0 Hz, 1H), 5.68 (s, 1H), 3.72 (s, 3H), 2.63 (q, <i>J</i> = 7.5 Hz, 3H), 1.67 (s, 3H), 1.41 (s, 3H), 1.19 (t, <i>J</i> = 7.5 Hz, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 204.4, 167.1, 147.6, 146.4, 139.2, 138.7, 135.5, 133.0, 132.2, 128.9, 128.4, 126.3, 116.3, 113.4, 100.8, 53.43, 53.1, 53.0, 33.6, 25.3, 23.7, 14.2; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>22</sub>H<sub>21</sub>IN<sub>2</sub>O<sub>5</sub> [M + H]<sup>+</sup>, 521.0568; found, 521.0597.</div></div><div id="sec5_2_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> Methyl 6-Cyano-2-(2-(4-ethyl-3-iodophenyl)propan-2-yl)-1<i>H</i>-indole-3-carboxylate (<b>34</b>)</h4><div class="NLM_p last">Compound <b>33</b> (14.0 g, 26 mmol) was dissolved in THF/EtOH/H<sub>2</sub>O (40 mL/40 mL/20 mL) and then Na<sub>2</sub>S<sub>2</sub>O<sub>4</sub> (28.1 g, 161 mmol) was added. The mixture was stirred at 100 °C for 4 h until the completion of the reaction. The mixture was diluted with EtOAc (80 mL) and extracted with EtOAc (3 × 40 mL), dried, filtered, and concentrated. The residue was purified by a chromatograph (PE/EtOAc, 150:1, v/v) to afford the intermediate <b>34</b> as a white powder (6.6 g, 50.2% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.22 (s, 1H), 8.19 (d, <i>J</i> = 8.5 Hz, 1H), 7.71 (d, <i>J</i> = 9.1 Hz, 2H), 7.46 (d, <i>J</i> = 8.4 Hz, 1H), 7.12 (s, 2H), 3.64 (s, 3H), 2.67 (q, <i>J</i> = 7.5 Hz, 2H), 1.89 (d, <i>J</i> = 1.3 Hz, 6H), 1.17 (t, <i>J</i> = 7.5 Hz, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 164.5, 155.7, 147.0, 144.6, 136.4, 132.4, 131.9, 128.2, 126.1, 124.8, 122.7, 120.4, 116.0, 105.0, 104.8, 100.5, 50.9, 41.3, 33.7, 28.7, 14.5.</div></div><div id="sec5_2_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 9-Ethyl-8-iodo-6,6-dimethyl-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>35</b>)</h4><div class="NLM_p last">Compound <b>34</b> was dissolved in Eaton reagent (10 mL, P<sub>2</sub>O<sub>5</sub>, 7.5 wt % in methanesulfonic acid). The mixture was stirred at room temperature for 2.5 h until the completion of the reaction. The mixture was diluted with water (20 mL) and extracted with EtOAc (3 × 20 mL), dried, filtered, and concentrated. The residue was purified by a chromatograph (DCM/MeOH) to afford the intermediate <b>35</b> as a white powder (2.9 g, 47.4% yield). <sup>1</sup>H NMR (400 MHz, DMSO) δ 12.82 (s, 1H), 8.32 (d, <i>J</i> = 7.7 Hz, 2H), 8.04 (d, <i>J</i> = 10.8 Hz, 2H), 7.63 (dd, <i>J</i> = 8.1, 1.4 Hz, 1H), 2.79 (q, <i>J</i> = 7.5 Hz, 2H), 1.76 (s, 6H), 1.22 (t, <i>J</i> = 7.5 Hz, 3H); <sup>13</sup>C NMR (101 MHz, DMSO) δ 179.3, 160.3, 147.5, 145.2, 137.8, 136.3, 131.9, 128.0, 125.6, 125.5, 122.1, 120.5, 117.0, 109.9, 107.3, 105.4, 36.6, 33.5, 30.1, 14.9; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>21</sub>H<sub>17</sub>IN<sub>2</sub>O [M + H]<sup>+</sup>, 441.0458; found, 411.0436.</div></div><div id="sec5_2_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 9-Ethyl-6,6-dimethyl-11-oxo-8-(piperazin-1-yl)-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>36</b>)</h4><div class="NLM_p last">To a solution of compound <b>35</b> (100 mg, 0.23 mmol), <i>tert</i>-butyl 2,5-diazabicyclo[2.2.1] heptane-2-carboxylate (86.61 mg, 0.45 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (10.40 mg, 0.011 mmol), and S-Phos (18 mg, 0.045 mmol) in dry 1,4-dioxane (6 mL) was added NaHMDS (2 M in THF, 0.4 mL) under an argon atmosphere. The mixture was degassed with argon for 10 min and then heated at 80 °C overnight until the completion of the reaction. The mixture was diluted with EtOAc (15 mL) and extracted with ethyl acetate (3 × 15 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and filtered. The filtrate was evaporated in vacuum to afford a crude product followed by treatment with TFA (50% in DCM) at room temperature until the completion of the reaction. The mixture was concentrated in vacuum and purified by a chromatograph (DCM/MeOH) to afford the title product <b>36</b> as a pale yellow solid (61 mg, 66.7% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.99 (s, 1H), 9.15 (s, 1H), 8.33 (d, <i>J</i> = 8.1 Hz, 1H), 8.09 (s, 1H), 8.04 (s, 1H), 7.62 (dd, <i>J</i> = 8.1, 1.4 Hz, 1H), 7.41 (s, 1H), 3.39–3.07 (m, 8H), 2.74 (q, <i>J</i> = 7.5 Hz, 2H), 1.79 (s, 6H), 1.30 (t, <i>J</i> = 7.5 Hz, 3H); <sup>13</sup>C NMR (101 MHz, DMSO) δ 179.5, 160.7, 154.4, 147.4, 136.9, 136.2, 128.1, 127.4, 126.5, 125.4, 122.1, 120.6, 117.3, 117.0, 109.8, 105.1, 49.2, 43.8, 37.0, 30.4, 23.0, 14.7; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>25</sub>H<sub>27</sub>N<sub>4</sub>O [M + H]<sup>+</sup>, 399.2179; found, 399.2181.</div></div><div id="sec5_2_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 9-Ethyl-6,6-dimethyl-11-oxo-8-(4-(piperazin-1-yl)piperidin-1-yl)-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazole-3-carbonitrile (<b>37</b>)</h4><div class="NLM_p last">Compound <b>37</b> was synthesized from compound <b>35</b> and <i>tert</i>-butyl 4-piperidin-4-ylpiperazine-1-carboxylate by following the general procedure for preparing compound <b>36</b> (yellow solid, 73.3%): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.32 (d, <i>J</i> = 8.2 Hz, 1H), 8.04 (s, 1H), 8.01 (s, 1H), 7.60 (dd, <i>J</i> = 1.5, 8.1 Hz, 1H), 7.33 (s, 1H), 3.38 (d, <i>J</i> = 7.3 Hz, 2H), 3.20 (d, <i>J</i> = 11.4 Hz, 2H), 2.99–2.89 (m, 4H), 2.78–2.68 (m, 4H), 2.65 (d, <i>J</i> = 4.8 Hz, 4H), 2.41 (td, <i>J</i> = 5.4, 9.1, 10.8 Hz, 1H), 1.89–1.83 (m, 2H), 1.76 (s, 6H), 1.64–1.55 (m, 2H), 1.29–1.25 (t, <i>J</i> = 7.5 Hz, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.7, 160.5, 155.9, 147.2, 136.6, 136.2, 128.2, 126.5, 126.3, 125.2, 122.1, 120.6, 116.9, 109.8, 104.9, 63.0, 61.5, 52.5, 52.1, 47.6, 44.7, 36.9, 30.5, 28.7, 23.0, 14.8, 7.7; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>30</sub>H<sub>36</sub>N<sub>5</sub>O [M + H]<sup>+</sup>, 482.2914; found, 482.2909.</div></div><div id="sec5_2_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 2-(4-(3-Cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazol-8-yl)piperazin-1-yl)acetic Acid (<b>40</b>)</h4><div class="NLM_p last">To a solution of compound <b>36</b> (200 mg, 0.50 mmol) in DMSO were added <i>tert</i>-butyl bromoacetate (162 μL, 1.00 mmol) and DIPEA (248 μL, 1.51 mmol). Then, the mixture was heated at 90 °C for 2.5 h until the completion of the reaction. The mixture was diluted with EtOAc (15 mL) and extracted with ethyl acetate (3 × 15 mL), dried, filtered, and concentrated. The residue was purified by a chromatograph (DCM/MeOH, 100:1, v/v) to afford the intermediate <b>38</b> (197 mg, 76.7% yield): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 11.58 (s, 1H), 8.54 (d, <i>J</i> = 8.2 Hz, 1H), 8.29 (s, 1H), 7.82 (dd, <i>J</i> = 1.3, 0.7 Hz, 1H), 7.54 (dd, <i>J</i> = 8.2, 1.4 Hz, 1H), 7.23 (s, 1H), 3.25 (s, 2H), 3.08 (m, <i>J</i> = 4.7 Hz, 4H), 2.80 (m, <i>J</i> = 4.6 Hz, 4H), 2.70 (d, <i>J</i> = 7.5 Hz, 2H), 1.89 (s, 6H), 1.51 (s, 9H), 1.20 (t, <i>J</i> = 7.5 Hz, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 181.4, 170.0, 160.4, 155.6, 146.8, 137.6, 136.0, 127.1, 126.9, 125.3, 122.5, 120.3, 116.5, 116.3, 105.5, 81.5, 60.1, 53.3, 52.0, 36.9, 30.7, 28.2, 23.2, 14.3. To a solution of intermediate <b>38</b> (100 mg, 0.20 mmol) in DCM (2 mL) was added TFA (1.5 mL), and the solution was stirred at room temperature until the completion of the reaction. Then, the solvent was removed under reduced pressure to afford the compound <b>40</b>, which was used directly for the next step without purification. HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>27</sub>H<sub>28</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 457.2234; found, 457.2298.</div></div><div id="sec5_2_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 2-(4-(1-(3-Cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazol-8-yl)piperidin-4-yl)piperazin-1-yl)acetic Acid (<b>41</b>)</h4><div class="NLM_p last">To a solution of compound <b>37</b> (200 mg, 0.41 mmol) in DMSO (2 mL) were added <i>tert</i>-butyl bromoacetate (134 μL, 0.83 mmol) and DIPEA (205 μL, 1.25 mmol). Then, the mixture was stirred at 90 °C for 3 h until the completion of the reaction. The mixture was diluted with H<sub>2</sub>O (16 mL) and extracted with ethyl acetate (3 × 15 mL), dried, filtered, and concentrated. The residue was purified by a chromatograph (DCM/MeOH, 100:1, v/v) to afford the intermediate <b>39</b> (225 mg, 91.1% yield): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.90 (s, 1H), 8.58 (d, <i>J</i> = 8.2 Hz, 1H), 8.32 (s, 1H), 7.82 (s, 1H), 7.60 (dd, <i>J</i> = 8.1, 1.4 Hz, 1H), 7.25 (s, 1H), 3.28 (s, 2H), 3.13 (m, <i>J</i> = 4.7 Hz, 4H), 2.85 (m, 4H), 2.77 (d, <i>J</i> = 7.5 Hz, 2H), 2.72 (d, <i>J</i> = 0.8 Hz, 1H), 1.85 (m, 7H), 1.72 (m, 7H), 1.55 (s, 9H), 1.34 (t, <i>J</i> = 7.5 Hz, 3H). To a solution of intermediate <b>39</b> (100 mg, 0.17 mmol) in DCM (2 mL) was added TFA (1.5 mL), and the solution was stirred at room temperature until the completion of the reaction. Then, the solvent was removed under reduced pressure to afford the compound <b>41</b>, which was used directly in the next step without purification. HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>32</sub>H<sub>37</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 540.2969; found, 540.3045.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i54"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00270" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46302" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46302" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00270?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00270</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Experimental methods for biological assays; <sup>1</sup>H and <sup>13</sup>C NMR spectra for key intermediates and all target compounds; mass spectrum and HPLC spectrogram for compound <b>17</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00270/suppl_file/jm1c00270_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">SMILES molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00270/suppl_file/jm1c00270_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00270/suppl_file/jm1c00270_si_001.pdf">jm1c00270_si_001.pdf (2.48 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00270/suppl_file/jm1c00270_si_002.csv">jm1c00270_si_002.csv (2.29 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00270" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88244" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88244" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jinyi Xu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-1961-0402" title="Orcid link">https://orcid.org/0000-0002-1961-0402</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#53393a3d2a3a2b2613303b3a3d327d303c3e"><span class="__cf_email__" data-cfemail="315b585f48584944715259585f501f525e5c">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shengtao Xu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-5705-6377" title="Orcid link">https://orcid.org/0000-0002-5705-6377</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#6a091a1f12191e2a5b5c5944090507"><span class="__cf_email__" data-cfemail="60031015181314205156534e030f0d">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shaowen Xie</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuan Sun</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yulin Liu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Organic Chemistry, China Pharmaceutical
University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xinnan Li</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xinuo Li</span> - <span class="hlFld-Affiliation affiliation">Key Lab of
Drug Metabolism & Pharmacokinetics, State Key Laboratory of Natural
Medicines, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenyi Zhong</span> - <span class="hlFld-Affiliation affiliation">Department
of Organic Chemistry, China Pharmaceutical
University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Feiyan Zhan</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jingjie Zhu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong Yao</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dong-Hua Yang</span> - <span class="hlFld-Affiliation affiliation">College
of Pharmacy and Health Sciences, St. John’s
University, 8000 Utopia Parkway, Queens, New York 11439, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhe-Sheng Chen</span> - <span class="hlFld-Affiliation affiliation">College
of Pharmacy and Health Sciences, St. John’s
University, 8000 Utopia Parkway, Queens, New York 11439, United
States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-8289-097X" title="Orcid link">https://orcid.org/0000-0002-8289-097X</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i56">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58217" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58217" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This study received financial support from the National Natural Science Foundation of China (nos. 81874289 and 81903446), Natural Science Foundation of Jiangsu Province (BK20190564), China Postdoctoral Science Foundation Grant (2019M652037), and “Double First-Class” University project of China Pharmaceutical University (CPU2018GY04 and CPU2018GY35).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ALCL</td><td class="NLM_def"><p class="first last">anaplastic large-cell lymphoma</p></td></tr><tr><td class="NLM_term">ALK</td><td class="NLM_def"><p class="first last">anaplastic lymphoma kinase</p></td></tr><tr><td class="NLM_term">CCl<sub>4</sub></td><td class="NLM_def"><p class="first last">carbon tetrachloride</p></td></tr><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>′-carbonyldiimidazole</p></td></tr><tr><td class="NLM_term">CRBN</td><td class="NLM_def"><p class="first last">cereblon</p></td></tr><tr><td class="NLM_term">DC<sub>50</sub></td><td class="NLM_def"><p class="first last">half degradation concentration</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">Et<sub>3</sub>N</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term">EML4</td><td class="NLM_def"><p class="first last">echinoderm microtubule-associated protein-like 4</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">2-(7-azabenzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">JUNB</td><td class="NLM_def"><p class="first last">Transcription factor jun-B</p></td></tr><tr><td class="NLM_term">MTT</td><td class="NLM_def"><p class="first last">3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2<i>H</i>-tetrazolium bromide</p></td></tr><tr><td class="NLM_term">NIS</td><td class="NLM_def"><p class="first last"><i>N</i>-iodosuccinimide</p></td></tr><tr><td class="NLM_term">NMR</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">NPM</td><td class="NLM_def"><p class="first last">nucleophosmin</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung cancer</p></td></tr><tr><td class="NLM_term">Pd<sub>2</sub>(dba)<sub>3</sub></td><td class="NLM_def"><p class="first last">tris(dibenzylideneacetone)dipalladium</p></td></tr><tr><td class="NLM_term">PROTACs</td><td class="NLM_def"><p class="first last">proteolysis-targeting chimeras</p></td></tr><tr><td class="NLM_term">SESN2</td><td class="NLM_def"><p class="first last">Sestrin-2</p></td></tr><tr><td class="NLM_term">SOCl<sub>2</sub></td><td class="NLM_def"><p class="first last">thionyl chloride</p></td></tr><tr><td class="NLM_term">SOCS3</td><td class="NLM_def"><p class="first last">Suppressor of cytokine signaling 3</p></td></tr><tr><td class="NLM_term">S-phos</td><td class="NLM_def"><p class="first last">2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl</p></td></tr><tr><td class="NLM_term">STAT3</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription 3</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">LTK</td><td class="NLM_def"><p class="first last">leukocyte tyrosine kinase</p></td></tr><tr><td class="NLM_term">NaHMDS</td><td class="NLM_def"><p class="first last">sodium bis(trimethylsilyl)amide</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i58">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33816" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33816" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 60 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemmon, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span> <span> </span><span class="NLM_article-title">Cell signaling by receptor tyrosine kinases</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">1117</span>– <span class="NLM_lpage">1134</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2010.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.cell.2010.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=20602996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovFartb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2010&pages=1117-1134&author=M.+A.+Lemmonauthor=J.+Schlessinger&title=Cell+signaling+by+receptor+tyrosine+kinases&doi=10.1016%2Fj.cell.2010.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cell signaling by receptor tyrosine kinases</span></div><div class="casAuthors">Lemmon, Mark A.; Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1117-1134</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Recent structural studies of receptor tyrosine kinases (RTKs) have revealed unexpected diversity in the mechanisms of their activation by growth factor ligands.  Strategies for inducing dimerization by ligand binding are surprisingly diverse, as are mechanisms that couple this event to activation of the intracellular tyrosine kinase domains.  As the understanding of these details becomes increasingly sophisticated, it provides an important context for therapeutically countering the effects of pathogenic RTK mutations in cancer and other diseases.  Much remains to be learned, however, about the complex signaling networks downstream from RTKs and how alterations in these networks are translated into cellular responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd5NvoN0Q9-7Vg90H21EOLACvtfcHk0livGyjadPPeiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovFartb0%253D&md5=b88b55fe7a3eebc6ff7e883425676e45</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2010.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2010.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DLemmon%26aufirst%3DM.%2BA.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DCell%2520signaling%2520by%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCell%26date%3D2010%26volume%3D141%26spage%3D1117%26epage%3D1134%26doi%3D10.1016%2Fj.cell.2010.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirstein, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dittmer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Look, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saltman, D. L.</span></span> <span> </span><span class="NLM_article-title">Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>267</i></span>,  <span class="NLM_fpage">316</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1126/science.267.5196.316-b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1126%2Fscience.267.5196.316-b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=7824924" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADyaK2MXjt12gurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1995&pages=316-317&author=S.+W.+Morrisauthor=M.+N.+Kirsteinauthor=M.+B.+Valentineauthor=K.+Dittmerauthor=D.+N.+Shapiroauthor=A.+T.+Lookauthor=D.+L.+Saltman&title=Fusion+of+a+kinase+gene%2C+ALK%2C+to+a+nucleolar+protein+gene%2C+NPM%2C+in+non-Hodgkin%E2%80%99s+lymphoma&doi=10.1126%2Fscience.267.5196.316-b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">NPM-ALK sequence (GenBank accession number U04946)</span></div><div class="casAuthors">Morris, S. W.; Kirstein, M. N.; Valentine, M. B.; Dittmer, K.; Shapiro, D. N.; Look, A. T.; Saltman, D. L.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue">5196</span>),
    <span class="NLM_cas:pages">316-17</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgQOJ6qNgzALVg90H21EOLACvtfcHk0livGyjadPPeiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjt12gurY%253D&md5=0951f3302d350098885887fb55e796ba</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1126%2Fscience.267.5196.316-b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.267.5196.316-b%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DKirstein%26aufirst%3DM.%2BN.%26aulast%3DValentine%26aufirst%3DM.%2BB.%26aulast%3DDittmer%26aufirst%3DK.%26aulast%3DShapiro%26aufirst%3DD.%2BN.%26aulast%3DLook%26aufirst%3DA.%2BT.%26aulast%3DSaltman%26aufirst%3DD.%2BL.%26atitle%3DFusion%2520of%2520a%2520kinase%2520gene%252C%2520ALK%252C%2520to%2520a%2520nucleolar%2520protein%2520gene%252C%2520NPM%252C%2520in%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%26jtitle%3DScience%26date%3D1995%26volume%3D267%26spage%3D316%26epage%3D317%26doi%3D10.1126%2Fscience.267.5196.316-b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pulford, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamant, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroud, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delsol, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, D. Y.</span></span> <span> </span><span class="NLM_article-title">Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">1394</span>– <span class="NLM_lpage">1404</span>, <span class="refDoi"> DOI: 10.1182/blood.V89.4.1394</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1182%2Fblood.V89.4.1394" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=9028963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADyaK2sXhtFant7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1997&pages=1394-1404&author=K.+Pulfordauthor=L.+Lamantauthor=S.+W.+Morrisauthor=L.+H.+Butlerauthor=K.+M.+Woodauthor=D.+Stroudauthor=G.+Delsolauthor=D.+Y.+Mason&title=Detection+of+anaplastic+lymphoma+kinase+%28ALK%29+and+nucleolar+protein+nucleophosmin+%28NPM%29-ALK+proteins+in+normal+and+neoplastic+cells+with+the+monoclonal+antibody+ALK1&doi=10.1182%2Fblood.V89.4.1394"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1</span></div><div class="casAuthors">Pulford, Karen; Lamant, Laurence; Morris, Stephan W.; Butler, Lisa H.; Wood, Katrina M.; Stroud, David; Delsol, Georges; Mason, David Y.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1394-1404</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">Saunders</span>)
        </div><div class="casAbstract">The t(2;5)(p23;q35) translocation, assocd. with anaplastic large-cell lymphoma (ALCL), results in the prodn. of the nucleolar protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) protein.  This report describes an immunocytochem. study of the distribution of ALK and NPM-ALK proteins using a new monoclonal antibody, ALK1, that recognizes a formalin resistant epitope in both the 8 kDa NPM-ALK chimeric and the 200 kDa normal human ALK proteins.  Cytoplasmic and nuclear labeling was seen in the t(2;5)+ SU-DHL-1 and Karpas 299 cell lines.  Normal ALK protein expression was restricted to the central nervous system (in scattered neurons, glial cells, and endothelial cells).  Two hundred and thirty-nine cases of lymphoma and 80 nonhematopoietic tumors were immunostained.  Antibody ALK1 labeled 53.4% (39 of 73 cases) of CD30+ ALCL.  A case of ALCL with a t(1;2) translocation was ALK1+.  Tree cases of CD30- ALCL with prominent nucleoli showed a unique pattern of coarse granular cytoplasmic labeling.  All other tumors, including Hodgkin's disease and lymphomatoid papulosis, were ALK1-.  These results indicate that reliable immunostaining of routine biopsy material for NPM-ALK and ALK proteins is feasible.  Such anal. is of diagnostic importance, esp. because t(2;5)+ ALCL cases have a good prognosis with appropriate treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvlTSV80OkXrVg90H21EOLACvtfcHk0lgnOIxHaRaXkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhtFant7g%253D&md5=745bdf860c7b04686062945aaa151f1c</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1182%2Fblood.V89.4.1394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V89.4.1394%26sid%3Dliteratum%253Aachs%26aulast%3DPulford%26aufirst%3DK.%26aulast%3DLamant%26aufirst%3DL.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DButler%26aufirst%3DL.%2BH.%26aulast%3DWood%26aufirst%3DK.%2BM.%26aulast%3DStroud%26aufirst%3DD.%26aulast%3DDelsol%26aufirst%3DG.%26aulast%3DMason%26aufirst%3DD.%2BY.%26atitle%3DDetection%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520and%2520nucleolar%2520protein%2520nucleophosmin%2520%2528NPM%2529-ALK%2520proteins%2520in%2520normal%2520and%2520neoplastic%2520cells%2520with%2520the%2520monoclonal%2520antibody%2520ALK1%26jtitle%3DBlood%26date%3D1997%26volume%3D89%26spage%3D1394%26epage%3D1404%26doi%3D10.1182%2Fblood.V89.4.1394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enomoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurashina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bando, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aburatani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mano, H.</span></span> <span> </span><span class="NLM_article-title">Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>448</i></span>,  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1038/nature05945</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1038%2Fnature05945" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=17625570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2007&pages=561-566&author=M.+Sodaauthor=Y.+L.+Choiauthor=M.+Enomotoauthor=S.+Takadaauthor=Y.+Yamashitaauthor=S.+Ishikawaauthor=S.+Fujiwaraauthor=H.+Watanabeauthor=K.+Kurashinaauthor=H.+Hatanakaauthor=M.+Bandoauthor=S.+Ohnoauthor=Y.+Ishikawaauthor=H.+Aburataniauthor=T.+Nikiauthor=Y.+Soharaauthor=Y.+Sugiyamaauthor=H.+Mano&title=Identification+of+the+transforming+EML4-ALK+fusion+gene+in+non-small-cell+lung+cancer&doi=10.1038%2Fnature05945"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</span></div><div class="casAuthors">Soda, Manabu; Choi, Young Lim; Enomoto, Munehiro; Takada, Shuji; Yamashita, Yoshihiro; Ishikawa, Shunpei; Fujiwara, Shin-ichiro; Watanabe, Hideki; Kurashina, Kentaro; Hatanaka, Hisashi; Bando, Masashi; Ohno, Shoji; Ishikawa, Yuichi; Aburatani, Hiroyuki; Niki, Toshiro; Sohara, Yasunori; Sugiyama, Yukihiko; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue">7153</span>),
    <span class="NLM_cas:pages">561-566</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Improvement in the clin. outcome of lung cancer is likely to be achieved by identification of the mol. events that underlie its pathogenesis.  Here we show that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-assocd. protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells.  Mouse 3T3 fibroblasts forced to express this human fusion tyrosine kinase generated transformed foci in culture and s.c. tumors in nude mice.  The EML4-ALK fusion transcript was detected in 6.7% (5 out of 75) of NSCLC patients examd.; these individuals were distinct from those harboring mutations in the epidermal growth factor receptor gene.  Our data demonstrate that a subset of NSCLC patients may express a transforming fusion kinase that is a promising candidate for a therapeutic target as well as for a diagnostic mol. marker in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomhAXuLtrJ6rVg90H21EOLACvtfcHk0lgnOIxHaRaXkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D&md5=7f567e80814b9ccc87e5bceeebb467a7</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnature05945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05945%26sid%3Dliteratum%253Aachs%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DEnomoto%26aufirst%3DM.%26aulast%3DTakada%26aufirst%3DS.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DS.%26aulast%3DFujiwara%26aufirst%3DS.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DKurashina%26aufirst%3DK.%26aulast%3DHatanaka%26aufirst%3DH.%26aulast%3DBando%26aufirst%3DM.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DAburatani%26aufirst%3DH.%26aulast%3DNiki%26aufirst%3DT.%26aulast%3DSohara%26aufirst%3DY.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520the%2520transforming%2520EML4-ALK%2520fusion%2520gene%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DNature%26date%3D2007%26volume%3D448%26spage%3D561%26epage%3D566%26doi%3D10.1038%2Fnature05945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coffin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elenitoba-Johnson, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, C. A.</span></span> <span> </span><span class="NLM_article-title">ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor</span>. <i>Mod. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">569</span>– <span class="NLM_lpage">576</span>, <span class="refDoi"> DOI: 10.1038/modpathol.3880352</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1038%2Fmodpathol.3880352" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=11406658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A280%3ADC%252BD3Mzktlensw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2001&pages=569-576&author=C.+M.+Coffinauthor=A.+Patelauthor=S.+Perkinsauthor=K.+S.+Elenitoba-Johnsonauthor=E.+Perlmanauthor=C.+A.+Griffin&title=ALK1+and+p80+expression+and+chromosomal+rearrangements+involving+2p23+in+inflammatory+myofibroblastic+tumor&doi=10.1038%2Fmodpathol.3880352"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor</span></div><div class="casAuthors">Coffin C M; Patel A; Perkins S; Elenitoba-Johnson K S; Perlman E; Griffin C A</div><div class="citationInfo"><span class="NLM_cas:title">Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">569-76</span>
        ISSN:<span class="NLM_cas:issn">0893-3952</span>.
    </div><div class="casAbstract">BACKGROUND:  Inflammatory myofibroblastic tumor (IMT) is an uncommon tumor of extrapulmonary and pulmonary tissues with an unpredictable clinical course, occasional recurrences, and rare malignant transformation.  Clonal abnormalities with rearrangements of chromosome of 2p23 and the ALK gene have been reported in a few cases.  The purpose of this study is to investigate whether these are consistent abnormalities among IMTs or represent a distinct subset.  DESIGN:  Formalin-fixed, paraffin-embedded archival tissue sections from 47 IMTs in 40 patients were immunostained with monoclonal antibodies against ALK and p80.  Fluorescence in situ hybridization for ALK rearrangements was done on 22 IMTs from 19 patients.  Findings were correlated with clinical features and outcome.  RESULTS:  ALK positivity was observed in 17 of 47 IMTs (36%) and p80 positivity in 16 of 47 IMTs (34%).  Fluorescence in situ hybridization showed ALK rearrangements in nine cases (47%), aneuploidy in three cases (16%), and no rearrangement in seven cases (37%).  IMTs with ALK abnormalities by immunohistochemistry and/or fluorescence in situ hybridization originated in the abdomen/pelvis/retroperitoneum, chest, and extremities.  The mean age was 6.6 years, with a male/female ratio of 1.3. 64% of patients had no evidence of disease at last follow-up, 45% had one or more recurrences, and 18% displayed histologic evidence of malignant transformation.  The IMTs without ALK abnormalities occurred in older children, were more frequent in females, and had fewer recurrences.  However, in this group of 40 patients, the differences between the groups with and without ALK abnormalities did not have statistical significance.  Aneuploidy without ALK abnormalities was associated with malignant transformation in three of five cases.  CONCLUSIONS:  Abnormalities of ALK and p80 and evidence of chromosomal rearrangements of 2p23 occur in a significant proportion of IMTs.  These changes are most frequent in abdominal and pulmonary IMTs in the first decade of life and are associated with a higher frequency of recurrence.  These findings confirm the neoplastic nature of a subset IMT with ALK abnormalities and suggest that aneuploid IMT is a subset with more aggressive clinical behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKhgHH19XaKCsZ1x6zOs0vfW6udTcc2ebpIg9xZUHmrLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3Mzktlensw%253D%253D&md5=95c8abf8ae15c36d927ac56ae473f526</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fmodpathol.3880352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmodpathol.3880352%26sid%3Dliteratum%253Aachs%26aulast%3DCoffin%26aufirst%3DC.%2BM.%26aulast%3DPatel%26aufirst%3DA.%26aulast%3DPerkins%26aufirst%3DS.%26aulast%3DElenitoba-Johnson%26aufirst%3DK.%2BS.%26aulast%3DPerlman%26aufirst%3DE.%26aulast%3DGriffin%26aufirst%3DC.%2BA.%26atitle%3DALK1%2520and%2520p80%2520expression%2520and%2520chromosomal%2520rearrangements%2520involving%25202p23%2520in%2520inflammatory%2520myofibroblastic%2520tumor%26jtitle%3DMod.%2520Pathol.%26date%3D2001%26volume%3D14%26spage%3D569%26epage%3D576%26doi%3D10.1038%2Fmodpathol.3880352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvorak, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henkle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellingham, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlman, E. J.</span></span> <span> </span><span class="NLM_article-title">Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2776</span>– <span class="NLM_lpage">2780</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10383129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADyaK1MXktVOktbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=2776-2780&author=C.+A.+Griffinauthor=A.+L.+Hawkinsauthor=C.+Dvorakauthor=C.+Henkleauthor=T.+Ellinghamauthor=E.+J.+Perlman&title=Recurrent+involvement+of+2p23+in+inflammatory+myofibroblastic+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors</span></div><div class="casAuthors">Griffin, Constance A.; Hawkins, Anita L.; Dvorak, Cecily; Henkle, Carol; Ellingham, Tara; Perlman, Elizabeth J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2776-2780</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">AACR Subscription Office</span>)
        </div><div class="casAbstract">Inflammatory myofibroblastic tumor (IMT) is a relatively rare soft tissue tumor.  The reactive vs. neoplastic pathogenesis of this tumor is unresolved.  We found clonal chromosome aberrations involving 2p23 upon metaphase anal. of two IMTs.  Fluorescence in situ hybridization with a probe flanking the ALK gene at 2p23 demonstrated rearrangement of the probe in both of these cases and in a third case, and immunohistochem. revealed ALK expression in all three cases.  A 2p22-24 involvement has been reported previously in four addnl. cases of IMT.  We suggest that chromosomal rearrangements involving 2p23 near or within ALK are recurrent alterations in IMT and that ALK may have a novel role outside its previously recognized realm of lymphoid neoplasms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocvXV2ukz3crVg90H21EOLACvtfcHk0liGdxd3NBrlww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXktVOktbk%253D&md5=8054eeaaf0cb85ee85afff461797c84c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGriffin%26aufirst%3DC.%2BA.%26aulast%3DHawkins%26aufirst%3DA.%2BL.%26aulast%3DDvorak%26aufirst%3DC.%26aulast%3DHenkle%26aufirst%3DC.%26aulast%3DEllingham%26aufirst%3DT.%26aulast%3DPerlman%26aufirst%3DE.%2BJ.%26atitle%3DRecurrent%2520involvement%2520of%25202p23%2520in%2520inflammatory%2520myofibroblastic%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26spage%3D2776%26epage%3D2780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gascoyne, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamant, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Subero, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lestou, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller-Hermelink, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horsman, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auvigne, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siebert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delsol, G.</span></span> <span> </span><span class="NLM_article-title">ALK-positive diffuse large B-cell lymphoma is associated with clathrin-ALK rearrangements: report of 6 cases</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">2568</span>– <span class="NLM_lpage">2573</span>, <span class="refDoi"> DOI: 10.1182/blood-2003-03-0786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1182%2Fblood-2003-03-0786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=12763927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnslykurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2003&pages=2568-2573&author=R.+D.+Gascoyneauthor=L.+Lamantauthor=J.+I.+Martin-Suberoauthor=V.+S.+Lestouauthor=N.+L.+Harrisauthor=H.+K.+M%C3%BCller-Hermelinkauthor=J.+F.+Seymourauthor=L.+J.+Campbellauthor=D.+E.+Horsmanauthor=I.+Auvigneauthor=E.+Espinosauthor=R.+Siebertauthor=G.+Delsol&title=ALK-positive+diffuse+large+B-cell+lymphoma+is+associated+with+clathrin-ALK+rearrangements%3A+report+of+6+cases&doi=10.1182%2Fblood-2003-03-0786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">ALK-positive diffuse large B-cell lymphoma is associated with clathrin-ALK rearrangements: Report of 6 cases</span></div><div class="casAuthors">Gascoyne, Randy D.; Lamant, Laurence; Martin-Subero, Jose I.; Lestou, Valia S.; Harris, Nancy Lee; Mueller-Hermelink, Hans-Konrad; Seymour, John F.; Campbell, Lynda J.; Horsman, Douglas E.; Auvigne, Isabelle; Espinos, Estelle; Siebert, Reiner; Delsol, Georges</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2568-2573</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Expression of ALK protein by lymphoid cells and the description of variant anaplastic lymphoma kinase (ALK) translocations have typically been restricted to cases of T-cell and null anaplastic large-cell lymphoma (ALCL).  All such cases result from a novel fusion created by the ALK gene on chromosome 2p23 and NPM on 5q35 or other variant translocation partners.  A rare variant of diffuse large B-cell lymphoma (DLBCL), originally described in 1997, was thought to overexpress full-length ALK in contrast to a chimeric protein characteristic of ALCL.  However, full-length ALK protein lacks tyrosine kinase activity and thus the mechanism of oncogenesis has remained elusive.  We describe 6 cases of ALK+ DLBCL characterized by a simple or complex t(2;17)(p23;q23) involving the clathrin gene (CLTC) at chromosome band 17q23 and the ALK gene at chromosome band 2p23.  All cases were studied using fluorescence in situ hybridization (FISH), complemented in one case with std. cytogenetic anal., multicolor karyotyping (M-FISH), and reverse transcriptase-polymerase chain reaction.  These results clearly demonstrate that most cases of ALK+ DLBCL share the same mechanism of deregulated ALK expression.  Moreover, these results demonstrate the presence of CLTC-ALK fusions in these tumors and extend the list of diseases assocd. with this genetic abnormality to include classical T-cell or null ALCL, ALK+ DLBCL, and inflammatory myofibroblastic tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3UcmsuahiXLVg90H21EOLACvtfcHk0liGdxd3NBrlww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnslykurw%253D&md5=9eedc8c22c580dbadee982b4d3da35a8</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1182%2Fblood-2003-03-0786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2003-03-0786%26sid%3Dliteratum%253Aachs%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DLamant%26aufirst%3DL.%26aulast%3DMartin-Subero%26aufirst%3DJ.%2BI.%26aulast%3DLestou%26aufirst%3DV.%2BS.%26aulast%3DHarris%26aufirst%3DN.%2BL.%26aulast%3DM%25C3%25BCller-Hermelink%26aufirst%3DH.%2BK.%26aulast%3DSeymour%26aufirst%3DJ.%2BF.%26aulast%3DCampbell%26aufirst%3DL.%2BJ.%26aulast%3DHorsman%26aufirst%3DD.%2BE.%26aulast%3DAuvigne%26aufirst%3DI.%26aulast%3DEspinos%26aufirst%3DE.%26aulast%3DSiebert%26aufirst%3DR.%26aulast%3DDelsol%26aufirst%3DG.%26atitle%3DALK-positive%2520diffuse%2520large%2520B-cell%2520lymphoma%2520is%2520associated%2520with%2520clathrin-ALK%2520rearrangements%253A%2520report%2520of%25206%2520cases%26jtitle%3DBlood%26date%3D2003%26volume%3D102%26spage%3D2568%26epage%3D2573%26doi%3D10.1182%2Fblood-2003-03-0786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mossé, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laudenslager, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attiyeh, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laquaglia, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sennett, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laureys, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speleman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hakonarson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torkamani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schork, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodeur, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonini, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rappaport, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maris, J. M.</span></span> <span> </span><span class="NLM_article-title">Identification of ALK as a major familial neuroblastoma predisposition gene</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>455</i></span>,  <span class="NLM_fpage">930</span>– <span class="NLM_lpage">935</span>, <span class="refDoi"> DOI: 10.1038/nature07261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1038%2Fnature07261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=18724359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Ggur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=930-935&author=Y.+P.+Moss%C3%A9author=M.+Laudenslagerauthor=L.+Longoauthor=K.+A.+Coleauthor=A.+Woodauthor=E.+F.+Attiyehauthor=M.+J.+Laquagliaauthor=R.+Sennettauthor=J.+E.+Lynchauthor=P.+Perriauthor=G.+Laureysauthor=F.+Spelemanauthor=C.+Kimauthor=C.+Houauthor=H.+Hakonarsonauthor=A.+Torkamaniauthor=N.+J.+Schorkauthor=G.+M.+Brodeurauthor=G.+P.+Toniniauthor=E.+Rappaportauthor=M.+Devotoauthor=J.+M.+Maris&title=Identification+of+ALK+as+a+major+familial+neuroblastoma+predisposition+gene&doi=10.1038%2Fnature07261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of ALK as a major familial neuroblastoma predisposition gene</span></div><div class="casAuthors">Mosse, Yael P.; Laudenslager, Marci; Longo, Luca; Cole, Kristina A.; Wood, Andrew; Attiyeh, Edward F.; Laquaglia, Michael J.; Sennett, Rachel; Lynch, Jill E.; Perri, Patrizia; Laureys, Genevieve; Speleman, Frank; Kim, Cecilia; Hou, Cuiping; Hakonarson, Hakon; Torkamani, Ali; Schork, Nicholas J.; Brodeur, Garrett M.; Tonini, Gian P.; Rappaport, Eric; Devoto, Marcella; Maris, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">455</span>
        (<span class="NLM_cas:issue">7215</span>),
    <span class="NLM_cas:pages">930-935</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neuroblastoma is a childhood cancer that can be inherited, but the genetic etiol. is largely unknown.  Here we show that germline mutations in the anaplastic lymphoma kinase (ALK) gene explain most hereditary neuroblastomas, and that activating mutations can also be somatically acquired.  We first identified a significant linkage signal at chromosome bands 2p23-24 using a whole-genome scan in neuroblastoma pedigrees.  Re-sequencing of regional candidate genes identified three sep. germline missense mutations in the tyrosine kinase domain of ALK that segregated with the disease in eight sep. families.  Re-sequencing in 194 high-risk neuroblastoma samples showed somatically acquired mutations in the tyrosine kinase domain in 12.4% of samples.  Nine of the ten mutations map to crit. regions of the kinase domain and were predicted, with high probability, to be oncogenic drivers.  Mutations resulted in constitutive phosphorylation, and targeted knockdown of ALK mRNA resulted in profound inhibition of growth in all cell lines harboring mutant or amplified ALK, as well as in two out of six wild-type cell lines for ALK.  Our results demonstrate that heritable mutations of ALK are the main cause of familial neuroblastoma, and that germline or acquired activation of this cell-surface kinase is a tractable therapeutic target for this lethal pediatric malignancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMNOcIFf5xjbVg90H21EOLACvtfcHk0liGdxd3NBrlww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Ggur%252FP&md5=bb998ef8f6bfbd85f928263e13954ce4</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnature07261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07261%26sid%3Dliteratum%253Aachs%26aulast%3DMoss%25C3%25A9%26aufirst%3DY.%2BP.%26aulast%3DLaudenslager%26aufirst%3DM.%26aulast%3DLongo%26aufirst%3DL.%26aulast%3DCole%26aufirst%3DK.%2BA.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DAttiyeh%26aufirst%3DE.%2BF.%26aulast%3DLaquaglia%26aufirst%3DM.%2BJ.%26aulast%3DSennett%26aufirst%3DR.%26aulast%3DLynch%26aufirst%3DJ.%2BE.%26aulast%3DPerri%26aufirst%3DP.%26aulast%3DLaureys%26aufirst%3DG.%26aulast%3DSpeleman%26aufirst%3DF.%26aulast%3DKim%26aufirst%3DC.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DHakonarson%26aufirst%3DH.%26aulast%3DTorkamani%26aufirst%3DA.%26aulast%3DSchork%26aufirst%3DN.%2BJ.%26aulast%3DBrodeur%26aufirst%3DG.%2BM.%26aulast%3DTonini%26aufirst%3DG.%2BP.%26aulast%3DRappaport%26aufirst%3DE.%26aulast%3DDevoto%26aufirst%3DM.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26atitle%3DIdentification%2520of%2520ALK%2520as%2520a%2520major%2520familial%2520neuroblastoma%2520predisposition%2520gene%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D930%26epage%3D935%26doi%3D10.1038%2Fnature07261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murugan, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, M.</span></span> <span> </span><span class="NLM_article-title">Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">4403</span>– <span class="NLM_lpage">4411</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-4041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1158%2F0008-5472.CAN-10-4041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=21596819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlersb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=4403-4411&author=A.+K.+Muruganauthor=M.+Xing&title=Anaplastic+thyroid+cancers+harbor+novel+oncogenic+mutations+of+the+ALK+gene&doi=10.1158%2F0008-5472.CAN-10-4041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene</span></div><div class="casAuthors">Murugan, Avaniyapuram Kannan; Xing, Mingzhao</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4403-4411</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Thyroid cancer is the most common endocrine cancer, and targeted approaches to treat it pose considerable interest.  In this study, the authors report the discovery of ALK gene mutations in thyroid cancer that may rationalize clin. evaluation of anaplastic lymphoma kinase (ALK) inhibitors in this setting.  In undifferentiated anaplastic thyroid cancer (ATC), the authors identified 2 novel point mutations, C3592T and G3602A, in exon 23 of the ALK gene, with a prevalence of 11.11%, but found no mutations in the matched normal tissues or in well-differentiated thyroid cancers.  These 2 mutations, resulting in L1198F and G1201E amino acid changes, resp., both reside within the ALK tyrosine kinase domain where they dramatically increased tyrosine kinase activities.  Similarly, these mutations heightened the ability of ALK to activate the phosphatidylinositol 3-kinase (PI3K)/Akt and mitogen-activated protein (MAP) kinase pathways in established mouse cells.  Further investigations showed that these 2 ALK mutants strongly promoted cell focus formation, anchorage-independent growth, and cell invasion.  Similar oncogenic properties were obsd. in the neuroblastoma-assocd. ALK mutants K1062M and F1174L but not in wild-type ALK.  Overall, the authors' results reveal 2 novel gain-of-function mutations of ALK in certain ATCs, and they suggest efforts to clin. evaluate the use of ALK kinase inhibitors to treat patients who harbor ATCs with these mutations.  Cancer Res; 71(13); 4403-11.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLyuBgJ52gn7Vg90H21EOLACvtfcHk0lhrKVDRPGKmxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlersb4%253D&md5=0316be9945baab3a8d08b6c75e2cd90f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-4041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-4041%26sid%3Dliteratum%253Aachs%26aulast%3DMurugan%26aufirst%3DA.%2BK.%26aulast%3DXing%26aufirst%3DM.%26atitle%3DAnaplastic%2520thyroid%2520cancers%2520harbor%2520novel%2520oncogenic%2520mutations%2520of%2520the%2520ALK%2520gene%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D4403%26epage%3D4411%26doi%3D10.1158%2F0008-5472.CAN-10-4041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosby, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haack, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beausoleil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innocenti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rush, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comb, M. J.</span></span> <span> </span><span class="NLM_article-title">Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">3312</span>– <span class="NLM_lpage">3323</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-3931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1158%2F0008-5472.CAN-11-3931" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=22570254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsFKku7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=3312-3323&author=H.+Renauthor=Z.+P.+Tanauthor=X.+Zhuauthor=K.+Crosbyauthor=H.+Haackauthor=J.+M.+Renauthor=S.+Beausoleilauthor=A.+Moritzauthor=G.+Innocentiauthor=J.+Rushauthor=Y.+Zhangauthor=X.+M.+Zhouauthor=T.+L.+Guauthor=Y.+F.+Yangauthor=M.+J.+Comb&title=Identification+of+anaplastic+lymphoma+kinase+as+a+potential+therapeutic+target+in+ovarian+cancer&doi=10.1158%2F0008-5472.CAN-11-3931"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer</span></div><div class="casAuthors">Ren, Hong; Tan, Zhi-Ping; Zhu, Xin; Crosby, Katherine; Haack, Herbert; Ren, Jian-Min; Beausoleil, Sean; Moritz, Albrecht; Innocenti, Gregory; Rush, John; Zhang, Yi; Zhou, Xin-Min; Gu, Ting-Lei; Yang, Yi-Feng; Comb, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3312-3323</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Findings suggest the use of ALK kinase inhibitors now in clin. development as potential agents for treatment of some patients with serous ovarian carcinoma or stromal sarcoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi924EZXGeJ7Vg90H21EOLACvtfcHk0lhrKVDRPGKmxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsFKku7w%253D&md5=a263a135244b307b864c098769d10a7a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-3931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-3931%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DZ.%2BP.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DCrosby%26aufirst%3DK.%26aulast%3DHaack%26aufirst%3DH.%26aulast%3DRen%26aufirst%3DJ.%2BM.%26aulast%3DBeausoleil%26aufirst%3DS.%26aulast%3DMoritz%26aufirst%3DA.%26aulast%3DInnocenti%26aufirst%3DG.%26aulast%3DRush%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.%2BM.%26aulast%3DGu%26aufirst%3DT.%2BL.%26aulast%3DYang%26aufirst%3DY.%2BF.%26aulast%3DComb%26aufirst%3DM.%2BJ.%26atitle%3DIdentification%2520of%2520anaplastic%2520lymphoma%2520kinase%2520as%2520a%2520potential%2520therapeutic%2520target%2520in%2520ovarian%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D3312%26epage%3D3323%26doi%3D10.1158%2F0008-5472.CAN-11-3931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naeve, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirstein, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, D. P.</span></span> <span> </span><span class="NLM_article-title">ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin’s lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2175</span>– <span class="NLM_lpage">2188</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1201062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1038%2Fsj.onc.1201062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=9174053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADyaK2sXjs1Gnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1997&pages=2175-2188&author=S.+W.+Morrisauthor=C.+Naeveauthor=P.+Mathewauthor=P.+L.+Jamesauthor=M.+N.+Kirsteinauthor=X.+Cuiauthor=D.+P.+Witte&title=ALK%2C+the+chromosome+2+gene+locus+altered+by+the+t%282%3B5%29+in+non-Hodgkin%E2%80%99s+lymphoma%2C+encodes+a+novel+neural+receptor+tyrosine+kinase+that+is+highly+related+to+leukocyte+tyrosine+kinase+%28LTK%29&doi=10.1038%2Fsj.onc.1201062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)</span></div><div class="casAuthors">Morris, Stephan W.; Naeve, Clayton; Mathew, Prasad; James, Payton L.; Kirstein, Mark N.; Cui, Xiaoli; Witte, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2175-2188</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Stockton</span>)
        </div><div class="casAbstract">Anaplastic Lymphoma Kinase (ALK) was originally identified as a member of the insulin receptor subfamily of receptor tyrosine kinases that acquires transforming capability when truncated and fused to nucleophosmin (NPM) in the t(2;5) chromosomal rearrangement assocd. with non-Hodgkin's lymphoma, but further insights into its normal structure and function are lacking.  Here, we characterize a full-length normal human ALK cDNA and its product, and det. the pattern of expression of its murine homolog in embryonic and adult tissues as a first step toward the functional assessment of the receptor.  Anal. of the 6226 bp ALK cDNA identified an open reading frame encoding a 1620-amino acid (aa) protein of predicted mass ∼177 kDa that is most closely related to leukocyte tyrosine kinase (LTK), the two exhibiting 57% aa identity and 71% similarity over their region of overlap.  Biochem. anal. demonstrated that the ∼177 kDa ALK polypeptide core undergoes co-translational N-linked glycosylation, emerging in its mature form as a 200 kDa single chain receptor.  Surface labeling studies indicated that the 200 kDa glycoprotein is exposed at the cell membrane, consistent with the prediction that ALK serves as the receptor for an unidentified ligand(s).  In situ hybridization studies revealed Alk expression beginning on embryonic day 11 and persisting into the neonatal and adult periods of development.  Alk transcripts were confined to the nervous system and included several thalamic and hypothalamic nuclei; the trigeminal, facial, and acoustic cranial ganglia; the anterior horns of the spinal cord in the region of the developing motor neurons; the sympathetic chain; and the ganglion cells of the gut.  Thus, ALK is a novel orphan receptor tyrosine kinase that appears to play an important role in the normal development and function of the nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4F75l637BuLVg90H21EOLACvtfcHk0lhrKVDRPGKmxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjs1Gnt7k%253D&md5=fdf7a14e88be831b2577891145cb6082</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1201062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1201062%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DNaeve%26aufirst%3DC.%26aulast%3DMathew%26aufirst%3DP.%26aulast%3DJames%26aufirst%3DP.%2BL.%26aulast%3DKirstein%26aufirst%3DM.%2BN.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DWitte%26aufirst%3DD.%2BP.%26atitle%3DALK%252C%2520the%2520chromosome%25202%2520gene%2520locus%2520altered%2520by%2520the%2520t%25282%253B5%2529%2520in%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%252C%2520encodes%2520a%2520novel%2520neural%2520receptor%2520tyrosine%2520kinase%2520that%2520is%2520highly%2520related%2520to%2520leukocyte%2520tyrosine%2520kinase%2520%2528LTK%2529%26jtitle%3DOncogene%26date%3D1997%26volume%3D14%26spage%3D2175%26epage%3D2188%26doi%3D10.1038%2Fsj.onc.1201062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwahara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimoto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cupples, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bucay, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arakawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratzkin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span> <span> </span><span class="NLM_article-title">Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">439</span>– <span class="NLM_lpage">449</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1200849</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1038%2Fsj.onc.1200849" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=9053841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADyaK2sXht1ensbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1997&pages=439-449&author=T.+Iwaharaauthor=J.+Fujimotoauthor=D.+Wenauthor=R.+Cupplesauthor=N.+Bucayauthor=T.+Arakawaauthor=S.+Moriauthor=B.+Ratzkinauthor=T.+Yamamoto&title=Molecular+characterization+of+ALK%2C+a+receptor+tyrosine+kinase+expressed+specifically+in+the+nervous+system&doi=10.1038%2Fsj.onc.1200849"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system</span></div><div class="casAuthors">Iwahara, Toshinori; Fujimoto, Jiro; Wen, Duanzhi; Cupples, Rod; Bucay, Nathan; Arakawa, Tsutomu; Mori, Shigeo; Ratzkin, Barry; Yamamoto, Tadashi</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">439-449</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Stockton</span>)
        </div><div class="casAbstract">The 2;5 chromosomal translocation is frequently assocd. with anaplastic large cell lymphomas (ALCLs).  The translocation creates a fusion gene consisting of the alk (anaplastic lymphoma kinase) gene and the nucelophosmin (npm) gene: the 3' half of alk derived from chromosome 2 is fused to the 5' portion of npm from chromosome 5.  A recent study shows that the product of the npm-alk fusion gene is oncogenic.  To help understand how the npm-alk oncogene transform cells, it is important to investigate the normal biol. function of the alk gene product, ALK.  Here, we show mol. cloning of cDNAs for both the human and mouse ALK proteins.  The deduced amino acid sequences reveal that ALK is a novel receptor protein-tyrosine kinase having a putative transmembrane domain and an extracellular domain.  These sequences are absent in the product of the transforming npm-alk gene.  ALK shows the greatest sequence similarity to LTK (leukocyte tyrosine kinase) whose biol. function is presently unknown.  RNA blot hybridization anal. of various tissues reveals that the alk mRNA is dominantly detected in the brain and spinal cord.  Immunoblotting with anti-ALK antibody shows that ALK is highly expressed in the neonatal brain.  Furthermore, RNA in situ hybridization anal. shows that the alk mRNA is dominantly expressed in neurons in specific regions of the nervous system such as the thalamus, mid-brain, olfactory bulb, and ganglia of embryonic and neonatal mice.  These data suggest that ALK plays an important role(s) in the development of the brain and exerts its effects on specific neurons in the nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-hGYy9uKgGbVg90H21EOLACvtfcHk0liUVTyrNYt1hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXht1ensbs%253D&md5=7143e0a25247dd354bbf564cfd1702b6</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1200849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1200849%26sid%3Dliteratum%253Aachs%26aulast%3DIwahara%26aufirst%3DT.%26aulast%3DFujimoto%26aufirst%3DJ.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DCupples%26aufirst%3DR.%26aulast%3DBucay%26aufirst%3DN.%26aulast%3DArakawa%26aufirst%3DT.%26aulast%3DMori%26aufirst%3DS.%26aulast%3DRatzkin%26aufirst%3DB.%26aulast%3DYamamoto%26aufirst%3DT.%26atitle%3DMolecular%2520characterization%2520of%2520ALK%252C%2520a%2520receptor%2520tyrosine%2520kinase%2520expressed%2520specifically%2520in%2520the%2520nervous%2520system%26jtitle%3DOncogene%26date%3D1997%26volume%3D14%26spage%3D439%26epage%3D449%26doi%3D10.1038%2Fsj.onc.1200849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran-Dubé, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nambu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botrous, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grodsky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padrique, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mroczkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6342</span>– <span class="NLM_lpage">6363</span>, <span class="refDoi"> DOI: 10.1021/jm2007613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&author=J.+J.+Cuiauthor=M.+Tran-Dub%C3%A9author=H.+Shenauthor=M.+Nambuauthor=P.+P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=E.+Padriqueauthor=G.+Altonauthor=S.+Timofeevskiauthor=S.+Yamazakiauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure+based+drug+design+of+crizotinib+%28PF-02341066%29%2C+a+potent+and+selective+dual+inhibitor+of+mesenchymal-epithelial+transition+factor+%28c-MET%29+kinase+and+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1021%2Fjm2007613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Cui, J. Jean; Tran-Dube, Michelle; Shen, Hong; Nambu, Mitchell; Kung, Pei-Pei; Pairish, Mason; Jia, Lei; Meng, Jerry; Funk, Lee; Botrous, Iriny; McTigue, Michele; Grodsky, Neil; Ryan, Kevin; Padrique, Ellen; Alton, Gordon; Timofeevski, Sergei; Yamazaki, Shinji; Li, Qiuhua; Zou, Helen; Christensen, James; Mroczkowski, Barbara; Bender, Steve; Kania, Robert S.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6342-6363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the crit. roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncol. targets for therapeutic intervention.  The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design.  A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3.  In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE).  Further optimization of the lead series generated the clin. candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHs_cKJ-U3t7Vg90H21EOLACvtfcHk0liUVTyrNYt1hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN&md5=dbab4c1b3e7c76180dbad04be2b6a474</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dub%25C3%25A9%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DPadrique%26aufirst%3DE.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure%2520based%2520drug%2520design%2520of%2520crizotinib%2520%2528PF-02341066%2529%252C%2520a%2520potent%2520and%2520selective%2520dual%2520inhibitor%2520of%2520mesenchymal-epithelial%2520transition%2520factor%2520%2528c-MET%2529%2520kinase%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6342%26epage%3D6363%26doi%3D10.1021%2Fjm2007613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marsilje, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkisova, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pferdekamper, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steensma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopiuk, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groessl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phimister, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aycinena, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanewsky, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P. Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5675</span>– <span class="NLM_lpage">5690</span>, <span class="refDoi"> DOI: 10.1021/jm400402q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400402q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptVWjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5675-5690&author=T.+H.+Marsiljeauthor=W.+Peiauthor=B.+Chenauthor=W.+Luauthor=T.+Unoauthor=Y.+Jinauthor=T.+Jiangauthor=S.+Kimauthor=N.+Liauthor=M.+Warmuthauthor=Y.+Sarkisovaauthor=F.+Sunauthor=A.+Steffyauthor=A.+C.+Pferdekamperauthor=A.+G.+Liauthor=S.+B.+Josephauthor=Y.+Kimauthor=B.+Liuauthor=T.+Tuntlandauthor=X.+Cuiauthor=N.+S.+Grayauthor=R.+Steensmaauthor=Y.+Wanauthor=J.+Jiangauthor=G.+Chopiukauthor=J.+Liauthor=W.+P.+Gordonauthor=W.+Richmondauthor=K.+Johnsonauthor=J.+Changauthor=T.+Groesslauthor=Y.+Q.+Heauthor=A.+Phimisterauthor=A.+Aycinenaauthor=C.+C.+Leeauthor=B.+Bursulayaauthor=D.+S.+Karanewskyauthor=H.+M.+Seidelauthor=J.+L.+Harrisauthor=P.+Y.+Michellys&title=Synthesis%2C+structure-activity+relationships%2C+and+in+vivo+efficacy+of+the+novel+potent+and+selective+anaplastic+lymphoma+kinase+%28ALK%29+inhibitor+5-chloro-N2-%282-isopropoxy-5-methyl-4-%28piperidin-4-yl%29phenyl%29-N4-%282-%28isopropylsulfonyl%29phenyl%29pyrimidine-2%2C4-diamine+%28LDK378%29+currently+in+phase+1+and+phase+2+clinical+trials&doi=10.1021%2Fjm400402q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Structure-Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials</span></div><div class="casAuthors">Marsilje, Thomas H.; Pei, Wei; Chen, Bei; Lu, Wenshuo; Uno, Tetsuo; Jin, Yunho; Jiang, Tao; Kim, Sungjoon; Li, Nanxin; Warmuth, Markus; Sarkisova, Yelena; Sun, Frank; Steffy, Auzon; Pferdekamper, AnneMarie C.; Li, Allen G.; Joseph, Sean B.; Kim, Young; Liu, Bo; Tuntland, Tove; Cui, Xiaoming; Gray, Nathanael S.; Steensma, Ruo; Wan, Yongqin; Jiang, Jiqing; Chopiuk, Greg; Li, Jie; Gordon, W. Perry; Richmond, Wendy; Johnson, Kevin; Chang, Jonathan; Groessl, Todd; He, You-Qun; Phimister, Andrew; Aycinena, Alex; Lee, Christian C.; Bursulaya, Badry; Karanewsky, Donald S.; Seidel, H. Martin; Harris, Jennifer L.; Michellys, Pierre-Yves</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5675-5690</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis, preclin. profile, and in vivo efficacy in rat xenograft models of the novel and selective anaplastic lymphoma kinase inhibitor (I; LDK378) are described.  In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation ALK inhibitor (II; TAE684).  Compd. I is currently in phase 1 and phase 2 clin. trials with substantial antitumor activity being obsd. in ALK-pos. cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ-y7ZuX2XLLVg90H21EOLACvtfcHk0lhMtssONqYvBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptVWjs7g%253D&md5=4b8f66e4acb27efe814956d7d0016068</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm400402q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400402q%26sid%3Dliteratum%253Aachs%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DPei%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DUno%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DSarkisova%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSteffy%26aufirst%3DA.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DA.%2BG.%26aulast%3DJoseph%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGordon%26aufirst%3DW.%2BP.%26aulast%3DRichmond%26aufirst%3DW.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DY.%2BQ.%26aulast%3DPhimister%26aufirst%3DA.%26aulast%3DAycinena%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DKaranewsky%26aufirst%3DD.%2BS.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DMichellys%26aufirst%3DP.%2BY.%26atitle%3DSynthesis%252C%2520structure-activity%2520relationships%252C%2520and%2520in%2520vivo%2520efficacy%2520of%2520the%2520novel%2520potent%2520and%2520selective%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitor%25205-chloro-N2-%25282-isopropoxy-5-methyl-4-%2528piperidin-4-yl%2529phenyl%2529-N4-%25282-%2528isopropylsulfonyl%2529phenyl%2529pyrimidine-2%252C4-diamine%2520%2528LDK378%2529%2520currently%2520in%2520phase%25201%2520and%2520phase%25202%2520clinical%2520trials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5675%26epage%3D5690%26doi%3D10.1021%2Fjm400402q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asoh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuichi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morikami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oikawa, N.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel tetracyclic compounds as anaplastic lymphoma kinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3788</span>– <span class="NLM_lpage">3793</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.04.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.bmcl.2011.04.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=21561771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntFKhtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=3788-3793&author=K.+Kinoshitaauthor=Y.+Onoauthor=T.+Emuraauthor=K.+Asohauthor=N.+Furuichiauthor=T.+Itoauthor=H.+Kawadaauthor=S.+Tanakaauthor=K.+Morikamiauthor=T.+Tsukaguchiauthor=H.+Sakamotoauthor=T.+Tsukudaauthor=N.+Oikawa&title=Discovery+of+novel+tetracyclic+compounds+as+anaplastic+lymphoma+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2011.04.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel tetracyclic compounds as anaplastic lymphoma kinase inhibitors</span></div><div class="casAuthors">Kinoshita, Kazutomo; Ono, Yoshiyuki; Emura, Takashi; Asoh, Kohsuke; Furuichi, Noriyuki; Ito, Toshiya; Kawada, Hatsuo; Tanaka, Shota; Morikami, Kenji; Tsukaguchi, Toshiyuki; Sakamoto, Hiroshi; Tsukuda, Takuo; Oikawa, Nobuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3788-3793</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) receptor tyrosine kinase is considered a promising therapeutic target for human cancers.  We identified novel tetracyclic derivs. as potent ALK inhibitors.  Among them, compd. 27 showed strong cytotoxicity against KARPAS-299 with an IC50 value of 21 nM and significant antitumor efficacy in ALK fusion-pos. blood and solid cancer xenograft models in mice without body wt. loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfNlq9E4lTLbVg90H21EOLACvtfcHk0lhMtssONqYvBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntFKhtrk%253D&md5=542e105e38318a56462edef6f0ea4620</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.04.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.04.020%26sid%3Dliteratum%253Aachs%26aulast%3DKinoshita%26aufirst%3DK.%26aulast%3DOno%26aufirst%3DY.%26aulast%3DEmura%26aufirst%3DT.%26aulast%3DAsoh%26aufirst%3DK.%26aulast%3DFuruichi%26aufirst%3DN.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DKawada%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DS.%26aulast%3DMorikami%26aufirst%3DK.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DOikawa%26aufirst%3DN.%26atitle%3DDiscovery%2520of%2520novel%2520tetracyclic%2520compounds%2520as%2520anaplastic%2520lymphoma%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D3788%26epage%3D3793%26doi%3D10.1016%2Fj.bmcl.2011.04.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asoh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuichi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohwada, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyagi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takanashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oikawa, N.</span></span> <span> </span><span class="NLM_article-title">9-substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as highly selective and potent anaplastic lymphoma kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6286</span>– <span class="NLM_lpage">6294</span>, <span class="refDoi"> DOI: 10.1021/jm200652u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200652u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVOns7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6286-6294&author=K.+Kinoshitaauthor=T.+Kobayashiauthor=K.+Asohauthor=N.+Furuichiauthor=T.+Itoauthor=H.+Kawadaauthor=S.+Haraauthor=J.+Ohwadaauthor=K.+Hattoriauthor=T.+Miyagiauthor=W.+S.+Hongauthor=M.+J.+Parkauthor=K.+Takanashiauthor=T.+Tsukaguchiauthor=H.+Sakamotoauthor=T.+Tsukudaauthor=N.+Oikawa&title=9-substituted+6%2C6-dimethyl-11-oxo-6%2C11-dihydro-5H-benzo%5Bb%5Dcarbazoles+as+highly+selective+and+potent+anaplastic+lymphoma+kinase+inhibitors&doi=10.1021%2Fjm200652u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase Inhibitors</span></div><div class="casAuthors">Kinoshita, Kazutomo; Kobayashi, Takamitsu; Asoh, Kohsuke; Furuichi, Noriyuki; Ito, Toshiya; Kawada, Hatsuo; Hara, Sousuke; Ohwada, Jun; Hattori, Kazuo; Miyagi, Takuho; Hong, Woo-Sang; Park, Min-Jeong; Takanashi, Kenji; Tsukaguchi, Toshiyuki; Sakamoto, Hiroshi; Tsukuda, Takuo; Oikawa, Nobuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6286-6294</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">9-Substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles were discovered as highly selective and potent anaplastic lymphoma kinase (ALK) inhibitors by structure-based drug design.  The high target selectivity was achieved by introducing a substituent close to the E0 region of the ATP binding site, which has a unique amino acid sequence.  Among the identified inhibitors, compd. 13d (I) showed highly selective and potent inhibitory activity against ALK with an IC50 value of 2.9 nM and strong antiproliferative activity against KARPAS-299 with an IC50 value of 12.8 nM.  The compd. also displayed significant antitumor efficacy in an established ALK fusion gene-pos. anaplastic large-cell lymphoma (ALCL) xenograft model in mice without body wt. loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfpJsdIdDvO7Vg90H21EOLACvtfcHk0lg6uh2D_v3vLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVOns7vP&md5=6293368243c840e12beefc8c8d6bb69a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm200652u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200652u%26sid%3Dliteratum%253Aachs%26aulast%3DKinoshita%26aufirst%3DK.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DAsoh%26aufirst%3DK.%26aulast%3DFuruichi%26aufirst%3DN.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DKawada%26aufirst%3DH.%26aulast%3DHara%26aufirst%3DS.%26aulast%3DOhwada%26aufirst%3DJ.%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DMiyagi%26aufirst%3DT.%26aulast%3DHong%26aufirst%3DW.%2BS.%26aulast%3DPark%26aufirst%3DM.%2BJ.%26aulast%3DTakanashi%26aufirst%3DK.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DOikawa%26aufirst%3DN.%26atitle%3D9-substituted%25206%252C6-dimethyl-11-oxo-6%252C11-dihydro-5H-benzo%255Bb%255Dcarbazoles%2520as%2520highly%2520selective%2520and%2520potent%2520anaplastic%2520lymphoma%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6286%26epage%3D6294%26doi%3D10.1021%2Fjm200652u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asoh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuichi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohwada, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyagi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takanashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oikawa, N.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1271</span>– <span class="NLM_lpage">1280</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.12.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.bmc.2011.12.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=22225917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSmu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=1271-1280&author=K.+Kinoshitaauthor=K.+Asohauthor=N.+Furuichiauthor=T.+Itoauthor=H.+Kawadaauthor=S.+Haraauthor=J.+Ohwadaauthor=T.+Miyagiauthor=T.+Kobayashiauthor=K.+Takanashiauthor=T.+Tsukaguchiauthor=H.+Sakamotoauthor=T.+Tsukudaauthor=N.+Oikawa&title=Design+and+synthesis+of+a+highly+selective%2C+orally+active+and+potent+anaplastic+lymphoma+kinase+inhibitor+%28CH5424802%29&doi=10.1016%2Fj.bmc.2011.12.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)</span></div><div class="casAuthors">Kinoshita, Kazutomo; Asoh, Kohsuke; Furuichi, Noriyuki; Ito, Toshiya; Kawada, Hatsuo; Hara, Sousuke; Ohwada, Jun; Miyagi, Takuho; Kobayashi, Takamitsu; Takanashi, Kenji; Tsukaguchi, Toshiyuki; Sakamoto, Hiroshi; Tsukuda, Takuo; Oikawa, Nobuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1271-1280</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) receptor tyrosine kinase is considered an attractive therapeutic target for human cancers, esp. non-small cell lung cancer (NSCLC).  Our previous study revealed that 8,9-side-chains of 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole scaffold crucially affected kinase selectivity, cellular activity, and metabolic stability.  In this work, we optimized the side-chains and identified highly selective, orally active and potent ALK inhibitor CH5424802 (18a) as the clin. candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG6Im56-4v17Vg90H21EOLACvtfcHk0lg6uh2D_v3vLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSmu70%253D&md5=cff263d2dd8c66de9fd687530fdadb06</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.12.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.12.021%26sid%3Dliteratum%253Aachs%26aulast%3DKinoshita%26aufirst%3DK.%26aulast%3DAsoh%26aufirst%3DK.%26aulast%3DFuruichi%26aufirst%3DN.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DKawada%26aufirst%3DH.%26aulast%3DHara%26aufirst%3DS.%26aulast%3DOhwada%26aufirst%3DJ.%26aulast%3DMiyagi%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DTakanashi%26aufirst%3DK.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DOikawa%26aufirst%3DN.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520a%2520highly%2520selective%252C%2520orally%2520active%2520and%2520potent%2520anaplastic%2520lymphoma%2520kinase%2520inhibitor%2520%2528CH5424802%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D1271%26epage%3D1280%26doi%3D10.1016%2Fj.bmc.2011.12.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwight, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodd, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toms, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parillon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anjum, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keats, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohemmad, Q. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narasimhan, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgarno, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of brigatinib (AP26113), a phosphine oxide-containing, potent, orally active inhibitor of anaplastic lymphoma kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4948</span>– <span class="NLM_lpage">4964</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00306</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00306" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlCgur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4948-4964&author=W.+S.+Huangauthor=S.+Liuauthor=D.+Zouauthor=M.+Thomasauthor=Y.+Wangauthor=T.+Zhouauthor=J.+Romeroauthor=A.+Kohlmannauthor=F.+Liauthor=J.+Qiauthor=L.+Caiauthor=T.+A.+Dwightauthor=Y.+Xuauthor=R.+Xuauthor=R.+Doddauthor=A.+Tomsauthor=L.+Parillonauthor=X.+Luauthor=R.+Anjumauthor=S.+Zhangauthor=F.+Wangauthor=J.+Keatsauthor=S.+D.+Wardwellauthor=Y.+Ningauthor=Q.+Xuauthor=L.+E.+Moranauthor=Q.+K.+Mohemmadauthor=H.+G.+Jangauthor=T.+Clacksonauthor=N.+I.+Narasimhanauthor=V.+M.+Riveraauthor=X.+Zhuauthor=D.+Dalgarnoauthor=W.+C.+Shakespeare&title=Discovery+of+brigatinib+%28AP26113%29%2C+a+phosphine+oxide-containing%2C+potent%2C+orally+active+inhibitor+of+anaplastic+lymphoma+kinase&doi=10.1021%2Facs.jmedchem.6b00306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase</span></div><div class="casAuthors">Huang, Wei-Sheng; Liu, Shuangying; Zou, Dong; Thomas, Mathew; Wang, Yihan; Zhou, Tianjun; Romero, Jan; Kohlmann, Anna; Li, Feng; Qi, Jiwei; Cai, Lisi; Dwight, Timothy A.; Xu, Yongjin; Xu, Rongsong; Dodd, Rory; Toms, Angela; Parillon, Lois; Lu, Xiaohui; Anjum, Rana; Zhang, Sen; Wang, Frank; Keats, Jeffrey; Wardwell, Scott D.; Ning, Yaoyu; Xu, Qihong; Moran, Lauren E.; Mohemmad, Qurish K.; Jang, Hyun Gyung; Clackson, Tim; Narasimhan, Narayana I.; Rivera, Victor M.; Zhu, Xiaotian; Dalgarno, David; Shakespeare, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4948-4964</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the treatment of echinoderm microtubule-assocd. protein-like 4 (EML4)-anaplastic lymphoma kinase pos. (ALK+) non-small-cell lung cancer (NSCLC), secondary mutations within the ALK kinase domain have emerged as a major resistance mechanism to both first- and second-generation ALK inhibitors.  This report describes the design and synthesis of a series of 2,4-diarylaminopyrimidine-based potent and selective ALK inhibitors culminating in identification of the investigational clin. candidate brigatinib.  A unique structural feature of brigatinib is a phosphine oxide, an overlooked but novel hydrogen-bond acceptor that drives potency and selectivity in addn. to favorable ADME properties.  Brigatinib displayed low nanomolar IC50s against native ALK and all tested clin. relevant ALK mutants in both enzyme-based biochem. and cell-based viability assays and demonstrated efficacy in multiple ALK+ xenografts in mice, including Karpas-299 (anaplastic large-cell lymphomas [ALCL]) and H3122 (NSCLC).  Brigatinib represents the most clin. advanced phosphine oxide-contg. drug candidate to date and is currently being evaluated in a global phase 2 registration trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5_iqprSA4QbVg90H21EOLACvtfcHk0lhVZZE2V7yixQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlCgur8%253D&md5=4cb93ff587579c97fda8aff0c7d43317</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00306%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%2BS.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DRomero%26aufirst%3DJ.%26aulast%3DKohlmann%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DL.%26aulast%3DDwight%26aufirst%3DT.%2BA.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DDodd%26aufirst%3DR.%26aulast%3DToms%26aufirst%3DA.%26aulast%3DParillon%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWardwell%26aufirst%3DS.%2BD.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMoran%26aufirst%3DL.%2BE.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DJang%26aufirst%3DH.%2BG.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3DDiscovery%2520of%2520brigatinib%2520%2528AP26113%2529%252C%2520a%2520phosphine%2520oxide-containing%252C%2520potent%252C%2520orally%2520active%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4948%26epage%3D4964%26doi%3D10.1021%2Facs.jmedchem.6b00306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deal, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4720</span>– <span class="NLM_lpage">4744</span>, <span class="refDoi"> DOI: 10.1021/jm500261q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500261q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4720-4744&author=T.+W.+Johnsonauthor=P.+F.+Richardsonauthor=S.+Baileyauthor=A.+Broounauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=J.+J.+Cuiauthor=J.+G.+Dealauthor=Y.+L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=Q.+Huangauthor=R.+S.+Kaniaauthor=J.+C.+Kathauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=L.+Lingardoauthor=W.+Liuauthor=M.+McTigueauthor=C.+L.+Palmerauthor=N.+W.+Sachauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=H.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Discovery+of+%2810R%29-7-amino-12-fluoro-2%2C10%2C16-trimethyl-15-oxo-10%2C15%2C16%2C17-tetrahydro-2H-8%2C4-%28metheno%29pyrazolo%5B4%2C3-h%5D%5B2%2C5%2C11%5D-benzoxadiazacyclotetradecine-3-carbonitrile+%28PF-06463922%29%2C+a+macrocyclic+inhibitor+of+anaplastic+lymphoma+kinase+%28ALK%29+and+c-ros+oncogene+1+%28ROS1%29+with+preclinical+brain+exposure+and+broad-spectrum+potency+against+ALK-resistant+mutations&doi=10.1021%2Fjm500261q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span></div><div class="casAuthors">Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4720-4744</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-pos. non-small-cell lung carcinoma patients, progression during treatment eventually develops.  Resistant patient samples revealed a variety of point mutations in the kinase domain of ALK, including the L1196M gatekeeper mutation.  In addn., some patients progress due to cancer metastasis in the brain.  Using structure-based drug design, lipophilic efficiency, and phys.-property-based optimization, highly potent macrocyclic ALK inhibitors were prepd. with good absorption, distribution, metab., and excretion (ADME), low propensity for p-glycoprotein 1-mediated efflux, and good passive permeability.  These structurally unusual macrocyclic inhibitors were potent against wild-type ALK and clin. reported ALK kinase domain mutations.  Significant synthetic challenges were overcome, utilizing novel transformations to enable the use of these macrocycles in drug discovery paradigms.  This work led to the discovery of 8k (PF-06463922), combining broad-spectrum potency, central nervous system ADME, and a high degree of kinase selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqXkb49ad31bVg90H21EOLACvtfcHk0lhVZZE2V7yixQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D&md5=db21844f8e9a2f9ca5953bca56ad7b1c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm500261q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500261q%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDiscovery%2520of%2520%252810R%2529-7-amino-12-fluoro-2%252C10%252C16-trimethyl-15-oxo-10%252C15%252C16%252C17-tetrahydro-2H-8%252C4-%2528metheno%2529pyrazolo%255B4%252C3-h%255D%255B2%252C5%252C11%255D-benzoxadiazacyclotetradecine-3-carbonitrile%2520%2528PF-06463922%2529%252C%2520a%2520macrocyclic%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520and%2520c-ros%2520oncogene%25201%2520%2528ROS1%2529%2520with%2520preclinical%2520brain%2520exposure%2520and%2520broad-spectrum%2520potency%2520against%2520ALK-resistant%2520mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4720%26epage%3D4744%26doi%3D10.1021%2Fjm500261q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, T.</span></span> <span> </span><span class="NLM_article-title">Drug discovery targeting anaplastic lymphoma kinase (ALK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">10927</span>– <span class="NLM_lpage">10954</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00446</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00446" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFyrur3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10927-10954&author=X.+Kongauthor=P.+Panauthor=H.+Sunauthor=H.+Xiaauthor=X.+Wangauthor=Y.+Liauthor=T.+Hou&title=Drug+discovery+targeting+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1021%2Facs.jmedchem.9b00446"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Kong, Xiaotian; Pan, Peichen; Sun, Huiyong; Xia, Hongguang; Wang, Xuwen; Li, Youyong; Hou, Tingjun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10927-10954</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  As a receptor tyrosine kinase of insulin receptor (IR) subfamily, anaplastic lymphoma kinase (ALK) has been validated to play important roles in various cancers, esp. anaplastic large cell lymphoma (ALCL), nonsmall cell lung cancer (NSCLC), and neuroblastomas.  Currently, five small-mol. inhibitors of ALK, including Crizotinib, Ceritinib, Alectinib, Brigatinib, and Lorlatinib, have been approved by the U.S.  Food and Drug Administration (FDA) against ALK-pos. NSCLCs.  Novel type-I1/2 and type-II ALK inhibitors with improved kinase selectivity and enhanced capability to combat drug resistance have also been reported.  Moreover, the "proteolysis targeting chimera" (PROTAC) technique has been successfully applied in developing ALK degraders, which opened a new avenue for targeted ALK therapies.  This review provides an overview of the physiol. and biol. functions of ALK, the discovery and development of drugs targeting ALK by focusing on their chemotypes, activity, selectivity, and resistance as well as potential therapeutic strategies to overcome drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7LmONQduM_bVg90H21EOLACvtfcHk0lhnC1qZfctNBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFyrur3E&md5=6c9aadf015cba2f11b2c2f747eea3eec</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00446%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DX.%26aulast%3DPan%26aufirst%3DP.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DXia%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHou%26aufirst%3DT.%26atitle%3DDrug%2520discovery%2520targeting%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D10927%26epage%3D10954%26doi%3D10.1021%2Facs.jmedchem.9b00446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Targeting ALK: precision medicine takes on drug resistance</span>. <i>Cancer Discov.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">155</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-16-1123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1158%2F2159-8290.CD-16-1123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=28122866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVCjs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=137-155&author=J.+J.+Linauthor=G.+J.+Rielyauthor=A.+T.+Shaw&title=Targeting+ALK%3A+precision+medicine+takes+on+drug+resistance&doi=10.1158%2F2159-8290.CD-16-1123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting ALK: Precision Medicine Takes on Drug Resistance</span></div><div class="casAuthors">Lin, Jessica J.; Riely, Gregory J.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">137-155</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Anaplastic lymphoma kinase (ALK) is a validated mol. target in several ALK-rearranged malignancies, including non-small cell lung cancer.  However, the clin. benefit of targeting ALK using tyrosine kinase inhibitors (TKI) is almost universally limited by the emergence of drug resistance.  Diverse mechanisms of resistance to ALK TKIs have now been discovered, and these basic mechanisms are informing the development of novel therapeutic strategies to overcome resistance in the clinic.  In this review, we summarize the current successes and challenges of targeting ALK.  Significance: Effective long-term treatment of ALK-rearranged cancers requires a mechanistic understanding of resistance to ALK TKIs so that rational therapies can be selected to combat resistance.  This review underscores the importance of serial biopsies in capturing the dynamic therapeutic vulnerabilities within a patient's tumor and offers a perspective into the complexity of on-target and off-target ALK TKI resistance mechanisms.  Therapeutic strategies that can successfully overcome, and potentially prevent, these resistance mechanisms will have the greatest impact on patient outcome.  Cancer Discov; 7(2); 137-55. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLmMz7s4fYu7Vg90H21EOLACvtfcHk0lhnC1qZfctNBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVCjs7c%253D&md5=6f7d5358d13c75b215b0d1e6ce8ac8ff</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-16-1123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-16-1123%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DJ.%2BJ.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DTargeting%2520ALK%253A%2520precision%2520medicine%2520takes%2520on%2520drug%2520resistance%26jtitle%3DCancer%2520Discov.%26date%3D2017%26volume%3D7%26spage%3D137%26epage%3D155%26doi%3D10.1158%2F2159-8290.CD-16-1123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takashima, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yatabe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haruta, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsudomi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanio, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mano, H.</span></span> <span> </span><span class="NLM_article-title">EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">1734</span>– <span class="NLM_lpage">1739</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1007478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1056%2FNEJMoa1007478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=20979473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1734-1739&author=Y.+L.+Choiauthor=M.+Sodaauthor=Y.+Yamashitaauthor=T.+Uenoauthor=J.+Takashimaauthor=T.+Nakajimaauthor=Y.+Yatabeauthor=K.+Takeuchiauthor=T.+Hamadaauthor=H.+Harutaauthor=Y.+Ishikawaauthor=H.+Kimuraauthor=T.+Mitsudomiauthor=Y.+Tanioauthor=H.+Mano&title=EML4-ALK+mutations+in+lung+cancer+that+confer+resistance+to+ALK+inhibitors&doi=10.1056%2FNEJMoa1007478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors</span></div><div class="casAuthors">Choi, Young Lim; Soda, Manabu; Yamashita, Yoshihiro; Ueno, Toshihide; Takashima, Junpei; Nakajima, Takahiro; Yatabe, Yasushi; Takeuchi, Kengo; Hamada, Toru; Haruta, Hidenori; Ishikawa, Yuichi; Kimura, Hideki; Mitsudomi, Tetsuya; Tanio, Yoshiro; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1734-1739</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The EML4 (echinoderm microtubule-assocd. protein-like 4)-ALK (anaplastic lymphoma kinase) fusion-type tyrosine kinase is an oncoprotein found in 4% to 5% of non-small-cell lung cancers, and clin. trials of specific inhibitors of ALK for the treatment of such tumors are currently under way.  Here, we report the discovery of two secondary mutations within the kinase domain of EML4-ALK in tumor cells isolated from a patient during the relapse phase of treatment with an ALK inhibitor.  Each mutation developed independently in subclones of the tumor and conferred marked resistance to two different ALK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCIrEIBi5MjrVg90H21EOLACvtfcHk0lhnC1qZfctNBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FJ&md5=d903151706575c159b7abcdc8999281c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1007478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1007478%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DUeno%26aufirst%3DT.%26aulast%3DTakashima%26aufirst%3DJ.%26aulast%3DNakajima%26aufirst%3DT.%26aulast%3DYatabe%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DHamada%26aufirst%3DT.%26aulast%3DHaruta%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DH.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DTanio%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DEML4-ALK%2520mutations%2520in%2520lung%2520cancer%2520that%2520confer%2520resistance%2520to%2520ALK%2520inhibitors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1734%26epage%3D1739%26doi%3D10.1056%2FNEJMoa1007478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neklesa, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Targeted protein degradation by PROTACs</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">138</span>– <span class="NLM_lpage">144</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2017.02.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.pharmthera.2017.02.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=28223226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtVemsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2017&pages=138-144&author=T.+K.+Neklesaauthor=J.+D.+Winklerauthor=C.+M.+Crews&title=Targeted+protein+degradation+by+PROTACs&doi=10.1016%2Fj.pharmthera.2017.02.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted protein degradation by PROTACs</span></div><div class="casAuthors">Neklesa, Taavi K.; Winkler, James D.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">138-144</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Targeted protein degrdn. using the PROTAC technol. is emerging as a novel therapeutic method to address diseases driven by the aberrant expression of a disease-causing protein.  PROTAC mols. are bifunctional small mols. that simultaneously bind a target protein and an E3-ubiquitin ligase, thus causing ubiquitination and degrdn. of the target protein by the proteasome.  Like small mols., PROTAC mols. possess good tissue distribution and the ability to target intracellular proteins.  Herein, we highlight the advantages of protein degrdn. using PROTACs, and provide specific examples where degrdn. offers therapeutic benefit over classical enzyme inhibition.  Foremost, PROTACs can degrade proteins regardless of their function.  This includes the currently "undruggable" proteome, which comprises approx. 85% of all human proteins.  Other beneficial aspects of protein degrdn. include the ability to target overexpressed and mutated proteins, as well as the potential to demonstrate prolonged pharmacodynamics effect beyond drug exposure.  Lastly, due to their catalytic nature and the pre-requisite ubiquitination step, an exquisitely potent mols. with a high degree of degrdn. selectivity can be designed.  Impressive preclin. in vitro and in vivo PROTAC data have been published, and these data have propelled the development of clin. viable PROTACs.  With the mol. wt. falling in the 700-1000 Da range, the delivery and bioavailability of PROTACs remain the largest hurdles on the way to the clinic.  Solving these issues and demonstrating proof of concept clin. data will be the focus of many labs over the next few years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4RSLWYqqBMrVg90H21EOLACvtfcHk0lj-NLF4ILvLHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtVemsbg%253D&md5=08a74402a274a13c8c484cd68167a5a1</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.02.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.02.027%26sid%3Dliteratum%253Aachs%26aulast%3DNeklesa%26aufirst%3DT.%2BK.%26aulast%3DWinkler%26aufirst%3DJ.%2BD.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DTargeted%2520protein%2520degradation%2520by%2520PROTACs%26jtitle%3DPharmacol.%2520Ther.%26date%3D2017%26volume%3D174%26spage%3D138%26epage%3D144%26doi%3D10.1016%2Fj.pharmthera.2017.02.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Induced protein degradation: an emerging drug discovery paradigm</span>. <i>Nat. Rev. Drug Discov.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1038%2Fnrd.2016.211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=27885283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=101-114&author=A.+C.+Laiauthor=C.+M.+Crews&title=Induced+protein+degradation%3A+an+emerging+drug+discovery+paradigm&doi=10.1038%2Fnrd.2016.211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Induced protein degradation: an emerging drug discovery paradigm</span></div><div class="casAuthors">Lai, Ashton C.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">101-114</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. drug discovery has traditionally focused on occupancy of a binding site that directly affects protein function, and this approach typically precludes targeting proteins that lack such amenable sites.  Furthermore, high systemic drug exposures may be needed to maintain sufficient target inhibition in vivo, increasing the risk of undesirable off-target effects.  Induced protein degrdn. is an alternative approach that is event-driven: upon drug binding, the target protein is tagged for elimination.  Emerging technologies based on proteolysis-targeting chimaeras (PROTACs) that exploit cellular quality control machinery to selectively degrade target proteins are attracting considerable attention in the pharmaceutical industry owing to the advantages they could offer over traditional small-mol. strategies.  These advantages include the potential to reduce systemic drug exposure, the ability to counteract increased target protein expression that often accompanies inhibition of protein function and the potential ability to target proteins that are not currently therapeutically tractable, such as transcription factors, scaffolding and regulatory proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj-O7zXGOpXLVg90H21EOLACvtfcHk0lj-NLF4ILvLHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP&md5=a01ff43e9b696fe4dc03f0815158a98f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.211%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%2BC.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DInduced%2520protein%2520degradation%253A%2520an%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discov.%26date%3D2017%26volume%3D16%26spage%3D101%26epage%3D114%26doi%3D10.1038%2Fnrd.2016.211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Powell, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donovan, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loehr, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahcall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Chemically induced degradation of anaplastic lymphoma kinase (ALK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4249</span>– <span class="NLM_lpage">4255</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01655</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01655" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC1cXns1OitrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4249-4255&author=C.+E.+Powellauthor=Y.+Gaoauthor=L.+Tanauthor=K.+A.+Donovanauthor=R.+P.+Nowakauthor=A.+Loehrauthor=M.+Bahcallauthor=E.+S.+Fischerauthor=P.+A.+J%C3%A4nneauthor=R.+E.+Georgeauthor=N.+S.+Gray&title=Chemically+induced+degradation+of+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1021%2Facs.jmedchem.7b01655"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Powell, Chelsea E.; Gao, Yang; Tan, Li; Donovan, Katherine A.; Nowak, Radoslaw P.; Loehr, Amanda; Bahcall, Magda; Fischer, Eric S.; Janne, Pasi A.; George, Rani E.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4249-4255</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We present the development of the first small mol. degraders that can induce anaplastic lymphoma kinase (ALK) degrdn., including in non-small-cell lung cancer (NSCLC), anaplastic large-cell lymphoma (ALCL), and neuroblastoma (NB) cell lines.  These degraders were developed through conjugation of known pyrimidine-based ALK inhibitors, TAE684 or LDK378, and the cereblon ligand pomalidomide.  We demonstrate that in some cell types degrader potency is compromised by expression of drug transporter ABCB1.  In addn., proteomic profiling demonstrated that these compds. also promote the degrdn. of addnl. kinases including PTK2 (FAK), Aurora A, FER, and RPS6KA1 (RSK1).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7mDH7Sj8EqbVg90H21EOLACvtfcHk0lj-NLF4ILvLHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXns1OitrY%253D&md5=486db11b3fbc2283700f38b09cc39bd7</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01655%26sid%3Dliteratum%253Aachs%26aulast%3DPowell%26aufirst%3DC.%2BE.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DDonovan%26aufirst%3DK.%2BA.%26aulast%3DNowak%26aufirst%3DR.%2BP.%26aulast%3DLoehr%26aufirst%3DA.%26aulast%3DBahcall%26aufirst%3DM.%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DChemically%2520induced%2520degradation%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4249%26epage%3D4255%26doi%3D10.1021%2Facs.jmedchem.7b01655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span> <span> </span><span class="NLM_article-title">Proteolysis targeting chimeras (PROTACs) of anaplastic lymphoma kinase (ALK)</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">304</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.ejmech.2018.03.071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=29627725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1ejs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=304-314&author=C.+Zhangauthor=X.+R.+Hanauthor=X.+Yangauthor=B.+Jiangauthor=J.+Liuauthor=Y.+Xiongauthor=J.+Jin&title=Proteolysis+targeting+chimeras+%28PROTACs%29+of+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1016%2Fj.ejmech.2018.03.071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Zhang, Chengwei; Han, Xiao-Ran; Yang, Xiaobao; Jiang, Biao; Liu, Jing; Xiong, Yue; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">304-314</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) activation has been assocd. with many types of human cancer.  Significant efforts have been devoted to the development of ALK inhibitors to antagonize the kinase activity of ALK.  Four ALK inhibitors have been approved by the FDA to date for treating patients with ALK-pos. nonsmall cell lung cancers (NSCLC).  However, drug resistance has been obsd. in the majority of patients treated with these inhibitors.  New therapeutic strategies (e.g., compds. with novel mechanisms of action) are needed to overcome the drug resistance issue.  The emerging PROTAC (Proteolysis Targeting Chimera) technol. has been successfully applied to selective degrdn. of multiple protein targets, but not ALK.  Since ALK protein levels are not important for viability in mammals, ALK PROTACs could lead to novel therapeutics with minimal toxicity.  Here the authors report the design, synthesis and biol. evaluation of novel PROTACs (degraders) of ALK.  MS4077 (I) and MS4078 (II) potently decreased cellular levels of oncogenic active ALK fusion proteins in a concn.- and time-dependent manner in SU-DHL-1 lymphoma and NCI-H2228 lung cancer cells.  The ALK protein degrdn. induced by compds. I and II was cereblon and proteasome dependent.  In addn., compds. I and II potently inhibited proliferation of SU-DHL-1 cells.  Furthermore, compd. II displayed good plasma exposure in a mouse pharmacokinetic study, thus is suitable for in vivo efficacy studies.  The authors also developed MS4748 and MS4740 , very close analogs of I and II resp., which are incapable to degrade the ALK fusion proteins, as neg. controls.  All 4 compds. are valuable chem. tools for investigating effects of ALK pharmacol. degrdn.  The study paved the way for developing the next generation of ALK PROTACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPGM3aAZZ6h7Vg90H21EOLACvtfcHk0lhvFVxWdellcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1ejs7Y%253D&md5=804324b95034f38b46e45f89e18e55be</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.071%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DX.%2BR.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DProteolysis%2520targeting%2520chimeras%2520%2528PROTACs%2529%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D304%26epage%3D314%26doi%3D10.1016%2Fj.ejmech.2018.03.071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaniskan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span> <span> </span><span class="NLM_article-title">Light-induced control of protein destruction by opto-PROTAC</span>. <i>Sci. Adv.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">eaay5154</span> <span class="refDoi"> DOI: 10.1126/sciadv.aay5154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1126%2Fsciadv.aay5154" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=32128407" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2020&author=J.+Liuauthor=H.+Chenauthor=L.+Maauthor=Z.+Heauthor=D.+Wangauthor=Y.+Liuauthor=Q.+Linauthor=T.+Zhangauthor=N.+Grayauthor=H.+Kaniskanauthor=J.+Jinauthor=W.+Wei&title=Light-induced+control+of+protein+destruction+by+opto-PROTAC&doi=10.1126%2Fsciadv.aay5154"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1126%2Fsciadv.aay5154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fsciadv.aay5154%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DKaniskan%26aufirst%3DH.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DW.%26atitle%3DLight-induced%2520control%2520of%2520protein%2520destruction%2520by%2520opto-PROTAC%26jtitle%3DSci.%2520Adv.%26date%3D2020%26volume%3D6%26doi%3D10.1126%2Fsciadv.aay5154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du Ha, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, J. Y.</span></span> <span> </span><span class="NLM_article-title">Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC)</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>505</i></span>,  <span class="NLM_fpage">542</span>– <span class="NLM_lpage">547</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2018.09.169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.bbrc.2018.09.169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=30274779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVejs7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=505&publication_year=2018&pages=542-547&author=C.+H.+Kangauthor=D.+H.+Leeauthor=C.+O.+Leeauthor=J.+Du+Haauthor=C.+H.+Parkauthor=J.+Y.+Hwang&title=Induced+protein+degradation+of+anaplastic+lymphoma+kinase+%28ALK%29+by+proteolysis+targeting+chimera+%28PROTAC%29&doi=10.1016%2Fj.bbrc.2018.09.169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC)</span></div><div class="casAuthors">Kang, Chung Hyo; Lee, Dong Ho; Lee, Chong Ock; Du Ha, Jae; Park, Chi Hoon; Hwang, Jong Yeon</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">505</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">542-547</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Recently, proteolysis targeting chimera (PROTAC) technol. is highlighted in drug discovery area as a new therapeutic approach.  PROTAC as a heterobifunctional mol. is comprised of two ligands, which recruit target protein and E3 ligase, resp.  To degrade the anaplastic lymphoma kinase (ALK) fusion protein, such as NPM-ALK or EML4-ALK, we generated several ALK-PROTAC mols. consisted of ceritinib, one of the ALK inhibitors, and ligand of von Hippel-Lindau (VHL) E3 ligase.  Among these mols., TD-004 effectively induced ALK degrdn. and inhibited the growth of ALK fusion pos. cell lines, SU-DHL-1 and H3122.  We also confirmed that TD-004 significantly reduced the tumor growth in H3122 xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8JUOZ5fYNW7Vg90H21EOLACvtfcHk0lhvFVxWdellcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVejs7fE&md5=cac9252fca98ebec4ad8e5aeed7b7550</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2018.09.169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2018.09.169%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DC.%2BH.%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DLee%26aufirst%3DC.%2BO.%26aulast%3DDu%2BHa%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DHwang%26aufirst%3DJ.%2BY.%26atitle%3DInduced%2520protein%2520degradation%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520by%2520proteolysis%2520targeting%2520chimera%2520%2528PROTAC%2529%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2018%26volume%3D505%26spage%3D542%26epage%3D547%26doi%3D10.1016%2Fj.bbrc.2018.09.169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span> <span> </span><span class="NLM_article-title">Discovery of a PROTAC targeting ALK with in vivo activity</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>212</i></span>,  <span class="NLM_fpage">113150</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.113150</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.ejmech.2020.113150" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=33453602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BB3MXhvVSjtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=212&publication_year=2021&pages=113150&author=G.+Yanauthor=X.+Zhongauthor=L.+Yueauthor=C.+Puauthor=H.+Shanauthor=S.+Lanauthor=M.+Zhouauthor=X.+Houauthor=J.+Yangauthor=R.+Li&title=Discovery+of+a+PROTAC+targeting+ALK+with+in+vivo+activity&doi=10.1016%2Fj.ejmech.2020.113150"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a PROTAC targeting ALK with in vivo activity</span></div><div class="casAuthors">Yan, Guoyi; Zhong, Xinxin; Yue, Lin; Pu, Chunlan; Shan, Huifang; Lan, Suke; Zhou, Meng; Hou, Xueyan; Yang, Jie; Li, Rui</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">212</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113150</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) was involved in the development of various cancer types.  Although several ALK inhibitors have been advanced to clin. trials, the emergence of drug resistance has limited the clin. application of them.  To overcome the drug resistance, proteolysis targeting chimeras (PROTACs) could be an alternative strategy.  In this study, a series of ALK degraders were designed and synthesized.  The degraders were developed through the conjugation of LDK378 and CRBN E3 ubiquitin ligase ligands.  Among all the mols., compd. B3 showed potent selective inhibitory activity to ALK and can decrease the cellular levels of ALK fusion proteins in a concn.- and time-dependent manner in H3122 cell line.  Meanwhile, B3 showed improved anticancer activity in vitro comparing with LDK378 and the antiproliferative activity to xenograft tumor model was acceptable.  All the results demonstrated that ALK degrader B3 with in vitro and in vivo anti-cancer activities was valuable for further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_7prECNonvrVg90H21EOLACvtfcHk0lhvFVxWdellcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXhvVSjtro%253D&md5=06c5a3f10a3beead2d51189ac383528a</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.113150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.113150%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DG.%26aulast%3DZhong%26aufirst%3DX.%26aulast%3DYue%26aufirst%3DL.%26aulast%3DPu%26aufirst%3DC.%26aulast%3DShan%26aufirst%3DH.%26aulast%3DLan%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DR.%26atitle%3DDiscovery%2520of%2520a%2520PROTAC%2520targeting%2520ALK%2520with%2520in%2520vivo%2520activity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D212%26spage%3D113150%26doi%3D10.1016%2Fj.ejmech.2020.113150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span> <span> </span><span class="NLM_article-title">Development of a brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>193</i></span>,  <span class="NLM_fpage">112190</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.ejmech.2020.112190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=32179332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvF2qu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=193&publication_year=2020&pages=112190&author=N.+Sunauthor=C.+Renauthor=Y.+Kongauthor=H.+Zhongauthor=J.+Chenauthor=Y.+Liauthor=J.+Zhangauthor=Y.+Zhouauthor=X.+Qiuauthor=H.+Linauthor=X.+Songauthor=X.+Yangauthor=B.+Jiang&title=Development+of+a+brigatinib+degrader+%28SIAIS117%29+as+a+potential+treatment+for+ALK+positive+cancer+resistance&doi=10.1016%2Fj.ejmech.2020.112190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance</span></div><div class="casAuthors">Sun, Ning; Ren, Chaowei; Kong, Ying; Zhong, Hui; Chen, Jinju; Li, Yan; Zhang, Jianshui; Zhou, Yuedong; Qiu, Xing; Lin, Haifan; Song, Xiaoling; Yang, Xiaobao; Jiang, Biao</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">193</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112190</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">EML4-ALK and NPM-ALK fusion proteins possess constitutively activated ALK (anaplastic lymphoma kinase) activity, which in turn leads to the development of non-small cell lung cancer and anaplastic large-cell lymphomas (ALCLs).  FDA-approved ALK inhibitor drugs cause significant cancer regression.  However, drug resistance eventually occurs and it becomes a big obstacle in clinic.  Novel proteolysis targeting chimera (PROTAC) technol. platform provides a potential therapeutic strategy for drug resistance.  Herein, we designed and synthesized a series of ALK PROTACs based on Brigatinib and VHL-1 conjunction, and screened SIAIS117 as the best degrader which not only blocked the growth of SR and H2228 cancer cell lines, but also degraded ALK protein.  In addn., SIAIS117 also showed much better growth inhibition effect than Brigatinib on 293T cell line that exogenously expressed G1202R-resistant ALK proteins.  Furthermore, it also degraded G1202R mutant ALK protein in vitro.  At last, it has the potentially anti-proliferation ability of small cell lung cancer.  Thus, we have successfully generated the degrader SIAIS117 that can potentially overcome resistance in cancer targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX9rzk88HMe7Vg90H21EOLACvtfcHk0ljX4V2E_pAjOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvF2qu70%253D&md5=61f0228111c806ae62473fc450fce276</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112190%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DN.%26aulast%3DRen%26aufirst%3DC.%26aulast%3DKong%26aufirst%3DY.%26aulast%3DZhong%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DQiu%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DB.%26atitle%3DDevelopment%2520of%2520a%2520brigatinib%2520degrader%2520%2528SIAIS117%2529%2520as%2520a%2520potential%2520treatment%2520for%2520ALK%2520positive%2520cancer%2520resistance%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D193%26spage%3D112190%26doi%3D10.1016%2Fj.ejmech.2020.112190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span> <span> </span><span class="NLM_article-title">Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from Alectinib</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>217</i></span>,  <span class="NLM_fpage">113335</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2021.113335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.ejmech.2021.113335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=33751979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BB3MXnt1Ohsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=217&publication_year=2021&pages=113335&author=C.+Renauthor=N.+Sunauthor=Y.+Kongauthor=X.+Quauthor=H.+Liuauthor=H.+Zhongauthor=X.+Songauthor=X.+Yangauthor=B.+Jiang&title=Structure-based+discovery+of+SIAIS001+as+an+oral+bioavailability+ALK+degrader+constructed+from+Alectinib&doi=10.1016%2Fj.ejmech.2021.113335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from Alectinib</span></div><div class="casAuthors">Ren, Chaowei; Sun, Ning; Kong, Ying; Qu, Xiaojuan; Liu, Haixia; Zhong, Hui; Song, Xiaoling; Yang, Xiaobao; Jiang, Biao</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">217</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113335</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Fusion proteins of the anaplastic lymphoma kinase (ALK) are promising therapeutic targets for cancer and other human diseases, esp. for non-small cell lung cancer (NSCLC) and anaplastic large-cell lymphomas (ALCLs).  We described herein a structure-based design, synthesis, and evaluation of ALK PROTACs (proteolysis-targeting chimeras) based on Alectinib as the warhead.  We firstly screened CRBN ligands as the E3 ligase moiety, then obtained a series of potent ALK degraders based on different CRBN ligands, exemplified by SIAIS091 and SIAIS001 with lenalidomide/thalidomide-based linkers.  Both of them induced effective ALK degrdn. at low nanomolar concns. in cells, and showed much better growth inhibition effects than Alectinib.  SIAIS091 or SIAIS001 also promoted cell cycle arrest in G1/S phase.  Finally, SIAIS001 exhibited good oral bioavailability in Pharmacokinetics study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZW4fwPhRGNLVg90H21EOLACvtfcHk0ljX4V2E_pAjOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXnt1Ohsrs%253D&md5=b1dc676e47efb1fdf8e9fb50cafec635</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2021.113335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2021.113335%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DN.%26aulast%3DKong%26aufirst%3DY.%26aulast%3DQu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DZhong%26aufirst%3DH.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DB.%26atitle%3DStructure-based%2520discovery%2520of%2520SIAIS001%2520as%2520an%2520oral%2520bioavailability%2520ALK%2520degrader%2520constructed%2520from%2520Alectinib%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D217%26spage%3D113335%26doi%3D10.1016%2Fj.ejmech.2021.113335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span>; <span class="NLM_string-name">Jiang, B.</span>; <span class="NLM_string-name">Song, X.</span>; <span class="NLM_string-name">Lin, H.</span>; <span class="NLM_string-name">Sun, N.</span>; <span class="NLM_string-name">Chen, J.</span>; <span class="NLM_string-name">Qiu, X.</span>; <span class="NLM_string-name">Ren, C.</span>; <span class="NLM_string-name">Kong, Y.</span></span> <span> </span><span class="NLM_article-title">ALK protein degradation agent and anti-tumor application thereof</span>. U.S. Patent <span class="NLM_patent">20200306273A1</span>, December 12, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=X.+Yang&author=B.+Jiang&author=X.+Song&author=H.+Lin&author=N.+Sun&author=J.+Chen&author=X.+Qiu&author=C.+Ren&author=Y.+Kong&title=ALK+protein+degradation+agent+and+anti-tumor+application+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.%26atitle%3DALK%2520protein%2520degradation%2520agent%2520and%2520anti-tumor%2520application%2520thereof%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cantrill, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaturvedi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rynn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrig Schaffland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittwer, M. B.</span></span> <span> </span><span class="NLM_article-title">Fundamental aspects of DMPK optimization of targeted protein degraders</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">969</span>– <span class="NLM_lpage">982</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2020.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.drudis.2020.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=32298797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntFGht7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&pages=969-982&author=C.+Cantrillauthor=P.+Chaturvediauthor=C.+Rynnauthor=J.+Petrig+Schafflandauthor=I.+Walterauthor=M.+B.+Wittwer&title=Fundamental+aspects+of+DMPK+optimization+of+targeted+protein+degraders&doi=10.1016%2Fj.drudis.2020.03.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Fundamental aspects of DMPK optimization of targeted protein degraders</span></div><div class="casAuthors">Cantrill, Carina; Chaturvedi, Prasoon; Rynn, Caroline; Petrig Schaffland, Jeannine; Walter, Isabelle; Wittwer, Matthias B.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">969-982</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Targeted protein degraders are an emerging modality.  Their properties fall outside the traditional small-mol. property space and are in the 'beyond rule of 5' space.  Consequently, drug discovery programs focused on developing orally bioavailable degraders are expected to face complex drug metab. and pharmacokinetics (DMPK) challenges compared with traditional small mols.  Nevertheless, little information is available on the DMPK optimization of oral degraders.  Therefore, in this review, we discuss our experience of these DMPK optimization challenges and present methodologies and strategies to overcome the hurdles dealing with this new small-mol. modality, specifically in developing oral degraders to treat cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoz2WUoP7TUvbVg90H21EOLACvtfcHk0lhB-YrDmkVkww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntFGht7s%253D&md5=465ad2dab5183e0f229aeec7e57e396a</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2020.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2020.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DCantrill%26aufirst%3DC.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DRynn%26aufirst%3DC.%26aulast%3DPetrig%2BSchaffland%26aufirst%3DJ.%26aulast%3DWalter%26aufirst%3DI.%26aulast%3DWittwer%26aufirst%3DM.%2BB.%26atitle%3DFundamental%2520aspects%2520of%2520DMPK%2520optimization%2520of%2520targeted%2520protein%2520degraders%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2020%26volume%3D25%26spage%3D969%26epage%3D982%26doi%3D10.1016%2Fj.drudis.2020.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiroshima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukami, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oikawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, Y.</span></span> <span> </span><span class="NLM_article-title">CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">679</span>– <span class="NLM_lpage">690</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2011.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.ccr.2011.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=21575866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFGlsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=679-690&author=H.+Sakamotoauthor=T.+Tsukaguchiauthor=S.+Hiroshimaauthor=T.+Kodamaauthor=T.+Kobayashiauthor=T.+A.+Fukamiauthor=N.+Oikawaauthor=T.+Tsukudaauthor=N.+Ishiiauthor=Y.+Aoki&title=CH5424802%2C+a+selective+ALK+inhibitor+capable+of+blocking+the+resistant+gatekeeper+mutant&doi=10.1016%2Fj.ccr.2011.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant</span></div><div class="casAuthors">Sakamoto, Hiroshi; Tsukaguchi, Toshiyuki; Hiroshima, Sayuri; Kodama, Tatsushi; Kobayashi, Takamitsu; Fukami, Takaaki A.; Oikawa, Nobuhiro; Tsukuda, Takuo; Ishii, Nobuya; Aoki, Yuko</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">679-690</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a tyrosine kinase that is constitutively activated in certain cancers, following gene alterations such as chromosomal translocation, amplification, or point mutation.  Here, the authors identified CH5424802, a potent, selective, and orally available ALK inhibitor with a unique chem. scaffold, showing preferential antitumor activity against cancers with gene alterations of ALK, such as non-small cell lung cancer (NSCLC) cells expressing EML4-ALK fusion and anaplastic large-cell lymphoma (ALCL) cells expressing NPM-ALK fusion in vitro and in vivo.  CH5424802 inhibited ALK L1196M, which corresponds to the gatekeeper mutation conferring common resistance to kinase inhibitors, and blocked EML4-ALK L1196M-driven cell growth.  The authors' results support the potential for clin. evaluation of CH5424802 for the treatment of patients with ALK-driven tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrk3zvzF9p67Vg90H21EOLACvtfcHk0lhB-YrDmkVkww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFGlsL8%253D&md5=cae32f3a3647926ba835293b68e776f8</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2011.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2011.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DHiroshima%26aufirst%3DS.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DFukami%26aufirst%3DT.%2BA.%26aulast%3DOikawa%26aufirst%3DN.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DAoki%26aufirst%3DY.%26atitle%3DCH5424802%252C%2520a%2520selective%2520ALK%2520inhibitor%2520capable%2520of%2520blocking%2520the%2520resistant%2520gatekeeper%2520mutant%26jtitle%3DCancer%2520Cell%26date%3D2011%26volume%3D19%26spage%3D679%26epage%3D690%26doi%3D10.1016%2Fj.ccr.2011.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Petris, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlesi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govindan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dingemans, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lena, H.</span></span> <span> </span><span class="NLM_article-title">Pooled systemic efficacy and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1552</span>– <span class="NLM_lpage">1560</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2017.06.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.jtho.2017.06.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=28689043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A280%3ADC%252BC1cjlslSnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1552-1560&author=J.+C.+H.+Yangauthor=S.+H.+I.+Ouauthor=L.+De+Petrisauthor=S.+Gadgeelauthor=L.+Gandhiauthor=D.+W.+Kimauthor=F.+Barlesiauthor=R.+Govindanauthor=A.+C.+Dingemansauthor=L.+Crinoauthor=H.+Lena&title=Pooled+systemic+efficacy+and+safety+data+from+the+pivotal+phase+II+studies+%28NP28673+and+NP28761%29+of+alectinib+in+ALK-positive+non-small+cell+lung+cancer&doi=10.1016%2Fj.jtho.2017.06.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Yang James Chih-Hsin; Ou Sai-Hong Ignatius; De Petris Luigi; Gadgeel Shirish; Gandhi Leena; Kim Dong-Wan; Barlesi Fabrice; Govindan Ramaswamy; Dingemans Anne-Marie C; Crino Lucio; Lena Herve; Popat Sanjay; Ahn Jin Seok; Dansin Eric; Golding Sophie; Bordogna Walter; Balas Bogdana; Zeaiter Ali; Morcos Peter N; Shaw Alice T</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1552-1560</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Alectinib demonstrated clinical efficacy and an acceptable safety profile in two phase II studies (NP28761 and NP28673).  Here we report the pooled efficacy and safety data after 15 and 18 months more follow-up than in the respective primary analyses.  METHODS:  Enrolled patients had ALK receptor tyrosine kinase gene (ALK)-positive NSCLC and had progressed while taking, or could not tolerate, crizotinib.  Patients received oral alectinib, 600 mg twice daily.  The primary end point in both studies was objective response rate assessed by an independent review committee (IRC) using the Response Evaluation Criteria in Solid Tumors, version 1.1.  Secondary end points included disease control rate, duration of response, progression-free survival, overall survival, and safety.  RESULTS:  The pooled data set included 225 patients (n = 138 in NP28673 and n = 87 in NP28761).  The response-evaluable population included 189 patients (84% [n = 122 in NP28673 and n = 67 in NP28761]).  In the response-evaluable population, objective response rate as assessed by the IRC was 51.3% (95% confidence interval [CI]: 44.0-58.6 [all PRs]), the disease control rate was 78.8% (95% CI: 72.3-84.4), and the median duration of response was 14.9 months (95% CI: 11.1-20.4) after 58% of events.  Median progression-free survival as assessed by the IRC was 8.3 months (95% CI: 7.0-11.3) and median overall survival was 26.0 months (95% CI: 21.4-not estimable).  Grade 3 or higher adverse events (AEs) occurred in 40% of patients, 6% of patients had treatment withdrawn on account of AEs, and 33% had AEs leading to dose interruptions/modification.  CONCLUSIONS:  This pooled data analysis confirmed the robust systemic efficacy of alectinib in ALK-positive NSCLC with a durable response rate.  Alectinib also had an acceptable safety profile with a longer duration of follow-up.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKYNXogQ0TxJHZzFRCXxVKfW6udTcc2eZiwDoD8QhBurntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjlslSnug%253D%253D&md5=6e811162d59e5c66ce21ceef64479b02</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2017.06.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2017.06.070%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%2BC.%2BH.%26aulast%3DOu%26aufirst%3DS.%2BH.%2BI.%26aulast%3DDe%2BPetris%26aufirst%3DL.%26aulast%3DGadgeel%26aufirst%3DS.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DBarlesi%26aufirst%3DF.%26aulast%3DGovindan%26aufirst%3DR.%26aulast%3DDingemans%26aufirst%3DA.%2BC.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DLena%26aufirst%3DH.%26atitle%3DPooled%2520systemic%2520efficacy%2520and%2520safety%2520data%2520from%2520the%2520pivotal%2520phase%2520II%2520studies%2520%2528NP28673%2520and%2520NP28761%2529%2520of%2520alectinib%2520in%2520ALK-positive%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2017%26volume%3D12%26spage%3D1552%26epage%3D1560%26doi%3D10.1016%2Fj.jtho.2017.06.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérol, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dziadziuszko, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeaiter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitry, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morcos, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T.</span></span> <span> </span><span class="NLM_article-title">Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">829</span>– <span class="NLM_lpage">838</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1704795</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1056%2FNEJMoa1704795" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=28586279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFSju7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=829-838&author=S.+Petersauthor=D.+R.+Camidgeauthor=A.+T.+Shawauthor=S.+Gadgeelauthor=J.+S.+Ahnauthor=D.+W.+Kimauthor=S.+I.+Ouauthor=M.+P%C3%A9rolauthor=R.+Dziadziuszkoauthor=R.+Rosellauthor=A.+Zeaiterauthor=E.+Mitryauthor=S.+Goldingauthor=B.+Balasauthor=J.+Noeauthor=P.+N.+Morcosauthor=T.+Mok&title=Alectinib+versus+crizotinib+in+untreated+ALK-positive+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa1704795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer</span></div><div class="casAuthors">Peters, Solange; Camidge, D. Ross; Shaw, Alice T.; Gadgeel, Shirish; Ahn, Jin S.; Kim, Dong-Wan; Ou, Sai-Hong I.; Perol, Maurice; Dziadziuszko, Rafal; Rosell, Rafael; Zeaiter, Ali; Mitry, Emmanuel; Golding, Sophie; Balas, Bogdana; Noe, Johannes; Morcos, Peter N.; Mok, Tony</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">829-838</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-pos. non-small-cell lung cancer (NSCLC).  We investigated alectinib as compared with crizotinib in patients with previously untreated, advanced ALK-pos. NSCLC, including those with asymptomatic CNS disease.  METHODS: In a randomized, open-label, phase 3 trial, we randomly assigned 303 patients with previously untreated, advanced ALK-pos. NSCLC to receive either alectinib (600 mg twice daily) or crizotinib (250 mg twice daily).  The primary end point was investigator assessed progression-free survival.  Secondary end points were independent review committee-assessed progression-free survival, time to CNS progression, objective response rate, and overall survival.  RESULTS: During a median follow-up of 17.6 mo (crizotinib) and 18.6 mo (alectinib), an event of disease progression or death occurred in 62 of 152 patients (41%) in the alectinib group and 102 of 151 patients (68%) in the crizotinib group.  The rate of investigator- assessed progression-free survival was significantly higher with alectinib than with crizotinib (12-mo event-free survival rate, 68.4% [95% confidence interval (CI), 61.0 to 75.9] with alectinib vs. 48.7% [95% CI, 40.4 to 56.9] with crizotinib; hazard ratio for disease progression or death, 0.47 [95% CI, 0.34 to 0.65]; P<0.001); the median progression-free survival with alectinib was not reached.  The results for independent review committee-assessed progression-free survival were consistent with those for the primary end point.  A total of 18 patients (12%) in the alectinib group had an event of CNS progression, as compared with 68 patients (45%) in the crizotinib group (cause-specific hazard ratio, 0.16; 95% CI, 0.10 to 0.28; P<0.001).  A response occurred in 126 patients in the alectinib group (response rate, 82.9%; 95% CI, 76.0 to 88.5) and in 114 patients in the crizotinib group (response rate, 75.5%; 95% CI, 67.8 to 82.1) (P = 0.09).  Grade 3 to 5 adverse events were less frequent with alectinib (41% vs. 50% with crizotinib).  CONCLUSIONS: As compared with crizotinib, alectinib showed superior efficacy and lower toxicity in primary treatment of ALK-pos. NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxaWsEV8z16LVg90H21EOLACvtfcHk0ljqmv5ke9dCOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFSju7nL&md5=cb58ab7eb5b266a3d292eb714a1c8104</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1704795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1704795%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DS.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DGadgeel%26aufirst%3DS.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DOu%26aufirst%3DS.%2BI.%26aulast%3DP%25C3%25A9rol%26aufirst%3DM.%26aulast%3DDziadziuszko%26aufirst%3DR.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DZeaiter%26aufirst%3DA.%26aulast%3DMitry%26aufirst%3DE.%26aulast%3DGolding%26aufirst%3DS.%26aulast%3DBalas%26aufirst%3DB.%26aulast%3DNoe%26aufirst%3DJ.%26aulast%3DMorcos%26aufirst%3DP.%2BN.%26aulast%3DMok%26aufirst%3DT.%26atitle%3DAlectinib%2520versus%2520crizotinib%2520in%2520untreated%2520ALK-positive%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26spage%3D829%26epage%3D838%26doi%3D10.1056%2FNEJMoa1704795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenfeld, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeap, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxena, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferris, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dagogo-Jack, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farago, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menon, S.</span></span> <span> </span><span class="NLM_article-title">Brigatinib in patients with alectinib-refractory ALK-positive NSCLC</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1530</span>– <span class="NLM_lpage">1538</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2018.06.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.jtho.2018.06.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=29935304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FhtVyqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=1530-1538&author=J.+J.+Linauthor=V.+W.+Zhuauthor=A.+J.+Schoenfeldauthor=B.+Y.+Yeapauthor=A.+Saxenaauthor=L.+A.+Ferrisauthor=I.+Dagogo-Jackauthor=A.+F.+Faragoauthor=A.+Taberauthor=A.+Traynorauthor=S.+Menon&title=Brigatinib+in+patients+with+alectinib-refractory+ALK-positive+NSCLC&doi=10.1016%2Fj.jtho.2018.06.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC</span></div><div class="casAuthors">Lin Jessica J; Yeap Beow Y; Ferris Lorin A; Dagogo-Jack Ibiayi; Farago Anna F; Gainor Justin F; Zhu Viola W; Ou Sai-Hong Ignatius; Schoenfeld Adam J; Riely Gregory J; Saxena Ashish; Taber Angela; Traynor Anne; Menon Smitha; Lennerz Jochen K; Plodkowski Andrew J; Digumarthy Subba R; Shaw Alice T</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1530-1538</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  The second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib recently showed superior efficacy compared to the first-generation ALK inhibitor crizotinib in advanced ALK-rearranged NSCLC, establishing alectinib as the new standard first-line therapy.  Brigatinib, another second-generation ALK inhibitor, has shown substantial activity in patients with crizotinib-refractory ALK-positive NSCLC; however, its activity in the alectinib-refractory setting is unknown.  METHODS:  A multicenter, retrospective study was performed at three institutions.  Patients were eligible if they had advanced, alectinib-refractory ALK-positive NSCLC and were treated with brigatinib.  Medical records were reviewed to determine clinical outcomes.  RESULTS:  Twenty-two patients were eligible for this study.  Confirmed objective responses to brigatinib were observed in 3 of 18 patients (17%) with measurable disease.  Nine patients (50%) had stable disease on brigatinib.  The median progression-free survival was 4.4 months (95% confidence interval [CI]: 1.8-5.6 months) with a median duration of treatment of 5.7 months (95% CI: 1.8-6.2 months).  Among 9 patients in this study who underwent post-alectinib/pre-brigatinib biopsies, 5 had an ALK I1171X or V1180L resistance mutation; of these, 1 had a confirmed partial response and 3 had stable disease on brigatinib.  One patient had an ALK G1202R mutation in a post-alectinib/pre-brigatinib biopsy, and had progressive disease as the best overall response to brigatinib.  CONCLUSIONS:  Brigatinib has limited clinical activity in alectinib-refractory ALK-positive NSCLC.  Additional studies are needed to establish biomarkers of response to brigatinib and to identify effective therapeutic options for alectinib-resistant ALK-positive NSCLC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcToxDZT6xxkHOqrn-c4Of3KfW6udTcc2eZVrMS84j0vsbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FhtVyqsA%253D%253D&md5=b2a4492952ebf6efe058e51e342e9fcd</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2018.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2018.06.005%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DJ.%2BJ.%26aulast%3DZhu%26aufirst%3DV.%2BW.%26aulast%3DSchoenfeld%26aufirst%3DA.%2BJ.%26aulast%3DYeap%26aufirst%3DB.%2BY.%26aulast%3DSaxena%26aufirst%3DA.%26aulast%3DFerris%26aufirst%3DL.%2BA.%26aulast%3DDagogo-Jack%26aufirst%3DI.%26aulast%3DFarago%26aufirst%3DA.%2BF.%26aulast%3DTaber%26aufirst%3DA.%26aulast%3DTraynor%26aufirst%3DA.%26aulast%3DMenon%26aufirst%3DS.%26atitle%3DBrigatinib%2520in%2520patients%2520with%2520alectinib-refractory%2520ALK-positive%2520NSCLC%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2018%26volume%3D13%26spage%3D1530%26epage%3D1538%26doi%3D10.1016%2Fj.jtho.2018.06.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dardaei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friboulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leshchiner, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dagogo-Jack, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, E.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1118</span>– <span class="NLM_lpage">1133</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-16-0596</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1158%2F2159-8290.CD-16-0596" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=27432227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1OhurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=1118-1133&author=J.+F.+Gainorauthor=L.+Dardaeiauthor=S.+Yodaauthor=L.+Fribouletauthor=I.+Leshchinerauthor=R.+Katayamaauthor=I.+Dagogo-Jackauthor=S.+Gadgeelauthor=K.+Schultzauthor=M.+Singhauthor=E.+Chin&title=Molecular+mechanisms+of+resistance+to+first-+and+second-generation+ALK+inhibitors+in+ALK-rearranged+lung+cancer&doi=10.1158%2F2159-8290.CD-16-0596"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer</span></div><div class="casAuthors">Gainor, Justin F.; Dardaei, Leila; Yoda, Satoshi; Friboulet, Luc; Leshchiner, Ignaty; Katayama, Ryohei; Dagogo-Jack, Ibiayi; Gadgeel, Shirish; Schultz, Katherine; Singh, Manrose; Chin, Emily; Parks, Melissa; Lee, Dana; DiCecca, Richard H.; Lockerman, Elizabeth; Huynh, Tiffany; Logan, Jennifer; Ritterhouse, Lauren L.; Le, Long P.; Muniappan, Ashok; Digumarthy, Subba; Channick, Colleen; Keyes, Colleen; Getz, Gad; Dias-Santagata, Dora; Heist, Rebecca S.; Lennerz, Jochen; Sequist, Lecia V.; Benes, Cyril H.; Iafrate, A. John; Mino-Kenudson, Mari; Engelman, Jeffrey A.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1118-1133</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Advanced, anaplastic lymphoma kinase (ALK)-pos. lung cancer is currently treated with the first-generation ALK inhibitor crizotinib followed by more potent, second-generation ALK inhibitors (e.g., ceritinib and alectinib) upon progression.  Second-generation inhibitors are generally effective even in the absence of crizotinib-resistant ALK mutations, likely reflecting incomplete inhibition of ALK by crizotinib in many cases.  Herein, we analyzed 103 repeat biopsies from ALK-pos. patients progressing on various ALK inhibitors.  We find that each ALK inhibitor is assocd. with a distinct spectrum of ALK resistance mutations and that the frequency of one mutation, ALKG1202R, increases significantly after treatment with second-generation agents.  To investigate strategies to overcome resistance to second-generation ALK inhibitors, we examine the activity of the third-generation ALK inhibitor lorlatinib in a series of ceritinib-resistant, patient-derived cell lines, and observe that the presence of ALK resistance mutations is highly predictive for sensitivity to lorlatinib, whereas those cell lines without ALK mutations are resistant.  Significance: Secondary ALK mutations are a common resistance mechanism to second-generation ALK inhibitors and predict for sensitivity to the third-generation ALK inhibitor lorlatinib.  These findings highlight the importance of repeat biopsies and genotyping following disease progression on targeted therapies, particularly second-generation ALK inhibitors.  Cancer Discov; 6(10); 1118-33. ©2016 AACR.  See related commentary by Qiao and Lovly, p. 1084.  This article is highlighted in the In This Issue feature, p.  1069.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg_wNC_RoH0LVg90H21EOLACvtfcHk0ljqmv5ke9dCOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1OhurrJ&md5=e68f42dbce3f4f4de0c6d9c64f6b7b82</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-16-0596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-16-0596%26sid%3Dliteratum%253Aachs%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DDardaei%26aufirst%3DL.%26aulast%3DYoda%26aufirst%3DS.%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DLeshchiner%26aufirst%3DI.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DDagogo-Jack%26aufirst%3DI.%26aulast%3DGadgeel%26aufirst%3DS.%26aulast%3DSchultz%26aufirst%3DK.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DChin%26aufirst%3DE.%26atitle%3DMolecular%2520mechanisms%2520of%2520resistance%2520to%2520first-%2520and%2520second-generation%2520ALK%2520inhibitors%2520in%2520ALK-rearranged%2520lung%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2016%26volume%3D6%26spage%3D1118%26epage%3D1133%26doi%3D10.1158%2F2159-8290.CD-16-0596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pirker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filipits, M.</span></span> <span> </span><span class="NLM_article-title">From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer</span>. <i>ESMO open</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e000548</span> <span class="refDoi"> DOI: 10.1136/esmoopen-2019-000548</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1136%2Fesmoopen-2019-000548" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=31555485" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&author=R.+Pirkerauthor=M.+Filipits&title=From+crizotinib+to+lorlatinib%3A+continuous+improvement+in+precision+treatment+of+ALK-positive+non-small+cell+lung+cancer&doi=10.1136%2Fesmoopen-2019-000548"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1136%2Fesmoopen-2019-000548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fesmoopen-2019-000548%26sid%3Dliteratum%253Aachs%26aulast%3DPirker%26aufirst%3DR.%26aulast%3DFilipits%26aufirst%3DM.%26atitle%3DFrom%2520crizotinib%2520to%2520lorlatinib%253A%2520continuous%2520improvement%2520in%2520precision%2520treatment%2520of%2520ALK-positive%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DESMO%2520open%26date%3D2019%26volume%3D4%26doi%3D10.1136%2Fesmoopen-2019-000548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, D. S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz-Ares, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geater, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortinovis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochmair, M.</span></span> <span> </span><span class="NLM_article-title">First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>389</i></span>,  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">929</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(17)30123-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2FS0140-6736%2817%2930123-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=28126333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFGku7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=2017&pages=917-929&author=J.+C.+Soriaauthor=D.+S.+W.+Tanauthor=R.+Chiariauthor=Y.+L.+Wuauthor=L.+Paz-Aresauthor=J.+Wolfauthor=S.+L.+Geaterauthor=S.+Orlovauthor=D.+Cortinovisauthor=C.+J.+Yuauthor=M.+Hochmair&title=First-line+ceritinib+versus+platinum-based+chemotherapy+in+advanced+ALK-rearranged+non-small-cell+lung+cancer+%28ASCEND-4%29%3A+a+randomised%2C+open-label%2C+phase+3+study&doi=10.1016%2FS0140-6736%2817%2930123-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study</span></div><div class="casAuthors">Soria, Jean-Charles; Tan, Daniel S. W.; Chiari, Rita; Wu, Yi-Long; Paz-Ares, Luis; Wolf, Juergen; Geater, Sarayut L.; Orlov, Sergey; Cortinovis, Diego; Yu, Chong-Jen; Hochmair, Maximillian; Cortot, Alexis B.; Tsai, Chun-Ming; Moro-Sibilot, Denis; Campelo, Rosario G.; McCulloch, Tracey; Sen, Paramita; Dugan, Margaret; Pantano, Serafino; Branle, Fabrice; Massacesi, Cristian; de Castro, Gilberto, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">389</span>
        (<span class="NLM_cas:issue">10072</span>),
    <span class="NLM_cas:pages">917-929</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The efficacy of ceritinib in patients with untreated anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC) is not known.  We assessed the efficacy and safety of ceritinib vs. platinum-based chemotherapy in these patients.  This randomised, open-label, phase 3 study in untreated patients with stage IIIB/IV ALK-rearranged non-squamous NSCLC was done in 134 centers across 28 countries.  Eligible patients were assigned via interactive response technol. to oral ceritinib 750 mg/day or platinum-based chemotherapy ([cisplatin 75 mg/m2 or carboplatin AUC 5-6 plus pemetrexed 500 mg/m2] every 3 wk for four cycles followed by maintenance pemetrexed); randomization was stratified by World Health Organization performance status (0 vs 1-2), previous neoadjuvant or adjuvant chemotherapy, and presence of brain metastases as per investigator's assessment at screening.  Investigators and patients were not masked to treatment assignment.  The primary endpoint was blinded independent review committee assessed progression-free survival, based on all randomly assigned patients (the full anal. set).  Efficacy analyses were done based on the full anal. set.  All safety analyses were done based on the safety set, which included all patients who received at least one dose of study drug.  This trial is registered with ClinicalTrials.gov, no. NCT01828099.  Between Aug 19, 2013, and May 11, 2015, 376 patients were randomly assigned to ceritinib (n=189) or chemotherapy (n=187).  Median progression-free survival (as assessed by blinded independent review committee) was 16·6 mo (95% CI 12·6-27·2) in the ceritinib group and 8·1 mo (5·8-11·1) in the chemotherapy group (hazard ratio 0·55 [95% CI 0·42-0·73]; p<0·00001).  The most common adverse events were diarrhoea (in 160 [85%] of 189 patients), nausea (130 [69%]), vomiting (125 [66%]), and an increase in alanine aminotransferase (114 [60%]) in the ceritinib group and nausea (in 97 [55%] of 175 patients), vomiting (63 [36%]), and anemia (62 [35%]) in the chemotherapy group.  First-line ceritinib showed a statistically significant and clin. meaningful improvement in progression-free survival vs. chemotherapy in patients with advanced ALK-rearranged NSCLC.  Novartis Pharmaceuticals Corporation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdGKYa204H9rVg90H21EOLACvtfcHk0ljJz_99h3_wbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFGku7Y%253D&md5=a51029d59399ff42f840ffc1b2b5caf7</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2817%2930123-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252817%252930123-X%26sid%3Dliteratum%253Aachs%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DTan%26aufirst%3DD.%2BS.%2BW.%26aulast%3DChiari%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DPaz-Ares%26aufirst%3DL.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DGeater%26aufirst%3DS.%2BL.%26aulast%3DOrlov%26aufirst%3DS.%26aulast%3DCortinovis%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DC.%2BJ.%26aulast%3DHochmair%26aufirst%3DM.%26atitle%3DFirst-line%2520ceritinib%2520versus%2520platinum-based%2520chemotherapy%2520in%2520advanced%2520ALK-rearranged%2520non-small-cell%2520lung%2520cancer%2520%2528ASCEND-4%2529%253A%2520a%2520randomised%252C%2520open-label%252C%2520phase%25203%2520study%26jtitle%3DLancet%26date%3D2017%26volume%3D389%26spage%3D917%26epage%3D929%26doi%3D10.1016%2FS0140-6736%2817%2930123-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veber, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopple, K. D.</span></span> <span> </span><span class="NLM_article-title">Molecular properties that influence the oral bioavailability of drug candidates</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">2615</span>– <span class="NLM_lpage">2623</span>, <span class="refDoi"> DOI: 10.1021/jm020017n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020017n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=2615-2623&author=D.+F.+Veberauthor=S.+R.+Johnsonauthor=H.+Y.+Chengauthor=B.+R.+Smithauthor=K.+W.+Wardauthor=K.+D.+Kopple&title=Molecular+properties+that+influence+the+oral+bioavailability+of+drug+candidates&doi=10.1021%2Fjm020017n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Properties That Influence the Oral Bioavailability of Drug Candidates</span></div><div class="casAuthors">Veber, Daniel F.; Johnson, Stephen R.; Cheng, Hung-Yuan; Smith, Brian R.; Ward, Keith W.; Kopple, Kenneth D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2615-2623</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oral bioavailability measurements in rats for over 1100 drug candidates studied at Smith-Kline Beecham Pharmaceuticals (now Glaxo Smith-Kline) have allowed us to analyze the relative importance of mol. properties considered to influence that drug property.  Reduced mol. flexibility, as measured by the no. of rotatable bonds, and low polar surface area or total hydrogen bond count (sum of donors and acceptors) are found to be important predictors of good oral bioavailability, independent of mol. wt.  That on av. both the no. of rotatable bonds and polar surface area or hydrogen bond count tend to increase with mol. wt. may in part explain the success of the mol. wt. parameter in predicting oral bioavailability.  The commonly applied mol. wt. cutoff at 500 does not itself significantly sep. compds. with poor oral bioavailability from those with acceptable values in this extensive data set.  Our observations suggest that compds. which meet only the 2 criteria of (1) 10 or fewer rotatable bonds and (2) polar surface area ≤140 Å2 (or 12 or fewer H-bond donors and acceptors) will have a high probability of good oral bioavailability in the rat.  Data sets for the artificial membrane permeation rate and for clearance in the rat were also examd.  Reduced polar surface area correlates better with increased permeation rate than does lipophilicity (C log P), and increased rotatable bond count has a neg. effect on the permeation rate.  A threshold permeation rate is a prerequisite of oral bioavailability.  The rotatable bond count does not correlate with the data examd. here for the in vivo clearance rate in the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3JtJEkO7yVLVg90H21EOLACvtfcHk0ljJz_99h3_wbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D&md5=eaad26ed6a259de82ad65a8834fc397d</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjm020017n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020017n%26sid%3Dliteratum%253Aachs%26aulast%3DVeber%26aufirst%3DD.%2BF.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DCheng%26aufirst%3DH.%2BY.%26aulast%3DSmith%26aufirst%3DB.%2BR.%26aulast%3DWard%26aufirst%3DK.%2BW.%26aulast%3DKopple%26aufirst%3DK.%2BD.%26atitle%3DMolecular%2520properties%2520that%2520influence%2520the%2520oral%2520bioavailability%2520of%2520drug%2520candidates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D2615%26epage%3D2623%26doi%3D10.1021%2Fjm020017n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goracci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desantis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valeri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eleuteri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruciani, G.</span></span> <span> </span><span class="NLM_article-title">Understanding the metabolism of proteolysis targeting chimeras (PROTACs): the next step toward pharmaceutical applications</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">11615</span>– <span class="NLM_lpage">11638</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00793</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00793" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvF2htrvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=11615-11638&author=L.+Goracciauthor=J.+Desantisauthor=A.+Valeriauthor=B.+Castellaniauthor=M.+Eleuteriauthor=G.+Cruciani&title=Understanding+the+metabolism+of+proteolysis+targeting+chimeras+%28PROTACs%29%3A+the+next+step+toward+pharmaceutical+applications&doi=10.1021%2Facs.jmedchem.0c00793"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding the Metabolism of Proteolysis Targeting Chimeras (PROTACs): The Next Step toward Pharmaceutical Applications</span></div><div class="casAuthors">Goracci, Laura; Desantis, Jenny; Valeri, Aurora; Castellani, Beatrice; Eleuteri, Michela; Cruciani, Gabriele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">11615-11638</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hetero-bifunctional PROteolysis TArgeting Chimeras (PROTACs) represent a new emerging class of small mols. designed to induce polyubiquitylation and proteasomal-dependent degrdn. of a target protein.  Despite the increasing no. of publications about the synthesis, biol. evaluation, and mechanism of action of PROTACs, the characterization of the pharmacokinetic properties of this class of compds. is still minimal.  Here, we report a study on the metab. of a series of 40 PROTACs in cryopreserved human hepatocytes at multiple time points.  Our results indicated that the metab. of PROTACs could not be predicted from that of their constituent ligands.  Their linkers' chem. nature and length resulted in playing a major role in the PROTACs' liability.  A subset of compds. was also tested for metab. by human cytochrome P 450 3A4 (CYP3A4) and human aldehyde oxidase (hAOX) for more in-depth data interpretation, and both enzymes resulted in active PROTAC metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx6vgKrJPXdbVg90H21EOLACvtfcHk0li3oFmD2iajuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvF2htrvN&md5=2423ce1317b64dae6dc7a9f5d19ce265</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00793%26sid%3Dliteratum%253Aachs%26aulast%3DGoracci%26aufirst%3DL.%26aulast%3DDesantis%26aufirst%3DJ.%26aulast%3DValeri%26aufirst%3DA.%26aulast%3DCastellani%26aufirst%3DB.%26aulast%3DEleuteri%26aufirst%3DM.%26aulast%3DCruciani%26aufirst%3DG.%26atitle%3DUnderstanding%2520the%2520metabolism%2520of%2520proteolysis%2520targeting%2520chimeras%2520%2528PROTACs%2529%253A%2520the%2520next%2520step%2520toward%2520pharmaceutical%2520applications%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D11615%26epage%3D11638%26doi%3D10.1021%2Facs.jmedchem.0c00793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pike, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harlfinger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGinnity, D. F.</span></span> <span> </span><span class="NLM_article-title">Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1793</span>– <span class="NLM_lpage">1800</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2020.07.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.drudis.2020.07.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVeru7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&pages=1793-1800&author=A.+Pikeauthor=B.+Williamsonauthor=S.+Harlfingerauthor=S.+Martinauthor=D.+F.+McGinnity&title=Optimising+proteolysis-targeting+chimeras+%28PROTACs%29+for+oral+drug+delivery%3A+a+drug+metabolism+and+pharmacokinetics+perspective&doi=10.1016%2Fj.drudis.2020.07.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective</span></div><div class="casAuthors">Pike, Andy; Williamson, Beth; Harlfinger, Stephanie; Martin, Scott; McGinnity, Dermot F.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1793-1800</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Proteolysis-targeting chimeras (PROTACs) are an emerging therapeutic modality with the potential to open target space not accessible to conventional small mols. via a degrdn.-based mechanism; however, their bifunctional nature can result in physicochem. properties that breach commonly accepted limits for small-mol. oral drugs.  We offer a drug metab. and pharmacokinetics (DMPK) perspective on the optimization of oral PROTACs across a diverse set of projects within Oncol. R&D at AstraZeneca, highlighting some of the challenges that they have presented to our established screening cascade.  Furthermore, we challenge some of the perceptions and dogma surrounding the feasibility of oral PROTACS and demonstrate that acceptable oral PK properties for this modality can be regularly achievable despite the physicochem. property challenges they present.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNes0zq6ODubVg90H21EOLACvtfcHk0li3oFmD2iajuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVeru7zF&md5=a26048e1fe2eb5f9e134a9132593df23</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2020.07.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2020.07.013%26sid%3Dliteratum%253Aachs%26aulast%3DPike%26aufirst%3DA.%26aulast%3DWilliamson%26aufirst%3DB.%26aulast%3DHarlfinger%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DMcGinnity%26aufirst%3DD.%2BF.%26atitle%3DOptimising%2520proteolysis-targeting%2520chimeras%2520%2528PROTACs%2529%2520for%2520oral%2520drug%2520delivery%253A%2520a%2520drug%2520metabolism%2520and%2520pharmacokinetics%2520perspective%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2020%26volume%3D25%26spage%3D1793%26epage%3D1800%26doi%3D10.1016%2Fj.drudis.2020.07.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, T. P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayle, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirza, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willems, H. M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skidmore, J.</span></span> <span> </span><span class="NLM_article-title">Systematic investigation of the permeability of androgen receptor PROTACs</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1539</span>– <span class="NLM_lpage">1547</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00194</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00194" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFWmt7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1539-1547&author=D.+E.+Scottauthor=T.+P.+C.+Rooneyauthor=E.+D.+Bayleauthor=T.+Mirzaauthor=H.+M.+G.+Willemsauthor=J.+H.+Clarkeauthor=S.+P.+Andrewsauthor=J.+Skidmore&title=Systematic+investigation+of+the+permeability+of+androgen+receptor+PROTACs&doi=10.1021%2Facsmedchemlett.0c00194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Systematic Investigation of the Permeability of Androgen Receptor PROTACs</span></div><div class="casAuthors">Scott, Duncan E.; Rooney, Timothy P. C.; Bayle, Elliott D.; Mirza, Tashfina; Willems, Henriette M. G.; Clarke, Jonathan H.; Andrews, Stephen P.; Skidmore, John</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1539-1547</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bifunctional mols. known as PROTACs simultaneously bind an E3 ligase and a protein of interest to direct ubiquitination and clearance of that protein, and they have emerged in the past decade as an exciting new paradigm in drug discovery.  In order to investigate the permeability and properties of these large mols., we synthesized two panels of PROTAC mols., constructed from a range of protein-target ligands, linkers, and E3 ligase ligands.  The androgen receptor, which is a well-studied protein in the PROTAC field was used as a model system.  The physicochem. properties and permeability of PROTACs are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG6Q_chyrzDLVg90H21EOLACvtfcHk0li3oFmD2iajuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFWmt7%252FO&md5=26c8ea71901a57a09c03f7fb79bbe2c9</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00194%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DD.%2BE.%26aulast%3DRooney%26aufirst%3DT.%2BP.%2BC.%26aulast%3DBayle%26aufirst%3DE.%2BD.%26aulast%3DMirza%26aufirst%3DT.%26aulast%3DWillems%26aufirst%3DH.%2BM.%2BG.%26aulast%3DClarke%26aufirst%3DJ.%2BH.%26aulast%3DAndrews%26aufirst%3DS.%2BP.%26aulast%3DSkidmore%26aufirst%3DJ.%26atitle%3DSystematic%2520investigation%2520of%2520the%2520permeability%2520of%2520androgen%2520receptor%2520PROTACs%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D1539%26epage%3D1547%26doi%3D10.1021%2Facsmedchemlett.0c00194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Edmondson, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallan, C.</span></span> <span> </span><span class="NLM_article-title">Proteolysis targeting chimeras (PROTACs) in ’beyond rule-of-five’ chemical space: recent progress and future challenges</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1555</span>– <span class="NLM_lpage">1564</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.04.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.bmcl.2019.04.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=31047748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC1MXos12gs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=1555-1564&author=S.+D.+Edmondsonauthor=B.+Yangauthor=C.+Fallan&title=Proteolysis+targeting+chimeras+%28PROTACs%29+in+%E2%80%99beyond+rule-of-five%E2%80%99+chemical+space%3A+recent+progress+and+future+challenges&doi=10.1016%2Fj.bmcl.2019.04.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges</span></div><div class="casAuthors">Edmondson, Scott D.; Yang, Bin; Fallan, Charlene</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1555-1564</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Proteolysis targeting chimeras (PROTACs) are heterobifunctional compds. with mol. wts. and other properties that lie outside the classic 'rule-of-five' space.  Consequently, PROTACs have unique challenges assocd. with their development as potential therapeutic agents.  This review summarizes and analyzes a representative set of recent PROTACs and highlights some of the potential future challenges facing this promising modality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDcS0gIul-K7Vg90H21EOLACvtfcHk0ljl9M8859AMvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXos12gs74%253D&md5=62a74500178bd711b1ddaa33d731b960</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.04.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.04.030%26sid%3Dliteratum%253Aachs%26aulast%3DEdmondson%26aufirst%3DS.%2BD.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DFallan%26aufirst%3DC.%26atitle%3DProteolysis%2520targeting%2520chimeras%2520%2528PROTACs%2529%2520in%2520%25E2%2580%2599beyond%2520rule-of-five%25E2%2580%2599%2520chemical%2520space%253A%2520recent%2520progress%2520and%2520future%2520challenges%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D1555%26epage%3D1564%26doi%3D10.1016%2Fj.bmcl.2019.04.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Salas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przybranowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">462</span>– <span class="NLM_lpage">481</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01816</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01816" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvVajsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=462-481&author=B.+Zhouauthor=J.+Huauthor=F.+Xuauthor=Z.+Chenauthor=L.+Baiauthor=E.+Fernandez-Salasauthor=M.+Linauthor=L.+Liuauthor=C.+Y.+Yangauthor=Y.+Zhaoauthor=D.+McEachernauthor=S.+Przybranowskiauthor=B.+Wenauthor=D.+Sunauthor=S.+Wang&title=Discovery+of+a+small-molecule+degrader+of+bromodomain+and+extra-terminal+%28BET%29+proteins+with+picomolar+cellular+potencies+and+capable+of+achieving+tumor+regression&doi=10.1021%2Facs.jmedchem.6b01816"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression</span></div><div class="casAuthors">Zhou, Bing; Hu, Jiantao; Xu, Fuming; Chen, Zhuo; Bai, Longchuan; Fernandez-Salas, Ester; Lin, Mei; Liu, Liu; Yang, Chao-Yie; Zhao, Yujun; McEachern, Donna; Przybranowski, Sally; Wen, Bo; Sun, Duxin; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">462-481</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The bromodomain and extra-terminal (BET) family proteins, consisting of BRD2, BRD3, BRD4, and testis-specific BRDT members, are epigenetic "readers" and play a key role in the regulation of gene transcription.  BET proteins are considered to be attractive therapeutic targets for cancer and other human diseases.  Recently, heterobifunctional small-mol. BET degraders have been designed based upon the proteolysis targeting chimera (PROTAC) concept to induce BET protein degrdn.  Herein, we present our design, synthesis, and evaluation of a new class of PROTAC BET degraders.  One of the most promising compds., 23, effectively degrades BRD4 protein at concns. as low as 30 pM in the RS4;11 leukemia cell line, achieves an IC50 value of 51 pM in inhibition of RS4;11 cell growth and induces rapid tumor regression in vivo against RS4;11 xenograft tumors.  These data establish that compd. 23 (BETd-260/ZBC260) is a highly potent and efficacious BET degrader.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqz2Lwp52x1rVg90H21EOLACvtfcHk0ljl9M8859AMvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvVajsb8%253D&md5=6b3a10ecd192a5812ef581dca1fdc82a</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01816%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DBai%26aufirst%3DL.%26aulast%3DFernandez-Salas%26aufirst%3DE.%26aulast%3DLin%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DMcEachern%26aufirst%3DD.%26aulast%3DPrzybranowski%26aufirst%3DS.%26aulast%3DWen%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520a%2520small-molecule%2520degrader%2520of%2520bromodomain%2520and%2520extra-terminal%2520%2528BET%2529%2520proteins%2520with%2520picomolar%2520cellular%2520potencies%2520and%2520capable%2520of%2520achieving%2520tumor%2520regression%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D462%26epage%3D481%26doi%3D10.1021%2Facs.jmedchem.6b01816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and selective epidermal growth factor receptor (EGFR) bifunctional small-molecule degraders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1216</span>– <span class="NLM_lpage">1232</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01566</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01566" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFWksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=1216-1232&author=M.+Chengauthor=X.+Yuauthor=K.+Luauthor=L.+Xieauthor=L.+Wangauthor=F.+Mengauthor=X.+Hanauthor=X.+Chenauthor=J.+Liuauthor=Y.+Xiongauthor=J.+Jin&title=Discovery+of+potent+and+selective+epidermal+growth+factor+receptor+%28EGFR%29+bifunctional+small-molecule+degraders&doi=10.1021%2Facs.jmedchem.9b01566"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders</span></div><div class="casAuthors">Cheng, Meng; Yu, Xufen; Lu, Kaylene; Xie, Ling; Wang, Li; Meng, Fanye; Han, Xiaoran; Chen, Xian; Liu, Jing; Xiong, Yue; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1216-1232</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors have been developed and approved by Food and Drug Administration for the treatment of non-small-cell lung cancers, but their efficacy can be compromised by acquired drug resistance conferred by EGFR-mutant variants.  Here, we described the discovery of a novel E3 ligase von Hippel-Lindau-recruiting EGFR degrader, MS39 (compd. 6), and a first-in-class E3 ligase cereblon-recruiting EGFR degrader, MS154 (compd. 10), using the proteolysis targeting chimera technol.  These compds. potently induced the degrdn. of mutant but not wild-type EGFR in an E3 ligase-dependent manner in cancer cell lines and effectively suppressed the growth of lung cancer cells compared with the corresponding neg. controls.  The global proteomic analyses revealed that the compds. were highly selective for EGFR.  Furthermore, both compds. were bioavailable in mouse pharmacokinetic studies, and compd. 6 is the first EGFR degrader suitable for in vivo efficacy studies.  Overall, we provide a set of well-characterized chem. tools to the research community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraFLSjUGE-6rVg90H21EOLACvtfcHk0lg4O1F8GkLS1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFWksA%253D%253D&md5=ec831897a4258f1968e254aa433426c3</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01566%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DK.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DF.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520bifunctional%2520small-molecule%2520degraders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D1216%26epage%3D1232%26doi%3D10.1021%2Facs.jmedchem.9b01566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavana, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banks, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crafter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingipalli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kouvchinov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachl, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solanki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valge-Archer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmondson, S. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of proteolysis-targeting chimera molecules that selectively degrade the IRAK3 pseudokinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">10460</span>– <span class="NLM_lpage">10473</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c01125</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01125" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1WktLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=10460-10473&author=S.+L.+Degorceauthor=O.+Tavanaauthor=E.+Banksauthor=C.+Crafterauthor=L.+Gingipalliauthor=D.+Kouvchinovauthor=Y.+Maoauthor=F.+Pachlauthor=A.+Solankiauthor=V.+Valge-Archerauthor=B.+Yangauthor=S.+D.+Edmondson&title=Discovery+of+proteolysis-targeting+chimera+molecules+that+selectively+degrade+the+IRAK3+pseudokinase&doi=10.1021%2Facs.jmedchem.0c01125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 Pseudokinase</span></div><div class="casAuthors">Degorce, Sebastien L.; Tavana, Omid; Banks, Erica; Crafter, Claire; Gingipalli, Lakshmaiah; Kouvchinov, David; Mao, Yumeng; Pachl, Fiona; Solanki, Anisha; Valge-Archer, Viia; Yang, Bin; Edmondson, Scott D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">10460-10473</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the first disclosure of IRAK3 degraders in the scientific literature.  Taking advantage of an opportune byproduct obtained during our efforts to identify IRAK4 inhibitors, we identified ready-to-use, selective IRAK3 ligands in our compd. collection with the required properties for conversion into proteolysis-targeting chimera (PROTAC) degraders.  This work culminated with the discovery of PROTAC 23(I), which we demonstrated to be a potent and selective degrader of IRAK3 after 16 h in THP1 cells. 23 induced proteasome-dependent degrdn. of IRAK3 and required both CRBN and IRAK3 binding for activity.  We conclude that PROTAC 23 constitutes an excellent in vitro tool with which to interrogate the biol. of IRAK3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqwc4uccsV7LVg90H21EOLACvtfcHk0lg4O1F8GkLS1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1WktLbF&md5=aba5d2bbecd9a66f4e4a6a3999e33e41</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01125%26sid%3Dliteratum%253Aachs%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DTavana%26aufirst%3DO.%26aulast%3DBanks%26aufirst%3DE.%26aulast%3DCrafter%26aufirst%3DC.%26aulast%3DGingipalli%26aufirst%3DL.%26aulast%3DKouvchinov%26aufirst%3DD.%26aulast%3DMao%26aufirst%3DY.%26aulast%3DPachl%26aufirst%3DF.%26aulast%3DSolanki%26aufirst%3DA.%26aulast%3DValge-Archer%26aufirst%3DV.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DEdmondson%26aufirst%3DS.%2BD.%26atitle%3DDiscovery%2520of%2520proteolysis-targeting%2520chimera%2520molecules%2520that%2520selectively%2520degrade%2520the%2520IRAK3%2520pseudokinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D10460%26epage%3D10473%26doi%3D10.1021%2Facs.jmedchem.0c01125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bondeson, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burslem, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhimschi, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaime-Figueroa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamman, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishchenko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Lessons in PROTAC design from selective degradation with a promiscuous warhead</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">78</span>– <span class="NLM_lpage">87.e5</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2017.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.chembiol.2017.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=29129718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2lsrjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=78-87.e5&author=D.+P.+Bondesonauthor=B.+E.+Smithauthor=G.+M.+Burslemauthor=A.+D.+Buhimschiauthor=J.+Hinesauthor=S.+Jaime-Figueroaauthor=J.+Wangauthor=B.+D.+Hammanauthor=A.+Ishchenkoauthor=C.+M.+Crews&title=Lessons+in+PROTAC+design+from+selective+degradation+with+a+promiscuous+warhead&doi=10.1016%2Fj.chembiol.2017.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead</span></div><div class="casAuthors">Bondeson, Daniel P.; Smith, Blake E.; Burslem, George M.; Buhimschi, Alexandru D.; Hines, John; Jaime-Figueroa, Saul; Wang, Jing; Hamman, Brian D.; Ishchenko, Alexey; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">78-87.e5</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Inhibiting protein function selectively is a major goal of modern drug discovery.  Here, we report a previously understudied benefit of small mol. proteolysis-targeting chimeras (PROTACs) that recruit E3 ubiquitin ligases to target proteins for their ubiquitination and subsequent proteasome-mediated degrdn.  Using promiscuous CRBN- and VHL-recruiting PROTACs that bind >50 kinases, we show that only a subset of bound targets is degraded.  The basis of this selectivity relies on protein-protein interactions between the E3 ubiquitin ligase and the target protein, as illustrated by engaged proteins that are not degraded as a result of unstable ternary complexes with PROTAC-recruited E3 ligases.  In contrast, weak PROTAC:target protein affinity can be stabilized by high-affinity target:PROTAC:ligase trimer interactions, leading to efficient degrdn.  This study highlights design guidelines for generating potent PROTACs as well as possibilities for degrading undruggable proteins immune to traditional small-mol. inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoISOBudOLyFrVg90H21EOLACvtfcHk0lg4O1F8GkLS1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2lsrjN&md5=30fac502705a2344c4261cf531e6bf9d</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DBondeson%26aufirst%3DD.%2BP.%26aulast%3DSmith%26aufirst%3DB.%2BE.%26aulast%3DBurslem%26aufirst%3DG.%2BM.%26aulast%3DBuhimschi%26aufirst%3DA.%2BD.%26aulast%3DHines%26aufirst%3DJ.%26aulast%3DJaime-Figueroa%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHamman%26aufirst%3DB.%2BD.%26aulast%3DIshchenko%26aufirst%3DA.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DLessons%2520in%2520PROTAC%2520design%2520from%2520selective%2520degradation%2520with%2520a%2520promiscuous%2520warhead%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2018%26volume%3D25%26spage%3D78%26epage%3D87.e5%26doi%3D10.1016%2Fj.chembiol.2017.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aberle, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Design and applications of bifunctional small molecules: why two heads are better than one</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">677</span>– <span class="NLM_lpage">692</span>, <span class="refDoi"> DOI: 10.1021/cb8001792</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb8001792" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1yiurzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=677-692&author=T.+W.+Corsonauthor=N.+Aberleauthor=C.+M.+Crews&title=Design+and+applications+of+bifunctional+small+molecules%3A+why+two+heads+are+better+than+one&doi=10.1021%2Fcb8001792"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Applications of Bifunctional Small Molecules: Why Two Heads Are Better Than One</span></div><div class="casAuthors">Corson, Timothy W.; Aberle, Nicholas; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">677-692</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Induction of protein-protein interactions is a daunting challenge, but recent studies show promise for small mols. that specifically bring two or more protein mols. together for enhanced or novel biol. effect.  The first such bifunctional mols. were the rapamycin- and FK506-based "chem. inducers of dimerization", but the field has since expanded with new mols. and new applications in chem. genetics and cell biol.  Examples include coumermycin-mediated gyrase B dimerization, proteolysis targeting chimeric mols. (PROTACs), drug hybrids, and strategies for exploiting multivalency in toxin binding and antibody recruitment.  This Review discusses these and other advances in the design and use of bifunctional small mols. and potential strategies for future systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-ZyBtc3QT9rVg90H21EOLACvtfcHk0ljx_-VGYhFJDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1yiurzF&md5=2edac15286d3a739dd66214a332a545b</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fcb8001792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb8001792%26sid%3Dliteratum%253Aachs%26aulast%3DCorson%26aufirst%3DT.%2BW.%26aulast%3DAberle%26aufirst%3DN.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DDesign%2520and%2520applications%2520of%2520bifunctional%2520small%2520molecules%253A%2520why%2520two%2520heads%2520are%2520better%2520than%2520one%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2008%26volume%3D3%26spage%3D677%26epage%3D692%26doi%3D10.1021%2Fcb8001792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cyrus, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehenkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span> <span> </span><span class="NLM_article-title">Impact of linker length on the activity of PROTACs</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">359</span>– <span class="NLM_lpage">364</span>, <span class="refDoi"> DOI: 10.1039/C0MB00074D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1039%2FC0MB00074D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=20922213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmslGhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=359-364&author=K.+Cyrusauthor=M.+Wehenkelauthor=E.+Y.+Choiauthor=H.+J.+Hanauthor=H.+Leeauthor=H.+Swansonauthor=K.+B.+Kim&title=Impact+of+linker+length+on+the+activity+of+PROTACs&doi=10.1039%2FC0MB00074D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of linker length on the activity of PROTACs</span></div><div class="casAuthors">Cyrus, Kedra; Wehenkel, Marie; Choi, Eun-Young; Han, Hyeong-Jun; Lee, Hyosung; Swanson, Hollie; Kim, Kyung-Bo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">359-364</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-206X</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Conventional genetic approaches have provided a powerful tool in the study of proteins.  However, these techniques often preclude selective manipulation of temporal and spatial protein functions, which is crucial for the investigation of dynamic cellular processes.  To overcome these limitations, a small mol.-based novel technol. termed "PROteolysis TArgeting ChimeraS (PROTACs)" has been developed, targeting proteins for degrdn. at the post-translational level.  Despite the promising potential of PROTACs to serve as mol. probes of complex signaling pathways, their design has not been generalized for broad application.  Here, we present the first generalized approach for PROTAC design by fine-tuning the distance between the two participating partner proteins, the E3 ubiquitin ligase and the target protein.  As such, we took a chem. approach to create estrogen receptor (ER)-α targeting PROTACs with varying linker lengths and the loss of the ER in cultured cells was monitored via western blot and fluorometric analyses.  We found a significant effect of chain length on PROTAC efficacy, and, in this case, the optimum distance between the E3 recognition motif and the ligand was a 16 atom chain length.  The information gathered from this expt. may offer a generalizable PROTAC design strategy to further the expansion of the PROTAC toolbox, opening new possibilities for the broad application of the PROTAC strategy in the study of multiple signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqP7hxQSvFw57Vg90H21EOLACvtfcHk0ljx_-VGYhFJDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmslGhsw%253D%253D&md5=56dc56cb3a73d17bc8903c4962d7648c</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1039%2FC0MB00074D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC0MB00074D%26sid%3Dliteratum%253Aachs%26aulast%3DCyrus%26aufirst%3DK.%26aulast%3DWehenkel%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DE.%2BY.%26aulast%3DHan%26aufirst%3DH.%2BJ.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DSwanson%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DK.%2BB.%26atitle%3DImpact%2520of%2520linker%2520length%2520on%2520the%2520activity%2520of%2520PROTACs%26jtitle%3DMol.%2520BioSyst.%26date%3D2011%26volume%3D7%26spage%3D359%26epage%3D364%26doi%3D10.1039%2FC0MB00074D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böhm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lydeard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadler, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavadini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serluca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingaraju, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tichkule, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schebesta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrester, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassiepen, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hild, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckwith, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomä, N. H.</span></span> <span> </span><span class="NLM_article-title">Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>512</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1038/nature13527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1038%2Fnature13527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=25043012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht12ms7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=512&publication_year=2014&pages=49-53&author=E.+S.+Fischerauthor=K.+B%C3%B6hmauthor=J.+R.+Lydeardauthor=H.+Yangauthor=M.+B.+Stadlerauthor=S.+Cavadiniauthor=J.+Nagelauthor=F.+Serlucaauthor=V.+Ackerauthor=G.+M.+Lingarajuauthor=R.+B.+Tichkuleauthor=M.+Schebestaauthor=W.+C.+Forresterauthor=M.+Schirleauthor=U.+Hassiepenauthor=J.+Ottlauthor=M.+Hildauthor=R.+E.+Beckwithauthor=J.+W.+Harperauthor=J.+L.+Jenkinsauthor=N.+H.+Thom%C3%A4&title=Structure+of+the+DDB1-CRBN+E3+ubiquitin+ligase+in+complex+with+thalidomide&doi=10.1038%2Fnature13527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide</span></div><div class="casAuthors">Fischer, Eric S.; Bohm, Kerstin; Lydeard, John R.; Yang, Haidi; Stadler, Michael B.; Cavadini, Simone; Nagel, Jane; Serluca, Fabrizio; Acker, Vincent; Lingaraju, Gondichatnahalli M.; Tichkule, Ritesh B.; Schebesta, Michael; Forrester, William C.; Schirle, Markus; Hassiepen, Ulrich; Ottl, Johannes; Hild, Marc; Beckwith, Rohan E. J.; Harper, J. Wade; Jenkins, Jeremy L.; Thoma, Nicolas H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">512</span>
        (<span class="NLM_cas:issue">7512</span>),
    <span class="NLM_cas:pages">49-53</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In the 1950s, the drug thalidomide, administered as a sedative to pregnant women, led to the birth of thousands of children with multiple defects.  Despite the teratogenicity of thalidomide and its derivs. lenalidomide and pomalidomide, these immunomodulatory drugs (IMiDs) recently emerged as effective treatments for multiple myeloma and 5q-deletion-assocd. dysplasia.  IMiDs target the E3 ubiquitin ligase CUL4-RBX1-DDB1-CRBN (known as CRL4CRBN) and promote the ubiquitination of the IKAROS family transcription factors IKZF1 and IKZF3 by CRL4CRBN.  Here we present crystal structures of the DDB1-CRBN complex bound to thalidomide, lenalidomide and pomalidomide.  The structure establishes that CRBN is a substrate receptor within CRL4CRBN and enantioselectively binds IMiDs.  Using an unbiased screen, we identified the homeobox transcription factor MEIS2 as an endogenous substrate of CRL4CRBN.  Our studies suggest that IMiDs block endogenous substrates (MEIS2) from binding to CRL4CRBN while the ligase complex is recruiting IKZF1 or IKZF3 for degrdn.  This dual activity implies that small mols. can modulate an E3 ubiquitin ligase and thereby upregulate or downregulate the ubiquitination of proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGt2Y9GecKr7Vg90H21EOLACvtfcHk0ljx_-VGYhFJDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht12ms7%252FP&md5=1c1eaa48bef87463cdd3f2b1e1bd400d</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fnature13527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13527%26sid%3Dliteratum%253Aachs%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DB%25C3%25B6hm%26aufirst%3DK.%26aulast%3DLydeard%26aufirst%3DJ.%2BR.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DStadler%26aufirst%3DM.%2BB.%26aulast%3DCavadini%26aufirst%3DS.%26aulast%3DNagel%26aufirst%3DJ.%26aulast%3DSerluca%26aufirst%3DF.%26aulast%3DAcker%26aufirst%3DV.%26aulast%3DLingaraju%26aufirst%3DG.%2BM.%26aulast%3DTichkule%26aufirst%3DR.%2BB.%26aulast%3DSchebesta%26aufirst%3DM.%26aulast%3DForrester%26aufirst%3DW.%2BC.%26aulast%3DSchirle%26aufirst%3DM.%26aulast%3DHassiepen%26aufirst%3DU.%26aulast%3DOttl%26aufirst%3DJ.%26aulast%3DHild%26aufirst%3DM.%26aulast%3DBeckwith%26aufirst%3DR.%2BE.%26aulast%3DHarper%26aufirst%3DJ.%2BW.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26aulast%3DThom%25C3%25A4%26aufirst%3DN.%2BH.%26atitle%3DStructure%2520of%2520the%2520DDB1-CRBN%2520E3%2520ubiquitin%2520ligase%2520in%2520complex%2520with%2520thalidomide%26jtitle%3DNature%26date%3D2014%26volume%3D512%26spage%3D49%26epage%3D53%26doi%3D10.1038%2Fnature13527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span> <span> </span><span class="NLM_article-title">Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2014.05.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.ccr.2014.05.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=25065853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1agsL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=207-221&author=H.+J.+Leeauthor=G.+Zhuangauthor=Y.+Caoauthor=P.+Duauthor=H.+J.+Kimauthor=J.+Settleman&title=Drug+resistance+via+feedback+activation+of+Stat3+in+oncogene-addicted+cancer+cells&doi=10.1016%2Fj.ccr.2014.05.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells</span></div><div class="casAuthors">Lee, Ho-June; Zhuang, Guanglei; Cao, Yi; Du, Pan; Kim, Hyo-Jin; Settleman, Jeff</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">207-221</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Pathway-targeted cancer drugs can produce dramatic responses that are invariably limited by the emergence of drug-resistant cells.  We found that many drug-treated "oncogene-addicted" cancer cells engage a pos. feedback loop leading to Stat3 activation, consequently promoting cell survival and limiting overall drug response.  This was obsd. in cancer cells driven by diverse activated kinases, including EGFR, HER2, ALK, and MET, as well as mutant KRAS.  Specifically, MEK inhibition led to autocrine activation of Stat3 via the FGF receptor and JAK kinases, and pharmacol. inhibition of MEK together with JAK and FGFR enhanced tumor regression.  These findings suggest that inhibition of a Stat3 feedback loop may augment the response to a broad spectrum of drugs that target pathways of oncogene addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9wv2-E6LTCLVg90H21EOLACvtfcHk0liKRUHIRRsVFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1agsL7I&md5=d180509b8b5a63331e8edbd0d2bf9a63</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2014.05.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2014.05.019%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DZhuang%26aufirst%3DG.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DDu%26aufirst%3DP.%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DDrug%2520resistance%2520via%2520feedback%2520activation%2520of%2520Stat3%2520in%2520oncogene-addicted%2520cancer%2520cells%26jtitle%3DCancer%2520Cell%26date%3D2014%26volume%3D26%26spage%3D207%26epage%3D221%26doi%3D10.1016%2Fj.ccr.2014.05.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilling, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutateladze, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weickhardt, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linderman, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heasley, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franklin, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varella-Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer</span>. <i>Clin. Cancer. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1472</span>– <span class="NLM_lpage">1482</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-2906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1158%2F1078-0432.CCR-11-2906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=22235099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Wksro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1472-1482&author=R.+C.+Doebeleauthor=A.+B.+Pillingauthor=D.+L.+Aisnerauthor=T.+G.+Kutateladzeauthor=A.+T.+Leauthor=A.+J.+Weickhardtauthor=K.+L.+Kondoauthor=D.+J.+Lindermanauthor=L.+E.+Heasleyauthor=W.+A.+Franklinauthor=M.+Varella-Garciaauthor=D.+R.+Camidge&title=Mechanisms+of+resistance+to+crizotinib+in+patients+with+ALK+gene+rearranged+non-small+cell+lung+cancer&doi=10.1158%2F1078-0432.CCR-11-2906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Doebele, Robert C.; Pilling, Amanda B.; Aisner, Dara L.; Kutateladze, Tatiana G.; Le, Anh T.; Weickhardt, Andrew J.; Kondo, Kimi L.; Linderman, Derek J.; Heasley, Lynn E.; Franklin, Wilbur A.; Varella-Garcia, Marileila; Camidge, D. Ross</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1472-1482</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with anaplastic lymphoma kinase (ALK) gene rearrangements often manifest dramatic responses to crizotinib, a small-mol. ALK inhibitor.  Unfortunately, not every patient responds and acquired drug resistance inevitably develops in those who do respond.  This study aimed to define mol. mechanisms of resistance to crizotinib in patients with ALK+ non-small cell lung cancer (NSCLC).  We analyzed tissue obtained from 14 patients with ALK+ NSCLC showing evidence of radiol. progression while on crizotinib to define mechanisms of intrinsic and acquired resistance to crizotinib.  Eleven patients had material evaluable for mol. anal.  Four patients (36%) developed secondary mutations in the tyrosine kinase domain of ALK.  A novel mutation in the ALK domain, encoding a G1269A amino acid substitution that confers resistance to crizotinib in vitro, was identified in two of these cases.  Two patients, one with a resistance mutation, exhibited new onset ALK copy no. gain (CNG).  One patient showed outgrowth of epidermal growth factor receptor (EGFR) mutant NSCLC without evidence of a persistent ALK gene rearrangement.  Two patients exhibited a KRAS mutation, one of which occurred without evidence of a persisting ALK gene rearrangement.  One patient showed the emergence of an ALK gene fusion-neg. tumor compared with the baseline sample but with no identifiable alternate driver.  Two patients retained ALK positivity with no identifiable resistance mechanism.  Crizotinib resistance in ALK+ NSCLC occurs through somatic kinase domain mutations, ALK gene fusion CNG, and emergence of sep. oncogenic drivers.  Clin Cancer Res; 18(5); 1472-82.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofhGQYtlS1w7Vg90H21EOLACvtfcHk0liKRUHIRRsVFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Wksro%253D&md5=575047615ef9e3d4af60d45605a747c5</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2906%26sid%3Dliteratum%253Aachs%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DPilling%26aufirst%3DA.%2BB.%26aulast%3DAisner%26aufirst%3DD.%2BL.%26aulast%3DKutateladze%26aufirst%3DT.%2BG.%26aulast%3DLe%26aufirst%3DA.%2BT.%26aulast%3DWeickhardt%26aufirst%3DA.%2BJ.%26aulast%3DKondo%26aufirst%3DK.%2BL.%26aulast%3DLinderman%26aufirst%3DD.%2BJ.%26aulast%3DHeasley%26aufirst%3DL.%2BE.%26aulast%3DFranklin%26aufirst%3DW.%2BA.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520crizotinib%2520in%2520patients%2520with%2520ALK%2520gene%2520rearranged%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer.%2520Res.%26date%3D2012%26volume%3D18%26spage%3D1472%26epage%3D1482%26doi%3D10.1158%2F1078-0432.CCR-11-2906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antoniu, S. A.</span></span> <span> </span><span class="NLM_article-title">Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease?</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">351</span>– <span class="NLM_lpage">353</span>, <span class="refDoi"> DOI: 10.1517/14728222.2011.550880</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1517%2F14728222.2011.550880" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=21208134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ymu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=351-353&author=S.+A.+Antoniu&title=Crizotinib+for+EML4-ALK+positive+lung+adenocarcinoma%3A+a+hope+for+the+advanced+disease%3F&doi=10.1517%2F14728222.2011.550880"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease?</span></div><div class="casAuthors">Antoniu, Sabina Antonela</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">351-353</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: In lung adenocarcinoma, certain mutations such as echinoderm microtubule-assocd. protein-like 4-anaplastic lymphoma kinase (ALK) are assocd. with lower sensitivity to chemotherapy, when used conventionally as the first-line therapy in the advanced stage of the disease.  Areas covered: This paper discusses the clin. and therapeutic importance of ALK mutations in NSCLC and the early clin. results of a Phase I study assessing crizotinib in patients with ALK mutations.  Expert opinion: Abnormal ALK is evolving as an important therapeutic target in patients with more aggressive lung adenocarcinoma.  Further clin. studies are needed in order to assess if crizotinib, an ALK inhibitor, is able to increase the efficacy of the conventional chemotherapy in this disease subset.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo65eAfRGofurVg90H21EOLACvtfcHk0liKRUHIRRsVFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ymu7g%253D&md5=07ac2378ef5fbbb9dd4e3232af7c8f94</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1517%2F14728222.2011.550880&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.2011.550880%26sid%3Dliteratum%253Aachs%26aulast%3DAntoniu%26aufirst%3DS.%2BA.%26atitle%3DCrizotinib%2520for%2520EML4-ALK%2520positive%2520lung%2520adenocarcinoma%253A%2520a%2520hope%2520for%2520the%2520advanced%2520disease%253F%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2011%26volume%3D15%26spage%3D351%26epage%3D353%26doi%3D10.1517%2F14728222.2011.550880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2012.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.phrs.2012.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=23201355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovVygtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=68-94&author=R.+Roskoski&title=Anaplastic+lymphoma+kinase+%28ALK%29%3A+structure%2C+oncogenic+activation%2C+and+pharmacological+inhibition&doi=10.1016%2Fj.phrs.2012.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition</span></div><div class="casAuthors">Roskoski, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">68-94</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Anaplastic lymphoma kinase was first described in 1994 as the NPM-ALK fusion protein that is expressed in the majority of anaplastic large-cell lymphomas.  ALK is a receptor protein-tyrosine kinase that was more fully characterized in 1997.  Physiol. ALK participates in embryonic nervous system development, but its expression decreases after birth.  ALK is a member of the insulin receptor superfamily and is most closely related to leukocyte tyrosine kinase (Ltk), which is a receptor protein-tyrosine kinase.  Twenty different ALK-fusion proteins have been described that result from various chromosomal rearrangements, and they have been implicated in the pathogenesis of several diseases including anaplastic large-cell lymphoma, diffuse large B-cell lymphoma, and inflammatory myofibroblastic tumors.  The EML4-ALK fusion protein and four other ALK-fusion proteins play a fundamental role in the development in about 5% of non-small cell lung cancers.  The formation of dimers by the amino-terminal portion of the ALK fusion proteins results in the activation of the ALK protein kinase domain that plays a key role in the tumorigenic process.  Downstream signaling from ALK fusion proteins involves the Ras/Raf/MEK/ERK1/2 cell proliferation module and the JAK/STAT cell survival pathway.  Furthermore, nearly two dozen ALK activating mutations participate in the pathogenesis of childhood neuroblastomas along with ALK overexpression.  The occurrence of oncogenic ALK, particularly in non-small cell lung cancer, has generated considerable interest and effort in developing ALK inhibitors.  Currently, crizotinib has been approved by the US Food and Drug Administration for the treatment of ALK-pos. non-small cell lung cancer along with an approved fluorescence in situ hybridization kit used for the diagnosis of the disease.  The emergence of crizotinib drug resistance with a median occurrence at approx. 10 mo after the initiation of therapy has stimulated the development of second-generation drugs for the treatment of non-small cell lung cancer and other disorders.  About 28% of the cases of crizotinib resistance are related to nearly a dozen different mutations of ALK in the EML4-ALK fusion protein; the other cases of resistance are related to the upregulation of alternative signaling pathways or to undefined mechanisms.  It is remarkable that the EML4-ALK fusion protein was discovered in 2007 and crizotinib was approved for the treatment of ALK-pos. non-small cell lung cancer in 2011, which is a remarkably short timeframe in the overall scheme of drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv-sp0x0gqkrVg90H21EOLACvtfcHk0ljKjzVeGjgIvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovVygtg%253D%253D&md5=c48d1a4b88a68d395b7acdf403f1875d</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2012.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2012.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%253A%2520structure%252C%2520oncogenic%2520activation%252C%2520and%2520pharmacological%2520inhibition%26jtitle%3DPharmacol.%2520Res.%26date%3D2013%26volume%3D68%26spage%3D68%26epage%3D94%26doi%3D10.1016%2Fj.phrs.2012.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matyskiela, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagarigan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houston, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmel, G.</span></span> <span> </span><span class="NLM_article-title">A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>535</i></span>,  <span class="NLM_fpage">252</span>– <span class="NLM_lpage">257</span>, <span class="refDoi"> DOI: 10.1038/nature18611</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1038%2Fnature18611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=27338790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVCltbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=535&publication_year=2016&pages=252-257&author=M.+E.+Matyskielaauthor=G.+Luauthor=T.+Itoauthor=B.+Pagariganauthor=C.+C.+Luauthor=K.+Millerauthor=W.+Fangauthor=N.+Y.+Wangauthor=D.+Nguyenauthor=J.+Houstonauthor=G.+Carmel&title=A+novel+cereblon+modulator+recruits+GSPT1+to+the+CRL4%28CRBN%29+ubiquitin+ligase&doi=10.1038%2Fnature18611"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase</span></div><div class="casAuthors">Matyskiela, Mary E.; Lu, Gang; Ito, Takumi; Pagarigan, Barbra; Lu, Chin-Chun; Miller, Karen; Fang, Wei; Wang, Nai-Yu; Nguyen, Derek; Houston, Jack; Carmel, Gilles; Tran, Tam; Riley, Mariko; Nosaka, Lyn'Al; Lander, Gabriel C.; Gaidarova, Svetlana; Xu, Shuichan; Ruchelman, Alexander L.; Handa, Hiroshi; Carmichael, James; Daniel, Thomas O.; Cathers, Brian E.; Lopez-Girona, Antonia; Chamberlain, Philip P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">535</span>
        (<span class="NLM_cas:issue">7611</span>),
    <span class="NLM_cas:pages">252-257</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Immunomodulatory drugs bind to cereblon (CRBN) to confer differentiated substrate specificity on the CRL4CRBN E3 ubiquitin ligase.  Here we report the identification of a new cereblon modulator, CC-885, with potent anti-tumor activity.  The anti-tumor activity of CC-885 is mediated through the cereblon-dependent ubiquitination and degrdn. of the translation termination factor GSPT1.  Patient-derived acute myeloid leukemia tumor cells exhibit high sensitivity to CC-885, indicating the clin. potential of this mechanism.  Crystallog. studies of the CRBN-DDB1-CC-885-GSPT1 complex reveal that GSPT1 binds to cereblon through a surface turn contg. a glycine residue at a key position, interacting with both CC-885 and a 'hotspot' on the cereblon surface.  Although GSPT1 possesses no obvious structural, sequence or functional homol. to previously known cereblon substrates, mutational anal. and modeling indicate that the cereblon substrate Ikaros uses a similar structural feature to bind cereblon, suggesting a common motif for substrate recruitment.  These findings define a structural degron underlying cereblon 'neosubstrate' selectivity, and identify an anti-tumor target rendered druggable by cereblon modulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgAWiXdlJgYLVg90H21EOLACvtfcHk0ljKjzVeGjgIvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVCltbnI&md5=1d4e340416aa0b08fc0f123faf638c3f</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fnature18611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature18611%26sid%3Dliteratum%253Aachs%26aulast%3DMatyskiela%26aufirst%3DM.%2BE.%26aulast%3DLu%26aufirst%3DG.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DPagarigan%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DC.%2BC.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DFang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DN.%2BY.%26aulast%3DNguyen%26aufirst%3DD.%26aulast%3DHouston%26aufirst%3DJ.%26aulast%3DCarmel%26aufirst%3DG.%26atitle%3DA%2520novel%2520cereblon%2520modulator%2520recruits%2520GSPT1%2520to%2520the%2520CRL4%2528CRBN%2529%2520ubiquitin%2520ligase%26jtitle%3DNature%26date%3D2016%26volume%3D535%26spage%3D252%26epage%3D257%26doi%3D10.1038%2Fnature18611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naniong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaelin, W. G.,  Jr.</span></span> <span> </span><span class="NLM_article-title">The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>343</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1126/science.1244917</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1126%2Fscience.1244917" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=24292623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtV2ktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2014&pages=305-309&author=G.+Luauthor=R.+E.+Middletonauthor=H.+Sunauthor=M.+Naniongauthor=C.+J.+Ottauthor=C.+S.+Mitsiadesauthor=K.+K.+Wongauthor=J.+E.+Bradnerauthor=W.+G.+Kaelin&title=The+myeloma+drug+lenalidomide+promotes+the+cereblon-dependent+destruction+of+Ikaros+proteins&doi=10.1126%2Fscience.1244917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins</span></div><div class="casAuthors">Lu, Gang; Middleton, Richard E.; Sun, Huahang; Naniong, MarkVic; Ott, Christopher J.; Mitsiades, Constantine S.; Wong, Kwok-Kin; Bradner, James E.; Kaelin, William G., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">6168</span>),
    <span class="NLM_cas:pages">305-309</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Thalidomide-like drugs such as lenalidomide are clin. important treatments for multiple myeloma and show promise for other B cell malignancies.  The biochem. mechanisms underlying their antitumor activity are unknown.  Thalidomide was recently shown to bind to, and inhibit, the cereblon ubiquitin ligase.  Cereblon loss in zebrafish causes fin defects reminiscent of the limb defects seen in children exposed to thalidomide in utero.  Here we show that lenalidomide-bound cereblon acquires the ability to target for proteasomal degrdn. two specific B cell transcription factors, Ikaros family zinc finger proteins 1 and 3 (IKZF1 and IKZF3).  Anal. of myeloma cell lines revealed that loss of IKZF1 and IKZF3 is both necessary and sufficient for lenalidomide's therapeutic effect, suggesting that the antitumor and teratogenic activities of thalidomide-like drugs are dissociable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0froz4Kipu7Vg90H21EOLACvtfcHk0ljKjzVeGjgIvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtV2ktg%253D%253D&md5=a9df5bbde0f676b92b1bec48fdbbb502</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1126%2Fscience.1244917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1244917%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DG.%26aulast%3DMiddleton%26aufirst%3DR.%2BE.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DNaniong%26aufirst%3DM.%26aulast%3DOtt%26aufirst%3DC.%2BJ.%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DKaelin%26aufirst%3DW.%2BG.%26atitle%3DThe%2520myeloma%2520drug%2520lenalidomide%2520promotes%2520the%2520cereblon-dependent%2520destruction%2520of%2520Ikaros%2520proteins%26jtitle%3DScience%26date%3D2014%26volume%3D343%26spage%3D305%26epage%3D309%26doi%3D10.1126%2Fscience.1244917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, K.</span>; <span class="NLM_string-name">Asoh, K.</span>; <span class="NLM_string-name">Furuichi, N.</span>; <span class="NLM_string-name">Ito, T.</span>; <span class="NLM_string-name">Kawada, H.</span>; <span class="NLM_string-name">Ishii, N.</span>; <span class="NLM_string-name">Sakamoto, H.</span>; <span class="NLM_string-name">Hong, W. S.</span>; <span class="NLM_string-name">Park, M. J.</span>; <span class="NLM_string-name">Ono, Y.</span>; <span class="NLM_string-name">Kato, Y.</span>; <span class="NLM_string-name">Morikami, K.</span>; <span class="NLM_string-name">Emura, T.</span>; <span class="NLM_string-name">Oikawa, N.</span></span> <span> </span><span class="NLM_article-title">Tetracyclic compound</span>. U.S. Patent <span class="NLM_patent">9,126,931 B2</span>, September 8, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=K.+Kinoshita&author=K.+Asoh&author=N.+Furuichi&author=T.+Ito&author=H.+Kawada&author=N.+Ishii&author=H.+Sakamoto&author=W.+S.+Hong&author=M.+J.+Park&author=Y.+Ono&author=Y.+Kato&author=K.+Morikami&author=T.+Emura&author=N.+Oikawa&title=Tetracyclic+compound"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKinoshita%26aufirst%3DK.%26atitle%3DTetracyclic%2520compound%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donovan, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Development of dual and selective degraders of cyclin-dependent kinases 4 and 6</span>. <i>Angew. Chem. Int. Ed. Engl.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6321</span>– <span class="NLM_lpage">6326</span>, <span class="refDoi"> DOI: 10.1002/anie.201901336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1002%2Fanie.201901336" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=30802347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A280%3ADC%252BB3cfnt1OqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=6321-6326&author=B.+Jiangauthor=E.+S.+Wangauthor=K.+A.+Donovanauthor=Y.+Liangauthor=E.+S.+Fischerauthor=T.+Zhangauthor=N.+S.+Gray&title=Development+of+dual+and+selective+degraders+of+cyclin-dependent+kinases+4+and+6&doi=10.1002%2Fanie.201901336"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6</span></div><div class="casAuthors">Jiang Baishan; Wang Eric S; Donovan Katherine A; Liang Yanke; Fischer Eric S; Zhang Tinghu; Gray Nathanael S</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie (International ed. in English)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6321-6326</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cyclin-dependent kinases 4 and 6 (CDK4/6) are key regulators of the cell cycle, and there are FDA-approved CDK4/6 inhibitors for treating patients with metastatic breast cancer.  However, due to conservation of their ATP-binding sites, development of selective agents has remained elusive.  Here, we report imide-based degrader molecules capable of degrading both CDK4/6, or selectively degrading either CDK4 or CDK6.  We were also able to tune the activity of these molecules against Ikaros (IKZF1) and Aiolos (IKZF3), which are well-established targets of imide-based degraders.  We found that in mantle cell lymphoma cell lines, combined IKZF1/3 degradation with dual CDK4/6 degradation produced enhanced anti-proliferative effects compared to CDK4/6 inhibition, CDK4/6 degradation, or IKZF1/3 degradation.  In summary, we report here the first compounds capable of inducing selective degradation of CDK4 and CDK6 as tools to pharmacologically dissect their distinct biological functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQvjF82FsSWX6qcneEtCi92fW6udTcc2eZU4Ncw2aLNW7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfnt1OqtA%253D%253D&md5=fa27938a9ec50a89644eb87812048329</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1002%2Fanie.201901336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201901336%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DE.%2BS.%26aulast%3DDonovan%26aufirst%3DK.%2BA.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDevelopment%2520of%2520dual%2520and%2520selective%2520degraders%2520of%2520cyclin-dependent%2520kinases%25204%2520and%25206%26jtitle%3DAngew.%2520Chem.%2520Int.%2520Ed.%2520Engl.%26date%3D2019%26volume%3D58%26spage%3D6321%26epage%3D6326%26doi%3D10.1002%2Fanie.201901336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0024.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of FDA-approved ALK small-molecule inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structures of reported ALK degraders.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Chemical structures, molecular weights, and cocrystal structure of ALK with alectinib (left; PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3AOX">3AOX</a>) and modeled structures of ALK in a complex with alectinib precursors <b>37</b> (middle) or <b>36</b> (right). (B) ALK binding affinities of alectinib and compounds <b>36</b> and <b>37</b> were measured by TR-FRTE ALK kinase assay. Data are presented as the mean ± SD from three independent experiments. (C) Cell growth inhibition in H3122 and Karpas 299 cell lines. The cells were treated with the indicated doses of alectinib (<b>3</b>) and compounds <b>36</b> and <b>37</b> for 72 h, and the IC<sub>50</sub> values were determined by an MTT assay. Data are presented as the mean ± SD of duplicate independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Chemical structures of designed alectinib-based ALK degraders and negative control <b>20</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effects of compounds <b>13</b>–<b>19</b> and <b>21</b>–<b>25</b> on reducing the ALK protein level in (A) H3122 cells and (B) Karpas 299 cells. Both cell lines were treated with the indicated compounds and concentrations for 16 or 24 h, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>17</b> concentration-dependently reduced ALK fusion protein levels and inhibited ALK phosphorylation. (A) H3122 and (B) Karpas 299 cells were treated with DMSO or serial dilutions of compounds for the indicated length of time. Data are presented as the mean ± SD from three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Compound <b>17</b> reduced ALK fusion protein levels in a time-dependent manner and inhibited ALK phosphorylation. (A) H3122 and (B) Karpas 299 cells were treated with DMSO or compounds for the indicated times.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Compound <b>17</b>-induced ALK fusion protein degradation is mediated through the E3 ubiquitin ligase component CRBN. Immunoblots after 4 h of pretreatment with DMSO, carfilzomib (Car), pomalidomide (Pom), MLN4924 (MLN), or alectinib (<b>3</b>) followed by (A) 16 h (H3122 cells) or (B) 24 h (Karpas 299 cells) of treatment with <b>17</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Sustained cellular degradative activity induced by compound <b>17</b> upon washout in (A) H3122 and (B) Karpas 299 cells. Cells were treated with compound <b>17</b> at the indicated times and concentrations, washed three times with PBS, and harvested at the indicated time points for western blot analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Pharmacodynamic study of compound <b>17</b> in Karpas 299 xenograft tumors in NCG (NOD/ShiltJGpt-Prkdcem26Cd52Il2rgem26Cd22/Gpt) mice. NCG mice bearing Karpas 299 xenograft tumors were treated with 10 mg/kg compound <b>17</b> (I.V.). Tumor lysates were analyzed by immunoblotting.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. <i>In vivo</i> antitumor activity of compound <b>17</b> in a Karpas 299 xenograft mouse model. Tumor volume and changes in body weight were measured for each group. (A) Tumor growth; (B) body weight changes of the mice during treatment; (C) weight of the excised tumors of each group (**<i>P</i> < 0.01; ***<i>P</i> < 0.001; ****<i>P</i> < 0.0001); (D) images of Karpas 299 tumors from the mice at 21 days after initiation of treatment. (E) H&E staining of the heart, liver, spleen, lung, and kidney of the mice. No abnormality of these organs was observed. (F) Immunoblotting of Karpas 299 xenograft tissue after 21 days of treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Selective inhibition and degradation of ALK by degrader <b>17</b>. Antiproliferative activity of alectinib, <b>36</b>, and <b>17</b> in (A) HFL-1 and (B) A549 cells. (C) Karpas 299 cells were treated with serial dilutions of compound <b>17</b> or alectinib for the indicated length of time. (D) Volcano plot showing changes in protein abundance. Karpas 299 cells were treated with DMSO or 1 μM degrader <b>17</b> for 24 h. The proteins were analyzed by the proteomic iTRAQ. The <i>x</i> axis displays the relative abundance of all identified proteins (6766) in DMSO-treated versus compound <b>17</b>-treated cells (log<sub>2</sub>FC). The <i>y</i> axis displays the <i>P</i> value (−log<sub>10</sub>) from triplicate experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0014.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>36</b>, <b>37</b>, <b>40</b>, and <b>41</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reaction conditions: (a) thionyl chloride (SOCl<sub>2</sub>), room temperature (rt) to 80 °C, 92.1%; (b) ethylbenzene, AlCl<sub>3</sub>, carbon tetrachloride (CCl<sub>4</sub>), −20 °C, 65.7%; (c) trimethyl orthoformate, ZnBr<sub>2</sub>, 100 °C, 96.3%; (d) <i>N</i>-iodosuccinimide (NIS), H<sub>2</sub>SO<sub>4</sub>, CH<sub>3</sub>COOH, 0 °C to rt, 84.2%; (e) NaOH, H<sub>2</sub>O:methanol (MeOH) = 1:5, 100 °C, 62.9%; (f) <i>N</i>,<i>N</i>′-carbonyldiimidazole (CDI), triethylamine (Et<sub>3</sub>N), MgCl<sub>2</sub>, MeCN, 80 °C, 84.7%; (g) 4-chloro-3-nitrobenzonitrile, Cs<sub>2</sub>CO<sub>3</sub>, dimethyl sulfoxide (DMSO), rt, 56.9%; (h) Na<sub>2</sub>S<sub>2</sub>O<sub>4</sub>, tetrahydrofuran (THF):MeOH:H<sub>2</sub>O = 2:2:1, 100 °C, 50.2%; (i) Eaton reagent, rt, 47.4%; (j) heterocyclic compounds, 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl (S-phos), tris(dibenzylideneacetone)dipalladium (Pd<sub>2</sub>(dba)<sub>3</sub>), sodium bis(trimethylsilyl)amide (NaHMDS), 1,4-dioxane, 80 °C, 47.8%; (k) trifluoroacetic acid (TFA), dichloromethane (DCM), rt, 66.7–73.3%; (l) <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA), DMSO, 90 °C, 76.7–91.1%.</p></p></figure><figure data-id="sch2" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0015.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>47</b>–<b>49</b> and <b>52</b>–<b>55</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reaction conditions: (a) DIPEA, DMSO, 90 °C, 73.2–80.4%; (b) TFA, DCM, rt., 54.7–69.8%.</p></p></figure><figure data-id="sch3" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0016.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>14</b>–<b>16</b> and <b>22</b>–<b>24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reaction conditions: (a) 2-(7-azabenzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium hexafluorophosphate (HATU), DIPEA, DMF, rt, 69.8–91.1%.</p></p></figure><figure data-id="sch4" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0017.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>17–20</b> and <b>25</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reaction conditions: (a) HATU, DIPEA, DMF, rt, 71.3–86.5%.</p></p></figure><figure data-id="sch5" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/medium/jm1c00270_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0018.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compound <b>13</b> and <b>21</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00270&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reaction conditions: (a) DIPEA, DMSO, 90 °C, 69.2–73.3%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i58">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21084" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21084" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 60 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemmon, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span> <span> </span><span class="NLM_article-title">Cell signaling by receptor tyrosine kinases</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">1117</span>– <span class="NLM_lpage">1134</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2010.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.cell.2010.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=20602996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovFartb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2010&pages=1117-1134&author=M.+A.+Lemmonauthor=J.+Schlessinger&title=Cell+signaling+by+receptor+tyrosine+kinases&doi=10.1016%2Fj.cell.2010.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cell signaling by receptor tyrosine kinases</span></div><div class="casAuthors">Lemmon, Mark A.; Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1117-1134</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Recent structural studies of receptor tyrosine kinases (RTKs) have revealed unexpected diversity in the mechanisms of their activation by growth factor ligands.  Strategies for inducing dimerization by ligand binding are surprisingly diverse, as are mechanisms that couple this event to activation of the intracellular tyrosine kinase domains.  As the understanding of these details becomes increasingly sophisticated, it provides an important context for therapeutically countering the effects of pathogenic RTK mutations in cancer and other diseases.  Much remains to be learned, however, about the complex signaling networks downstream from RTKs and how alterations in these networks are translated into cellular responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd5NvoN0Q9-7Vg90H21EOLACvtfcHk0lhSRxH6zdanjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovFartb0%253D&md5=b88b55fe7a3eebc6ff7e883425676e45</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2010.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2010.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DLemmon%26aufirst%3DM.%2BA.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DCell%2520signaling%2520by%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCell%26date%3D2010%26volume%3D141%26spage%3D1117%26epage%3D1134%26doi%3D10.1016%2Fj.cell.2010.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirstein, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dittmer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Look, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saltman, D. L.</span></span> <span> </span><span class="NLM_article-title">Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>267</i></span>,  <span class="NLM_fpage">316</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1126/science.267.5196.316-b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1126%2Fscience.267.5196.316-b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=7824924" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADyaK2MXjt12gurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1995&pages=316-317&author=S.+W.+Morrisauthor=M.+N.+Kirsteinauthor=M.+B.+Valentineauthor=K.+Dittmerauthor=D.+N.+Shapiroauthor=A.+T.+Lookauthor=D.+L.+Saltman&title=Fusion+of+a+kinase+gene%2C+ALK%2C+to+a+nucleolar+protein+gene%2C+NPM%2C+in+non-Hodgkin%E2%80%99s+lymphoma&doi=10.1126%2Fscience.267.5196.316-b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">NPM-ALK sequence (GenBank accession number U04946)</span></div><div class="casAuthors">Morris, S. W.; Kirstein, M. N.; Valentine, M. B.; Dittmer, K.; Shapiro, D. N.; Look, A. T.; Saltman, D. L.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue">5196</span>),
    <span class="NLM_cas:pages">316-17</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgQOJ6qNgzALVg90H21EOLACvtfcHk0lhSRxH6zdanjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjt12gurY%253D&md5=0951f3302d350098885887fb55e796ba</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1126%2Fscience.267.5196.316-b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.267.5196.316-b%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DKirstein%26aufirst%3DM.%2BN.%26aulast%3DValentine%26aufirst%3DM.%2BB.%26aulast%3DDittmer%26aufirst%3DK.%26aulast%3DShapiro%26aufirst%3DD.%2BN.%26aulast%3DLook%26aufirst%3DA.%2BT.%26aulast%3DSaltman%26aufirst%3DD.%2BL.%26atitle%3DFusion%2520of%2520a%2520kinase%2520gene%252C%2520ALK%252C%2520to%2520a%2520nucleolar%2520protein%2520gene%252C%2520NPM%252C%2520in%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%26jtitle%3DScience%26date%3D1995%26volume%3D267%26spage%3D316%26epage%3D317%26doi%3D10.1126%2Fscience.267.5196.316-b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pulford, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamant, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroud, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delsol, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, D. Y.</span></span> <span> </span><span class="NLM_article-title">Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">1394</span>– <span class="NLM_lpage">1404</span>, <span class="refDoi"> DOI: 10.1182/blood.V89.4.1394</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1182%2Fblood.V89.4.1394" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=9028963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADyaK2sXhtFant7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1997&pages=1394-1404&author=K.+Pulfordauthor=L.+Lamantauthor=S.+W.+Morrisauthor=L.+H.+Butlerauthor=K.+M.+Woodauthor=D.+Stroudauthor=G.+Delsolauthor=D.+Y.+Mason&title=Detection+of+anaplastic+lymphoma+kinase+%28ALK%29+and+nucleolar+protein+nucleophosmin+%28NPM%29-ALK+proteins+in+normal+and+neoplastic+cells+with+the+monoclonal+antibody+ALK1&doi=10.1182%2Fblood.V89.4.1394"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1</span></div><div class="casAuthors">Pulford, Karen; Lamant, Laurence; Morris, Stephan W.; Butler, Lisa H.; Wood, Katrina M.; Stroud, David; Delsol, Georges; Mason, David Y.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1394-1404</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">Saunders</span>)
        </div><div class="casAbstract">The t(2;5)(p23;q35) translocation, assocd. with anaplastic large-cell lymphoma (ALCL), results in the prodn. of the nucleolar protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) protein.  This report describes an immunocytochem. study of the distribution of ALK and NPM-ALK proteins using a new monoclonal antibody, ALK1, that recognizes a formalin resistant epitope in both the 8 kDa NPM-ALK chimeric and the 200 kDa normal human ALK proteins.  Cytoplasmic and nuclear labeling was seen in the t(2;5)+ SU-DHL-1 and Karpas 299 cell lines.  Normal ALK protein expression was restricted to the central nervous system (in scattered neurons, glial cells, and endothelial cells).  Two hundred and thirty-nine cases of lymphoma and 80 nonhematopoietic tumors were immunostained.  Antibody ALK1 labeled 53.4% (39 of 73 cases) of CD30+ ALCL.  A case of ALCL with a t(1;2) translocation was ALK1+.  Tree cases of CD30- ALCL with prominent nucleoli showed a unique pattern of coarse granular cytoplasmic labeling.  All other tumors, including Hodgkin's disease and lymphomatoid papulosis, were ALK1-.  These results indicate that reliable immunostaining of routine biopsy material for NPM-ALK and ALK proteins is feasible.  Such anal. is of diagnostic importance, esp. because t(2;5)+ ALCL cases have a good prognosis with appropriate treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvlTSV80OkXrVg90H21EOLACvtfcHk0lhSRxH6zdanjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhtFant7g%253D&md5=745bdf860c7b04686062945aaa151f1c</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1182%2Fblood.V89.4.1394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V89.4.1394%26sid%3Dliteratum%253Aachs%26aulast%3DPulford%26aufirst%3DK.%26aulast%3DLamant%26aufirst%3DL.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DButler%26aufirst%3DL.%2BH.%26aulast%3DWood%26aufirst%3DK.%2BM.%26aulast%3DStroud%26aufirst%3DD.%26aulast%3DDelsol%26aufirst%3DG.%26aulast%3DMason%26aufirst%3DD.%2BY.%26atitle%3DDetection%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520and%2520nucleolar%2520protein%2520nucleophosmin%2520%2528NPM%2529-ALK%2520proteins%2520in%2520normal%2520and%2520neoplastic%2520cells%2520with%2520the%2520monoclonal%2520antibody%2520ALK1%26jtitle%3DBlood%26date%3D1997%26volume%3D89%26spage%3D1394%26epage%3D1404%26doi%3D10.1182%2Fblood.V89.4.1394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enomoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurashina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bando, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aburatani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mano, H.</span></span> <span> </span><span class="NLM_article-title">Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>448</i></span>,  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1038/nature05945</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1038%2Fnature05945" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=17625570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2007&pages=561-566&author=M.+Sodaauthor=Y.+L.+Choiauthor=M.+Enomotoauthor=S.+Takadaauthor=Y.+Yamashitaauthor=S.+Ishikawaauthor=S.+Fujiwaraauthor=H.+Watanabeauthor=K.+Kurashinaauthor=H.+Hatanakaauthor=M.+Bandoauthor=S.+Ohnoauthor=Y.+Ishikawaauthor=H.+Aburataniauthor=T.+Nikiauthor=Y.+Soharaauthor=Y.+Sugiyamaauthor=H.+Mano&title=Identification+of+the+transforming+EML4-ALK+fusion+gene+in+non-small-cell+lung+cancer&doi=10.1038%2Fnature05945"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</span></div><div class="casAuthors">Soda, Manabu; Choi, Young Lim; Enomoto, Munehiro; Takada, Shuji; Yamashita, Yoshihiro; Ishikawa, Shunpei; Fujiwara, Shin-ichiro; Watanabe, Hideki; Kurashina, Kentaro; Hatanaka, Hisashi; Bando, Masashi; Ohno, Shoji; Ishikawa, Yuichi; Aburatani, Hiroyuki; Niki, Toshiro; Sohara, Yasunori; Sugiyama, Yukihiko; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue">7153</span>),
    <span class="NLM_cas:pages">561-566</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Improvement in the clin. outcome of lung cancer is likely to be achieved by identification of the mol. events that underlie its pathogenesis.  Here we show that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-assocd. protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells.  Mouse 3T3 fibroblasts forced to express this human fusion tyrosine kinase generated transformed foci in culture and s.c. tumors in nude mice.  The EML4-ALK fusion transcript was detected in 6.7% (5 out of 75) of NSCLC patients examd.; these individuals were distinct from those harboring mutations in the epidermal growth factor receptor gene.  Our data demonstrate that a subset of NSCLC patients may express a transforming fusion kinase that is a promising candidate for a therapeutic target as well as for a diagnostic mol. marker in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomhAXuLtrJ6rVg90H21EOLACvtfcHk0lgU9cox5Wzctg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D&md5=7f567e80814b9ccc87e5bceeebb467a7</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnature05945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05945%26sid%3Dliteratum%253Aachs%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DEnomoto%26aufirst%3DM.%26aulast%3DTakada%26aufirst%3DS.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DS.%26aulast%3DFujiwara%26aufirst%3DS.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DKurashina%26aufirst%3DK.%26aulast%3DHatanaka%26aufirst%3DH.%26aulast%3DBando%26aufirst%3DM.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DAburatani%26aufirst%3DH.%26aulast%3DNiki%26aufirst%3DT.%26aulast%3DSohara%26aufirst%3DY.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520the%2520transforming%2520EML4-ALK%2520fusion%2520gene%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DNature%26date%3D2007%26volume%3D448%26spage%3D561%26epage%3D566%26doi%3D10.1038%2Fnature05945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coffin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elenitoba-Johnson, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, C. A.</span></span> <span> </span><span class="NLM_article-title">ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor</span>. <i>Mod. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">569</span>– <span class="NLM_lpage">576</span>, <span class="refDoi"> DOI: 10.1038/modpathol.3880352</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1038%2Fmodpathol.3880352" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=11406658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A280%3ADC%252BD3Mzktlensw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2001&pages=569-576&author=C.+M.+Coffinauthor=A.+Patelauthor=S.+Perkinsauthor=K.+S.+Elenitoba-Johnsonauthor=E.+Perlmanauthor=C.+A.+Griffin&title=ALK1+and+p80+expression+and+chromosomal+rearrangements+involving+2p23+in+inflammatory+myofibroblastic+tumor&doi=10.1038%2Fmodpathol.3880352"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor</span></div><div class="casAuthors">Coffin C M; Patel A; Perkins S; Elenitoba-Johnson K S; Perlman E; Griffin C A</div><div class="citationInfo"><span class="NLM_cas:title">Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">569-76</span>
        ISSN:<span class="NLM_cas:issn">0893-3952</span>.
    </div><div class="casAbstract">BACKGROUND:  Inflammatory myofibroblastic tumor (IMT) is an uncommon tumor of extrapulmonary and pulmonary tissues with an unpredictable clinical course, occasional recurrences, and rare malignant transformation.  Clonal abnormalities with rearrangements of chromosome of 2p23 and the ALK gene have been reported in a few cases.  The purpose of this study is to investigate whether these are consistent abnormalities among IMTs or represent a distinct subset.  DESIGN:  Formalin-fixed, paraffin-embedded archival tissue sections from 47 IMTs in 40 patients were immunostained with monoclonal antibodies against ALK and p80.  Fluorescence in situ hybridization for ALK rearrangements was done on 22 IMTs from 19 patients.  Findings were correlated with clinical features and outcome.  RESULTS:  ALK positivity was observed in 17 of 47 IMTs (36%) and p80 positivity in 16 of 47 IMTs (34%).  Fluorescence in situ hybridization showed ALK rearrangements in nine cases (47%), aneuploidy in three cases (16%), and no rearrangement in seven cases (37%).  IMTs with ALK abnormalities by immunohistochemistry and/or fluorescence in situ hybridization originated in the abdomen/pelvis/retroperitoneum, chest, and extremities.  The mean age was 6.6 years, with a male/female ratio of 1.3. 64% of patients had no evidence of disease at last follow-up, 45% had one or more recurrences, and 18% displayed histologic evidence of malignant transformation.  The IMTs without ALK abnormalities occurred in older children, were more frequent in females, and had fewer recurrences.  However, in this group of 40 patients, the differences between the groups with and without ALK abnormalities did not have statistical significance.  Aneuploidy without ALK abnormalities was associated with malignant transformation in three of five cases.  CONCLUSIONS:  Abnormalities of ALK and p80 and evidence of chromosomal rearrangements of 2p23 occur in a significant proportion of IMTs.  These changes are most frequent in abdominal and pulmonary IMTs in the first decade of life and are associated with a higher frequency of recurrence.  These findings confirm the neoplastic nature of a subset IMT with ALK abnormalities and suggest that aneuploid IMT is a subset with more aggressive clinical behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKhgHH19XaKCsZ1x6zOs0vfW6udTcc2eYddh_WJiOBWLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3Mzktlensw%253D%253D&md5=95c8abf8ae15c36d927ac56ae473f526</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fmodpathol.3880352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmodpathol.3880352%26sid%3Dliteratum%253Aachs%26aulast%3DCoffin%26aufirst%3DC.%2BM.%26aulast%3DPatel%26aufirst%3DA.%26aulast%3DPerkins%26aufirst%3DS.%26aulast%3DElenitoba-Johnson%26aufirst%3DK.%2BS.%26aulast%3DPerlman%26aufirst%3DE.%26aulast%3DGriffin%26aufirst%3DC.%2BA.%26atitle%3DALK1%2520and%2520p80%2520expression%2520and%2520chromosomal%2520rearrangements%2520involving%25202p23%2520in%2520inflammatory%2520myofibroblastic%2520tumor%26jtitle%3DMod.%2520Pathol.%26date%3D2001%26volume%3D14%26spage%3D569%26epage%3D576%26doi%3D10.1038%2Fmodpathol.3880352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvorak, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henkle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellingham, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlman, E. J.</span></span> <span> </span><span class="NLM_article-title">Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2776</span>– <span class="NLM_lpage">2780</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10383129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADyaK1MXktVOktbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=2776-2780&author=C.+A.+Griffinauthor=A.+L.+Hawkinsauthor=C.+Dvorakauthor=C.+Henkleauthor=T.+Ellinghamauthor=E.+J.+Perlman&title=Recurrent+involvement+of+2p23+in+inflammatory+myofibroblastic+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors</span></div><div class="casAuthors">Griffin, Constance A.; Hawkins, Anita L.; Dvorak, Cecily; Henkle, Carol; Ellingham, Tara; Perlman, Elizabeth J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2776-2780</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">AACR Subscription Office</span>)
        </div><div class="casAbstract">Inflammatory myofibroblastic tumor (IMT) is a relatively rare soft tissue tumor.  The reactive vs. neoplastic pathogenesis of this tumor is unresolved.  We found clonal chromosome aberrations involving 2p23 upon metaphase anal. of two IMTs.  Fluorescence in situ hybridization with a probe flanking the ALK gene at 2p23 demonstrated rearrangement of the probe in both of these cases and in a third case, and immunohistochem. revealed ALK expression in all three cases.  A 2p22-24 involvement has been reported previously in four addnl. cases of IMT.  We suggest that chromosomal rearrangements involving 2p23 near or within ALK are recurrent alterations in IMT and that ALK may have a novel role outside its previously recognized realm of lymphoid neoplasms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocvXV2ukz3crVg90H21EOLACvtfcHk0lgU9cox5Wzctg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXktVOktbk%253D&md5=8054eeaaf0cb85ee85afff461797c84c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGriffin%26aufirst%3DC.%2BA.%26aulast%3DHawkins%26aufirst%3DA.%2BL.%26aulast%3DDvorak%26aufirst%3DC.%26aulast%3DHenkle%26aufirst%3DC.%26aulast%3DEllingham%26aufirst%3DT.%26aulast%3DPerlman%26aufirst%3DE.%2BJ.%26atitle%3DRecurrent%2520involvement%2520of%25202p23%2520in%2520inflammatory%2520myofibroblastic%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26spage%3D2776%26epage%3D2780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gascoyne, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamant, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Subero, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lestou, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller-Hermelink, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horsman, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auvigne, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siebert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delsol, G.</span></span> <span> </span><span class="NLM_article-title">ALK-positive diffuse large B-cell lymphoma is associated with clathrin-ALK rearrangements: report of 6 cases</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">2568</span>– <span class="NLM_lpage">2573</span>, <span class="refDoi"> DOI: 10.1182/blood-2003-03-0786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1182%2Fblood-2003-03-0786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=12763927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnslykurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2003&pages=2568-2573&author=R.+D.+Gascoyneauthor=L.+Lamantauthor=J.+I.+Martin-Suberoauthor=V.+S.+Lestouauthor=N.+L.+Harrisauthor=H.+K.+M%C3%BCller-Hermelinkauthor=J.+F.+Seymourauthor=L.+J.+Campbellauthor=D.+E.+Horsmanauthor=I.+Auvigneauthor=E.+Espinosauthor=R.+Siebertauthor=G.+Delsol&title=ALK-positive+diffuse+large+B-cell+lymphoma+is+associated+with+clathrin-ALK+rearrangements%3A+report+of+6+cases&doi=10.1182%2Fblood-2003-03-0786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">ALK-positive diffuse large B-cell lymphoma is associated with clathrin-ALK rearrangements: Report of 6 cases</span></div><div class="casAuthors">Gascoyne, Randy D.; Lamant, Laurence; Martin-Subero, Jose I.; Lestou, Valia S.; Harris, Nancy Lee; Mueller-Hermelink, Hans-Konrad; Seymour, John F.; Campbell, Lynda J.; Horsman, Douglas E.; Auvigne, Isabelle; Espinos, Estelle; Siebert, Reiner; Delsol, Georges</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2568-2573</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Expression of ALK protein by lymphoid cells and the description of variant anaplastic lymphoma kinase (ALK) translocations have typically been restricted to cases of T-cell and null anaplastic large-cell lymphoma (ALCL).  All such cases result from a novel fusion created by the ALK gene on chromosome 2p23 and NPM on 5q35 or other variant translocation partners.  A rare variant of diffuse large B-cell lymphoma (DLBCL), originally described in 1997, was thought to overexpress full-length ALK in contrast to a chimeric protein characteristic of ALCL.  However, full-length ALK protein lacks tyrosine kinase activity and thus the mechanism of oncogenesis has remained elusive.  We describe 6 cases of ALK+ DLBCL characterized by a simple or complex t(2;17)(p23;q23) involving the clathrin gene (CLTC) at chromosome band 17q23 and the ALK gene at chromosome band 2p23.  All cases were studied using fluorescence in situ hybridization (FISH), complemented in one case with std. cytogenetic anal., multicolor karyotyping (M-FISH), and reverse transcriptase-polymerase chain reaction.  These results clearly demonstrate that most cases of ALK+ DLBCL share the same mechanism of deregulated ALK expression.  Moreover, these results demonstrate the presence of CLTC-ALK fusions in these tumors and extend the list of diseases assocd. with this genetic abnormality to include classical T-cell or null ALCL, ALK+ DLBCL, and inflammatory myofibroblastic tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3UcmsuahiXLVg90H21EOLACvtfcHk0lgM7aME5JjpvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnslykurw%253D&md5=9eedc8c22c580dbadee982b4d3da35a8</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1182%2Fblood-2003-03-0786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2003-03-0786%26sid%3Dliteratum%253Aachs%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DLamant%26aufirst%3DL.%26aulast%3DMartin-Subero%26aufirst%3DJ.%2BI.%26aulast%3DLestou%26aufirst%3DV.%2BS.%26aulast%3DHarris%26aufirst%3DN.%2BL.%26aulast%3DM%25C3%25BCller-Hermelink%26aufirst%3DH.%2BK.%26aulast%3DSeymour%26aufirst%3DJ.%2BF.%26aulast%3DCampbell%26aufirst%3DL.%2BJ.%26aulast%3DHorsman%26aufirst%3DD.%2BE.%26aulast%3DAuvigne%26aufirst%3DI.%26aulast%3DEspinos%26aufirst%3DE.%26aulast%3DSiebert%26aufirst%3DR.%26aulast%3DDelsol%26aufirst%3DG.%26atitle%3DALK-positive%2520diffuse%2520large%2520B-cell%2520lymphoma%2520is%2520associated%2520with%2520clathrin-ALK%2520rearrangements%253A%2520report%2520of%25206%2520cases%26jtitle%3DBlood%26date%3D2003%26volume%3D102%26spage%3D2568%26epage%3D2573%26doi%3D10.1182%2Fblood-2003-03-0786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mossé, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laudenslager, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attiyeh, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laquaglia, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sennett, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laureys, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speleman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hakonarson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torkamani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schork, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodeur, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonini, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rappaport, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maris, J. M.</span></span> <span> </span><span class="NLM_article-title">Identification of ALK as a major familial neuroblastoma predisposition gene</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>455</i></span>,  <span class="NLM_fpage">930</span>– <span class="NLM_lpage">935</span>, <span class="refDoi"> DOI: 10.1038/nature07261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1038%2Fnature07261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=18724359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Ggur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=930-935&author=Y.+P.+Moss%C3%A9author=M.+Laudenslagerauthor=L.+Longoauthor=K.+A.+Coleauthor=A.+Woodauthor=E.+F.+Attiyehauthor=M.+J.+Laquagliaauthor=R.+Sennettauthor=J.+E.+Lynchauthor=P.+Perriauthor=G.+Laureysauthor=F.+Spelemanauthor=C.+Kimauthor=C.+Houauthor=H.+Hakonarsonauthor=A.+Torkamaniauthor=N.+J.+Schorkauthor=G.+M.+Brodeurauthor=G.+P.+Toniniauthor=E.+Rappaportauthor=M.+Devotoauthor=J.+M.+Maris&title=Identification+of+ALK+as+a+major+familial+neuroblastoma+predisposition+gene&doi=10.1038%2Fnature07261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of ALK as a major familial neuroblastoma predisposition gene</span></div><div class="casAuthors">Mosse, Yael P.; Laudenslager, Marci; Longo, Luca; Cole, Kristina A.; Wood, Andrew; Attiyeh, Edward F.; Laquaglia, Michael J.; Sennett, Rachel; Lynch, Jill E.; Perri, Patrizia; Laureys, Genevieve; Speleman, Frank; Kim, Cecilia; Hou, Cuiping; Hakonarson, Hakon; Torkamani, Ali; Schork, Nicholas J.; Brodeur, Garrett M.; Tonini, Gian P.; Rappaport, Eric; Devoto, Marcella; Maris, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">455</span>
        (<span class="NLM_cas:issue">7215</span>),
    <span class="NLM_cas:pages">930-935</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neuroblastoma is a childhood cancer that can be inherited, but the genetic etiol. is largely unknown.  Here we show that germline mutations in the anaplastic lymphoma kinase (ALK) gene explain most hereditary neuroblastomas, and that activating mutations can also be somatically acquired.  We first identified a significant linkage signal at chromosome bands 2p23-24 using a whole-genome scan in neuroblastoma pedigrees.  Re-sequencing of regional candidate genes identified three sep. germline missense mutations in the tyrosine kinase domain of ALK that segregated with the disease in eight sep. families.  Re-sequencing in 194 high-risk neuroblastoma samples showed somatically acquired mutations in the tyrosine kinase domain in 12.4% of samples.  Nine of the ten mutations map to crit. regions of the kinase domain and were predicted, with high probability, to be oncogenic drivers.  Mutations resulted in constitutive phosphorylation, and targeted knockdown of ALK mRNA resulted in profound inhibition of growth in all cell lines harboring mutant or amplified ALK, as well as in two out of six wild-type cell lines for ALK.  Our results demonstrate that heritable mutations of ALK are the main cause of familial neuroblastoma, and that germline or acquired activation of this cell-surface kinase is a tractable therapeutic target for this lethal pediatric malignancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMNOcIFf5xjbVg90H21EOLACvtfcHk0lgM7aME5JjpvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Ggur%252FP&md5=bb998ef8f6bfbd85f928263e13954ce4</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnature07261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07261%26sid%3Dliteratum%253Aachs%26aulast%3DMoss%25C3%25A9%26aufirst%3DY.%2BP.%26aulast%3DLaudenslager%26aufirst%3DM.%26aulast%3DLongo%26aufirst%3DL.%26aulast%3DCole%26aufirst%3DK.%2BA.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DAttiyeh%26aufirst%3DE.%2BF.%26aulast%3DLaquaglia%26aufirst%3DM.%2BJ.%26aulast%3DSennett%26aufirst%3DR.%26aulast%3DLynch%26aufirst%3DJ.%2BE.%26aulast%3DPerri%26aufirst%3DP.%26aulast%3DLaureys%26aufirst%3DG.%26aulast%3DSpeleman%26aufirst%3DF.%26aulast%3DKim%26aufirst%3DC.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DHakonarson%26aufirst%3DH.%26aulast%3DTorkamani%26aufirst%3DA.%26aulast%3DSchork%26aufirst%3DN.%2BJ.%26aulast%3DBrodeur%26aufirst%3DG.%2BM.%26aulast%3DTonini%26aufirst%3DG.%2BP.%26aulast%3DRappaport%26aufirst%3DE.%26aulast%3DDevoto%26aufirst%3DM.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26atitle%3DIdentification%2520of%2520ALK%2520as%2520a%2520major%2520familial%2520neuroblastoma%2520predisposition%2520gene%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D930%26epage%3D935%26doi%3D10.1038%2Fnature07261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murugan, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, M.</span></span> <span> </span><span class="NLM_article-title">Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">4403</span>– <span class="NLM_lpage">4411</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-4041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1158%2F0008-5472.CAN-10-4041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=21596819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlersb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=4403-4411&author=A.+K.+Muruganauthor=M.+Xing&title=Anaplastic+thyroid+cancers+harbor+novel+oncogenic+mutations+of+the+ALK+gene&doi=10.1158%2F0008-5472.CAN-10-4041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene</span></div><div class="casAuthors">Murugan, Avaniyapuram Kannan; Xing, Mingzhao</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4403-4411</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Thyroid cancer is the most common endocrine cancer, and targeted approaches to treat it pose considerable interest.  In this study, the authors report the discovery of ALK gene mutations in thyroid cancer that may rationalize clin. evaluation of anaplastic lymphoma kinase (ALK) inhibitors in this setting.  In undifferentiated anaplastic thyroid cancer (ATC), the authors identified 2 novel point mutations, C3592T and G3602A, in exon 23 of the ALK gene, with a prevalence of 11.11%, but found no mutations in the matched normal tissues or in well-differentiated thyroid cancers.  These 2 mutations, resulting in L1198F and G1201E amino acid changes, resp., both reside within the ALK tyrosine kinase domain where they dramatically increased tyrosine kinase activities.  Similarly, these mutations heightened the ability of ALK to activate the phosphatidylinositol 3-kinase (PI3K)/Akt and mitogen-activated protein (MAP) kinase pathways in established mouse cells.  Further investigations showed that these 2 ALK mutants strongly promoted cell focus formation, anchorage-independent growth, and cell invasion.  Similar oncogenic properties were obsd. in the neuroblastoma-assocd. ALK mutants K1062M and F1174L but not in wild-type ALK.  Overall, the authors' results reveal 2 novel gain-of-function mutations of ALK in certain ATCs, and they suggest efforts to clin. evaluate the use of ALK kinase inhibitors to treat patients who harbor ATCs with these mutations.  Cancer Res; 71(13); 4403-11.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLyuBgJ52gn7Vg90H21EOLACvtfcHk0lgM7aME5JjpvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlersb4%253D&md5=0316be9945baab3a8d08b6c75e2cd90f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-4041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-4041%26sid%3Dliteratum%253Aachs%26aulast%3DMurugan%26aufirst%3DA.%2BK.%26aulast%3DXing%26aufirst%3DM.%26atitle%3DAnaplastic%2520thyroid%2520cancers%2520harbor%2520novel%2520oncogenic%2520mutations%2520of%2520the%2520ALK%2520gene%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D4403%26epage%3D4411%26doi%3D10.1158%2F0008-5472.CAN-10-4041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosby, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haack, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beausoleil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innocenti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rush, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comb, M. J.</span></span> <span> </span><span class="NLM_article-title">Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">3312</span>– <span class="NLM_lpage">3323</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-3931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1158%2F0008-5472.CAN-11-3931" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=22570254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsFKku7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=3312-3323&author=H.+Renauthor=Z.+P.+Tanauthor=X.+Zhuauthor=K.+Crosbyauthor=H.+Haackauthor=J.+M.+Renauthor=S.+Beausoleilauthor=A.+Moritzauthor=G.+Innocentiauthor=J.+Rushauthor=Y.+Zhangauthor=X.+M.+Zhouauthor=T.+L.+Guauthor=Y.+F.+Yangauthor=M.+J.+Comb&title=Identification+of+anaplastic+lymphoma+kinase+as+a+potential+therapeutic+target+in+ovarian+cancer&doi=10.1158%2F0008-5472.CAN-11-3931"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer</span></div><div class="casAuthors">Ren, Hong; Tan, Zhi-Ping; Zhu, Xin; Crosby, Katherine; Haack, Herbert; Ren, Jian-Min; Beausoleil, Sean; Moritz, Albrecht; Innocenti, Gregory; Rush, John; Zhang, Yi; Zhou, Xin-Min; Gu, Ting-Lei; Yang, Yi-Feng; Comb, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3312-3323</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Findings suggest the use of ALK kinase inhibitors now in clin. development as potential agents for treatment of some patients with serous ovarian carcinoma or stromal sarcoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi924EZXGeJ7Vg90H21EOLACvtfcHk0ljmEpzheb03ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsFKku7w%253D&md5=a263a135244b307b864c098769d10a7a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-3931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-3931%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DZ.%2BP.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DCrosby%26aufirst%3DK.%26aulast%3DHaack%26aufirst%3DH.%26aulast%3DRen%26aufirst%3DJ.%2BM.%26aulast%3DBeausoleil%26aufirst%3DS.%26aulast%3DMoritz%26aufirst%3DA.%26aulast%3DInnocenti%26aufirst%3DG.%26aulast%3DRush%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.%2BM.%26aulast%3DGu%26aufirst%3DT.%2BL.%26aulast%3DYang%26aufirst%3DY.%2BF.%26aulast%3DComb%26aufirst%3DM.%2BJ.%26atitle%3DIdentification%2520of%2520anaplastic%2520lymphoma%2520kinase%2520as%2520a%2520potential%2520therapeutic%2520target%2520in%2520ovarian%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D3312%26epage%3D3323%26doi%3D10.1158%2F0008-5472.CAN-11-3931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naeve, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirstein, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, D. P.</span></span> <span> </span><span class="NLM_article-title">ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin’s lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2175</span>– <span class="NLM_lpage">2188</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1201062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1038%2Fsj.onc.1201062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=9174053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADyaK2sXjs1Gnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1997&pages=2175-2188&author=S.+W.+Morrisauthor=C.+Naeveauthor=P.+Mathewauthor=P.+L.+Jamesauthor=M.+N.+Kirsteinauthor=X.+Cuiauthor=D.+P.+Witte&title=ALK%2C+the+chromosome+2+gene+locus+altered+by+the+t%282%3B5%29+in+non-Hodgkin%E2%80%99s+lymphoma%2C+encodes+a+novel+neural+receptor+tyrosine+kinase+that+is+highly+related+to+leukocyte+tyrosine+kinase+%28LTK%29&doi=10.1038%2Fsj.onc.1201062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)</span></div><div class="casAuthors">Morris, Stephan W.; Naeve, Clayton; Mathew, Prasad; James, Payton L.; Kirstein, Mark N.; Cui, Xiaoli; Witte, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2175-2188</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Stockton</span>)
        </div><div class="casAbstract">Anaplastic Lymphoma Kinase (ALK) was originally identified as a member of the insulin receptor subfamily of receptor tyrosine kinases that acquires transforming capability when truncated and fused to nucleophosmin (NPM) in the t(2;5) chromosomal rearrangement assocd. with non-Hodgkin's lymphoma, but further insights into its normal structure and function are lacking.  Here, we characterize a full-length normal human ALK cDNA and its product, and det. the pattern of expression of its murine homolog in embryonic and adult tissues as a first step toward the functional assessment of the receptor.  Anal. of the 6226 bp ALK cDNA identified an open reading frame encoding a 1620-amino acid (aa) protein of predicted mass ∼177 kDa that is most closely related to leukocyte tyrosine kinase (LTK), the two exhibiting 57% aa identity and 71% similarity over their region of overlap.  Biochem. anal. demonstrated that the ∼177 kDa ALK polypeptide core undergoes co-translational N-linked glycosylation, emerging in its mature form as a 200 kDa single chain receptor.  Surface labeling studies indicated that the 200 kDa glycoprotein is exposed at the cell membrane, consistent with the prediction that ALK serves as the receptor for an unidentified ligand(s).  In situ hybridization studies revealed Alk expression beginning on embryonic day 11 and persisting into the neonatal and adult periods of development.  Alk transcripts were confined to the nervous system and included several thalamic and hypothalamic nuclei; the trigeminal, facial, and acoustic cranial ganglia; the anterior horns of the spinal cord in the region of the developing motor neurons; the sympathetic chain; and the ganglion cells of the gut.  Thus, ALK is a novel orphan receptor tyrosine kinase that appears to play an important role in the normal development and function of the nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4F75l637BuLVg90H21EOLACvtfcHk0ljmEpzheb03ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjs1Gnt7k%253D&md5=fdf7a14e88be831b2577891145cb6082</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1201062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1201062%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DNaeve%26aufirst%3DC.%26aulast%3DMathew%26aufirst%3DP.%26aulast%3DJames%26aufirst%3DP.%2BL.%26aulast%3DKirstein%26aufirst%3DM.%2BN.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DWitte%26aufirst%3DD.%2BP.%26atitle%3DALK%252C%2520the%2520chromosome%25202%2520gene%2520locus%2520altered%2520by%2520the%2520t%25282%253B5%2529%2520in%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%252C%2520encodes%2520a%2520novel%2520neural%2520receptor%2520tyrosine%2520kinase%2520that%2520is%2520highly%2520related%2520to%2520leukocyte%2520tyrosine%2520kinase%2520%2528LTK%2529%26jtitle%3DOncogene%26date%3D1997%26volume%3D14%26spage%3D2175%26epage%3D2188%26doi%3D10.1038%2Fsj.onc.1201062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwahara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimoto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cupples, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bucay, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arakawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratzkin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span> <span> </span><span class="NLM_article-title">Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">439</span>– <span class="NLM_lpage">449</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1200849</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1038%2Fsj.onc.1200849" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=9053841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADyaK2sXht1ensbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1997&pages=439-449&author=T.+Iwaharaauthor=J.+Fujimotoauthor=D.+Wenauthor=R.+Cupplesauthor=N.+Bucayauthor=T.+Arakawaauthor=S.+Moriauthor=B.+Ratzkinauthor=T.+Yamamoto&title=Molecular+characterization+of+ALK%2C+a+receptor+tyrosine+kinase+expressed+specifically+in+the+nervous+system&doi=10.1038%2Fsj.onc.1200849"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system</span></div><div class="casAuthors">Iwahara, Toshinori; Fujimoto, Jiro; Wen, Duanzhi; Cupples, Rod; Bucay, Nathan; Arakawa, Tsutomu; Mori, Shigeo; Ratzkin, Barry; Yamamoto, Tadashi</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">439-449</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Stockton</span>)
        </div><div class="casAbstract">The 2;5 chromosomal translocation is frequently assocd. with anaplastic large cell lymphomas (ALCLs).  The translocation creates a fusion gene consisting of the alk (anaplastic lymphoma kinase) gene and the nucelophosmin (npm) gene: the 3' half of alk derived from chromosome 2 is fused to the 5' portion of npm from chromosome 5.  A recent study shows that the product of the npm-alk fusion gene is oncogenic.  To help understand how the npm-alk oncogene transform cells, it is important to investigate the normal biol. function of the alk gene product, ALK.  Here, we show mol. cloning of cDNAs for both the human and mouse ALK proteins.  The deduced amino acid sequences reveal that ALK is a novel receptor protein-tyrosine kinase having a putative transmembrane domain and an extracellular domain.  These sequences are absent in the product of the transforming npm-alk gene.  ALK shows the greatest sequence similarity to LTK (leukocyte tyrosine kinase) whose biol. function is presently unknown.  RNA blot hybridization anal. of various tissues reveals that the alk mRNA is dominantly detected in the brain and spinal cord.  Immunoblotting with anti-ALK antibody shows that ALK is highly expressed in the neonatal brain.  Furthermore, RNA in situ hybridization anal. shows that the alk mRNA is dominantly expressed in neurons in specific regions of the nervous system such as the thalamus, mid-brain, olfactory bulb, and ganglia of embryonic and neonatal mice.  These data suggest that ALK plays an important role(s) in the development of the brain and exerts its effects on specific neurons in the nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-hGYy9uKgGbVg90H21EOLACvtfcHk0ljmkVNj4L35Bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXht1ensbs%253D&md5=7143e0a25247dd354bbf564cfd1702b6</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1200849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1200849%26sid%3Dliteratum%253Aachs%26aulast%3DIwahara%26aufirst%3DT.%26aulast%3DFujimoto%26aufirst%3DJ.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DCupples%26aufirst%3DR.%26aulast%3DBucay%26aufirst%3DN.%26aulast%3DArakawa%26aufirst%3DT.%26aulast%3DMori%26aufirst%3DS.%26aulast%3DRatzkin%26aufirst%3DB.%26aulast%3DYamamoto%26aufirst%3DT.%26atitle%3DMolecular%2520characterization%2520of%2520ALK%252C%2520a%2520receptor%2520tyrosine%2520kinase%2520expressed%2520specifically%2520in%2520the%2520nervous%2520system%26jtitle%3DOncogene%26date%3D1997%26volume%3D14%26spage%3D439%26epage%3D449%26doi%3D10.1038%2Fsj.onc.1200849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran-Dubé, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nambu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botrous, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grodsky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padrique, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mroczkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6342</span>– <span class="NLM_lpage">6363</span>, <span class="refDoi"> DOI: 10.1021/jm2007613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&author=J.+J.+Cuiauthor=M.+Tran-Dub%C3%A9author=H.+Shenauthor=M.+Nambuauthor=P.+P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=E.+Padriqueauthor=G.+Altonauthor=S.+Timofeevskiauthor=S.+Yamazakiauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure+based+drug+design+of+crizotinib+%28PF-02341066%29%2C+a+potent+and+selective+dual+inhibitor+of+mesenchymal-epithelial+transition+factor+%28c-MET%29+kinase+and+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1021%2Fjm2007613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Cui, J. Jean; Tran-Dube, Michelle; Shen, Hong; Nambu, Mitchell; Kung, Pei-Pei; Pairish, Mason; Jia, Lei; Meng, Jerry; Funk, Lee; Botrous, Iriny; McTigue, Michele; Grodsky, Neil; Ryan, Kevin; Padrique, Ellen; Alton, Gordon; Timofeevski, Sergei; Yamazaki, Shinji; Li, Qiuhua; Zou, Helen; Christensen, James; Mroczkowski, Barbara; Bender, Steve; Kania, Robert S.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6342-6363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the crit. roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncol. targets for therapeutic intervention.  The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design.  A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3.  In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE).  Further optimization of the lead series generated the clin. candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHs_cKJ-U3t7Vg90H21EOLACvtfcHk0ljmkVNj4L35Bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN&md5=dbab4c1b3e7c76180dbad04be2b6a474</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dub%25C3%25A9%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DPadrique%26aufirst%3DE.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure%2520based%2520drug%2520design%2520of%2520crizotinib%2520%2528PF-02341066%2529%252C%2520a%2520potent%2520and%2520selective%2520dual%2520inhibitor%2520of%2520mesenchymal-epithelial%2520transition%2520factor%2520%2528c-MET%2529%2520kinase%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6342%26epage%3D6363%26doi%3D10.1021%2Fjm2007613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marsilje, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkisova, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pferdekamper, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steensma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopiuk, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groessl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phimister, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aycinena, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanewsky, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P. Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5675</span>– <span class="NLM_lpage">5690</span>, <span class="refDoi"> DOI: 10.1021/jm400402q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400402q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptVWjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5675-5690&author=T.+H.+Marsiljeauthor=W.+Peiauthor=B.+Chenauthor=W.+Luauthor=T.+Unoauthor=Y.+Jinauthor=T.+Jiangauthor=S.+Kimauthor=N.+Liauthor=M.+Warmuthauthor=Y.+Sarkisovaauthor=F.+Sunauthor=A.+Steffyauthor=A.+C.+Pferdekamperauthor=A.+G.+Liauthor=S.+B.+Josephauthor=Y.+Kimauthor=B.+Liuauthor=T.+Tuntlandauthor=X.+Cuiauthor=N.+S.+Grayauthor=R.+Steensmaauthor=Y.+Wanauthor=J.+Jiangauthor=G.+Chopiukauthor=J.+Liauthor=W.+P.+Gordonauthor=W.+Richmondauthor=K.+Johnsonauthor=J.+Changauthor=T.+Groesslauthor=Y.+Q.+Heauthor=A.+Phimisterauthor=A.+Aycinenaauthor=C.+C.+Leeauthor=B.+Bursulayaauthor=D.+S.+Karanewskyauthor=H.+M.+Seidelauthor=J.+L.+Harrisauthor=P.+Y.+Michellys&title=Synthesis%2C+structure-activity+relationships%2C+and+in+vivo+efficacy+of+the+novel+potent+and+selective+anaplastic+lymphoma+kinase+%28ALK%29+inhibitor+5-chloro-N2-%282-isopropoxy-5-methyl-4-%28piperidin-4-yl%29phenyl%29-N4-%282-%28isopropylsulfonyl%29phenyl%29pyrimidine-2%2C4-diamine+%28LDK378%29+currently+in+phase+1+and+phase+2+clinical+trials&doi=10.1021%2Fjm400402q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Structure-Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials</span></div><div class="casAuthors">Marsilje, Thomas H.; Pei, Wei; Chen, Bei; Lu, Wenshuo; Uno, Tetsuo; Jin, Yunho; Jiang, Tao; Kim, Sungjoon; Li, Nanxin; Warmuth, Markus; Sarkisova, Yelena; Sun, Frank; Steffy, Auzon; Pferdekamper, AnneMarie C.; Li, Allen G.; Joseph, Sean B.; Kim, Young; Liu, Bo; Tuntland, Tove; Cui, Xiaoming; Gray, Nathanael S.; Steensma, Ruo; Wan, Yongqin; Jiang, Jiqing; Chopiuk, Greg; Li, Jie; Gordon, W. Perry; Richmond, Wendy; Johnson, Kevin; Chang, Jonathan; Groessl, Todd; He, You-Qun; Phimister, Andrew; Aycinena, Alex; Lee, Christian C.; Bursulaya, Badry; Karanewsky, Donald S.; Seidel, H. Martin; Harris, Jennifer L.; Michellys, Pierre-Yves</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5675-5690</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis, preclin. profile, and in vivo efficacy in rat xenograft models of the novel and selective anaplastic lymphoma kinase inhibitor (I; LDK378) are described.  In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation ALK inhibitor (II; TAE684).  Compd. I is currently in phase 1 and phase 2 clin. trials with substantial antitumor activity being obsd. in ALK-pos. cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ-y7ZuX2XLLVg90H21EOLACvtfcHk0liRMEBQkStBGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptVWjs7g%253D&md5=4b8f66e4acb27efe814956d7d0016068</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm400402q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400402q%26sid%3Dliteratum%253Aachs%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DPei%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DUno%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DSarkisova%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSteffy%26aufirst%3DA.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DA.%2BG.%26aulast%3DJoseph%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGordon%26aufirst%3DW.%2BP.%26aulast%3DRichmond%26aufirst%3DW.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DY.%2BQ.%26aulast%3DPhimister%26aufirst%3DA.%26aulast%3DAycinena%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DKaranewsky%26aufirst%3DD.%2BS.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DMichellys%26aufirst%3DP.%2BY.%26atitle%3DSynthesis%252C%2520structure-activity%2520relationships%252C%2520and%2520in%2520vivo%2520efficacy%2520of%2520the%2520novel%2520potent%2520and%2520selective%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitor%25205-chloro-N2-%25282-isopropoxy-5-methyl-4-%2528piperidin-4-yl%2529phenyl%2529-N4-%25282-%2528isopropylsulfonyl%2529phenyl%2529pyrimidine-2%252C4-diamine%2520%2528LDK378%2529%2520currently%2520in%2520phase%25201%2520and%2520phase%25202%2520clinical%2520trials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5675%26epage%3D5690%26doi%3D10.1021%2Fjm400402q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asoh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuichi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morikami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oikawa, N.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel tetracyclic compounds as anaplastic lymphoma kinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3788</span>– <span class="NLM_lpage">3793</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.04.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.bmcl.2011.04.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=21561771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntFKhtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=3788-3793&author=K.+Kinoshitaauthor=Y.+Onoauthor=T.+Emuraauthor=K.+Asohauthor=N.+Furuichiauthor=T.+Itoauthor=H.+Kawadaauthor=S.+Tanakaauthor=K.+Morikamiauthor=T.+Tsukaguchiauthor=H.+Sakamotoauthor=T.+Tsukudaauthor=N.+Oikawa&title=Discovery+of+novel+tetracyclic+compounds+as+anaplastic+lymphoma+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2011.04.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel tetracyclic compounds as anaplastic lymphoma kinase inhibitors</span></div><div class="casAuthors">Kinoshita, Kazutomo; Ono, Yoshiyuki; Emura, Takashi; Asoh, Kohsuke; Furuichi, Noriyuki; Ito, Toshiya; Kawada, Hatsuo; Tanaka, Shota; Morikami, Kenji; Tsukaguchi, Toshiyuki; Sakamoto, Hiroshi; Tsukuda, Takuo; Oikawa, Nobuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3788-3793</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) receptor tyrosine kinase is considered a promising therapeutic target for human cancers.  We identified novel tetracyclic derivs. as potent ALK inhibitors.  Among them, compd. 27 showed strong cytotoxicity against KARPAS-299 with an IC50 value of 21 nM and significant antitumor efficacy in ALK fusion-pos. blood and solid cancer xenograft models in mice without body wt. loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfNlq9E4lTLbVg90H21EOLACvtfcHk0liRMEBQkStBGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntFKhtrk%253D&md5=542e105e38318a56462edef6f0ea4620</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.04.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.04.020%26sid%3Dliteratum%253Aachs%26aulast%3DKinoshita%26aufirst%3DK.%26aulast%3DOno%26aufirst%3DY.%26aulast%3DEmura%26aufirst%3DT.%26aulast%3DAsoh%26aufirst%3DK.%26aulast%3DFuruichi%26aufirst%3DN.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DKawada%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DS.%26aulast%3DMorikami%26aufirst%3DK.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DOikawa%26aufirst%3DN.%26atitle%3DDiscovery%2520of%2520novel%2520tetracyclic%2520compounds%2520as%2520anaplastic%2520lymphoma%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D3788%26epage%3D3793%26doi%3D10.1016%2Fj.bmcl.2011.04.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asoh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuichi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohwada, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyagi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takanashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oikawa, N.</span></span> <span> </span><span class="NLM_article-title">9-substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as highly selective and potent anaplastic lymphoma kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6286</span>– <span class="NLM_lpage">6294</span>, <span class="refDoi"> DOI: 10.1021/jm200652u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200652u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVOns7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6286-6294&author=K.+Kinoshitaauthor=T.+Kobayashiauthor=K.+Asohauthor=N.+Furuichiauthor=T.+Itoauthor=H.+Kawadaauthor=S.+Haraauthor=J.+Ohwadaauthor=K.+Hattoriauthor=T.+Miyagiauthor=W.+S.+Hongauthor=M.+J.+Parkauthor=K.+Takanashiauthor=T.+Tsukaguchiauthor=H.+Sakamotoauthor=T.+Tsukudaauthor=N.+Oikawa&title=9-substituted+6%2C6-dimethyl-11-oxo-6%2C11-dihydro-5H-benzo%5Bb%5Dcarbazoles+as+highly+selective+and+potent+anaplastic+lymphoma+kinase+inhibitors&doi=10.1021%2Fjm200652u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase Inhibitors</span></div><div class="casAuthors">Kinoshita, Kazutomo; Kobayashi, Takamitsu; Asoh, Kohsuke; Furuichi, Noriyuki; Ito, Toshiya; Kawada, Hatsuo; Hara, Sousuke; Ohwada, Jun; Hattori, Kazuo; Miyagi, Takuho; Hong, Woo-Sang; Park, Min-Jeong; Takanashi, Kenji; Tsukaguchi, Toshiyuki; Sakamoto, Hiroshi; Tsukuda, Takuo; Oikawa, Nobuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6286-6294</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">9-Substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles were discovered as highly selective and potent anaplastic lymphoma kinase (ALK) inhibitors by structure-based drug design.  The high target selectivity was achieved by introducing a substituent close to the E0 region of the ATP binding site, which has a unique amino acid sequence.  Among the identified inhibitors, compd. 13d (I) showed highly selective and potent inhibitory activity against ALK with an IC50 value of 2.9 nM and strong antiproliferative activity against KARPAS-299 with an IC50 value of 12.8 nM.  The compd. also displayed significant antitumor efficacy in an established ALK fusion gene-pos. anaplastic large-cell lymphoma (ALCL) xenograft model in mice without body wt. loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfpJsdIdDvO7Vg90H21EOLACvtfcHk0liRMEBQkStBGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVOns7vP&md5=6293368243c840e12beefc8c8d6bb69a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm200652u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200652u%26sid%3Dliteratum%253Aachs%26aulast%3DKinoshita%26aufirst%3DK.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DAsoh%26aufirst%3DK.%26aulast%3DFuruichi%26aufirst%3DN.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DKawada%26aufirst%3DH.%26aulast%3DHara%26aufirst%3DS.%26aulast%3DOhwada%26aufirst%3DJ.%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DMiyagi%26aufirst%3DT.%26aulast%3DHong%26aufirst%3DW.%2BS.%26aulast%3DPark%26aufirst%3DM.%2BJ.%26aulast%3DTakanashi%26aufirst%3DK.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DOikawa%26aufirst%3DN.%26atitle%3D9-substituted%25206%252C6-dimethyl-11-oxo-6%252C11-dihydro-5H-benzo%255Bb%255Dcarbazoles%2520as%2520highly%2520selective%2520and%2520potent%2520anaplastic%2520lymphoma%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6286%26epage%3D6294%26doi%3D10.1021%2Fjm200652u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asoh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuichi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohwada, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyagi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takanashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oikawa, N.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1271</span>– <span class="NLM_lpage">1280</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.12.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.bmc.2011.12.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=22225917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSmu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=1271-1280&author=K.+Kinoshitaauthor=K.+Asohauthor=N.+Furuichiauthor=T.+Itoauthor=H.+Kawadaauthor=S.+Haraauthor=J.+Ohwadaauthor=T.+Miyagiauthor=T.+Kobayashiauthor=K.+Takanashiauthor=T.+Tsukaguchiauthor=H.+Sakamotoauthor=T.+Tsukudaauthor=N.+Oikawa&title=Design+and+synthesis+of+a+highly+selective%2C+orally+active+and+potent+anaplastic+lymphoma+kinase+inhibitor+%28CH5424802%29&doi=10.1016%2Fj.bmc.2011.12.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)</span></div><div class="casAuthors">Kinoshita, Kazutomo; Asoh, Kohsuke; Furuichi, Noriyuki; Ito, Toshiya; Kawada, Hatsuo; Hara, Sousuke; Ohwada, Jun; Miyagi, Takuho; Kobayashi, Takamitsu; Takanashi, Kenji; Tsukaguchi, Toshiyuki; Sakamoto, Hiroshi; Tsukuda, Takuo; Oikawa, Nobuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1271-1280</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) receptor tyrosine kinase is considered an attractive therapeutic target for human cancers, esp. non-small cell lung cancer (NSCLC).  Our previous study revealed that 8,9-side-chains of 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole scaffold crucially affected kinase selectivity, cellular activity, and metabolic stability.  In this work, we optimized the side-chains and identified highly selective, orally active and potent ALK inhibitor CH5424802 (18a) as the clin. candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG6Im56-4v17Vg90H21EOLACvtfcHk0lhJugc3SFyTWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSmu70%253D&md5=cff263d2dd8c66de9fd687530fdadb06</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.12.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.12.021%26sid%3Dliteratum%253Aachs%26aulast%3DKinoshita%26aufirst%3DK.%26aulast%3DAsoh%26aufirst%3DK.%26aulast%3DFuruichi%26aufirst%3DN.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DKawada%26aufirst%3DH.%26aulast%3DHara%26aufirst%3DS.%26aulast%3DOhwada%26aufirst%3DJ.%26aulast%3DMiyagi%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DTakanashi%26aufirst%3DK.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DOikawa%26aufirst%3DN.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520a%2520highly%2520selective%252C%2520orally%2520active%2520and%2520potent%2520anaplastic%2520lymphoma%2520kinase%2520inhibitor%2520%2528CH5424802%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D1271%26epage%3D1280%26doi%3D10.1016%2Fj.bmc.2011.12.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwight, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodd, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toms, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parillon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anjum, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keats, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohemmad, Q. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narasimhan, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgarno, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of brigatinib (AP26113), a phosphine oxide-containing, potent, orally active inhibitor of anaplastic lymphoma kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4948</span>– <span class="NLM_lpage">4964</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00306</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00306" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlCgur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4948-4964&author=W.+S.+Huangauthor=S.+Liuauthor=D.+Zouauthor=M.+Thomasauthor=Y.+Wangauthor=T.+Zhouauthor=J.+Romeroauthor=A.+Kohlmannauthor=F.+Liauthor=J.+Qiauthor=L.+Caiauthor=T.+A.+Dwightauthor=Y.+Xuauthor=R.+Xuauthor=R.+Doddauthor=A.+Tomsauthor=L.+Parillonauthor=X.+Luauthor=R.+Anjumauthor=S.+Zhangauthor=F.+Wangauthor=J.+Keatsauthor=S.+D.+Wardwellauthor=Y.+Ningauthor=Q.+Xuauthor=L.+E.+Moranauthor=Q.+K.+Mohemmadauthor=H.+G.+Jangauthor=T.+Clacksonauthor=N.+I.+Narasimhanauthor=V.+M.+Riveraauthor=X.+Zhuauthor=D.+Dalgarnoauthor=W.+C.+Shakespeare&title=Discovery+of+brigatinib+%28AP26113%29%2C+a+phosphine+oxide-containing%2C+potent%2C+orally+active+inhibitor+of+anaplastic+lymphoma+kinase&doi=10.1021%2Facs.jmedchem.6b00306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase</span></div><div class="casAuthors">Huang, Wei-Sheng; Liu, Shuangying; Zou, Dong; Thomas, Mathew; Wang, Yihan; Zhou, Tianjun; Romero, Jan; Kohlmann, Anna; Li, Feng; Qi, Jiwei; Cai, Lisi; Dwight, Timothy A.; Xu, Yongjin; Xu, Rongsong; Dodd, Rory; Toms, Angela; Parillon, Lois; Lu, Xiaohui; Anjum, Rana; Zhang, Sen; Wang, Frank; Keats, Jeffrey; Wardwell, Scott D.; Ning, Yaoyu; Xu, Qihong; Moran, Lauren E.; Mohemmad, Qurish K.; Jang, Hyun Gyung; Clackson, Tim; Narasimhan, Narayana I.; Rivera, Victor M.; Zhu, Xiaotian; Dalgarno, David; Shakespeare, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4948-4964</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the treatment of echinoderm microtubule-assocd. protein-like 4 (EML4)-anaplastic lymphoma kinase pos. (ALK+) non-small-cell lung cancer (NSCLC), secondary mutations within the ALK kinase domain have emerged as a major resistance mechanism to both first- and second-generation ALK inhibitors.  This report describes the design and synthesis of a series of 2,4-diarylaminopyrimidine-based potent and selective ALK inhibitors culminating in identification of the investigational clin. candidate brigatinib.  A unique structural feature of brigatinib is a phosphine oxide, an overlooked but novel hydrogen-bond acceptor that drives potency and selectivity in addn. to favorable ADME properties.  Brigatinib displayed low nanomolar IC50s against native ALK and all tested clin. relevant ALK mutants in both enzyme-based biochem. and cell-based viability assays and demonstrated efficacy in multiple ALK+ xenografts in mice, including Karpas-299 (anaplastic large-cell lymphomas [ALCL]) and H3122 (NSCLC).  Brigatinib represents the most clin. advanced phosphine oxide-contg. drug candidate to date and is currently being evaluated in a global phase 2 registration trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5_iqprSA4QbVg90H21EOLACvtfcHk0lhJugc3SFyTWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlCgur8%253D&md5=4cb93ff587579c97fda8aff0c7d43317</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00306%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%2BS.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DRomero%26aufirst%3DJ.%26aulast%3DKohlmann%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DL.%26aulast%3DDwight%26aufirst%3DT.%2BA.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DDodd%26aufirst%3DR.%26aulast%3DToms%26aufirst%3DA.%26aulast%3DParillon%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWardwell%26aufirst%3DS.%2BD.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMoran%26aufirst%3DL.%2BE.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DJang%26aufirst%3DH.%2BG.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3DDiscovery%2520of%2520brigatinib%2520%2528AP26113%2529%252C%2520a%2520phosphine%2520oxide-containing%252C%2520potent%252C%2520orally%2520active%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4948%26epage%3D4964%26doi%3D10.1021%2Facs.jmedchem.6b00306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deal, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4720</span>– <span class="NLM_lpage">4744</span>, <span class="refDoi"> DOI: 10.1021/jm500261q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500261q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4720-4744&author=T.+W.+Johnsonauthor=P.+F.+Richardsonauthor=S.+Baileyauthor=A.+Broounauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=J.+J.+Cuiauthor=J.+G.+Dealauthor=Y.+L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=Q.+Huangauthor=R.+S.+Kaniaauthor=J.+C.+Kathauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=L.+Lingardoauthor=W.+Liuauthor=M.+McTigueauthor=C.+L.+Palmerauthor=N.+W.+Sachauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=H.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Discovery+of+%2810R%29-7-amino-12-fluoro-2%2C10%2C16-trimethyl-15-oxo-10%2C15%2C16%2C17-tetrahydro-2H-8%2C4-%28metheno%29pyrazolo%5B4%2C3-h%5D%5B2%2C5%2C11%5D-benzoxadiazacyclotetradecine-3-carbonitrile+%28PF-06463922%29%2C+a+macrocyclic+inhibitor+of+anaplastic+lymphoma+kinase+%28ALK%29+and+c-ros+oncogene+1+%28ROS1%29+with+preclinical+brain+exposure+and+broad-spectrum+potency+against+ALK-resistant+mutations&doi=10.1021%2Fjm500261q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span></div><div class="casAuthors">Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4720-4744</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-pos. non-small-cell lung carcinoma patients, progression during treatment eventually develops.  Resistant patient samples revealed a variety of point mutations in the kinase domain of ALK, including the L1196M gatekeeper mutation.  In addn., some patients progress due to cancer metastasis in the brain.  Using structure-based drug design, lipophilic efficiency, and phys.-property-based optimization, highly potent macrocyclic ALK inhibitors were prepd. with good absorption, distribution, metab., and excretion (ADME), low propensity for p-glycoprotein 1-mediated efflux, and good passive permeability.  These structurally unusual macrocyclic inhibitors were potent against wild-type ALK and clin. reported ALK kinase domain mutations.  Significant synthetic challenges were overcome, utilizing novel transformations to enable the use of these macrocycles in drug discovery paradigms.  This work led to the discovery of 8k (PF-06463922), combining broad-spectrum potency, central nervous system ADME, and a high degree of kinase selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqXkb49ad31bVg90H21EOLACvtfcHk0liSMMLXGwrs7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D&md5=db21844f8e9a2f9ca5953bca56ad7b1c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm500261q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500261q%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDiscovery%2520of%2520%252810R%2529-7-amino-12-fluoro-2%252C10%252C16-trimethyl-15-oxo-10%252C15%252C16%252C17-tetrahydro-2H-8%252C4-%2528metheno%2529pyrazolo%255B4%252C3-h%255D%255B2%252C5%252C11%255D-benzoxadiazacyclotetradecine-3-carbonitrile%2520%2528PF-06463922%2529%252C%2520a%2520macrocyclic%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520and%2520c-ros%2520oncogene%25201%2520%2528ROS1%2529%2520with%2520preclinical%2520brain%2520exposure%2520and%2520broad-spectrum%2520potency%2520against%2520ALK-resistant%2520mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4720%26epage%3D4744%26doi%3D10.1021%2Fjm500261q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, T.</span></span> <span> </span><span class="NLM_article-title">Drug discovery targeting anaplastic lymphoma kinase (ALK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">10927</span>– <span class="NLM_lpage">10954</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00446</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00446" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFyrur3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10927-10954&author=X.+Kongauthor=P.+Panauthor=H.+Sunauthor=H.+Xiaauthor=X.+Wangauthor=Y.+Liauthor=T.+Hou&title=Drug+discovery+targeting+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1021%2Facs.jmedchem.9b00446"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Kong, Xiaotian; Pan, Peichen; Sun, Huiyong; Xia, Hongguang; Wang, Xuwen; Li, Youyong; Hou, Tingjun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10927-10954</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  As a receptor tyrosine kinase of insulin receptor (IR) subfamily, anaplastic lymphoma kinase (ALK) has been validated to play important roles in various cancers, esp. anaplastic large cell lymphoma (ALCL), nonsmall cell lung cancer (NSCLC), and neuroblastomas.  Currently, five small-mol. inhibitors of ALK, including Crizotinib, Ceritinib, Alectinib, Brigatinib, and Lorlatinib, have been approved by the U.S.  Food and Drug Administration (FDA) against ALK-pos. NSCLCs.  Novel type-I1/2 and type-II ALK inhibitors with improved kinase selectivity and enhanced capability to combat drug resistance have also been reported.  Moreover, the "proteolysis targeting chimera" (PROTAC) technique has been successfully applied in developing ALK degraders, which opened a new avenue for targeted ALK therapies.  This review provides an overview of the physiol. and biol. functions of ALK, the discovery and development of drugs targeting ALK by focusing on their chemotypes, activity, selectivity, and resistance as well as potential therapeutic strategies to overcome drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7LmONQduM_bVg90H21EOLACvtfcHk0liSMMLXGwrs7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFyrur3E&md5=6c9aadf015cba2f11b2c2f747eea3eec</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00446%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DX.%26aulast%3DPan%26aufirst%3DP.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DXia%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHou%26aufirst%3DT.%26atitle%3DDrug%2520discovery%2520targeting%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D10927%26epage%3D10954%26doi%3D10.1021%2Facs.jmedchem.9b00446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Targeting ALK: precision medicine takes on drug resistance</span>. <i>Cancer Discov.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">155</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-16-1123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1158%2F2159-8290.CD-16-1123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=28122866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVCjs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=137-155&author=J.+J.+Linauthor=G.+J.+Rielyauthor=A.+T.+Shaw&title=Targeting+ALK%3A+precision+medicine+takes+on+drug+resistance&doi=10.1158%2F2159-8290.CD-16-1123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting ALK: Precision Medicine Takes on Drug Resistance</span></div><div class="casAuthors">Lin, Jessica J.; Riely, Gregory J.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">137-155</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Anaplastic lymphoma kinase (ALK) is a validated mol. target in several ALK-rearranged malignancies, including non-small cell lung cancer.  However, the clin. benefit of targeting ALK using tyrosine kinase inhibitors (TKI) is almost universally limited by the emergence of drug resistance.  Diverse mechanisms of resistance to ALK TKIs have now been discovered, and these basic mechanisms are informing the development of novel therapeutic strategies to overcome resistance in the clinic.  In this review, we summarize the current successes and challenges of targeting ALK.  Significance: Effective long-term treatment of ALK-rearranged cancers requires a mechanistic understanding of resistance to ALK TKIs so that rational therapies can be selected to combat resistance.  This review underscores the importance of serial biopsies in capturing the dynamic therapeutic vulnerabilities within a patient's tumor and offers a perspective into the complexity of on-target and off-target ALK TKI resistance mechanisms.  Therapeutic strategies that can successfully overcome, and potentially prevent, these resistance mechanisms will have the greatest impact on patient outcome.  Cancer Discov; 7(2); 137-55. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLmMz7s4fYu7Vg90H21EOLACvtfcHk0ljRa0gwkqSE1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVCjs7c%253D&md5=6f7d5358d13c75b215b0d1e6ce8ac8ff</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-16-1123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-16-1123%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DJ.%2BJ.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DTargeting%2520ALK%253A%2520precision%2520medicine%2520takes%2520on%2520drug%2520resistance%26jtitle%3DCancer%2520Discov.%26date%3D2017%26volume%3D7%26spage%3D137%26epage%3D155%26doi%3D10.1158%2F2159-8290.CD-16-1123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takashima, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yatabe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haruta, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsudomi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanio, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mano, H.</span></span> <span> </span><span class="NLM_article-title">EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">1734</span>– <span class="NLM_lpage">1739</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1007478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1056%2FNEJMoa1007478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=20979473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1734-1739&author=Y.+L.+Choiauthor=M.+Sodaauthor=Y.+Yamashitaauthor=T.+Uenoauthor=J.+Takashimaauthor=T.+Nakajimaauthor=Y.+Yatabeauthor=K.+Takeuchiauthor=T.+Hamadaauthor=H.+Harutaauthor=Y.+Ishikawaauthor=H.+Kimuraauthor=T.+Mitsudomiauthor=Y.+Tanioauthor=H.+Mano&title=EML4-ALK+mutations+in+lung+cancer+that+confer+resistance+to+ALK+inhibitors&doi=10.1056%2FNEJMoa1007478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors</span></div><div class="casAuthors">Choi, Young Lim; Soda, Manabu; Yamashita, Yoshihiro; Ueno, Toshihide; Takashima, Junpei; Nakajima, Takahiro; Yatabe, Yasushi; Takeuchi, Kengo; Hamada, Toru; Haruta, Hidenori; Ishikawa, Yuichi; Kimura, Hideki; Mitsudomi, Tetsuya; Tanio, Yoshiro; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1734-1739</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The EML4 (echinoderm microtubule-assocd. protein-like 4)-ALK (anaplastic lymphoma kinase) fusion-type tyrosine kinase is an oncoprotein found in 4% to 5% of non-small-cell lung cancers, and clin. trials of specific inhibitors of ALK for the treatment of such tumors are currently under way.  Here, we report the discovery of two secondary mutations within the kinase domain of EML4-ALK in tumor cells isolated from a patient during the relapse phase of treatment with an ALK inhibitor.  Each mutation developed independently in subclones of the tumor and conferred marked resistance to two different ALK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCIrEIBi5MjrVg90H21EOLACvtfcHk0ljRa0gwkqSE1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FJ&md5=d903151706575c159b7abcdc8999281c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1007478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1007478%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DUeno%26aufirst%3DT.%26aulast%3DTakashima%26aufirst%3DJ.%26aulast%3DNakajima%26aufirst%3DT.%26aulast%3DYatabe%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DHamada%26aufirst%3DT.%26aulast%3DHaruta%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DH.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DTanio%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DEML4-ALK%2520mutations%2520in%2520lung%2520cancer%2520that%2520confer%2520resistance%2520to%2520ALK%2520inhibitors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1734%26epage%3D1739%26doi%3D10.1056%2FNEJMoa1007478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neklesa, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Targeted protein degradation by PROTACs</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">138</span>– <span class="NLM_lpage">144</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2017.02.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.pharmthera.2017.02.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=28223226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtVemsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2017&pages=138-144&author=T.+K.+Neklesaauthor=J.+D.+Winklerauthor=C.+M.+Crews&title=Targeted+protein+degradation+by+PROTACs&doi=10.1016%2Fj.pharmthera.2017.02.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted protein degradation by PROTACs</span></div><div class="casAuthors">Neklesa, Taavi K.; Winkler, James D.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">138-144</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Targeted protein degrdn. using the PROTAC technol. is emerging as a novel therapeutic method to address diseases driven by the aberrant expression of a disease-causing protein.  PROTAC mols. are bifunctional small mols. that simultaneously bind a target protein and an E3-ubiquitin ligase, thus causing ubiquitination and degrdn. of the target protein by the proteasome.  Like small mols., PROTAC mols. possess good tissue distribution and the ability to target intracellular proteins.  Herein, we highlight the advantages of protein degrdn. using PROTACs, and provide specific examples where degrdn. offers therapeutic benefit over classical enzyme inhibition.  Foremost, PROTACs can degrade proteins regardless of their function.  This includes the currently "undruggable" proteome, which comprises approx. 85% of all human proteins.  Other beneficial aspects of protein degrdn. include the ability to target overexpressed and mutated proteins, as well as the potential to demonstrate prolonged pharmacodynamics effect beyond drug exposure.  Lastly, due to their catalytic nature and the pre-requisite ubiquitination step, an exquisitely potent mols. with a high degree of degrdn. selectivity can be designed.  Impressive preclin. in vitro and in vivo PROTAC data have been published, and these data have propelled the development of clin. viable PROTACs.  With the mol. wt. falling in the 700-1000 Da range, the delivery and bioavailability of PROTACs remain the largest hurdles on the way to the clinic.  Solving these issues and demonstrating proof of concept clin. data will be the focus of many labs over the next few years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4RSLWYqqBMrVg90H21EOLACvtfcHk0ljRa0gwkqSE1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtVemsbg%253D&md5=08a74402a274a13c8c484cd68167a5a1</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.02.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.02.027%26sid%3Dliteratum%253Aachs%26aulast%3DNeklesa%26aufirst%3DT.%2BK.%26aulast%3DWinkler%26aufirst%3DJ.%2BD.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DTargeted%2520protein%2520degradation%2520by%2520PROTACs%26jtitle%3DPharmacol.%2520Ther.%26date%3D2017%26volume%3D174%26spage%3D138%26epage%3D144%26doi%3D10.1016%2Fj.pharmthera.2017.02.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Induced protein degradation: an emerging drug discovery paradigm</span>. <i>Nat. Rev. Drug Discov.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1038%2Fnrd.2016.211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=27885283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=101-114&author=A.+C.+Laiauthor=C.+M.+Crews&title=Induced+protein+degradation%3A+an+emerging+drug+discovery+paradigm&doi=10.1038%2Fnrd.2016.211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Induced protein degradation: an emerging drug discovery paradigm</span></div><div class="casAuthors">Lai, Ashton C.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">101-114</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. drug discovery has traditionally focused on occupancy of a binding site that directly affects protein function, and this approach typically precludes targeting proteins that lack such amenable sites.  Furthermore, high systemic drug exposures may be needed to maintain sufficient target inhibition in vivo, increasing the risk of undesirable off-target effects.  Induced protein degrdn. is an alternative approach that is event-driven: upon drug binding, the target protein is tagged for elimination.  Emerging technologies based on proteolysis-targeting chimaeras (PROTACs) that exploit cellular quality control machinery to selectively degrade target proteins are attracting considerable attention in the pharmaceutical industry owing to the advantages they could offer over traditional small-mol. strategies.  These advantages include the potential to reduce systemic drug exposure, the ability to counteract increased target protein expression that often accompanies inhibition of protein function and the potential ability to target proteins that are not currently therapeutically tractable, such as transcription factors, scaffolding and regulatory proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj-O7zXGOpXLVg90H21EOLACvtfcHk0ljRa0gwkqSE1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP&md5=a01ff43e9b696fe4dc03f0815158a98f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.211%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%2BC.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DInduced%2520protein%2520degradation%253A%2520an%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discov.%26date%3D2017%26volume%3D16%26spage%3D101%26epage%3D114%26doi%3D10.1038%2Fnrd.2016.211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Powell, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donovan, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loehr, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahcall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Chemically induced degradation of anaplastic lymphoma kinase (ALK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4249</span>– <span class="NLM_lpage">4255</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01655</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01655" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC1cXns1OitrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4249-4255&author=C.+E.+Powellauthor=Y.+Gaoauthor=L.+Tanauthor=K.+A.+Donovanauthor=R.+P.+Nowakauthor=A.+Loehrauthor=M.+Bahcallauthor=E.+S.+Fischerauthor=P.+A.+J%C3%A4nneauthor=R.+E.+Georgeauthor=N.+S.+Gray&title=Chemically+induced+degradation+of+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1021%2Facs.jmedchem.7b01655"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Powell, Chelsea E.; Gao, Yang; Tan, Li; Donovan, Katherine A.; Nowak, Radoslaw P.; Loehr, Amanda; Bahcall, Magda; Fischer, Eric S.; Janne, Pasi A.; George, Rani E.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4249-4255</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We present the development of the first small mol. degraders that can induce anaplastic lymphoma kinase (ALK) degrdn., including in non-small-cell lung cancer (NSCLC), anaplastic large-cell lymphoma (ALCL), and neuroblastoma (NB) cell lines.  These degraders were developed through conjugation of known pyrimidine-based ALK inhibitors, TAE684 or LDK378, and the cereblon ligand pomalidomide.  We demonstrate that in some cell types degrader potency is compromised by expression of drug transporter ABCB1.  In addn., proteomic profiling demonstrated that these compds. also promote the degrdn. of addnl. kinases including PTK2 (FAK), Aurora A, FER, and RPS6KA1 (RSK1).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7mDH7Sj8EqbVg90H21EOLACvtfcHk0ljnzCyUTU82zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXns1OitrY%253D&md5=486db11b3fbc2283700f38b09cc39bd7</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01655%26sid%3Dliteratum%253Aachs%26aulast%3DPowell%26aufirst%3DC.%2BE.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DDonovan%26aufirst%3DK.%2BA.%26aulast%3DNowak%26aufirst%3DR.%2BP.%26aulast%3DLoehr%26aufirst%3DA.%26aulast%3DBahcall%26aufirst%3DM.%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DChemically%2520induced%2520degradation%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4249%26epage%3D4255%26doi%3D10.1021%2Facs.jmedchem.7b01655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span> <span> </span><span class="NLM_article-title">Proteolysis targeting chimeras (PROTACs) of anaplastic lymphoma kinase (ALK)</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">304</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.ejmech.2018.03.071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=29627725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1ejs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=304-314&author=C.+Zhangauthor=X.+R.+Hanauthor=X.+Yangauthor=B.+Jiangauthor=J.+Liuauthor=Y.+Xiongauthor=J.+Jin&title=Proteolysis+targeting+chimeras+%28PROTACs%29+of+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1016%2Fj.ejmech.2018.03.071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Zhang, Chengwei; Han, Xiao-Ran; Yang, Xiaobao; Jiang, Biao; Liu, Jing; Xiong, Yue; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">304-314</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) activation has been assocd. with many types of human cancer.  Significant efforts have been devoted to the development of ALK inhibitors to antagonize the kinase activity of ALK.  Four ALK inhibitors have been approved by the FDA to date for treating patients with ALK-pos. nonsmall cell lung cancers (NSCLC).  However, drug resistance has been obsd. in the majority of patients treated with these inhibitors.  New therapeutic strategies (e.g., compds. with novel mechanisms of action) are needed to overcome the drug resistance issue.  The emerging PROTAC (Proteolysis Targeting Chimera) technol. has been successfully applied to selective degrdn. of multiple protein targets, but not ALK.  Since ALK protein levels are not important for viability in mammals, ALK PROTACs could lead to novel therapeutics with minimal toxicity.  Here the authors report the design, synthesis and biol. evaluation of novel PROTACs (degraders) of ALK.  MS4077 (I) and MS4078 (II) potently decreased cellular levels of oncogenic active ALK fusion proteins in a concn.- and time-dependent manner in SU-DHL-1 lymphoma and NCI-H2228 lung cancer cells.  The ALK protein degrdn. induced by compds. I and II was cereblon and proteasome dependent.  In addn., compds. I and II potently inhibited proliferation of SU-DHL-1 cells.  Furthermore, compd. II displayed good plasma exposure in a mouse pharmacokinetic study, thus is suitable for in vivo efficacy studies.  The authors also developed MS4748 and MS4740 , very close analogs of I and II resp., which are incapable to degrade the ALK fusion proteins, as neg. controls.  All 4 compds. are valuable chem. tools for investigating effects of ALK pharmacol. degrdn.  The study paved the way for developing the next generation of ALK PROTACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPGM3aAZZ6h7Vg90H21EOLACvtfcHk0ljnzCyUTU82zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1ejs7Y%253D&md5=804324b95034f38b46e45f89e18e55be</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.071%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DX.%2BR.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DProteolysis%2520targeting%2520chimeras%2520%2528PROTACs%2529%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D304%26epage%3D314%26doi%3D10.1016%2Fj.ejmech.2018.03.071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaniskan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span> <span> </span><span class="NLM_article-title">Light-induced control of protein destruction by opto-PROTAC</span>. <i>Sci. Adv.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">eaay5154</span> <span class="refDoi"> DOI: 10.1126/sciadv.aay5154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1126%2Fsciadv.aay5154" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=32128407" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2020&author=J.+Liuauthor=H.+Chenauthor=L.+Maauthor=Z.+Heauthor=D.+Wangauthor=Y.+Liuauthor=Q.+Linauthor=T.+Zhangauthor=N.+Grayauthor=H.+Kaniskanauthor=J.+Jinauthor=W.+Wei&title=Light-induced+control+of+protein+destruction+by+opto-PROTAC&doi=10.1126%2Fsciadv.aay5154"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1126%2Fsciadv.aay5154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fsciadv.aay5154%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DKaniskan%26aufirst%3DH.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DW.%26atitle%3DLight-induced%2520control%2520of%2520protein%2520destruction%2520by%2520opto-PROTAC%26jtitle%3DSci.%2520Adv.%26date%3D2020%26volume%3D6%26doi%3D10.1126%2Fsciadv.aay5154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du Ha, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, J. Y.</span></span> <span> </span><span class="NLM_article-title">Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC)</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>505</i></span>,  <span class="NLM_fpage">542</span>– <span class="NLM_lpage">547</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2018.09.169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.bbrc.2018.09.169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=30274779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVejs7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=505&publication_year=2018&pages=542-547&author=C.+H.+Kangauthor=D.+H.+Leeauthor=C.+O.+Leeauthor=J.+Du+Haauthor=C.+H.+Parkauthor=J.+Y.+Hwang&title=Induced+protein+degradation+of+anaplastic+lymphoma+kinase+%28ALK%29+by+proteolysis+targeting+chimera+%28PROTAC%29&doi=10.1016%2Fj.bbrc.2018.09.169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC)</span></div><div class="casAuthors">Kang, Chung Hyo; Lee, Dong Ho; Lee, Chong Ock; Du Ha, Jae; Park, Chi Hoon; Hwang, Jong Yeon</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">505</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">542-547</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Recently, proteolysis targeting chimera (PROTAC) technol. is highlighted in drug discovery area as a new therapeutic approach.  PROTAC as a heterobifunctional mol. is comprised of two ligands, which recruit target protein and E3 ligase, resp.  To degrade the anaplastic lymphoma kinase (ALK) fusion protein, such as NPM-ALK or EML4-ALK, we generated several ALK-PROTAC mols. consisted of ceritinib, one of the ALK inhibitors, and ligand of von Hippel-Lindau (VHL) E3 ligase.  Among these mols., TD-004 effectively induced ALK degrdn. and inhibited the growth of ALK fusion pos. cell lines, SU-DHL-1 and H3122.  We also confirmed that TD-004 significantly reduced the tumor growth in H3122 xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8JUOZ5fYNW7Vg90H21EOLACvtfcHk0liUe9VZl1QQXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVejs7fE&md5=cac9252fca98ebec4ad8e5aeed7b7550</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2018.09.169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2018.09.169%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DC.%2BH.%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DLee%26aufirst%3DC.%2BO.%26aulast%3DDu%2BHa%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DHwang%26aufirst%3DJ.%2BY.%26atitle%3DInduced%2520protein%2520degradation%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520by%2520proteolysis%2520targeting%2520chimera%2520%2528PROTAC%2529%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2018%26volume%3D505%26spage%3D542%26epage%3D547%26doi%3D10.1016%2Fj.bbrc.2018.09.169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span> <span> </span><span class="NLM_article-title">Discovery of a PROTAC targeting ALK with in vivo activity</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>212</i></span>,  <span class="NLM_fpage">113150</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.113150</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.ejmech.2020.113150" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=33453602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BB3MXhvVSjtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=212&publication_year=2021&pages=113150&author=G.+Yanauthor=X.+Zhongauthor=L.+Yueauthor=C.+Puauthor=H.+Shanauthor=S.+Lanauthor=M.+Zhouauthor=X.+Houauthor=J.+Yangauthor=R.+Li&title=Discovery+of+a+PROTAC+targeting+ALK+with+in+vivo+activity&doi=10.1016%2Fj.ejmech.2020.113150"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a PROTAC targeting ALK with in vivo activity</span></div><div class="casAuthors">Yan, Guoyi; Zhong, Xinxin; Yue, Lin; Pu, Chunlan; Shan, Huifang; Lan, Suke; Zhou, Meng; Hou, Xueyan; Yang, Jie; Li, Rui</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">212</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113150</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) was involved in the development of various cancer types.  Although several ALK inhibitors have been advanced to clin. trials, the emergence of drug resistance has limited the clin. application of them.  To overcome the drug resistance, proteolysis targeting chimeras (PROTACs) could be an alternative strategy.  In this study, a series of ALK degraders were designed and synthesized.  The degraders were developed through the conjugation of LDK378 and CRBN E3 ubiquitin ligase ligands.  Among all the mols., compd. B3 showed potent selective inhibitory activity to ALK and can decrease the cellular levels of ALK fusion proteins in a concn.- and time-dependent manner in H3122 cell line.  Meanwhile, B3 showed improved anticancer activity in vitro comparing with LDK378 and the antiproliferative activity to xenograft tumor model was acceptable.  All the results demonstrated that ALK degrader B3 with in vitro and in vivo anti-cancer activities was valuable for further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_7prECNonvrVg90H21EOLACvtfcHk0liUe9VZl1QQXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXhvVSjtro%253D&md5=06c5a3f10a3beead2d51189ac383528a</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.113150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.113150%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DG.%26aulast%3DZhong%26aufirst%3DX.%26aulast%3DYue%26aufirst%3DL.%26aulast%3DPu%26aufirst%3DC.%26aulast%3DShan%26aufirst%3DH.%26aulast%3DLan%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DR.%26atitle%3DDiscovery%2520of%2520a%2520PROTAC%2520targeting%2520ALK%2520with%2520in%2520vivo%2520activity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D212%26spage%3D113150%26doi%3D10.1016%2Fj.ejmech.2020.113150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span> <span> </span><span class="NLM_article-title">Development of a brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>193</i></span>,  <span class="NLM_fpage">112190</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.ejmech.2020.112190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=32179332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvF2qu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=193&publication_year=2020&pages=112190&author=N.+Sunauthor=C.+Renauthor=Y.+Kongauthor=H.+Zhongauthor=J.+Chenauthor=Y.+Liauthor=J.+Zhangauthor=Y.+Zhouauthor=X.+Qiuauthor=H.+Linauthor=X.+Songauthor=X.+Yangauthor=B.+Jiang&title=Development+of+a+brigatinib+degrader+%28SIAIS117%29+as+a+potential+treatment+for+ALK+positive+cancer+resistance&doi=10.1016%2Fj.ejmech.2020.112190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance</span></div><div class="casAuthors">Sun, Ning; Ren, Chaowei; Kong, Ying; Zhong, Hui; Chen, Jinju; Li, Yan; Zhang, Jianshui; Zhou, Yuedong; Qiu, Xing; Lin, Haifan; Song, Xiaoling; Yang, Xiaobao; Jiang, Biao</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">193</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112190</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">EML4-ALK and NPM-ALK fusion proteins possess constitutively activated ALK (anaplastic lymphoma kinase) activity, which in turn leads to the development of non-small cell lung cancer and anaplastic large-cell lymphomas (ALCLs).  FDA-approved ALK inhibitor drugs cause significant cancer regression.  However, drug resistance eventually occurs and it becomes a big obstacle in clinic.  Novel proteolysis targeting chimera (PROTAC) technol. platform provides a potential therapeutic strategy for drug resistance.  Herein, we designed and synthesized a series of ALK PROTACs based on Brigatinib and VHL-1 conjunction, and screened SIAIS117 as the best degrader which not only blocked the growth of SR and H2228 cancer cell lines, but also degraded ALK protein.  In addn., SIAIS117 also showed much better growth inhibition effect than Brigatinib on 293T cell line that exogenously expressed G1202R-resistant ALK proteins.  Furthermore, it also degraded G1202R mutant ALK protein in vitro.  At last, it has the potentially anti-proliferation ability of small cell lung cancer.  Thus, we have successfully generated the degrader SIAIS117 that can potentially overcome resistance in cancer targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX9rzk88HMe7Vg90H21EOLACvtfcHk0liUe9VZl1QQXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvF2qu70%253D&md5=61f0228111c806ae62473fc450fce276</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112190%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DN.%26aulast%3DRen%26aufirst%3DC.%26aulast%3DKong%26aufirst%3DY.%26aulast%3DZhong%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DQiu%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DB.%26atitle%3DDevelopment%2520of%2520a%2520brigatinib%2520degrader%2520%2528SIAIS117%2529%2520as%2520a%2520potential%2520treatment%2520for%2520ALK%2520positive%2520cancer%2520resistance%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D193%26spage%3D112190%26doi%3D10.1016%2Fj.ejmech.2020.112190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span> <span> </span><span class="NLM_article-title">Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from Alectinib</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>217</i></span>,  <span class="NLM_fpage">113335</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2021.113335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.ejmech.2021.113335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=33751979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BB3MXnt1Ohsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=217&publication_year=2021&pages=113335&author=C.+Renauthor=N.+Sunauthor=Y.+Kongauthor=X.+Quauthor=H.+Liuauthor=H.+Zhongauthor=X.+Songauthor=X.+Yangauthor=B.+Jiang&title=Structure-based+discovery+of+SIAIS001+as+an+oral+bioavailability+ALK+degrader+constructed+from+Alectinib&doi=10.1016%2Fj.ejmech.2021.113335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from Alectinib</span></div><div class="casAuthors">Ren, Chaowei; Sun, Ning; Kong, Ying; Qu, Xiaojuan; Liu, Haixia; Zhong, Hui; Song, Xiaoling; Yang, Xiaobao; Jiang, Biao</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">217</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113335</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Fusion proteins of the anaplastic lymphoma kinase (ALK) are promising therapeutic targets for cancer and other human diseases, esp. for non-small cell lung cancer (NSCLC) and anaplastic large-cell lymphomas (ALCLs).  We described herein a structure-based design, synthesis, and evaluation of ALK PROTACs (proteolysis-targeting chimeras) based on Alectinib as the warhead.  We firstly screened CRBN ligands as the E3 ligase moiety, then obtained a series of potent ALK degraders based on different CRBN ligands, exemplified by SIAIS091 and SIAIS001 with lenalidomide/thalidomide-based linkers.  Both of them induced effective ALK degrdn. at low nanomolar concns. in cells, and showed much better growth inhibition effects than Alectinib.  SIAIS091 or SIAIS001 also promoted cell cycle arrest in G1/S phase.  Finally, SIAIS001 exhibited good oral bioavailability in Pharmacokinetics study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZW4fwPhRGNLVg90H21EOLACvtfcHk0lhvdBVYEXVXAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXnt1Ohsrs%253D&md5=b1dc676e47efb1fdf8e9fb50cafec635</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2021.113335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2021.113335%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DN.%26aulast%3DKong%26aufirst%3DY.%26aulast%3DQu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DZhong%26aufirst%3DH.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DB.%26atitle%3DStructure-based%2520discovery%2520of%2520SIAIS001%2520as%2520an%2520oral%2520bioavailability%2520ALK%2520degrader%2520constructed%2520from%2520Alectinib%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D217%26spage%3D113335%26doi%3D10.1016%2Fj.ejmech.2021.113335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span>; <span class="NLM_string-name">Jiang, B.</span>; <span class="NLM_string-name">Song, X.</span>; <span class="NLM_string-name">Lin, H.</span>; <span class="NLM_string-name">Sun, N.</span>; <span class="NLM_string-name">Chen, J.</span>; <span class="NLM_string-name">Qiu, X.</span>; <span class="NLM_string-name">Ren, C.</span>; <span class="NLM_string-name">Kong, Y.</span></span> <span> </span><span class="NLM_article-title">ALK protein degradation agent and anti-tumor application thereof</span>. U.S. Patent <span class="NLM_patent">20200306273A1</span>, December 12, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=X.+Yang&author=B.+Jiang&author=X.+Song&author=H.+Lin&author=N.+Sun&author=J.+Chen&author=X.+Qiu&author=C.+Ren&author=Y.+Kong&title=ALK+protein+degradation+agent+and+anti-tumor+application+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.%26atitle%3DALK%2520protein%2520degradation%2520agent%2520and%2520anti-tumor%2520application%2520thereof%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cantrill, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaturvedi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rynn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrig Schaffland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittwer, M. B.</span></span> <span> </span><span class="NLM_article-title">Fundamental aspects of DMPK optimization of targeted protein degraders</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">969</span>– <span class="NLM_lpage">982</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2020.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.drudis.2020.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=32298797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntFGht7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&pages=969-982&author=C.+Cantrillauthor=P.+Chaturvediauthor=C.+Rynnauthor=J.+Petrig+Schafflandauthor=I.+Walterauthor=M.+B.+Wittwer&title=Fundamental+aspects+of+DMPK+optimization+of+targeted+protein+degraders&doi=10.1016%2Fj.drudis.2020.03.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Fundamental aspects of DMPK optimization of targeted protein degraders</span></div><div class="casAuthors">Cantrill, Carina; Chaturvedi, Prasoon; Rynn, Caroline; Petrig Schaffland, Jeannine; Walter, Isabelle; Wittwer, Matthias B.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">969-982</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Targeted protein degraders are an emerging modality.  Their properties fall outside the traditional small-mol. property space and are in the 'beyond rule of 5' space.  Consequently, drug discovery programs focused on developing orally bioavailable degraders are expected to face complex drug metab. and pharmacokinetics (DMPK) challenges compared with traditional small mols.  Nevertheless, little information is available on the DMPK optimization of oral degraders.  Therefore, in this review, we discuss our experience of these DMPK optimization challenges and present methodologies and strategies to overcome the hurdles dealing with this new small-mol. modality, specifically in developing oral degraders to treat cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoz2WUoP7TUvbVg90H21EOLACvtfcHk0lhvdBVYEXVXAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntFGht7s%253D&md5=465ad2dab5183e0f229aeec7e57e396a</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2020.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2020.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DCantrill%26aufirst%3DC.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DRynn%26aufirst%3DC.%26aulast%3DPetrig%2BSchaffland%26aufirst%3DJ.%26aulast%3DWalter%26aufirst%3DI.%26aulast%3DWittwer%26aufirst%3DM.%2BB.%26atitle%3DFundamental%2520aspects%2520of%2520DMPK%2520optimization%2520of%2520targeted%2520protein%2520degraders%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2020%26volume%3D25%26spage%3D969%26epage%3D982%26doi%3D10.1016%2Fj.drudis.2020.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiroshima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukami, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oikawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, Y.</span></span> <span> </span><span class="NLM_article-title">CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">679</span>– <span class="NLM_lpage">690</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2011.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.ccr.2011.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=21575866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFGlsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=679-690&author=H.+Sakamotoauthor=T.+Tsukaguchiauthor=S.+Hiroshimaauthor=T.+Kodamaauthor=T.+Kobayashiauthor=T.+A.+Fukamiauthor=N.+Oikawaauthor=T.+Tsukudaauthor=N.+Ishiiauthor=Y.+Aoki&title=CH5424802%2C+a+selective+ALK+inhibitor+capable+of+blocking+the+resistant+gatekeeper+mutant&doi=10.1016%2Fj.ccr.2011.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant</span></div><div class="casAuthors">Sakamoto, Hiroshi; Tsukaguchi, Toshiyuki; Hiroshima, Sayuri; Kodama, Tatsushi; Kobayashi, Takamitsu; Fukami, Takaaki A.; Oikawa, Nobuhiro; Tsukuda, Takuo; Ishii, Nobuya; Aoki, Yuko</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">679-690</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a tyrosine kinase that is constitutively activated in certain cancers, following gene alterations such as chromosomal translocation, amplification, or point mutation.  Here, the authors identified CH5424802, a potent, selective, and orally available ALK inhibitor with a unique chem. scaffold, showing preferential antitumor activity against cancers with gene alterations of ALK, such as non-small cell lung cancer (NSCLC) cells expressing EML4-ALK fusion and anaplastic large-cell lymphoma (ALCL) cells expressing NPM-ALK fusion in vitro and in vivo.  CH5424802 inhibited ALK L1196M, which corresponds to the gatekeeper mutation conferring common resistance to kinase inhibitors, and blocked EML4-ALK L1196M-driven cell growth.  The authors' results support the potential for clin. evaluation of CH5424802 for the treatment of patients with ALK-driven tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrk3zvzF9p67Vg90H21EOLACvtfcHk0lhvdBVYEXVXAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFGlsL8%253D&md5=cae32f3a3647926ba835293b68e776f8</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2011.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2011.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DHiroshima%26aufirst%3DS.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DFukami%26aufirst%3DT.%2BA.%26aulast%3DOikawa%26aufirst%3DN.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DAoki%26aufirst%3DY.%26atitle%3DCH5424802%252C%2520a%2520selective%2520ALK%2520inhibitor%2520capable%2520of%2520blocking%2520the%2520resistant%2520gatekeeper%2520mutant%26jtitle%3DCancer%2520Cell%26date%3D2011%26volume%3D19%26spage%3D679%26epage%3D690%26doi%3D10.1016%2Fj.ccr.2011.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Petris, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlesi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govindan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dingemans, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lena, H.</span></span> <span> </span><span class="NLM_article-title">Pooled systemic efficacy and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1552</span>– <span class="NLM_lpage">1560</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2017.06.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.jtho.2017.06.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=28689043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A280%3ADC%252BC1cjlslSnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1552-1560&author=J.+C.+H.+Yangauthor=S.+H.+I.+Ouauthor=L.+De+Petrisauthor=S.+Gadgeelauthor=L.+Gandhiauthor=D.+W.+Kimauthor=F.+Barlesiauthor=R.+Govindanauthor=A.+C.+Dingemansauthor=L.+Crinoauthor=H.+Lena&title=Pooled+systemic+efficacy+and+safety+data+from+the+pivotal+phase+II+studies+%28NP28673+and+NP28761%29+of+alectinib+in+ALK-positive+non-small+cell+lung+cancer&doi=10.1016%2Fj.jtho.2017.06.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Yang James Chih-Hsin; Ou Sai-Hong Ignatius; De Petris Luigi; Gadgeel Shirish; Gandhi Leena; Kim Dong-Wan; Barlesi Fabrice; Govindan Ramaswamy; Dingemans Anne-Marie C; Crino Lucio; Lena Herve; Popat Sanjay; Ahn Jin Seok; Dansin Eric; Golding Sophie; Bordogna Walter; Balas Bogdana; Zeaiter Ali; Morcos Peter N; Shaw Alice T</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1552-1560</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Alectinib demonstrated clinical efficacy and an acceptable safety profile in two phase II studies (NP28761 and NP28673).  Here we report the pooled efficacy and safety data after 15 and 18 months more follow-up than in the respective primary analyses.  METHODS:  Enrolled patients had ALK receptor tyrosine kinase gene (ALK)-positive NSCLC and had progressed while taking, or could not tolerate, crizotinib.  Patients received oral alectinib, 600 mg twice daily.  The primary end point in both studies was objective response rate assessed by an independent review committee (IRC) using the Response Evaluation Criteria in Solid Tumors, version 1.1.  Secondary end points included disease control rate, duration of response, progression-free survival, overall survival, and safety.  RESULTS:  The pooled data set included 225 patients (n = 138 in NP28673 and n = 87 in NP28761).  The response-evaluable population included 189 patients (84% [n = 122 in NP28673 and n = 67 in NP28761]).  In the response-evaluable population, objective response rate as assessed by the IRC was 51.3% (95% confidence interval [CI]: 44.0-58.6 [all PRs]), the disease control rate was 78.8% (95% CI: 72.3-84.4), and the median duration of response was 14.9 months (95% CI: 11.1-20.4) after 58% of events.  Median progression-free survival as assessed by the IRC was 8.3 months (95% CI: 7.0-11.3) and median overall survival was 26.0 months (95% CI: 21.4-not estimable).  Grade 3 or higher adverse events (AEs) occurred in 40% of patients, 6% of patients had treatment withdrawn on account of AEs, and 33% had AEs leading to dose interruptions/modification.  CONCLUSIONS:  This pooled data analysis confirmed the robust systemic efficacy of alectinib in ALK-positive NSCLC with a durable response rate.  Alectinib also had an acceptable safety profile with a longer duration of follow-up.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKYNXogQ0TxJHZzFRCXxVKfW6udTcc2ebAsKf5bsl-rbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjlslSnug%253D%253D&md5=6e811162d59e5c66ce21ceef64479b02</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2017.06.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2017.06.070%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%2BC.%2BH.%26aulast%3DOu%26aufirst%3DS.%2BH.%2BI.%26aulast%3DDe%2BPetris%26aufirst%3DL.%26aulast%3DGadgeel%26aufirst%3DS.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DBarlesi%26aufirst%3DF.%26aulast%3DGovindan%26aufirst%3DR.%26aulast%3DDingemans%26aufirst%3DA.%2BC.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DLena%26aufirst%3DH.%26atitle%3DPooled%2520systemic%2520efficacy%2520and%2520safety%2520data%2520from%2520the%2520pivotal%2520phase%2520II%2520studies%2520%2528NP28673%2520and%2520NP28761%2529%2520of%2520alectinib%2520in%2520ALK-positive%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2017%26volume%3D12%26spage%3D1552%26epage%3D1560%26doi%3D10.1016%2Fj.jtho.2017.06.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérol, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dziadziuszko, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeaiter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitry, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morcos, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T.</span></span> <span> </span><span class="NLM_article-title">Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">829</span>– <span class="NLM_lpage">838</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1704795</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1056%2FNEJMoa1704795" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=28586279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFSju7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=829-838&author=S.+Petersauthor=D.+R.+Camidgeauthor=A.+T.+Shawauthor=S.+Gadgeelauthor=J.+S.+Ahnauthor=D.+W.+Kimauthor=S.+I.+Ouauthor=M.+P%C3%A9rolauthor=R.+Dziadziuszkoauthor=R.+Rosellauthor=A.+Zeaiterauthor=E.+Mitryauthor=S.+Goldingauthor=B.+Balasauthor=J.+Noeauthor=P.+N.+Morcosauthor=T.+Mok&title=Alectinib+versus+crizotinib+in+untreated+ALK-positive+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa1704795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer</span></div><div class="casAuthors">Peters, Solange; Camidge, D. Ross; Shaw, Alice T.; Gadgeel, Shirish; Ahn, Jin S.; Kim, Dong-Wan; Ou, Sai-Hong I.; Perol, Maurice; Dziadziuszko, Rafal; Rosell, Rafael; Zeaiter, Ali; Mitry, Emmanuel; Golding, Sophie; Balas, Bogdana; Noe, Johannes; Morcos, Peter N.; Mok, Tony</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">829-838</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-pos. non-small-cell lung cancer (NSCLC).  We investigated alectinib as compared with crizotinib in patients with previously untreated, advanced ALK-pos. NSCLC, including those with asymptomatic CNS disease.  METHODS: In a randomized, open-label, phase 3 trial, we randomly assigned 303 patients with previously untreated, advanced ALK-pos. NSCLC to receive either alectinib (600 mg twice daily) or crizotinib (250 mg twice daily).  The primary end point was investigator assessed progression-free survival.  Secondary end points were independent review committee-assessed progression-free survival, time to CNS progression, objective response rate, and overall survival.  RESULTS: During a median follow-up of 17.6 mo (crizotinib) and 18.6 mo (alectinib), an event of disease progression or death occurred in 62 of 152 patients (41%) in the alectinib group and 102 of 151 patients (68%) in the crizotinib group.  The rate of investigator- assessed progression-free survival was significantly higher with alectinib than with crizotinib (12-mo event-free survival rate, 68.4% [95% confidence interval (CI), 61.0 to 75.9] with alectinib vs. 48.7% [95% CI, 40.4 to 56.9] with crizotinib; hazard ratio for disease progression or death, 0.47 [95% CI, 0.34 to 0.65]; P<0.001); the median progression-free survival with alectinib was not reached.  The results for independent review committee-assessed progression-free survival were consistent with those for the primary end point.  A total of 18 patients (12%) in the alectinib group had an event of CNS progression, as compared with 68 patients (45%) in the crizotinib group (cause-specific hazard ratio, 0.16; 95% CI, 0.10 to 0.28; P<0.001).  A response occurred in 126 patients in the alectinib group (response rate, 82.9%; 95% CI, 76.0 to 88.5) and in 114 patients in the crizotinib group (response rate, 75.5%; 95% CI, 67.8 to 82.1) (P = 0.09).  Grade 3 to 5 adverse events were less frequent with alectinib (41% vs. 50% with crizotinib).  CONCLUSIONS: As compared with crizotinib, alectinib showed superior efficacy and lower toxicity in primary treatment of ALK-pos. NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxaWsEV8z16LVg90H21EOLACvtfcHk0liLdkPh3BOveA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFSju7nL&md5=cb58ab7eb5b266a3d292eb714a1c8104</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1704795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1704795%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DS.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DGadgeel%26aufirst%3DS.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DOu%26aufirst%3DS.%2BI.%26aulast%3DP%25C3%25A9rol%26aufirst%3DM.%26aulast%3DDziadziuszko%26aufirst%3DR.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DZeaiter%26aufirst%3DA.%26aulast%3DMitry%26aufirst%3DE.%26aulast%3DGolding%26aufirst%3DS.%26aulast%3DBalas%26aufirst%3DB.%26aulast%3DNoe%26aufirst%3DJ.%26aulast%3DMorcos%26aufirst%3DP.%2BN.%26aulast%3DMok%26aufirst%3DT.%26atitle%3DAlectinib%2520versus%2520crizotinib%2520in%2520untreated%2520ALK-positive%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26spage%3D829%26epage%3D838%26doi%3D10.1056%2FNEJMoa1704795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenfeld, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeap, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxena, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferris, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dagogo-Jack, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farago, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menon, S.</span></span> <span> </span><span class="NLM_article-title">Brigatinib in patients with alectinib-refractory ALK-positive NSCLC</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1530</span>– <span class="NLM_lpage">1538</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2018.06.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.jtho.2018.06.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=29935304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FhtVyqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=1530-1538&author=J.+J.+Linauthor=V.+W.+Zhuauthor=A.+J.+Schoenfeldauthor=B.+Y.+Yeapauthor=A.+Saxenaauthor=L.+A.+Ferrisauthor=I.+Dagogo-Jackauthor=A.+F.+Faragoauthor=A.+Taberauthor=A.+Traynorauthor=S.+Menon&title=Brigatinib+in+patients+with+alectinib-refractory+ALK-positive+NSCLC&doi=10.1016%2Fj.jtho.2018.06.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC</span></div><div class="casAuthors">Lin Jessica J; Yeap Beow Y; Ferris Lorin A; Dagogo-Jack Ibiayi; Farago Anna F; Gainor Justin F; Zhu Viola W; Ou Sai-Hong Ignatius; Schoenfeld Adam J; Riely Gregory J; Saxena Ashish; Taber Angela; Traynor Anne; Menon Smitha; Lennerz Jochen K; Plodkowski Andrew J; Digumarthy Subba R; Shaw Alice T</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1530-1538</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  The second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib recently showed superior efficacy compared to the first-generation ALK inhibitor crizotinib in advanced ALK-rearranged NSCLC, establishing alectinib as the new standard first-line therapy.  Brigatinib, another second-generation ALK inhibitor, has shown substantial activity in patients with crizotinib-refractory ALK-positive NSCLC; however, its activity in the alectinib-refractory setting is unknown.  METHODS:  A multicenter, retrospective study was performed at three institutions.  Patients were eligible if they had advanced, alectinib-refractory ALK-positive NSCLC and were treated with brigatinib.  Medical records were reviewed to determine clinical outcomes.  RESULTS:  Twenty-two patients were eligible for this study.  Confirmed objective responses to brigatinib were observed in 3 of 18 patients (17%) with measurable disease.  Nine patients (50%) had stable disease on brigatinib.  The median progression-free survival was 4.4 months (95% confidence interval [CI]: 1.8-5.6 months) with a median duration of treatment of 5.7 months (95% CI: 1.8-6.2 months).  Among 9 patients in this study who underwent post-alectinib/pre-brigatinib biopsies, 5 had an ALK I1171X or V1180L resistance mutation; of these, 1 had a confirmed partial response and 3 had stable disease on brigatinib.  One patient had an ALK G1202R mutation in a post-alectinib/pre-brigatinib biopsy, and had progressive disease as the best overall response to brigatinib.  CONCLUSIONS:  Brigatinib has limited clinical activity in alectinib-refractory ALK-positive NSCLC.  Additional studies are needed to establish biomarkers of response to brigatinib and to identify effective therapeutic options for alectinib-resistant ALK-positive NSCLC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcToxDZT6xxkHOqrn-c4Of3KfW6udTcc2ebAsKf5bsl-rbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FhtVyqsA%253D%253D&md5=b2a4492952ebf6efe058e51e342e9fcd</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2018.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2018.06.005%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DJ.%2BJ.%26aulast%3DZhu%26aufirst%3DV.%2BW.%26aulast%3DSchoenfeld%26aufirst%3DA.%2BJ.%26aulast%3DYeap%26aufirst%3DB.%2BY.%26aulast%3DSaxena%26aufirst%3DA.%26aulast%3DFerris%26aufirst%3DL.%2BA.%26aulast%3DDagogo-Jack%26aufirst%3DI.%26aulast%3DFarago%26aufirst%3DA.%2BF.%26aulast%3DTaber%26aufirst%3DA.%26aulast%3DTraynor%26aufirst%3DA.%26aulast%3DMenon%26aufirst%3DS.%26atitle%3DBrigatinib%2520in%2520patients%2520with%2520alectinib-refractory%2520ALK-positive%2520NSCLC%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2018%26volume%3D13%26spage%3D1530%26epage%3D1538%26doi%3D10.1016%2Fj.jtho.2018.06.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dardaei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friboulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leshchiner, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dagogo-Jack, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, E.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1118</span>– <span class="NLM_lpage">1133</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-16-0596</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1158%2F2159-8290.CD-16-0596" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=27432227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1OhurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=1118-1133&author=J.+F.+Gainorauthor=L.+Dardaeiauthor=S.+Yodaauthor=L.+Fribouletauthor=I.+Leshchinerauthor=R.+Katayamaauthor=I.+Dagogo-Jackauthor=S.+Gadgeelauthor=K.+Schultzauthor=M.+Singhauthor=E.+Chin&title=Molecular+mechanisms+of+resistance+to+first-+and+second-generation+ALK+inhibitors+in+ALK-rearranged+lung+cancer&doi=10.1158%2F2159-8290.CD-16-0596"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer</span></div><div class="casAuthors">Gainor, Justin F.; Dardaei, Leila; Yoda, Satoshi; Friboulet, Luc; Leshchiner, Ignaty; Katayama, Ryohei; Dagogo-Jack, Ibiayi; Gadgeel, Shirish; Schultz, Katherine; Singh, Manrose; Chin, Emily; Parks, Melissa; Lee, Dana; DiCecca, Richard H.; Lockerman, Elizabeth; Huynh, Tiffany; Logan, Jennifer; Ritterhouse, Lauren L.; Le, Long P.; Muniappan, Ashok; Digumarthy, Subba; Channick, Colleen; Keyes, Colleen; Getz, Gad; Dias-Santagata, Dora; Heist, Rebecca S.; Lennerz, Jochen; Sequist, Lecia V.; Benes, Cyril H.; Iafrate, A. John; Mino-Kenudson, Mari; Engelman, Jeffrey A.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1118-1133</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Advanced, anaplastic lymphoma kinase (ALK)-pos. lung cancer is currently treated with the first-generation ALK inhibitor crizotinib followed by more potent, second-generation ALK inhibitors (e.g., ceritinib and alectinib) upon progression.  Second-generation inhibitors are generally effective even in the absence of crizotinib-resistant ALK mutations, likely reflecting incomplete inhibition of ALK by crizotinib in many cases.  Herein, we analyzed 103 repeat biopsies from ALK-pos. patients progressing on various ALK inhibitors.  We find that each ALK inhibitor is assocd. with a distinct spectrum of ALK resistance mutations and that the frequency of one mutation, ALKG1202R, increases significantly after treatment with second-generation agents.  To investigate strategies to overcome resistance to second-generation ALK inhibitors, we examine the activity of the third-generation ALK inhibitor lorlatinib in a series of ceritinib-resistant, patient-derived cell lines, and observe that the presence of ALK resistance mutations is highly predictive for sensitivity to lorlatinib, whereas those cell lines without ALK mutations are resistant.  Significance: Secondary ALK mutations are a common resistance mechanism to second-generation ALK inhibitors and predict for sensitivity to the third-generation ALK inhibitor lorlatinib.  These findings highlight the importance of repeat biopsies and genotyping following disease progression on targeted therapies, particularly second-generation ALK inhibitors.  Cancer Discov; 6(10); 1118-33. ©2016 AACR.  See related commentary by Qiao and Lovly, p. 1084.  This article is highlighted in the In This Issue feature, p.  1069.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg_wNC_RoH0LVg90H21EOLACvtfcHk0lha81KENDFr_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1OhurrJ&md5=e68f42dbce3f4f4de0c6d9c64f6b7b82</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-16-0596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-16-0596%26sid%3Dliteratum%253Aachs%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DDardaei%26aufirst%3DL.%26aulast%3DYoda%26aufirst%3DS.%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DLeshchiner%26aufirst%3DI.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DDagogo-Jack%26aufirst%3DI.%26aulast%3DGadgeel%26aufirst%3DS.%26aulast%3DSchultz%26aufirst%3DK.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DChin%26aufirst%3DE.%26atitle%3DMolecular%2520mechanisms%2520of%2520resistance%2520to%2520first-%2520and%2520second-generation%2520ALK%2520inhibitors%2520in%2520ALK-rearranged%2520lung%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2016%26volume%3D6%26spage%3D1118%26epage%3D1133%26doi%3D10.1158%2F2159-8290.CD-16-0596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pirker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filipits, M.</span></span> <span> </span><span class="NLM_article-title">From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer</span>. <i>ESMO open</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e000548</span> <span class="refDoi"> DOI: 10.1136/esmoopen-2019-000548</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1136%2Fesmoopen-2019-000548" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=31555485" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&author=R.+Pirkerauthor=M.+Filipits&title=From+crizotinib+to+lorlatinib%3A+continuous+improvement+in+precision+treatment+of+ALK-positive+non-small+cell+lung+cancer&doi=10.1136%2Fesmoopen-2019-000548"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1136%2Fesmoopen-2019-000548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fesmoopen-2019-000548%26sid%3Dliteratum%253Aachs%26aulast%3DPirker%26aufirst%3DR.%26aulast%3DFilipits%26aufirst%3DM.%26atitle%3DFrom%2520crizotinib%2520to%2520lorlatinib%253A%2520continuous%2520improvement%2520in%2520precision%2520treatment%2520of%2520ALK-positive%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DESMO%2520open%26date%3D2019%26volume%3D4%26doi%3D10.1136%2Fesmoopen-2019-000548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, D. S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz-Ares, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geater, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortinovis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochmair, M.</span></span> <span> </span><span class="NLM_article-title">First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>389</i></span>,  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">929</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(17)30123-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2FS0140-6736%2817%2930123-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=28126333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFGku7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=2017&pages=917-929&author=J.+C.+Soriaauthor=D.+S.+W.+Tanauthor=R.+Chiariauthor=Y.+L.+Wuauthor=L.+Paz-Aresauthor=J.+Wolfauthor=S.+L.+Geaterauthor=S.+Orlovauthor=D.+Cortinovisauthor=C.+J.+Yuauthor=M.+Hochmair&title=First-line+ceritinib+versus+platinum-based+chemotherapy+in+advanced+ALK-rearranged+non-small-cell+lung+cancer+%28ASCEND-4%29%3A+a+randomised%2C+open-label%2C+phase+3+study&doi=10.1016%2FS0140-6736%2817%2930123-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study</span></div><div class="casAuthors">Soria, Jean-Charles; Tan, Daniel S. W.; Chiari, Rita; Wu, Yi-Long; Paz-Ares, Luis; Wolf, Juergen; Geater, Sarayut L.; Orlov, Sergey; Cortinovis, Diego; Yu, Chong-Jen; Hochmair, Maximillian; Cortot, Alexis B.; Tsai, Chun-Ming; Moro-Sibilot, Denis; Campelo, Rosario G.; McCulloch, Tracey; Sen, Paramita; Dugan, Margaret; Pantano, Serafino; Branle, Fabrice; Massacesi, Cristian; de Castro, Gilberto, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">389</span>
        (<span class="NLM_cas:issue">10072</span>),
    <span class="NLM_cas:pages">917-929</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The efficacy of ceritinib in patients with untreated anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC) is not known.  We assessed the efficacy and safety of ceritinib vs. platinum-based chemotherapy in these patients.  This randomised, open-label, phase 3 study in untreated patients with stage IIIB/IV ALK-rearranged non-squamous NSCLC was done in 134 centers across 28 countries.  Eligible patients were assigned via interactive response technol. to oral ceritinib 750 mg/day or platinum-based chemotherapy ([cisplatin 75 mg/m2 or carboplatin AUC 5-6 plus pemetrexed 500 mg/m2] every 3 wk for four cycles followed by maintenance pemetrexed); randomization was stratified by World Health Organization performance status (0 vs 1-2), previous neoadjuvant or adjuvant chemotherapy, and presence of brain metastases as per investigator's assessment at screening.  Investigators and patients were not masked to treatment assignment.  The primary endpoint was blinded independent review committee assessed progression-free survival, based on all randomly assigned patients (the full anal. set).  Efficacy analyses were done based on the full anal. set.  All safety analyses were done based on the safety set, which included all patients who received at least one dose of study drug.  This trial is registered with ClinicalTrials.gov, no. NCT01828099.  Between Aug 19, 2013, and May 11, 2015, 376 patients were randomly assigned to ceritinib (n=189) or chemotherapy (n=187).  Median progression-free survival (as assessed by blinded independent review committee) was 16·6 mo (95% CI 12·6-27·2) in the ceritinib group and 8·1 mo (5·8-11·1) in the chemotherapy group (hazard ratio 0·55 [95% CI 0·42-0·73]; p<0·00001).  The most common adverse events were diarrhoea (in 160 [85%] of 189 patients), nausea (130 [69%]), vomiting (125 [66%]), and an increase in alanine aminotransferase (114 [60%]) in the ceritinib group and nausea (in 97 [55%] of 175 patients), vomiting (63 [36%]), and anemia (62 [35%]) in the chemotherapy group.  First-line ceritinib showed a statistically significant and clin. meaningful improvement in progression-free survival vs. chemotherapy in patients with advanced ALK-rearranged NSCLC.  Novartis Pharmaceuticals Corporation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdGKYa204H9rVg90H21EOLACvtfcHk0lha81KENDFr_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFGku7Y%253D&md5=a51029d59399ff42f840ffc1b2b5caf7</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2817%2930123-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252817%252930123-X%26sid%3Dliteratum%253Aachs%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DTan%26aufirst%3DD.%2BS.%2BW.%26aulast%3DChiari%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DPaz-Ares%26aufirst%3DL.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DGeater%26aufirst%3DS.%2BL.%26aulast%3DOrlov%26aufirst%3DS.%26aulast%3DCortinovis%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DC.%2BJ.%26aulast%3DHochmair%26aufirst%3DM.%26atitle%3DFirst-line%2520ceritinib%2520versus%2520platinum-based%2520chemotherapy%2520in%2520advanced%2520ALK-rearranged%2520non-small-cell%2520lung%2520cancer%2520%2528ASCEND-4%2529%253A%2520a%2520randomised%252C%2520open-label%252C%2520phase%25203%2520study%26jtitle%3DLancet%26date%3D2017%26volume%3D389%26spage%3D917%26epage%3D929%26doi%3D10.1016%2FS0140-6736%2817%2930123-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veber, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopple, K. D.</span></span> <span> </span><span class="NLM_article-title">Molecular properties that influence the oral bioavailability of drug candidates</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">2615</span>– <span class="NLM_lpage">2623</span>, <span class="refDoi"> DOI: 10.1021/jm020017n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020017n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=2615-2623&author=D.+F.+Veberauthor=S.+R.+Johnsonauthor=H.+Y.+Chengauthor=B.+R.+Smithauthor=K.+W.+Wardauthor=K.+D.+Kopple&title=Molecular+properties+that+influence+the+oral+bioavailability+of+drug+candidates&doi=10.1021%2Fjm020017n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Properties That Influence the Oral Bioavailability of Drug Candidates</span></div><div class="casAuthors">Veber, Daniel F.; Johnson, Stephen R.; Cheng, Hung-Yuan; Smith, Brian R.; Ward, Keith W.; Kopple, Kenneth D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2615-2623</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oral bioavailability measurements in rats for over 1100 drug candidates studied at Smith-Kline Beecham Pharmaceuticals (now Glaxo Smith-Kline) have allowed us to analyze the relative importance of mol. properties considered to influence that drug property.  Reduced mol. flexibility, as measured by the no. of rotatable bonds, and low polar surface area or total hydrogen bond count (sum of donors and acceptors) are found to be important predictors of good oral bioavailability, independent of mol. wt.  That on av. both the no. of rotatable bonds and polar surface area or hydrogen bond count tend to increase with mol. wt. may in part explain the success of the mol. wt. parameter in predicting oral bioavailability.  The commonly applied mol. wt. cutoff at 500 does not itself significantly sep. compds. with poor oral bioavailability from those with acceptable values in this extensive data set.  Our observations suggest that compds. which meet only the 2 criteria of (1) 10 or fewer rotatable bonds and (2) polar surface area ≤140 Å2 (or 12 or fewer H-bond donors and acceptors) will have a high probability of good oral bioavailability in the rat.  Data sets for the artificial membrane permeation rate and for clearance in the rat were also examd.  Reduced polar surface area correlates better with increased permeation rate than does lipophilicity (C log P), and increased rotatable bond count has a neg. effect on the permeation rate.  A threshold permeation rate is a prerequisite of oral bioavailability.  The rotatable bond count does not correlate with the data examd. here for the in vivo clearance rate in the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3JtJEkO7yVLVg90H21EOLACvtfcHk0lg08JxPAFCQCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D&md5=eaad26ed6a259de82ad65a8834fc397d</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjm020017n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020017n%26sid%3Dliteratum%253Aachs%26aulast%3DVeber%26aufirst%3DD.%2BF.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DCheng%26aufirst%3DH.%2BY.%26aulast%3DSmith%26aufirst%3DB.%2BR.%26aulast%3DWard%26aufirst%3DK.%2BW.%26aulast%3DKopple%26aufirst%3DK.%2BD.%26atitle%3DMolecular%2520properties%2520that%2520influence%2520the%2520oral%2520bioavailability%2520of%2520drug%2520candidates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D2615%26epage%3D2623%26doi%3D10.1021%2Fjm020017n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goracci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desantis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valeri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eleuteri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruciani, G.</span></span> <span> </span><span class="NLM_article-title">Understanding the metabolism of proteolysis targeting chimeras (PROTACs): the next step toward pharmaceutical applications</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">11615</span>– <span class="NLM_lpage">11638</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00793</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00793" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvF2htrvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=11615-11638&author=L.+Goracciauthor=J.+Desantisauthor=A.+Valeriauthor=B.+Castellaniauthor=M.+Eleuteriauthor=G.+Cruciani&title=Understanding+the+metabolism+of+proteolysis+targeting+chimeras+%28PROTACs%29%3A+the+next+step+toward+pharmaceutical+applications&doi=10.1021%2Facs.jmedchem.0c00793"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding the Metabolism of Proteolysis Targeting Chimeras (PROTACs): The Next Step toward Pharmaceutical Applications</span></div><div class="casAuthors">Goracci, Laura; Desantis, Jenny; Valeri, Aurora; Castellani, Beatrice; Eleuteri, Michela; Cruciani, Gabriele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">11615-11638</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hetero-bifunctional PROteolysis TArgeting Chimeras (PROTACs) represent a new emerging class of small mols. designed to induce polyubiquitylation and proteasomal-dependent degrdn. of a target protein.  Despite the increasing no. of publications about the synthesis, biol. evaluation, and mechanism of action of PROTACs, the characterization of the pharmacokinetic properties of this class of compds. is still minimal.  Here, we report a study on the metab. of a series of 40 PROTACs in cryopreserved human hepatocytes at multiple time points.  Our results indicated that the metab. of PROTACs could not be predicted from that of their constituent ligands.  Their linkers' chem. nature and length resulted in playing a major role in the PROTACs' liability.  A subset of compds. was also tested for metab. by human cytochrome P 450 3A4 (CYP3A4) and human aldehyde oxidase (hAOX) for more in-depth data interpretation, and both enzymes resulted in active PROTAC metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx6vgKrJPXdbVg90H21EOLACvtfcHk0lg08JxPAFCQCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvF2htrvN&md5=2423ce1317b64dae6dc7a9f5d19ce265</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00793%26sid%3Dliteratum%253Aachs%26aulast%3DGoracci%26aufirst%3DL.%26aulast%3DDesantis%26aufirst%3DJ.%26aulast%3DValeri%26aufirst%3DA.%26aulast%3DCastellani%26aufirst%3DB.%26aulast%3DEleuteri%26aufirst%3DM.%26aulast%3DCruciani%26aufirst%3DG.%26atitle%3DUnderstanding%2520the%2520metabolism%2520of%2520proteolysis%2520targeting%2520chimeras%2520%2528PROTACs%2529%253A%2520the%2520next%2520step%2520toward%2520pharmaceutical%2520applications%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D11615%26epage%3D11638%26doi%3D10.1021%2Facs.jmedchem.0c00793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pike, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harlfinger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGinnity, D. F.</span></span> <span> </span><span class="NLM_article-title">Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1793</span>– <span class="NLM_lpage">1800</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2020.07.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.drudis.2020.07.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVeru7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&pages=1793-1800&author=A.+Pikeauthor=B.+Williamsonauthor=S.+Harlfingerauthor=S.+Martinauthor=D.+F.+McGinnity&title=Optimising+proteolysis-targeting+chimeras+%28PROTACs%29+for+oral+drug+delivery%3A+a+drug+metabolism+and+pharmacokinetics+perspective&doi=10.1016%2Fj.drudis.2020.07.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective</span></div><div class="casAuthors">Pike, Andy; Williamson, Beth; Harlfinger, Stephanie; Martin, Scott; McGinnity, Dermot F.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1793-1800</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Proteolysis-targeting chimeras (PROTACs) are an emerging therapeutic modality with the potential to open target space not accessible to conventional small mols. via a degrdn.-based mechanism; however, their bifunctional nature can result in physicochem. properties that breach commonly accepted limits for small-mol. oral drugs.  We offer a drug metab. and pharmacokinetics (DMPK) perspective on the optimization of oral PROTACs across a diverse set of projects within Oncol. R&D at AstraZeneca, highlighting some of the challenges that they have presented to our established screening cascade.  Furthermore, we challenge some of the perceptions and dogma surrounding the feasibility of oral PROTACS and demonstrate that acceptable oral PK properties for this modality can be regularly achievable despite the physicochem. property challenges they present.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNes0zq6ODubVg90H21EOLACvtfcHk0lg08JxPAFCQCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVeru7zF&md5=a26048e1fe2eb5f9e134a9132593df23</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2020.07.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2020.07.013%26sid%3Dliteratum%253Aachs%26aulast%3DPike%26aufirst%3DA.%26aulast%3DWilliamson%26aufirst%3DB.%26aulast%3DHarlfinger%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DMcGinnity%26aufirst%3DD.%2BF.%26atitle%3DOptimising%2520proteolysis-targeting%2520chimeras%2520%2528PROTACs%2529%2520for%2520oral%2520drug%2520delivery%253A%2520a%2520drug%2520metabolism%2520and%2520pharmacokinetics%2520perspective%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2020%26volume%3D25%26spage%3D1793%26epage%3D1800%26doi%3D10.1016%2Fj.drudis.2020.07.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, T. P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayle, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirza, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willems, H. M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skidmore, J.</span></span> <span> </span><span class="NLM_article-title">Systematic investigation of the permeability of androgen receptor PROTACs</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1539</span>– <span class="NLM_lpage">1547</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00194</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00194" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFWmt7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1539-1547&author=D.+E.+Scottauthor=T.+P.+C.+Rooneyauthor=E.+D.+Bayleauthor=T.+Mirzaauthor=H.+M.+G.+Willemsauthor=J.+H.+Clarkeauthor=S.+P.+Andrewsauthor=J.+Skidmore&title=Systematic+investigation+of+the+permeability+of+androgen+receptor+PROTACs&doi=10.1021%2Facsmedchemlett.0c00194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Systematic Investigation of the Permeability of Androgen Receptor PROTACs</span></div><div class="casAuthors">Scott, Duncan E.; Rooney, Timothy P. C.; Bayle, Elliott D.; Mirza, Tashfina; Willems, Henriette M. G.; Clarke, Jonathan H.; Andrews, Stephen P.; Skidmore, John</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1539-1547</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bifunctional mols. known as PROTACs simultaneously bind an E3 ligase and a protein of interest to direct ubiquitination and clearance of that protein, and they have emerged in the past decade as an exciting new paradigm in drug discovery.  In order to investigate the permeability and properties of these large mols., we synthesized two panels of PROTAC mols., constructed from a range of protein-target ligands, linkers, and E3 ligase ligands.  The androgen receptor, which is a well-studied protein in the PROTAC field was used as a model system.  The physicochem. properties and permeability of PROTACs are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG6Q_chyrzDLVg90H21EOLACvtfcHk0liRK4om_AWopw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFWmt7%252FO&md5=26c8ea71901a57a09c03f7fb79bbe2c9</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00194%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DD.%2BE.%26aulast%3DRooney%26aufirst%3DT.%2BP.%2BC.%26aulast%3DBayle%26aufirst%3DE.%2BD.%26aulast%3DMirza%26aufirst%3DT.%26aulast%3DWillems%26aufirst%3DH.%2BM.%2BG.%26aulast%3DClarke%26aufirst%3DJ.%2BH.%26aulast%3DAndrews%26aufirst%3DS.%2BP.%26aulast%3DSkidmore%26aufirst%3DJ.%26atitle%3DSystematic%2520investigation%2520of%2520the%2520permeability%2520of%2520androgen%2520receptor%2520PROTACs%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D1539%26epage%3D1547%26doi%3D10.1021%2Facsmedchemlett.0c00194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Edmondson, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallan, C.</span></span> <span> </span><span class="NLM_article-title">Proteolysis targeting chimeras (PROTACs) in ’beyond rule-of-five’ chemical space: recent progress and future challenges</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1555</span>– <span class="NLM_lpage">1564</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.04.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.bmcl.2019.04.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=31047748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC1MXos12gs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=1555-1564&author=S.+D.+Edmondsonauthor=B.+Yangauthor=C.+Fallan&title=Proteolysis+targeting+chimeras+%28PROTACs%29+in+%E2%80%99beyond+rule-of-five%E2%80%99+chemical+space%3A+recent+progress+and+future+challenges&doi=10.1016%2Fj.bmcl.2019.04.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges</span></div><div class="casAuthors">Edmondson, Scott D.; Yang, Bin; Fallan, Charlene</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1555-1564</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Proteolysis targeting chimeras (PROTACs) are heterobifunctional compds. with mol. wts. and other properties that lie outside the classic 'rule-of-five' space.  Consequently, PROTACs have unique challenges assocd. with their development as potential therapeutic agents.  This review summarizes and analyzes a representative set of recent PROTACs and highlights some of the potential future challenges facing this promising modality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDcS0gIul-K7Vg90H21EOLACvtfcHk0liRK4om_AWopw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXos12gs74%253D&md5=62a74500178bd711b1ddaa33d731b960</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.04.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.04.030%26sid%3Dliteratum%253Aachs%26aulast%3DEdmondson%26aufirst%3DS.%2BD.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DFallan%26aufirst%3DC.%26atitle%3DProteolysis%2520targeting%2520chimeras%2520%2528PROTACs%2529%2520in%2520%25E2%2580%2599beyond%2520rule-of-five%25E2%2580%2599%2520chemical%2520space%253A%2520recent%2520progress%2520and%2520future%2520challenges%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D1555%26epage%3D1564%26doi%3D10.1016%2Fj.bmcl.2019.04.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Salas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przybranowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">462</span>– <span class="NLM_lpage">481</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01816</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01816" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvVajsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=462-481&author=B.+Zhouauthor=J.+Huauthor=F.+Xuauthor=Z.+Chenauthor=L.+Baiauthor=E.+Fernandez-Salasauthor=M.+Linauthor=L.+Liuauthor=C.+Y.+Yangauthor=Y.+Zhaoauthor=D.+McEachernauthor=S.+Przybranowskiauthor=B.+Wenauthor=D.+Sunauthor=S.+Wang&title=Discovery+of+a+small-molecule+degrader+of+bromodomain+and+extra-terminal+%28BET%29+proteins+with+picomolar+cellular+potencies+and+capable+of+achieving+tumor+regression&doi=10.1021%2Facs.jmedchem.6b01816"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression</span></div><div class="casAuthors">Zhou, Bing; Hu, Jiantao; Xu, Fuming; Chen, Zhuo; Bai, Longchuan; Fernandez-Salas, Ester; Lin, Mei; Liu, Liu; Yang, Chao-Yie; Zhao, Yujun; McEachern, Donna; Przybranowski, Sally; Wen, Bo; Sun, Duxin; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">462-481</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The bromodomain and extra-terminal (BET) family proteins, consisting of BRD2, BRD3, BRD4, and testis-specific BRDT members, are epigenetic "readers" and play a key role in the regulation of gene transcription.  BET proteins are considered to be attractive therapeutic targets for cancer and other human diseases.  Recently, heterobifunctional small-mol. BET degraders have been designed based upon the proteolysis targeting chimera (PROTAC) concept to induce BET protein degrdn.  Herein, we present our design, synthesis, and evaluation of a new class of PROTAC BET degraders.  One of the most promising compds., 23, effectively degrades BRD4 protein at concns. as low as 30 pM in the RS4;11 leukemia cell line, achieves an IC50 value of 51 pM in inhibition of RS4;11 cell growth and induces rapid tumor regression in vivo against RS4;11 xenograft tumors.  These data establish that compd. 23 (BETd-260/ZBC260) is a highly potent and efficacious BET degrader.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqz2Lwp52x1rVg90H21EOLACvtfcHk0liRK4om_AWopw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvVajsb8%253D&md5=6b3a10ecd192a5812ef581dca1fdc82a</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01816%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DBai%26aufirst%3DL.%26aulast%3DFernandez-Salas%26aufirst%3DE.%26aulast%3DLin%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DMcEachern%26aufirst%3DD.%26aulast%3DPrzybranowski%26aufirst%3DS.%26aulast%3DWen%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520a%2520small-molecule%2520degrader%2520of%2520bromodomain%2520and%2520extra-terminal%2520%2528BET%2529%2520proteins%2520with%2520picomolar%2520cellular%2520potencies%2520and%2520capable%2520of%2520achieving%2520tumor%2520regression%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D462%26epage%3D481%26doi%3D10.1021%2Facs.jmedchem.6b01816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and selective epidermal growth factor receptor (EGFR) bifunctional small-molecule degraders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1216</span>– <span class="NLM_lpage">1232</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01566</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01566" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFWksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=1216-1232&author=M.+Chengauthor=X.+Yuauthor=K.+Luauthor=L.+Xieauthor=L.+Wangauthor=F.+Mengauthor=X.+Hanauthor=X.+Chenauthor=J.+Liuauthor=Y.+Xiongauthor=J.+Jin&title=Discovery+of+potent+and+selective+epidermal+growth+factor+receptor+%28EGFR%29+bifunctional+small-molecule+degraders&doi=10.1021%2Facs.jmedchem.9b01566"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders</span></div><div class="casAuthors">Cheng, Meng; Yu, Xufen; Lu, Kaylene; Xie, Ling; Wang, Li; Meng, Fanye; Han, Xiaoran; Chen, Xian; Liu, Jing; Xiong, Yue; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1216-1232</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors have been developed and approved by Food and Drug Administration for the treatment of non-small-cell lung cancers, but their efficacy can be compromised by acquired drug resistance conferred by EGFR-mutant variants.  Here, we described the discovery of a novel E3 ligase von Hippel-Lindau-recruiting EGFR degrader, MS39 (compd. 6), and a first-in-class E3 ligase cereblon-recruiting EGFR degrader, MS154 (compd. 10), using the proteolysis targeting chimera technol.  These compds. potently induced the degrdn. of mutant but not wild-type EGFR in an E3 ligase-dependent manner in cancer cell lines and effectively suppressed the growth of lung cancer cells compared with the corresponding neg. controls.  The global proteomic analyses revealed that the compds. were highly selective for EGFR.  Furthermore, both compds. were bioavailable in mouse pharmacokinetic studies, and compd. 6 is the first EGFR degrader suitable for in vivo efficacy studies.  Overall, we provide a set of well-characterized chem. tools to the research community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraFLSjUGE-6rVg90H21EOLACvtfcHk0lgZEPosEFxDEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFWksA%253D%253D&md5=ec831897a4258f1968e254aa433426c3</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01566%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DK.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DF.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520bifunctional%2520small-molecule%2520degraders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D1216%26epage%3D1232%26doi%3D10.1021%2Facs.jmedchem.9b01566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavana, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banks, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crafter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingipalli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kouvchinov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachl, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solanki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valge-Archer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmondson, S. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of proteolysis-targeting chimera molecules that selectively degrade the IRAK3 pseudokinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">10460</span>– <span class="NLM_lpage">10473</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c01125</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01125" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1WktLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=10460-10473&author=S.+L.+Degorceauthor=O.+Tavanaauthor=E.+Banksauthor=C.+Crafterauthor=L.+Gingipalliauthor=D.+Kouvchinovauthor=Y.+Maoauthor=F.+Pachlauthor=A.+Solankiauthor=V.+Valge-Archerauthor=B.+Yangauthor=S.+D.+Edmondson&title=Discovery+of+proteolysis-targeting+chimera+molecules+that+selectively+degrade+the+IRAK3+pseudokinase&doi=10.1021%2Facs.jmedchem.0c01125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 Pseudokinase</span></div><div class="casAuthors">Degorce, Sebastien L.; Tavana, Omid; Banks, Erica; Crafter, Claire; Gingipalli, Lakshmaiah; Kouvchinov, David; Mao, Yumeng; Pachl, Fiona; Solanki, Anisha; Valge-Archer, Viia; Yang, Bin; Edmondson, Scott D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">10460-10473</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the first disclosure of IRAK3 degraders in the scientific literature.  Taking advantage of an opportune byproduct obtained during our efforts to identify IRAK4 inhibitors, we identified ready-to-use, selective IRAK3 ligands in our compd. collection with the required properties for conversion into proteolysis-targeting chimera (PROTAC) degraders.  This work culminated with the discovery of PROTAC 23(I), which we demonstrated to be a potent and selective degrader of IRAK3 after 16 h in THP1 cells. 23 induced proteasome-dependent degrdn. of IRAK3 and required both CRBN and IRAK3 binding for activity.  We conclude that PROTAC 23 constitutes an excellent in vitro tool with which to interrogate the biol. of IRAK3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqwc4uccsV7LVg90H21EOLACvtfcHk0lgZEPosEFxDEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1WktLbF&md5=aba5d2bbecd9a66f4e4a6a3999e33e41</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01125%26sid%3Dliteratum%253Aachs%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DTavana%26aufirst%3DO.%26aulast%3DBanks%26aufirst%3DE.%26aulast%3DCrafter%26aufirst%3DC.%26aulast%3DGingipalli%26aufirst%3DL.%26aulast%3DKouvchinov%26aufirst%3DD.%26aulast%3DMao%26aufirst%3DY.%26aulast%3DPachl%26aufirst%3DF.%26aulast%3DSolanki%26aufirst%3DA.%26aulast%3DValge-Archer%26aufirst%3DV.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DEdmondson%26aufirst%3DS.%2BD.%26atitle%3DDiscovery%2520of%2520proteolysis-targeting%2520chimera%2520molecules%2520that%2520selectively%2520degrade%2520the%2520IRAK3%2520pseudokinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D10460%26epage%3D10473%26doi%3D10.1021%2Facs.jmedchem.0c01125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bondeson, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burslem, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhimschi, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaime-Figueroa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamman, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishchenko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Lessons in PROTAC design from selective degradation with a promiscuous warhead</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">78</span>– <span class="NLM_lpage">87.e5</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2017.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.chembiol.2017.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=29129718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2lsrjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=78-87.e5&author=D.+P.+Bondesonauthor=B.+E.+Smithauthor=G.+M.+Burslemauthor=A.+D.+Buhimschiauthor=J.+Hinesauthor=S.+Jaime-Figueroaauthor=J.+Wangauthor=B.+D.+Hammanauthor=A.+Ishchenkoauthor=C.+M.+Crews&title=Lessons+in+PROTAC+design+from+selective+degradation+with+a+promiscuous+warhead&doi=10.1016%2Fj.chembiol.2017.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead</span></div><div class="casAuthors">Bondeson, Daniel P.; Smith, Blake E.; Burslem, George M.; Buhimschi, Alexandru D.; Hines, John; Jaime-Figueroa, Saul; Wang, Jing; Hamman, Brian D.; Ishchenko, Alexey; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">78-87.e5</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Inhibiting protein function selectively is a major goal of modern drug discovery.  Here, we report a previously understudied benefit of small mol. proteolysis-targeting chimeras (PROTACs) that recruit E3 ubiquitin ligases to target proteins for their ubiquitination and subsequent proteasome-mediated degrdn.  Using promiscuous CRBN- and VHL-recruiting PROTACs that bind >50 kinases, we show that only a subset of bound targets is degraded.  The basis of this selectivity relies on protein-protein interactions between the E3 ubiquitin ligase and the target protein, as illustrated by engaged proteins that are not degraded as a result of unstable ternary complexes with PROTAC-recruited E3 ligases.  In contrast, weak PROTAC:target protein affinity can be stabilized by high-affinity target:PROTAC:ligase trimer interactions, leading to efficient degrdn.  This study highlights design guidelines for generating potent PROTACs as well as possibilities for degrading undruggable proteins immune to traditional small-mol. inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoISOBudOLyFrVg90H21EOLACvtfcHk0lgZEPosEFxDEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2lsrjN&md5=30fac502705a2344c4261cf531e6bf9d</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DBondeson%26aufirst%3DD.%2BP.%26aulast%3DSmith%26aufirst%3DB.%2BE.%26aulast%3DBurslem%26aufirst%3DG.%2BM.%26aulast%3DBuhimschi%26aufirst%3DA.%2BD.%26aulast%3DHines%26aufirst%3DJ.%26aulast%3DJaime-Figueroa%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHamman%26aufirst%3DB.%2BD.%26aulast%3DIshchenko%26aufirst%3DA.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DLessons%2520in%2520PROTAC%2520design%2520from%2520selective%2520degradation%2520with%2520a%2520promiscuous%2520warhead%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2018%26volume%3D25%26spage%3D78%26epage%3D87.e5%26doi%3D10.1016%2Fj.chembiol.2017.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aberle, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Design and applications of bifunctional small molecules: why two heads are better than one</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">677</span>– <span class="NLM_lpage">692</span>, <span class="refDoi"> DOI: 10.1021/cb8001792</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb8001792" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1yiurzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=677-692&author=T.+W.+Corsonauthor=N.+Aberleauthor=C.+M.+Crews&title=Design+and+applications+of+bifunctional+small+molecules%3A+why+two+heads+are+better+than+one&doi=10.1021%2Fcb8001792"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Applications of Bifunctional Small Molecules: Why Two Heads Are Better Than One</span></div><div class="casAuthors">Corson, Timothy W.; Aberle, Nicholas; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">677-692</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Induction of protein-protein interactions is a daunting challenge, but recent studies show promise for small mols. that specifically bring two or more protein mols. together for enhanced or novel biol. effect.  The first such bifunctional mols. were the rapamycin- and FK506-based "chem. inducers of dimerization", but the field has since expanded with new mols. and new applications in chem. genetics and cell biol.  Examples include coumermycin-mediated gyrase B dimerization, proteolysis targeting chimeric mols. (PROTACs), drug hybrids, and strategies for exploiting multivalency in toxin binding and antibody recruitment.  This Review discusses these and other advances in the design and use of bifunctional small mols. and potential strategies for future systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-ZyBtc3QT9rVg90H21EOLACvtfcHk0ljAJcVoEMy04Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1yiurzF&md5=2edac15286d3a739dd66214a332a545b</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fcb8001792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb8001792%26sid%3Dliteratum%253Aachs%26aulast%3DCorson%26aufirst%3DT.%2BW.%26aulast%3DAberle%26aufirst%3DN.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DDesign%2520and%2520applications%2520of%2520bifunctional%2520small%2520molecules%253A%2520why%2520two%2520heads%2520are%2520better%2520than%2520one%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2008%26volume%3D3%26spage%3D677%26epage%3D692%26doi%3D10.1021%2Fcb8001792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cyrus, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehenkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span> <span> </span><span class="NLM_article-title">Impact of linker length on the activity of PROTACs</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">359</span>– <span class="NLM_lpage">364</span>, <span class="refDoi"> DOI: 10.1039/C0MB00074D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1039%2FC0MB00074D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=20922213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmslGhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=359-364&author=K.+Cyrusauthor=M.+Wehenkelauthor=E.+Y.+Choiauthor=H.+J.+Hanauthor=H.+Leeauthor=H.+Swansonauthor=K.+B.+Kim&title=Impact+of+linker+length+on+the+activity+of+PROTACs&doi=10.1039%2FC0MB00074D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of linker length on the activity of PROTACs</span></div><div class="casAuthors">Cyrus, Kedra; Wehenkel, Marie; Choi, Eun-Young; Han, Hyeong-Jun; Lee, Hyosung; Swanson, Hollie; Kim, Kyung-Bo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">359-364</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-206X</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Conventional genetic approaches have provided a powerful tool in the study of proteins.  However, these techniques often preclude selective manipulation of temporal and spatial protein functions, which is crucial for the investigation of dynamic cellular processes.  To overcome these limitations, a small mol.-based novel technol. termed "PROteolysis TArgeting ChimeraS (PROTACs)" has been developed, targeting proteins for degrdn. at the post-translational level.  Despite the promising potential of PROTACs to serve as mol. probes of complex signaling pathways, their design has not been generalized for broad application.  Here, we present the first generalized approach for PROTAC design by fine-tuning the distance between the two participating partner proteins, the E3 ubiquitin ligase and the target protein.  As such, we took a chem. approach to create estrogen receptor (ER)-α targeting PROTACs with varying linker lengths and the loss of the ER in cultured cells was monitored via western blot and fluorometric analyses.  We found a significant effect of chain length on PROTAC efficacy, and, in this case, the optimum distance between the E3 recognition motif and the ligand was a 16 atom chain length.  The information gathered from this expt. may offer a generalizable PROTAC design strategy to further the expansion of the PROTAC toolbox, opening new possibilities for the broad application of the PROTAC strategy in the study of multiple signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqP7hxQSvFw57Vg90H21EOLACvtfcHk0ljAJcVoEMy04Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmslGhsw%253D%253D&md5=56dc56cb3a73d17bc8903c4962d7648c</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1039%2FC0MB00074D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC0MB00074D%26sid%3Dliteratum%253Aachs%26aulast%3DCyrus%26aufirst%3DK.%26aulast%3DWehenkel%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DE.%2BY.%26aulast%3DHan%26aufirst%3DH.%2BJ.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DSwanson%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DK.%2BB.%26atitle%3DImpact%2520of%2520linker%2520length%2520on%2520the%2520activity%2520of%2520PROTACs%26jtitle%3DMol.%2520BioSyst.%26date%3D2011%26volume%3D7%26spage%3D359%26epage%3D364%26doi%3D10.1039%2FC0MB00074D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böhm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lydeard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadler, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavadini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serluca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingaraju, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tichkule, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schebesta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrester, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassiepen, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hild, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckwith, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomä, N. H.</span></span> <span> </span><span class="NLM_article-title">Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>512</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1038/nature13527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1038%2Fnature13527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=25043012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht12ms7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=512&publication_year=2014&pages=49-53&author=E.+S.+Fischerauthor=K.+B%C3%B6hmauthor=J.+R.+Lydeardauthor=H.+Yangauthor=M.+B.+Stadlerauthor=S.+Cavadiniauthor=J.+Nagelauthor=F.+Serlucaauthor=V.+Ackerauthor=G.+M.+Lingarajuauthor=R.+B.+Tichkuleauthor=M.+Schebestaauthor=W.+C.+Forresterauthor=M.+Schirleauthor=U.+Hassiepenauthor=J.+Ottlauthor=M.+Hildauthor=R.+E.+Beckwithauthor=J.+W.+Harperauthor=J.+L.+Jenkinsauthor=N.+H.+Thom%C3%A4&title=Structure+of+the+DDB1-CRBN+E3+ubiquitin+ligase+in+complex+with+thalidomide&doi=10.1038%2Fnature13527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide</span></div><div class="casAuthors">Fischer, Eric S.; Bohm, Kerstin; Lydeard, John R.; Yang, Haidi; Stadler, Michael B.; Cavadini, Simone; Nagel, Jane; Serluca, Fabrizio; Acker, Vincent; Lingaraju, Gondichatnahalli M.; Tichkule, Ritesh B.; Schebesta, Michael; Forrester, William C.; Schirle, Markus; Hassiepen, Ulrich; Ottl, Johannes; Hild, Marc; Beckwith, Rohan E. J.; Harper, J. Wade; Jenkins, Jeremy L.; Thoma, Nicolas H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">512</span>
        (<span class="NLM_cas:issue">7512</span>),
    <span class="NLM_cas:pages">49-53</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In the 1950s, the drug thalidomide, administered as a sedative to pregnant women, led to the birth of thousands of children with multiple defects.  Despite the teratogenicity of thalidomide and its derivs. lenalidomide and pomalidomide, these immunomodulatory drugs (IMiDs) recently emerged as effective treatments for multiple myeloma and 5q-deletion-assocd. dysplasia.  IMiDs target the E3 ubiquitin ligase CUL4-RBX1-DDB1-CRBN (known as CRL4CRBN) and promote the ubiquitination of the IKAROS family transcription factors IKZF1 and IKZF3 by CRL4CRBN.  Here we present crystal structures of the DDB1-CRBN complex bound to thalidomide, lenalidomide and pomalidomide.  The structure establishes that CRBN is a substrate receptor within CRL4CRBN and enantioselectively binds IMiDs.  Using an unbiased screen, we identified the homeobox transcription factor MEIS2 as an endogenous substrate of CRL4CRBN.  Our studies suggest that IMiDs block endogenous substrates (MEIS2) from binding to CRL4CRBN while the ligase complex is recruiting IKZF1 or IKZF3 for degrdn.  This dual activity implies that small mols. can modulate an E3 ubiquitin ligase and thereby upregulate or downregulate the ubiquitination of proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGt2Y9GecKr7Vg90H21EOLACvtfcHk0ljAJcVoEMy04Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht12ms7%252FP&md5=1c1eaa48bef87463cdd3f2b1e1bd400d</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fnature13527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13527%26sid%3Dliteratum%253Aachs%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DB%25C3%25B6hm%26aufirst%3DK.%26aulast%3DLydeard%26aufirst%3DJ.%2BR.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DStadler%26aufirst%3DM.%2BB.%26aulast%3DCavadini%26aufirst%3DS.%26aulast%3DNagel%26aufirst%3DJ.%26aulast%3DSerluca%26aufirst%3DF.%26aulast%3DAcker%26aufirst%3DV.%26aulast%3DLingaraju%26aufirst%3DG.%2BM.%26aulast%3DTichkule%26aufirst%3DR.%2BB.%26aulast%3DSchebesta%26aufirst%3DM.%26aulast%3DForrester%26aufirst%3DW.%2BC.%26aulast%3DSchirle%26aufirst%3DM.%26aulast%3DHassiepen%26aufirst%3DU.%26aulast%3DOttl%26aufirst%3DJ.%26aulast%3DHild%26aufirst%3DM.%26aulast%3DBeckwith%26aufirst%3DR.%2BE.%26aulast%3DHarper%26aufirst%3DJ.%2BW.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26aulast%3DThom%25C3%25A4%26aufirst%3DN.%2BH.%26atitle%3DStructure%2520of%2520the%2520DDB1-CRBN%2520E3%2520ubiquitin%2520ligase%2520in%2520complex%2520with%2520thalidomide%26jtitle%3DNature%26date%3D2014%26volume%3D512%26spage%3D49%26epage%3D53%26doi%3D10.1038%2Fnature13527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span> <span> </span><span class="NLM_article-title">Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2014.05.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.ccr.2014.05.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=25065853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1agsL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=207-221&author=H.+J.+Leeauthor=G.+Zhuangauthor=Y.+Caoauthor=P.+Duauthor=H.+J.+Kimauthor=J.+Settleman&title=Drug+resistance+via+feedback+activation+of+Stat3+in+oncogene-addicted+cancer+cells&doi=10.1016%2Fj.ccr.2014.05.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells</span></div><div class="casAuthors">Lee, Ho-June; Zhuang, Guanglei; Cao, Yi; Du, Pan; Kim, Hyo-Jin; Settleman, Jeff</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">207-221</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Pathway-targeted cancer drugs can produce dramatic responses that are invariably limited by the emergence of drug-resistant cells.  We found that many drug-treated "oncogene-addicted" cancer cells engage a pos. feedback loop leading to Stat3 activation, consequently promoting cell survival and limiting overall drug response.  This was obsd. in cancer cells driven by diverse activated kinases, including EGFR, HER2, ALK, and MET, as well as mutant KRAS.  Specifically, MEK inhibition led to autocrine activation of Stat3 via the FGF receptor and JAK kinases, and pharmacol. inhibition of MEK together with JAK and FGFR enhanced tumor regression.  These findings suggest that inhibition of a Stat3 feedback loop may augment the response to a broad spectrum of drugs that target pathways of oncogene addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9wv2-E6LTCLVg90H21EOLACvtfcHk0liYf3XqclIDGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1agsL7I&md5=d180509b8b5a63331e8edbd0d2bf9a63</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2014.05.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2014.05.019%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DZhuang%26aufirst%3DG.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DDu%26aufirst%3DP.%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DDrug%2520resistance%2520via%2520feedback%2520activation%2520of%2520Stat3%2520in%2520oncogene-addicted%2520cancer%2520cells%26jtitle%3DCancer%2520Cell%26date%3D2014%26volume%3D26%26spage%3D207%26epage%3D221%26doi%3D10.1016%2Fj.ccr.2014.05.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilling, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutateladze, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weickhardt, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linderman, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heasley, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franklin, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varella-Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer</span>. <i>Clin. Cancer. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1472</span>– <span class="NLM_lpage">1482</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-2906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1158%2F1078-0432.CCR-11-2906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=22235099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Wksro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1472-1482&author=R.+C.+Doebeleauthor=A.+B.+Pillingauthor=D.+L.+Aisnerauthor=T.+G.+Kutateladzeauthor=A.+T.+Leauthor=A.+J.+Weickhardtauthor=K.+L.+Kondoauthor=D.+J.+Lindermanauthor=L.+E.+Heasleyauthor=W.+A.+Franklinauthor=M.+Varella-Garciaauthor=D.+R.+Camidge&title=Mechanisms+of+resistance+to+crizotinib+in+patients+with+ALK+gene+rearranged+non-small+cell+lung+cancer&doi=10.1158%2F1078-0432.CCR-11-2906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Doebele, Robert C.; Pilling, Amanda B.; Aisner, Dara L.; Kutateladze, Tatiana G.; Le, Anh T.; Weickhardt, Andrew J.; Kondo, Kimi L.; Linderman, Derek J.; Heasley, Lynn E.; Franklin, Wilbur A.; Varella-Garcia, Marileila; Camidge, D. Ross</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1472-1482</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with anaplastic lymphoma kinase (ALK) gene rearrangements often manifest dramatic responses to crizotinib, a small-mol. ALK inhibitor.  Unfortunately, not every patient responds and acquired drug resistance inevitably develops in those who do respond.  This study aimed to define mol. mechanisms of resistance to crizotinib in patients with ALK+ non-small cell lung cancer (NSCLC).  We analyzed tissue obtained from 14 patients with ALK+ NSCLC showing evidence of radiol. progression while on crizotinib to define mechanisms of intrinsic and acquired resistance to crizotinib.  Eleven patients had material evaluable for mol. anal.  Four patients (36%) developed secondary mutations in the tyrosine kinase domain of ALK.  A novel mutation in the ALK domain, encoding a G1269A amino acid substitution that confers resistance to crizotinib in vitro, was identified in two of these cases.  Two patients, one with a resistance mutation, exhibited new onset ALK copy no. gain (CNG).  One patient showed outgrowth of epidermal growth factor receptor (EGFR) mutant NSCLC without evidence of a persistent ALK gene rearrangement.  Two patients exhibited a KRAS mutation, one of which occurred without evidence of a persisting ALK gene rearrangement.  One patient showed the emergence of an ALK gene fusion-neg. tumor compared with the baseline sample but with no identifiable alternate driver.  Two patients retained ALK positivity with no identifiable resistance mechanism.  Crizotinib resistance in ALK+ NSCLC occurs through somatic kinase domain mutations, ALK gene fusion CNG, and emergence of sep. oncogenic drivers.  Clin Cancer Res; 18(5); 1472-82.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofhGQYtlS1w7Vg90H21EOLACvtfcHk0liYf3XqclIDGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Wksro%253D&md5=575047615ef9e3d4af60d45605a747c5</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2906%26sid%3Dliteratum%253Aachs%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DPilling%26aufirst%3DA.%2BB.%26aulast%3DAisner%26aufirst%3DD.%2BL.%26aulast%3DKutateladze%26aufirst%3DT.%2BG.%26aulast%3DLe%26aufirst%3DA.%2BT.%26aulast%3DWeickhardt%26aufirst%3DA.%2BJ.%26aulast%3DKondo%26aufirst%3DK.%2BL.%26aulast%3DLinderman%26aufirst%3DD.%2BJ.%26aulast%3DHeasley%26aufirst%3DL.%2BE.%26aulast%3DFranklin%26aufirst%3DW.%2BA.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520crizotinib%2520in%2520patients%2520with%2520ALK%2520gene%2520rearranged%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer.%2520Res.%26date%3D2012%26volume%3D18%26spage%3D1472%26epage%3D1482%26doi%3D10.1158%2F1078-0432.CCR-11-2906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antoniu, S. A.</span></span> <span> </span><span class="NLM_article-title">Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease?</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">351</span>– <span class="NLM_lpage">353</span>, <span class="refDoi"> DOI: 10.1517/14728222.2011.550880</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1517%2F14728222.2011.550880" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=21208134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ymu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=351-353&author=S.+A.+Antoniu&title=Crizotinib+for+EML4-ALK+positive+lung+adenocarcinoma%3A+a+hope+for+the+advanced+disease%3F&doi=10.1517%2F14728222.2011.550880"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease?</span></div><div class="casAuthors">Antoniu, Sabina Antonela</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">351-353</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: In lung adenocarcinoma, certain mutations such as echinoderm microtubule-assocd. protein-like 4-anaplastic lymphoma kinase (ALK) are assocd. with lower sensitivity to chemotherapy, when used conventionally as the first-line therapy in the advanced stage of the disease.  Areas covered: This paper discusses the clin. and therapeutic importance of ALK mutations in NSCLC and the early clin. results of a Phase I study assessing crizotinib in patients with ALK mutations.  Expert opinion: Abnormal ALK is evolving as an important therapeutic target in patients with more aggressive lung adenocarcinoma.  Further clin. studies are needed in order to assess if crizotinib, an ALK inhibitor, is able to increase the efficacy of the conventional chemotherapy in this disease subset.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo65eAfRGofurVg90H21EOLACvtfcHk0liYf3XqclIDGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ymu7g%253D&md5=07ac2378ef5fbbb9dd4e3232af7c8f94</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1517%2F14728222.2011.550880&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.2011.550880%26sid%3Dliteratum%253Aachs%26aulast%3DAntoniu%26aufirst%3DS.%2BA.%26atitle%3DCrizotinib%2520for%2520EML4-ALK%2520positive%2520lung%2520adenocarcinoma%253A%2520a%2520hope%2520for%2520the%2520advanced%2520disease%253F%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2011%26volume%3D15%26spage%3D351%26epage%3D353%26doi%3D10.1517%2F14728222.2011.550880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2012.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1016%2Fj.phrs.2012.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=23201355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovVygtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=68-94&author=R.+Roskoski&title=Anaplastic+lymphoma+kinase+%28ALK%29%3A+structure%2C+oncogenic+activation%2C+and+pharmacological+inhibition&doi=10.1016%2Fj.phrs.2012.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition</span></div><div class="casAuthors">Roskoski, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">68-94</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Anaplastic lymphoma kinase was first described in 1994 as the NPM-ALK fusion protein that is expressed in the majority of anaplastic large-cell lymphomas.  ALK is a receptor protein-tyrosine kinase that was more fully characterized in 1997.  Physiol. ALK participates in embryonic nervous system development, but its expression decreases after birth.  ALK is a member of the insulin receptor superfamily and is most closely related to leukocyte tyrosine kinase (Ltk), which is a receptor protein-tyrosine kinase.  Twenty different ALK-fusion proteins have been described that result from various chromosomal rearrangements, and they have been implicated in the pathogenesis of several diseases including anaplastic large-cell lymphoma, diffuse large B-cell lymphoma, and inflammatory myofibroblastic tumors.  The EML4-ALK fusion protein and four other ALK-fusion proteins play a fundamental role in the development in about 5% of non-small cell lung cancers.  The formation of dimers by the amino-terminal portion of the ALK fusion proteins results in the activation of the ALK protein kinase domain that plays a key role in the tumorigenic process.  Downstream signaling from ALK fusion proteins involves the Ras/Raf/MEK/ERK1/2 cell proliferation module and the JAK/STAT cell survival pathway.  Furthermore, nearly two dozen ALK activating mutations participate in the pathogenesis of childhood neuroblastomas along with ALK overexpression.  The occurrence of oncogenic ALK, particularly in non-small cell lung cancer, has generated considerable interest and effort in developing ALK inhibitors.  Currently, crizotinib has been approved by the US Food and Drug Administration for the treatment of ALK-pos. non-small cell lung cancer along with an approved fluorescence in situ hybridization kit used for the diagnosis of the disease.  The emergence of crizotinib drug resistance with a median occurrence at approx. 10 mo after the initiation of therapy has stimulated the development of second-generation drugs for the treatment of non-small cell lung cancer and other disorders.  About 28% of the cases of crizotinib resistance are related to nearly a dozen different mutations of ALK in the EML4-ALK fusion protein; the other cases of resistance are related to the upregulation of alternative signaling pathways or to undefined mechanisms.  It is remarkable that the EML4-ALK fusion protein was discovered in 2007 and crizotinib was approved for the treatment of ALK-pos. non-small cell lung cancer in 2011, which is a remarkably short timeframe in the overall scheme of drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv-sp0x0gqkrVg90H21EOLACvtfcHk0lgxG0JhITbjPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovVygtg%253D%253D&md5=c48d1a4b88a68d395b7acdf403f1875d</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2012.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2012.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%253A%2520structure%252C%2520oncogenic%2520activation%252C%2520and%2520pharmacological%2520inhibition%26jtitle%3DPharmacol.%2520Res.%26date%3D2013%26volume%3D68%26spage%3D68%26epage%3D94%26doi%3D10.1016%2Fj.phrs.2012.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matyskiela, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagarigan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houston, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmel, G.</span></span> <span> </span><span class="NLM_article-title">A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>535</i></span>,  <span class="NLM_fpage">252</span>– <span class="NLM_lpage">257</span>, <span class="refDoi"> DOI: 10.1038/nature18611</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1038%2Fnature18611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=27338790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVCltbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=535&publication_year=2016&pages=252-257&author=M.+E.+Matyskielaauthor=G.+Luauthor=T.+Itoauthor=B.+Pagariganauthor=C.+C.+Luauthor=K.+Millerauthor=W.+Fangauthor=N.+Y.+Wangauthor=D.+Nguyenauthor=J.+Houstonauthor=G.+Carmel&title=A+novel+cereblon+modulator+recruits+GSPT1+to+the+CRL4%28CRBN%29+ubiquitin+ligase&doi=10.1038%2Fnature18611"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase</span></div><div class="casAuthors">Matyskiela, Mary E.; Lu, Gang; Ito, Takumi; Pagarigan, Barbra; Lu, Chin-Chun; Miller, Karen; Fang, Wei; Wang, Nai-Yu; Nguyen, Derek; Houston, Jack; Carmel, Gilles; Tran, Tam; Riley, Mariko; Nosaka, Lyn'Al; Lander, Gabriel C.; Gaidarova, Svetlana; Xu, Shuichan; Ruchelman, Alexander L.; Handa, Hiroshi; Carmichael, James; Daniel, Thomas O.; Cathers, Brian E.; Lopez-Girona, Antonia; Chamberlain, Philip P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">535</span>
        (<span class="NLM_cas:issue">7611</span>),
    <span class="NLM_cas:pages">252-257</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Immunomodulatory drugs bind to cereblon (CRBN) to confer differentiated substrate specificity on the CRL4CRBN E3 ubiquitin ligase.  Here we report the identification of a new cereblon modulator, CC-885, with potent anti-tumor activity.  The anti-tumor activity of CC-885 is mediated through the cereblon-dependent ubiquitination and degrdn. of the translation termination factor GSPT1.  Patient-derived acute myeloid leukemia tumor cells exhibit high sensitivity to CC-885, indicating the clin. potential of this mechanism.  Crystallog. studies of the CRBN-DDB1-CC-885-GSPT1 complex reveal that GSPT1 binds to cereblon through a surface turn contg. a glycine residue at a key position, interacting with both CC-885 and a 'hotspot' on the cereblon surface.  Although GSPT1 possesses no obvious structural, sequence or functional homol. to previously known cereblon substrates, mutational anal. and modeling indicate that the cereblon substrate Ikaros uses a similar structural feature to bind cereblon, suggesting a common motif for substrate recruitment.  These findings define a structural degron underlying cereblon 'neosubstrate' selectivity, and identify an anti-tumor target rendered druggable by cereblon modulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgAWiXdlJgYLVg90H21EOLACvtfcHk0lgxG0JhITbjPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVCltbnI&md5=1d4e340416aa0b08fc0f123faf638c3f</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fnature18611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature18611%26sid%3Dliteratum%253Aachs%26aulast%3DMatyskiela%26aufirst%3DM.%2BE.%26aulast%3DLu%26aufirst%3DG.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DPagarigan%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DC.%2BC.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DFang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DN.%2BY.%26aulast%3DNguyen%26aufirst%3DD.%26aulast%3DHouston%26aufirst%3DJ.%26aulast%3DCarmel%26aufirst%3DG.%26atitle%3DA%2520novel%2520cereblon%2520modulator%2520recruits%2520GSPT1%2520to%2520the%2520CRL4%2528CRBN%2529%2520ubiquitin%2520ligase%26jtitle%3DNature%26date%3D2016%26volume%3D535%26spage%3D252%26epage%3D257%26doi%3D10.1038%2Fnature18611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naniong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaelin, W. G.,  Jr.</span></span> <span> </span><span class="NLM_article-title">The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>343</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1126/science.1244917</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1126%2Fscience.1244917" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=24292623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtV2ktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2014&pages=305-309&author=G.+Luauthor=R.+E.+Middletonauthor=H.+Sunauthor=M.+Naniongauthor=C.+J.+Ottauthor=C.+S.+Mitsiadesauthor=K.+K.+Wongauthor=J.+E.+Bradnerauthor=W.+G.+Kaelin&title=The+myeloma+drug+lenalidomide+promotes+the+cereblon-dependent+destruction+of+Ikaros+proteins&doi=10.1126%2Fscience.1244917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins</span></div><div class="casAuthors">Lu, Gang; Middleton, Richard E.; Sun, Huahang; Naniong, MarkVic; Ott, Christopher J.; Mitsiades, Constantine S.; Wong, Kwok-Kin; Bradner, James E.; Kaelin, William G., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">6168</span>),
    <span class="NLM_cas:pages">305-309</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Thalidomide-like drugs such as lenalidomide are clin. important treatments for multiple myeloma and show promise for other B cell malignancies.  The biochem. mechanisms underlying their antitumor activity are unknown.  Thalidomide was recently shown to bind to, and inhibit, the cereblon ubiquitin ligase.  Cereblon loss in zebrafish causes fin defects reminiscent of the limb defects seen in children exposed to thalidomide in utero.  Here we show that lenalidomide-bound cereblon acquires the ability to target for proteasomal degrdn. two specific B cell transcription factors, Ikaros family zinc finger proteins 1 and 3 (IKZF1 and IKZF3).  Anal. of myeloma cell lines revealed that loss of IKZF1 and IKZF3 is both necessary and sufficient for lenalidomide's therapeutic effect, suggesting that the antitumor and teratogenic activities of thalidomide-like drugs are dissociable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0froz4Kipu7Vg90H21EOLACvtfcHk0lgxG0JhITbjPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtV2ktg%253D%253D&md5=a9df5bbde0f676b92b1bec48fdbbb502</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1126%2Fscience.1244917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1244917%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DG.%26aulast%3DMiddleton%26aufirst%3DR.%2BE.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DNaniong%26aufirst%3DM.%26aulast%3DOtt%26aufirst%3DC.%2BJ.%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DKaelin%26aufirst%3DW.%2BG.%26atitle%3DThe%2520myeloma%2520drug%2520lenalidomide%2520promotes%2520the%2520cereblon-dependent%2520destruction%2520of%2520Ikaros%2520proteins%26jtitle%3DScience%26date%3D2014%26volume%3D343%26spage%3D305%26epage%3D309%26doi%3D10.1126%2Fscience.1244917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, K.</span>; <span class="NLM_string-name">Asoh, K.</span>; <span class="NLM_string-name">Furuichi, N.</span>; <span class="NLM_string-name">Ito, T.</span>; <span class="NLM_string-name">Kawada, H.</span>; <span class="NLM_string-name">Ishii, N.</span>; <span class="NLM_string-name">Sakamoto, H.</span>; <span class="NLM_string-name">Hong, W. S.</span>; <span class="NLM_string-name">Park, M. J.</span>; <span class="NLM_string-name">Ono, Y.</span>; <span class="NLM_string-name">Kato, Y.</span>; <span class="NLM_string-name">Morikami, K.</span>; <span class="NLM_string-name">Emura, T.</span>; <span class="NLM_string-name">Oikawa, N.</span></span> <span> </span><span class="NLM_article-title">Tetracyclic compound</span>. U.S. Patent <span class="NLM_patent">9,126,931 B2</span>, September 8, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=K.+Kinoshita&author=K.+Asoh&author=N.+Furuichi&author=T.+Ito&author=H.+Kawada&author=N.+Ishii&author=H.+Sakamoto&author=W.+S.+Hong&author=M.+J.+Park&author=Y.+Ono&author=Y.+Kato&author=K.+Morikami&author=T.+Emura&author=N.+Oikawa&title=Tetracyclic+compound"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKinoshita%26aufirst%3DK.%26atitle%3DTetracyclic%2520compound%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donovan, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Development of dual and selective degraders of cyclin-dependent kinases 4 and 6</span>. <i>Angew. Chem. Int. Ed. Engl.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6321</span>– <span class="NLM_lpage">6326</span>, <span class="refDoi"> DOI: 10.1002/anie.201901336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=10.1002%2Fanie.201901336" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=30802347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;key=1%3ACAS%3A280%3ADC%252BB3cfnt1OqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=6321-6326&author=B.+Jiangauthor=E.+S.+Wangauthor=K.+A.+Donovanauthor=Y.+Liangauthor=E.+S.+Fischerauthor=T.+Zhangauthor=N.+S.+Gray&title=Development+of+dual+and+selective+degraders+of+cyclin-dependent+kinases+4+and+6&doi=10.1002%2Fanie.201901336"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6</span></div><div class="casAuthors">Jiang Baishan; Wang Eric S; Donovan Katherine A; Liang Yanke; Fischer Eric S; Zhang Tinghu; Gray Nathanael S</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie (International ed. in English)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6321-6326</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cyclin-dependent kinases 4 and 6 (CDK4/6) are key regulators of the cell cycle, and there are FDA-approved CDK4/6 inhibitors for treating patients with metastatic breast cancer.  However, due to conservation of their ATP-binding sites, development of selective agents has remained elusive.  Here, we report imide-based degrader molecules capable of degrading both CDK4/6, or selectively degrading either CDK4 or CDK6.  We were also able to tune the activity of these molecules against Ikaros (IKZF1) and Aiolos (IKZF3), which are well-established targets of imide-based degraders.  We found that in mantle cell lymphoma cell lines, combined IKZF1/3 degradation with dual CDK4/6 degradation produced enhanced anti-proliferative effects compared to CDK4/6 inhibition, CDK4/6 degradation, or IKZF1/3 degradation.  In summary, we report here the first compounds capable of inducing selective degradation of CDK4 and CDK6 as tools to pharmacologically dissect their distinct biological functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQvjF82FsSWX6qcneEtCi92fW6udTcc2eaMO4i1hfuJ_Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfnt1OqtA%253D%253D&md5=fa27938a9ec50a89644eb87812048329</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1002%2Fanie.201901336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201901336%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DE.%2BS.%26aulast%3DDonovan%26aufirst%3DK.%2BA.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDevelopment%2520of%2520dual%2520and%2520selective%2520degraders%2520of%2520cyclin-dependent%2520kinases%25204%2520and%25206%26jtitle%3DAngew.%2520Chem.%2520Int.%2520Ed.%2520Engl.%26date%3D2019%26volume%3D58%26spage%3D6321%26epage%3D6326%26doi%3D10.1002%2Fanie.201901336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3AOX" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3AOX','PDB','3AOX'); return false;">PDB: 3AOX</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i54"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00270">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_13217"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00270?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00270</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Experimental methods for biological assays; <sup>1</sup>H and <sup>13</sup>C NMR spectra for key intermediates and all target compounds; mass spectrum and HPLC spectrogram for compound <b>17</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00270/suppl_file/jm1c00270_si_001.pdf">PDF</a>)</p></li><li><p class="inline">SMILES molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00270/suppl_file/jm1c00270_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00270/suppl_file/jm1c00270_si_001.pdf">jm1c00270_si_001.pdf (2.48 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00270/suppl_file/jm1c00270_si_002.csv">jm1c00270_si_002.csv (2.29 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00270&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00270%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-13%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00270" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                10MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a6e2b5d393cac","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
